
<html lang="en"     class="pb-page"  data-request-id="307f92f2-9fbd-4320-b402-51e6edebbc09"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-13;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.1c00174"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery and Optimization of a Novel 2H-Pyrazolo[3,4-d]pyrimidine Derivative as a Potent Irreversible Pan-Fibroblast Growth Factor Receptor Inhibitor" /></meta><meta name="dc.Creator" content="Yujiao  Wei" /></meta><meta name="dc.Creator" content="Yanting  Tang" /></meta><meta name="dc.Creator" content="Yunyun  Zhou" /></meta><meta name="dc.Creator" content="Yuyu  Yang" /></meta><meta name="dc.Creator" content="Yetong  Cui" /></meta><meta name="dc.Creator" content="Xuan  Wang" /></meta><meta name="dc.Creator" content="Yubo  Wang" /></meta><meta name="dc.Creator" content="Yulin  Liu" /></meta><meta name="dc.Creator" content="Ning  Liu" /></meta><meta name="dc.Creator" content="Qianqian  Wang" /></meta><meta name="dc.Creator" content="Chong  Li" /></meta><meta name="dc.Creator" content="Hao  Ruan" /></meta><meta name="dc.Creator" content="Honggang  Zhou" /></meta><meta name="dc.Creator" content="Mingming  Wei" /></meta><meta name="dc.Creator" content="Guang  Yang" /></meta><meta name="dc.Creator" content="Cheng  Yang" /></meta><meta name="dc.Description" content="Fibroblast growth factor receptors (FGFRs) have become promising therapeutic targets in various types of cancers. In fact, several selective irreversible inhibitors capable of covalently reacting w..." /></meta><meta name="Description" content="Fibroblast growth factor receptors (FGFRs) have become promising therapeutic targets in various types of cancers. In fact, several selective irreversible inhibitors capable of covalently reacting w..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 15, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00174" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00174" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00174" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00174" /></link>
        
    
    

<title>Discovery and Optimization of a Novel 2H-Pyrazolo[3,4-d]pyrimidine Derivative as a Potent Irreversible Pan-Fibroblast Growth Factor Receptor Inhibitor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00174" /></meta><meta property="og:title" content="Discovery and Optimization of a Novel 2H-Pyrazolo[3,4-d]pyrimidine Derivative as a Potent Irreversible Pan-Fibroblast Growth Factor Receptor Inhibitor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0011.jpeg" /></meta><meta property="og:description" content="Fibroblast growth factor receptors (FGFRs) have become promising therapeutic targets in various types of cancers. In fact, several selective irreversible inhibitors capable of covalently reacting with the conserved cysteine of FGFRs are currently being evaluated in clinical trials. In this article, we optimized and discovered a novel lead compound 36 with remarkable inhibitory effects against FGFR (1–3), which is a derivative of 2H-pyrazolo[3,4-d]pyrimidine. The irreversible binding to FGFRs was characterized by LC–MS. This compound has been shown to exhibit significant anti-proliferation effects against NCI-H1581 and SNU-16 cancer cell lines both in vitro and in vivo. Compound 36 has also demonstrated a low toxicity profile and adequate pharmacokinetic properties and is currently under validation as a potential drug candidate." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00174"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00174">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00174&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00174&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00174&amp;href=/doi/10.1021/acs.jmedchem.1c00174" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 9078-9099</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00159" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00204" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Optimization of a Novel 2<i>H</i>-Pyrazolo[3,4-d]pyrimidine Derivative as a Potent Irreversible Pan-Fibroblast Growth Factor Receptor Inhibitor</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yujiao Wei</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yujiao Wei</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yujiao++Wei">Yujiao Wei</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yanting Tang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yanting Tang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yanting++Tang">Yanting Tang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yunyun Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yunyun Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yunyun++Zhou">Yunyun Zhou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuyu Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuyu Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuyu++Yang">Yuyu Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yetong Cui</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yetong Cui</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yetong++Cui">Yetong Cui</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xuan Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xuan Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xuan++Wang">Xuan Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yubo Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yubo Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yubo++Wang">Yubo Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yulin Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yulin Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yulin++Liu">Yulin Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ning Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ning Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ning++Liu">Ning Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qianqian Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qianqian Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qianqian++Wang">Qianqian Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chong Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chong Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chong++Li">Chong Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hao Ruan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hao Ruan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hao++Ruan">Hao Ruan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Honggang Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Honggang Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Honggang++Zhou">Honggang Zhou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mingming Wei</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mingming Wei</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#d3bebabdb4bebabdb4a0bbb6bdb4a4a693e2e5e0fdb0bcbe"><span class="__cf_email__" data-cfemail="c9a4a0a7aea4a0a7aebaa1aca7aebebc89f8fffae7aaa6a4">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mingming++Wei">Mingming Wei</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Guang Yang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guang Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#c483b1a5aaa3eabda5aaa384aaa5aaafa5adeaa1a0b1eaa7aa"><span class="__cf_email__" data-cfemail="ca8dbfaba4ade4b3aba4ad8aa4aba4a1aba3e4afaebfe4a9a4">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guang++Yang">Guang Yang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-1773-9392" title="Orcid link">https://orcid.org/0000-0002-1773-9392</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Cheng Yang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cheng Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#9fdcf7faf1f8b1e6fef1f8dff1fef1f4fef6b1fafbeab1fcf1"><span class="__cf_email__" data-cfemail="acefc4c9c2cb82d5cdc2cbecc2cdc2c7cdc582c9c8d982cfc2">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cheng++Yang">Cheng Yang</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00174&amp;href=/doi/10.1021%2Facs.jmedchem.1c00174" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 9078–9099</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 15, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>31 January 2021</li><li><span class="item_label"><b>Published</b> online</span>15 June 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 July 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00174" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00174</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9078%26pageCount%3D22%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYujiao%2BWei%252C%2BYanting%2BTang%252C%2BYunyun%2BZhou%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D13%26contentID%3Dacs.jmedchem.1c00174%26title%3DDiscovery%2Band%2BOptimization%2Bof%2Ba%2BNovel%2B2H-Pyrazolo%255B3%252C4-d%255Dpyrimidine%2BDerivative%2Bas%2Ba%2BPotent%2BIrreversible%2BPan-Fibroblast%2BGrowth%2BFactor%2BReceptor%2BInhibitor%26numPages%3D22%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9099%26publicationDate%3DJuly%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00174"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1132</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00174" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Optimization of a Novel 2H-Pyrazolo[3,4-d]pyrimidine Derivative as a Potent Irreversible Pan-Fibroblast Growth Factor Receptor Inhibitor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yujiao&quot;,&quot;last_name&quot;:&quot;Wei&quot;},{&quot;first_name&quot;:&quot;Yanting&quot;,&quot;last_name&quot;:&quot;Tang&quot;},{&quot;first_name&quot;:&quot;Yunyun&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Yuyu&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Yetong&quot;,&quot;last_name&quot;:&quot;Cui&quot;},{&quot;first_name&quot;:&quot;Xuan&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Yubo&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Yulin&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Ning&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Qianqian&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Chong&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Hao&quot;,&quot;last_name&quot;:&quot;Ruan&quot;},{&quot;first_name&quot;:&quot;Honggang&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Mingming&quot;,&quot;last_name&quot;:&quot;Wei&quot;},{&quot;first_name&quot;:&quot;Guang&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Cheng&quot;,&quot;last_name&quot;:&quot;Yang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;9078-9099&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00174&quot;},&quot;abstract&quot;:&quot;Fibroblast growth factor receptors (FGFRs) have become promising therapeutic targets in various types of cancers. In fact, several selective irreversible inhibitors capable of covalently reacting with the conserved cysteine of FGFRs are currently being evaluated in clinical trials. In this article, we optimized and discovered a novel lead compound 36 with remarkable inhibitory effects against FGFR (1–3), which is a derivative of 2H-pyrazolo[3,4-d]pyrimidine. The irreversible binding to FGFRs was characterized by LC–MS. This compound has been shown to exhibit significant anti-proliferation effects against NCI-H1581 and SNU-16 cancer cell lines both in vitro and in vivo. Compound 36 has also demonstrated a low toxicity profile and adequate pharmacokinetic properties and is currently under validation as a potential drug candidate.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00174&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00174" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00174&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00174" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00174&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00174" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00174&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00174&amp;href=/doi/10.1021/acs.jmedchem.1c00174" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00174" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00174" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00174%26sid%3Dliteratum%253Aachs%26pmid%3D34129329%26genre%3Darticle%26aulast%3DWei%26date%3D2021%26atitle%3DDiscovery%2Band%2BOptimization%2Bof%2Ba%2BNovel%2B2H-Pyrazolo%255B3%252C4-d%255Dpyrimidine%2BDerivative%2Bas%2Ba%2BPotent%2BIrreversible%2BPan-Fibroblast%2BGrowth%2BFactor%2BReceptor%2BInhibitor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D13%26spage%3D9078%26epage%3D9099%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291235" title="Column chromatography">Column chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=292492" title="Liquids">Liquids</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/medium/jm1c00174_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00174&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Fibroblast growth factor receptors (FGFRs) have become promising therapeutic targets in various types of cancers. In fact, several selective irreversible inhibitors capable of covalently reacting with the conserved cysteine of FGFRs are currently being evaluated in clinical trials. In this article, we optimized and discovered a novel lead compound <b>36</b> with remarkable inhibitory effects against FGFR (1–3), which is a derivative of 2<i>H</i>-pyrazolo[3,4-d]pyrimidine. The irreversible binding to FGFRs was characterized by LC–MS. This compound has been shown to exhibit significant anti-proliferation effects against NCI-H1581 and SNU-16 cancer cell lines both <i>in vitro</i> and <i>in vivo</i>. Compound <b>36</b> has also demonstrated a low toxicity profile and adequate pharmacokinetic properties and is currently under validation as a potential drug candidate.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33130" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33130" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The family of fibroblast growth factor receptor (FGFR) is a subfamily of receptor tyrosine kinases (RTKs), which comprises four highly conserved transmembrane RTKs: FGFR1, FGFR2, FGFR3, and FGFR4. The binding of ligands to the FGFR receptors leads to the activation of a cascade of intracellular downstream signaling pathways, such as STATs, Akt, MAPK, and PLCγ, by which FGFRs regulate a series of cell functions, such as cell proliferation and differentiation and crucial biological processes including development, angiogenesis, homeostasis, and wound repair.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> Abnormalities in FGF/FGFR signaling pathways have been involved in various tumor development and progression and associated with poor patient prognosis. For instance, amplifications of FGFR1 preponderate in squamous cell lung carcinoma (20%), breast cancer (10%), ovarian cancer (∼5%), and bladder cancer (3%). FGFR2 alterations have been dominated in gastric cancer (10%), endometrial cancer (12%), squamous cell lung carcinoma (5%), and triple-negative breast cancer (4%). Additionally, FGFR3 mutations have been depicted in bladder cancer (50–60%) and myeloma (15–20%). Aberrant FGF19/FGFR4 have been closely associated with hepatocellular carcinomas.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4−6)</a> Based on all these facts, the development of novel FGFR inhibitors provides promising therapeutic strategies for FGFR-dependent cancers.</div><div class="NLM_p">Great efforts have been devoted to develop FGFR inhibitors as anticancer agents.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> First, several TKIs were originally developed for clinical treatment of various cancers bearing alternated FGFRs, such as dovitinib,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> lucitanib,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> nintedanib,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and ponatinib.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> These early examples of FGFR inhibitors were nonselective and less efficient. Hence, several selective FGFR inhibitors adopted various scaffolds and were later developed; some TKIs are currently under different stages of clinical study, such as AZD-4547<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> (phase III), BGJ-398<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> (phase II), LY-2874455<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> (phase II), and JNJ-42756493<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> (phase II). These selective FGFR inhibitors are ATP competitive inhibitors that bind to active forms of FGFRs. To be noticed, there are two FGFR inhibitors with FDA approval: erdafitinib for bladder cancer and pemigatinib for cholangiocarcinoma.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a></div><div class="NLM_p last">More recently, the great clinical success of irreversible inhibitors, such as neratinib (HER2 inhibitor), osimertinib (a selective EGFR-T790M inhibitor), and ibrutinib (a selective BTK inhibitor), have appealed medicinal chemists to discover novel irreversible inhibitors that might be effective as anti-FGFR therapies. FIIN-1 was reported as the first irreversible inhibitor of FGFR1–4 and could covalently react with conserved cysteines in four FGFR proteins.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Some outstanding medicinal groups have also identified potent irreversible FGFR inhibitors with similar characteristics for development of novel anticancer therapeutics.<a onclick="showRef(event, 'ref19 ref20 ref21 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21 ref22 ref23 ref24">(19−24)</a> Two irreversible inhibitors of FGFR, TAS-120 and PRN-1371, are currently under clinical trials.<a onclick="showRef(event, 'ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27">(25−27)</a> Previously, the listed drug molecule ibrutinib demonstrated a moderate inhibitory effect against FGFRs. We hypothesized that ibrutinib might be an ideal lead compound to develop novel FGFR inhibitors. In this paper, we reported our discovery and optimization of a novel 2<i>H</i>-pyrazolo[3,4-d]pyrimidine derivative as a potent irreversible pan-FGFR inhibitor.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52277" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52277" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Structure–Activity Relationship Studies of Small Libraries of Compounds</h3><div class="NLM_p">We initially identified the structural features of three crucial regions of the ATP-binding pocket and structure-based design to generate small-focused libraries of possible active molecules.<a onclick="showRef(event, 'ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30">(28−30)</a> Specifically, 2H-pyrazolo[3,4-d]pyrimidine was employed as a core structure to occupy the adenine region. Various substituted aryl groups were constructed into the core to accommodate the hydrophobic region by π–π interactions. Terminal substituted acrylamide moieties were synthesized as Michael receptors, which were joined to the thiol group of Cys491 by core structures with different patterns of linkers (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/medium/jm1c00174_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Design of the irreversible inhibitors based on the structure of the ATP-binding pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00174&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Based on the design hypothesis for initial lead generation depicted, a small series of compound libraries were prepared, and their structures are displayed in the following table (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). To screen the most potent FGFR inhibitors, biochemical enzyme assays were performed by testing the inhibitory potencies of these compounds against FGFR1, FGFR2, FGFR3, and FGFR4, respectively, followed by an analysis of the structure and activity relationship (SAR). First of all, we denoted our study of the 3,5-dimethoxyphenyl moiety as the “Ar” group because it was the previously optimal aromatic group.<a onclick="showRef(event, 'ref12 ref14 ref15 ref21 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref12 ref14 ref15 ref21 ref23 ref24">(12,14,15,21,23,24)</a> Different linkers were employed to conjugate the main core and covalent binding group, an acrylamide structure. Compounds <b>1</b> to <b>12</b> were then synthesized. Compound <b>10</b> was selected for having the most potent inhibitory effect against FGFR1, FGFR2, and FGFR3 among all the compounds (IC<sub>50</sub> was 3.21, 1.42, and 2.74 nM, respectively). Based on the discovery of the best linker, significant efforts were put into optimizing the Ar group. Unfortunately, although we prepared more than 20 compounds (compound <b>13</b> to <b>35</b>) with various aromatic groups, the 3,5-dimethoxyphenyl substitution was still the most suitable structure to fit the hydrophobic region of the FGFR proteins. Interestingly, terminal-CF<sub>3</sub> with substituted acrylamide groups provided the most potent covalent binding to FGFR proteins. Compound <b>36</b> was discovered to be the most potent compound, with the optimized combination of an alterable moiety in our design. Moreover, its IC<sub>50</sub> values against FGFR1, FGFR2, FGFR3, and FGFR4 were 0.7, 0.7, 0.9, and 809 nM, respectively.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR Study Based on the Results of Enzymatic Activity<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/medium/jm1c00174_0008.gif" alt="" id="GRAPHIC-d7e417-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/medium/jm1c00174_0009.gif" alt="" id="gr7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/medium/jm1c00174_0010.gif" alt="" id="GRAPHIC-d7e419-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are given as the means  from at least three separate experiments.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Compound <b>36</b> Suppresses the Proliferation of FGFR-Dependent Cancer Cells <i>In Vitro</i></h3><div class="NLM_p">To evaluate the efficacy and selectivity of compound <b>36</b> on the proliferation of FGFR-dependent cancer cell, cancer cell lines with high FGFR expression or low FGFR expression were selected for CCK-8 assay, and AZD-4547 and TAS-120 were used as reference. The results suggested that compound <b>36</b> strongly inhibited the cell proliferation of the NCI-H1581 (FGFR1 gene amplification) and SNU-16 (FGFR2 gene amplification) cell lines with the IC<sub>50</sub> values of 16 and 6 nM, respectively, which was nearly comparable with AZD-4547 and TAS-120. Nonetheless, compound <b>36</b> only demonstrated moderate and negligible inhibitory effects on the SK-hep-1 (FGFR4 gene amplification) and Huh-7 and NCI-H460 (non-FGFR-driven) cell lines, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). These results indicated that compound <b>36</b> acted as a potent FGFR inhibitor.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Antiproliferative Activities of Compound <b>36</b> on Selected Cancer Cell Lines<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char="±">IC<sub>50</sub>/μM</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="±">NCI-H1581 FGFR1 amplification</th><th class="colsep0 rowsep0" align="center" char="±">SNU-16 FGFR2 amplification</th><th class="colsep0 rowsep0" align="center" char="±">SK-hep-1 FGFR4 amplification</th><th class="colsep0 rowsep0" align="center">Huh-7</th><th class="colsep0 rowsep0" align="center">NCI-H460</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>AZD-4547</b></td><td class="colsep0 rowsep0" align="char" char="±">0.024 ± 0.003</td><td class="colsep0 rowsep0" align="char" char="±">0.006 ± 0.001</td><td class="colsep0 rowsep0" align="char" char="±">2.78 ± 0.069</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>TAS-120</b></td><td class="colsep0 rowsep0" align="char" char="±">0.007 ± 0.0006</td><td class="colsep0 rowsep0" align="char" char="±">0.004 ± 0.0005</td><td class="colsep0 rowsep0" align="char" char="±">0.152 ± 0.011</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="char" char="±">0.016 ± 0.003</td><td class="colsep0 rowsep0" align="char" char="±">0.006 ± 0.0008</td><td class="colsep0 rowsep0" align="char" char="±">3.05 ± 0.120</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are given as the means ± SD from at least three separate experiments.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Compound <b>36</b> Inhibits Cellular FGFR Signaling Pathways</h3><div class="NLM_p">Next, we further investigated the efficacy of compound <b>36</b> on cellular FGFR signaling in NCI-H1581 and SNU-16 tumor cell lines (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Tumor cells were treated with different concentrations of compound <b>36</b>, and then, the changes were analyzed in the phosphorylation levels of FGFR and its downstream effectors, including PLCγ, AKT1/2/3, and ERK1/2. The western blotting results revealed that in the FGFR1-amplificated NCI-H1581 cell line, compound <b>36</b> did not only significantly inhibit the phosphorylation of FGFR1 but also the downstream signaling molecules PLCγ and ERK1/2 in a dose-dependent manner and displayed only slight inhibition on the phosphorylation of AKT1/2/3. Similar results were also found in the SNU-16 cell line with FGFR2 amplification, except for the phosphorylation of AKT1/2/3. For this case, the inhibition of positive control TAS-120 on cellular FGFR signaling was also detected in the two cell lines, and the results were consistent (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00174/suppl_file/jm1c00174_si_003.pdf" class="ext-link">Figure S1</a>). Consequently, we considered that the phosphorylation of AKT1/2/3 may be mainly regulated by other signal pathways in NCI-H1581 and SNU-16 cell lines, which merit further investigation. Overall, compound <b>36</b> was shown to strongly suppress cellular FGFR and its regulated-downstream signaling pathways.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/medium/jm1c00174_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>36</b> inhibits FGFR signaling pathways. Phosphorylation of FGFRs, PLCγ, AKT1/2/3, and ERK1/2 was evaluated by western blotting in NCI-H1581 (A) and SNU-16 (B) cells treated with compound <b>36</b> for 12 h. β-Actin was used as control proteins.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00174&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Compound <b>36</b> Reacts with Target Proteins by Forming Irreversible Bonds</h3><div class="NLM_p">To determine the specific reaction residues formed by compound <b>36</b> in FGFR2, a recombinant human FGFR2 protein was incubated with and without compound <b>36</b>. Both samples were initially analyzed by liquid chromatography matrix-assisted laser desorption ionization time-of-flight. After the incubation with compound <b>36</b>, the protein’s molecule ion (35795.6016 Da) disappeared. A 547.5768 Da mass shift (36343.1784 Da) matching the molecular weight of compound <b>36</b> was observed, which indicated that a 1:1 covalent additive product was obtained quantitatively (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A,B). With these encouraging results at hand, these FGFR2 protein samples were then treated with trypsin, and the digested peptides were analyzed by LC–MS/MS (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C,D). Calculations and database retrieval identified a peptide with a mass of 3,095.5841 Da, which is 547.2671 Da larger than the C491-containing peptide DKLTLGKPLGEGCFGQVVMAEAVGIDK (calculated mass was 2548.3170 Da). The mass difference perfectly matched the molecular weight of compound <b>36</b>. Tandem mass spectrometry of this peptide revealed that this mass shift extends from the y15 to the y23 fragment ions, suggesting that compound <b>36</b> covalently reacted with the thiol group of the C491 residue. Contrastingly, the peptides incubated without the addition of compound <b>36</b> had a mass shift of 57.02146 Da, which indicated that it was modified by carbamidomethane. Using the same method, we also have proven that the compound <b>36</b> was an irreversible inhibitor, covalently targeting on cysteine of FGFR1 and FGFR3 (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00174/suppl_file/jm1c00174_si_003.pdf" class="ext-link">Figures S2 and S3</a>). Furthermore, based on these data, the binding mode of compound <b>36</b> to FGFRs is shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00174/suppl_file/jm1c00174_si_003.pdf" class="ext-link">Supporting Information</a> (Figure S4).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/medium/jm1c00174_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>36</b> covalently binds to the C491 residue of FGFR2. (A,B) MS spectrums of recombinant human FGFR2 without or with incubation of compound <b>36</b>, respectively. (C,D) MS/MS analysis of recombinant human FGFR2 without or with incubation of compound <b>36</b>, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00174&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Kinase Selectivity Test of Compound <b>36</b><i>In Vitro</i></h3><div class="NLM_p">An activity assay of compound <b>36</b> against a panel of 48 kinases was conducted to evaluate the kinase selectivity (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The assay pointed out that compound <b>36</b> exhibited a strong inhibitory activity against SRC kinase, with inhibitory rates of 83% at 1000 nM. Kinases DDR2, EIF2AK2, ITK, LCK PDGFRα, and RET were suppressed moderately (inhibitory rate >20%). This lead compound demonstrated negligible effects against the remaining selected kinases. These data indicated that our lead compound <b>36</b> might be a potent and selective FGFR<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> kinase inhibitor.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Inhibitory Effects of Compound <b>36</b> against Various Kinases<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">inhibition % at 1000 nM</th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">inhibition % at 1000 nM</th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">inhibition % at 1000 nM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ABL1</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left">NIK</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">EIF2AK2</td><td class="colsep0 rowsep0" align="char" char=".">27</td><td class="colsep0 rowsep0" align="left">NEK2</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AKT3</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="left">FAK</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="left">NEK3</td><td class="colsep0 rowsep0" align="char" char=".">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ASK1</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">FYNA</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">PAK3</td><td class="colsep0 rowsep0" align="char" char=".">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AURORA</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">FLT3</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">PKA</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AXL</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">GSK3 alpha</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">PDGFRa</td><td class="colsep0 rowsep0" align="char" char=".">42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BTK</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">GSK3 beta</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">PIM1</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BRAF</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left">HER2</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">P38alpha</td><td class="colsep0 rowsep0" align="char" char=".">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CAMK2 alpha</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">ITK</td><td class="colsep0 rowsep0" align="char" char=".">35</td><td class="colsep0 rowsep0" align="left">RET</td><td class="colsep0 rowsep0" align="char" char=".">24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK4</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">IRAK4</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">ROCK1</td><td class="colsep0 rowsep0" align="char" char=".">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CK2alpha1</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">JNK1</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left">RON</td><td class="colsep0 rowsep0" align="char" char=".">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CHK1</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left">JAK3</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="left">SRC</td><td class="colsep0 rowsep0" align="char" char=".">83</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLK1</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">LCK</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="left">TBK1</td><td class="colsep0 rowsep0" align="char" char=".">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-MER</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="left">MET</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">TGFbR1</td><td class="colsep0 rowsep0" align="char" char=".">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CSK</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">MAPK1</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="left">TAOK1</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DDR2</td><td class="colsep0 rowsep0" align="char" char=".">21</td><td class="colsep0 rowsep0" align="left">MELK</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">VEGFR2</td><td class="colsep0 rowsep0" align="char" char=".">7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Three duplicate wells were set for each kinase, and the data were shown as the means.</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Preliminary Pharmacokinetic Study of Compound <b>36</b> in Rats</h3><div class="NLM_p">The preliminary pharmacokinetic (PK) studies were carried out in Sprague-Dawley rats. The plasma concentration–time curves for compound <b>36</b> after a single dose in these rats are illustrated in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>. The PK parameters of compound <b>36</b> determined by a non-compartmental model are delineated in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. Adequate PK properties (calculated by WinNonlin) of compound <b>36</b> have been shown with an acceptable oral administration rate and a rapid clearance from the plasma.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/medium/jm1c00174_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Plasma concentration–time curves for compound <b>36</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00174&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. PK Parameters of Compound <b>36</b> in Rats</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PK parameters</th><th class="colsep0 rowsep0" align="center">PO administration of <b>36</b> (5 mg/Kg)</th><th class="colsep0 rowsep0" align="center">IV administration of <b>36</b> (5 mg/Kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>0</sub> (ng/L)</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">519</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/L)</td><td class="colsep0 rowsep0" align="left">185</td><td class="colsep0 rowsep0" align="left">399</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.28</td><td class="colsep0 rowsep0" align="left">0.36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.139</td><td class="colsep0 rowsep0" align="left">0.083</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">clearance (L/h)</td><td class="colsep0 rowsep0" align="left">16826</td><td class="colsep0 rowsep0" align="left">3698</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L)</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">4668</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT</td><td class="colsep0 rowsep0" align="left">0.3180</td><td class="colsep0 rowsep0" align="left">1.009</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (ng h/L)</td><td class="colsep0 rowsep0" align="left">76.8</td><td class="colsep0 rowsep0" align="left">309</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> %</td><td class="colsep0 rowsep0" align="left">24.9%</td><td class="colsep0 rowsep0" align="left">NA</td></tr></tbody></table></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Preliminary hERG-Binding Test of Compound <b>36</b><i>In Vitro</i></h3><div class="NLM_p">To evaluate the possible cardiotoxicity of compound <b>36</b>, its potency for binding the hERG channel was tested. Cisplatin was used as reference (see <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Cisplatin demonstrated a strong binding affinity with the hERG channel, indicating that it might had severe heart toxicity. Compound <b>36</b> was elicited a significantly lower hERG potency with IC<sub>50</sub> = 3211 nM, implying that it carries a very low risk of cardiotoxicity.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. hERG-Binding Test of Compound <b>36</b><i>In Vitro</i><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center" char="±">hERG/IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="char" char="±">3211 ± 42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cisplatin</td><td class="colsep0 rowsep0" align="char" char="±">298 ± 24</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are given as the means ± SD from at least three separate experiments.</p></div></div></div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Preliminary Toxicity Evaluation of Compound <b>36</b> in a Mice Model</h3><div class="NLM_p last">In a preliminary toxicological study, C57/BL6 mice were treated with compound <b>36</b>. For this purpose, animals were orally administered this compound for 7 days (500 mg/kg/day, <i>n</i> = 5). All the mice treated with compound <b>36</b> were well tolerated. These results suggest that compound <b>36</b> is safe for further investigation <i>in vivo</i>.</div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Compound <b>36</b> Considerably Suppresses Tumor Growth <i>In Vivo</i></h3><div class="NLM_p">Finally, we assess the antitumor efficacy of compound <b>36</b> in two xenograft models, bearing NCI-H1581 and SNU-16 tumor cells, respectively. Compound <b>36</b> was orally administrated once daily at doses of 50 and 100 mg/kg for 26 or 40 consecutive days. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, in the NCI-H1581 xenograft model, compound <b>36</b> significantly inhibited tumor growth at a dose of 50 mg/kg (TGI = 69.54%) or 100 mg/kg (TGI = 88.86%). Similar results were also found in the SUN-16 xenograft model, in which the tumor growth inhibition was 67.93 or 89.40% for dosing 50 or 100 mg/kg, respectively. Furthermore, the absence of any significant body weight loss indicated that all the doses of compound <b>36</b> were well tolerated <i>in vivo</i>. The above results indicated that compound <b>36</b> effectively suppressed tumor growth with good tolerance <i>in vivo</i>.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/medium/jm1c00174_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>36</b> suppresses tumor growth in xenograft mouse models. In the NCI-H1581 or SNU-16 xenograft model treated with compound <b>36</b> for indicated concentrations (<i>n</i> = 6), tumor volume (A,D) and body weight (C,F) changes during the treatment and (B,E) weights of tumor tissues from the three groups on the terminated days. Data are presented as means ± SEM; ****<i>P</i> < 0.0001, Student’s <i>t</i>-test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00174&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Chemical Synthesis of Compound <b>36</b></h3><div class="NLM_p">The preparation of compound <b>36</b> is described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The synthesis used the commercially available bromide compound <b>41</b> as starting material. Alcohol <b>42</b> was coupled with a 2<i>H</i>-pyrazolo[3,4-d]pyrimidine core to furnish an intermediate <b>43</b> bearing an unusual phosphoranylidene structure under Mitsunobu conditions. Subsequently, Suzuki coupling with boronic acid <b>44</b> provided compound <b>45</b> in high chemical yield. Next, the Boc protecting group was removed in the presence of trifluoroacetic acid (TFA). The resulting free amine was sequentially reacted with CF<sub>3</sub>-substituted acryl chloride <b>46</b> to yield compound <b>47</b>. Triphenylphosphoranylidene was finally hydrolyzed under optimized conditions to obtain the required molecule <b>36</b> in 20% overall yield.</div><figure id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/medium/jm1c00174_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound <b>36</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00174&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56118" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56118" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we discovered and optimized a novel 2<i>H</i>-pyrazolo[3,4-d]pyrimidine derivative known as compound <b>36</b>, which is a potent and selective inhibitor against FGFR1, FGFR2, and FGFR3. The irreversible binding effect of compound <b>36</b> to target proteins was characterized by LC–MS/MS. This lead compound could not only suppress cellular FGFR signaling pathways at low concentrations but also elicit significant anti-proliferation effects against NCI-H1581 and SNU-16 cancer cell lines both <i>in vitro</i> and <i>in vivo</i>. Additionally, compound <b>36</b> demonstrated a low toxicity and adequate PK properties, and is currently under validation as a potential drug candidate against FGFR-dependent tumors.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52778" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52778" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General</h3><div class="NLM_p">All reagents and solvents were purchased from Shanghai Bide Pharmatech Ltd. Co., unless otherwise specified, and used without further purification. Flash column chromatography employed silica gel (100–200 mesh). All compounds were demonstrated to be homogeneous by analytical TLC on precoated silica gel TLC plates (purchased from Qingdao Haiyang Chemical Ltd. Co. 60 F245 on glass, layer thickness 250 μm), and chromatograms were visualized by phosphomolybdic acid staining. Melting points were determined on a micromelting point apparatus. NMR spectra were recorded in CDCl<sub>3</sub>, unless otherwise stated, on Bruker 400 (<sup>1</sup> H at 400 MHz and <sup>13</sup>C at 100 MHz) NMR spectrometers, and chemical shifts are reported in units of δ relative to internal tetramethylsilane. Multiplicities are indicated as br (broadened), s (singlet), d (doublet), t (triplet), q (quartet), and m (multiplet), and coupling constants (<i>J</i>) are reported in hertz (Hz). Low- and high-resolution mass spectra were performed in The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University. Mass spectral data are reported in the form of <i>m</i>/<i>z</i> (intensity relative to base = 100). Purities of the tested compounds were determined by HPLC analysis using Agela Technologies HPLC with an Agela Technologies MP C18 column (5 μm, 4.6 mm × 50 mm column and methanol/water) and were >95%. Animals were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Synthesis of the Compounds <b>36</b></h4><div id="sec4_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> <i>tert</i>-Butyl-4-(5-(3-bromo-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazine-1-carboxylate (<b>43</b>)</h5><div class="NLM_p last">To a solution of compound <b>41</b> (0.50 g, 2.3 mmol), PPh<sub>3</sub> (2.1 g, 7.9 mmol), and compound <b>42</b> (0.96 g, 3.4 mmol) in THF (23 mL) was treated with diisopropyl azodicarboxylate (1.6 g, 7.9 mmol) at −20 °C dropwise. After stirring at −20 °C for 4 h under a nitrogen atmosphere, the resulting mixture was concentrated <i>in vacuo</i> to afford a crude which was purified by flash column chromatography on silica gel (PE/EA = 3:1) to obtain <b>43</b> (1.2 g, 65%) as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.05 (s, 1H), 7.92 (dd, <i>J</i> = 12.3, 7.6 Hz, 6H), 7.56 (t, <i>J</i> = 7.0 Hz, 3H), 7.47 (t, <i>J</i> = 6.5 Hz, 6H), 4.28 (t, <i>J</i> = 7.0 Hz, 2H), 3.41 (s, 4H), 2.30 (dd, <i>J</i> = 17.9, 10.3 Hz, 6H), 1.88 (dd, <i>J</i> = 14.5, 7.1 Hz, 2H), 1.53–1.43 (m, 11H), 1.32 (d, <i>J</i> = 7.4 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.1, 163.0, 155.8, 155.8, 155.7, 154.7, 154.2, 154.1, 153.5, 153.5, 133.3, 132.2, 132.2, 128.9, 128.6, 128.6, 128.5, 120.2, 107.1, 107.1, 100.0, 79.6, 70.6, 58.4, 58.4, 52.9, 52.8, 47.1, 47.1, 29.7, 29.6, 28.4, 26.2, 24.5, 24.5, 22.7, 21.7. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>37</sub>H<sub>43</sub>BrN<sub>7</sub>NaO<sub>2</sub>P<sup>+</sup>, 750.2291; found, 750.2293.</div></div><div id="sec4_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> <i>tert</i>-Butyl-4-(5-(3-(3,5-dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazine-1-carboxylate (<b>45</b>)</h5><div class="NLM_p last">To a solution of compound <b>43</b> (1.2 g, 1.5 mmol), K<sub>2</sub>CO<sub>3</sub> (0.41 g, 3.0 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (0.17 g, 0.15 mmol) in a mixture of 1,4-dioxane and H<sub>2</sub>O (4 mL, 3:1) was added compound <b>44</b> (0.35 g, 1.9 mmol) in 1,4-dioxane at room temperature. After stirring at 80 °C for 8 h under a nitrogen atmosphere, the mixture was diluted with EtOAc (5 mL), washed with saturated NaCl solution (15 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH = 35:1) to afford compound <b>45</b> (0.83 g, 68%) as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.06 (s, 1H), 7.93–7.78 (m, 6H), 7.55–7.50 (m, 3H), 7.48 (s, 2H), 7.41 (t, <i>J</i> = 6.5 Hz, 6H), 6.56 (s, 1H), 4.37 (t, <i>J</i> = 7.1 Hz, 2H), 3.75 (s, 6H), 3.41 (s, 4H), 2.37–2.29 (m, 6H), 1.98–1.88 (m, 2H), 1.56–1.50 (m, 2H), 1.44 (s, 9H), 1.39–1.33 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.9, 163.9, 155.7, 154.8, 154.8, 154.7, 154.7, 154.5, 145.6, 135.8, 133.4, 133.3, 132.2, 131.9, 131.9, 129.3, 128.9, 128.6, 128.5, 128.4, 128.3, 127.9, 120.1, 107.9, 107.6, 107.4, 107.2, 105.7, 105.4, 100.5, 79.6, 58.5, 58.4, 52.9, 47.0, 46.8, 43.8, 42.9, 29.7, 29.6, 28.4, 28.2, 26.3, 24.6, 24.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>45</sub>H<sub>52</sub>N<sub>7</sub>NaO<sub>4</sub>P<sup>+</sup>, 808.3711; found, 808.3713.</div></div><div id="sec4_1_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> (<i>E</i>)-1-(4-(5-(3-(3,5-Dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)-4,4,4-trifluorobut-2-en-1-one (<b>47</b>)</h5><div class="NLM_p last">To a solution of compound <b>45</b> (0.83 g, 1.1 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) was added TFA (1.5 mL) at room temperature. After stirring for 30 min, the resulting mixture was concentrated <i>in vacuo</i> to afford a crude product. The resulting crude compound was then mixed with TEA (0.31 mL, 2.2 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) and added to <b>46</b> (0.21 g, 1.3 mmol) at 0 °C. After stirring at room temperature for 1 h, the mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (10 mL), washed with saturated NaCl solution (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH = 20:1) to afford compound <b>47</b> (0.53 g, 59%) as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.00 (s, 1H), 7.74 (ddt, <i>J</i> = 12.2, 7.0, 1.4 Hz, 6H), 7.50–7.43 (m, 3H), 7.41 (d, <i>J</i> = 2.3 Hz, 2H), 7.35 (td, <i>J</i> = 7.7, 3.0 Hz, 6H), 6.86 (dq, <i>J</i> = 15.3, 2.0 Hz, 1H), 6.63 (dq, <i>J</i> = 15.4, 6.6 Hz, 1H), 6.50 (t, <i>J</i> = 2.3 Hz, 1H), 4.32 (t, <i>J</i> = 7.2 Hz, 2H), 3.69 (s, 6H), 3.60 (d, <i>J</i> = 5.5 Hz, 2H), 3.42 (s, 2H), 2.39–2.22 (m, 6H), 1.89 (t, <i>J</i> = 7.6 Hz, 2H), 1.51–1.42 (m, 2H), 1.30 (t, <i>J</i> = 7.2 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 162.8, 160.9, 159.2, 159.2, 154.1, 153.8, 153.5, 144.6, 134.7, 132.4, 132.4, 132.4, 132.4, 132.3, 132.3, 130.9, 130.9, 130.9, 128.4, 128.19, 128.1, 127.4, 127.4, 127.4, 127.3, 127.3, 127.3, 127.2, 126.8, 126.7, 120.1, 106.9, 106.9, 99.3, 57.0, 54.2, 52.2, 51.5, 45.7, 44.9, 41.2, 28.6, 25.2, 23.4. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>44</sub>H<sub>45</sub>F<sub>3</sub>N<sub>7</sub>NaO<sub>3</sub>P<sup>+</sup>, 830.3166; found, 830.3168.</div></div><div id="sec4_1_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> (<i>E</i>)-1-(4-(5-(4-Amino-3-(3,5-dimethoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)-4,4,4-trifluorobut-2-en-1-one (<b>36</b>)</h5><div class="NLM_p">To a solution of compound <b>47</b> (0.53 g, 0.68 mmol) in THF (1 mL) was added AcOH/THF/H<sub>2</sub>O (12 mL, 3:1:2) at room temperature. After stirring for 18 h, the mixture was neutralized by saturated NaHCO<sub>3</sub> to pH = 7. The mixture was extracted with EtOAc (3*30 mL), and the combined organic phases were dried and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH = 15:1) to afford compound <b>36</b> (0.25 g, 70%) as a white solid. mp 261–263 °C; IR (KBr): 3401, 3200, 2975, 2843, 1590, 1245, 1140, 975 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.32 (s, 1H), 6.92 (dt, <i>J</i> = 15.4, 2.1 Hz, 1H), 6.78 (d, <i>J</i> = 2.3 Hz, 2H), 6.73–6.64 (m, 1H), 6.52 (t, <i>J</i> = 2.3 Hz, 1H), 4.40 (t, <i>J</i> = 7.2 Hz, 2H), 3.82 (s, 6H), 3.65 (t, <i>J</i> = 5.2 Hz, 2H), 3.50 (t, <i>J</i> = 5.0 Hz, 2H), 2.40 (q, <i>J</i> = 4.7 Hz, 4H), 2.32 (t, <i>J</i> = 7.5 Hz, 2H), 1.96 (p, <i>J</i> = 7.4 Hz, 2H), 1.52 (q, <i>J</i> = 7.6 Hz, 2H), 1.36 (q, <i>J</i> = 8.2 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 162.3, 161.8, 158.1, 155.8, 154.3, 144.4, 135.3, 129.7, 129.4, 128.0, 127.9, 121.4, 106.6, 101.3, 98.5, 58.3, 55.8, 53.5, 52.7, 47.3, 46.2, 42.5, 29.9, 29.8, 26.4, 24.7. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>): δ −65.0. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>26</sub>H<sub>32</sub>F<sub>3</sub>N<sub>7</sub>NaO<sub>3</sub><sup>+</sup>, 570.2411; found, 570.2413. HPLC purity: 99.1%.</div><div class="NLM_p last">The synthesis of the compounds <b>1a–9a</b>, <b>11a–17a</b>, <b>23a–27a</b>, <b>34a–35a</b>, <b>1b–9b</b>, <b>11b–17b</b>, <b>23b–27b</b>, <b>34b–35b</b>, <b>1c–3c</b>, <b>5c–12c</b>, <b>1–40</b>, <b>43</b>, <b>45</b>, <b>47</b>.</div></div><div id="sec4_1_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> <i>tert</i>-Butyl-3-((3-bromo-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)azetidine-1-carboxylate (<b>1a</b>)</h5><div class="NLM_p last">To a solution of compound <b>41</b> (0.50 g, 2.3 mmol), PPh<sub>3</sub> (2.1 g, 7.9 mmol), and 1-Boc-azetidine-3-ylMethanol (0.60 g, 3.5 mmol) in THF (23 mL) was added diisopropyl azodicarboxylate (1.6 g, 7.9 mmol) at −20 °C. After stirring at −20 °C for 4 h under a nitrogen atmosphere, the resulting mixture was concentrated in vacuo to afford a crude which was purified by flash column chromatography on silica gel (PE/EA = 5:1) to obtain <b>1a</b> (0.15 g, 61%) as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.96–7.87 (m, 6H), 7.64–7.45 (m, 9H), 4.48 (d, <i>J</i> = 7.3 Hz, 2H), 3.97 (t, <i>J</i> = 8.5 Hz, 2H), 3.88–3.74 (m, 2H), 3.19–2.98 (m, 1H), 1.41 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.1, 163.1, 156.2, 155.9, 154.6, 154.5, 133.4, 133.4, 133.3, 133.2, 132.4, 132.3, 132.3, 128.8, 128.7, 128.7, 128.6, 128.6, 128.5, 128.4, 127.8, 127.4, 120.9, 107.1, 79.3, 53.0, 51.5, 49.7, 28.8, 28.4, 21.8, 14.2. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>32</sub>H<sub>32</sub>BrN<sub>6</sub>NaO<sub>2</sub>P<sup>+</sup>, 665.1400; found, 665.1402.</div></div><div id="sec4_1_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> <i>tert</i>-Butyl-3-((3-bromo-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carboxylate (<b>2a</b>)</h5><div class="NLM_p last">The titled compound <b>2a</b> was obtained following the procedure described for <b>1a</b> using 1-Boc-3-hydroxymethylpyrrolidine (0.69 g, 3.4 mmol). Flash column chromatography (PE/EA = 8:1). 0.98 g, 65%, as a white liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.05 (d, <i>J</i> = 3.7 Hz, 1H), 7.96–7.89 (m, 6H), 7.57 (td, <i>J</i> = 7.4, 1.8 Hz, 3H), 7.48 (td, <i>J</i> = 7.7, 2.9 Hz, 6H), 4.30 (d, <i>J</i> = 7.4 Hz, 2H), 4.12 (q, <i>J</i> = 7.1 Hz, 1H), 3.45 (dq, <i>J</i> = 17.0, 10.4, 8.4 Hz, 2H), 3.29 (dq, <i>J</i> = 11.7, 5.7, 3.7 Hz, 1H), 3.13 (td, <i>J</i> = 11.7, 7.1 Hz, 1H), 2.86 (p, <i>J</i> = 7.3 Hz, 1H), 1.91 (dd, <i>J</i> = 13.1, 6.6 Hz, 1H), 1.6–1.61 (m, 1H), 1.43 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.9, 163.8, 160.2, 155.2, 155.2, 154.6, 154.5, 146.0, 135.6, 133.4, 133.1, 132.0, 132.0, 129.2, 128.5, 128.4, 128.3, 128.2, 107.9, 105.7, 105.4, 100.6, 79.1, 55.3, 49.5, 49.1, 48.8, 48.7, 45.0, 39.4, 38.6, 29.3, 28.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>33</sub>H<sub>34</sub>BrN<sub>6</sub>NaO<sub>2</sub>P<sup>+</sup>, 679.1556; found, 679.1558.</div></div><div id="sec4_1_1_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> <i>tert</i>-Butyl-4-(3-bromo-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate (<b>3a</b>)</h5><div class="NLM_p last">The titled compound <b>3a</b> was obtained following the procedure described for <b>1a</b> using <i>N</i>-Boc-4-Hydroxypiperidine (0.69 g, 3.4 mmol). Flash column chromatography (PE/EA = 8:1). 0.91 g, 61%, as a white liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.05 (s, 1H), 7.96–7.89 (m, 6H), 7.56 (td, <i>J</i> = 7.3, 1.6 Hz, 3H), 7.47 (td, <i>J</i> = 7.6, 3.0 Hz, 6H), 4.77 (tt, <i>J</i> = 11.7, 4.1 Hz, 1H), 4.37–4.09 (m, 2H), 3.01–2.72 (m, 2H), 2.19 (dt, <i>J</i> = 12.5, 6.3 Hz, 2H), 1.91 (d, <i>J</i> = 12.8 Hz, 2H), 1.47 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.1, 163.1, 156.0, 155.9, 133.4,133.4, 133.3, 133.3, 132.3, 132.3, 132.2, 132.2, 128.9, 128.7, 128.6, 128.6, 128.5, 128.5, 127.9, 127.7, 121.9, 84.8, 68.9, 60.3, 30.3, 30.1, 29.2, 28.4, 25.3, 22.5, 22.2, 22.1, 21.7. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>33</sub>H<sub>34</sub>BrN<sub>6</sub>NaO<sub>2</sub>P<sup>+</sup>, 679.1556; found, 679.1558.</div></div><div id="sec4_1_1_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> <i>tert</i>-Butyl-4-((3-bromo-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate (<b>4a</b>)</h5><div class="NLM_p last">The titled compound <b>4a</b> was obtained following the procedure described for <b>1a</b> using <i>N</i>-Boc-4-piperidinemethanol (0.48 g, 3.4 mmol). Flash column chromatography (PE/EA = 10:1). 0.97 g, 64%, as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.07–8.02 (m, 1H), 7.91 (h, <i>J</i> = 6.8 Hz, 6H), 7.66–7.38 (m, 9H), 4.17 (q, <i>J</i> = 6.7 Hz, 2H), 3.88 (d, <i>J</i> = 12.5 Hz, 2H), 2.88–2.62 (m, 2H), 2.20 (s, 1H), 1.66 (q, <i>J</i> = 12.2, 11.3 Hz, 2H), 1.24 (q, <i>J</i> = 5.7 Hz, 11H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.1, 163.0, 155.8, 154.7, 154.6, 133.4, 133.3, 132.2, 132.2, 132.0, 128.9, 128.6, 128.6, 128.5,128.5, 127.9, 127.9, 127.9, 120.6, 107.3, 107.0, 79.3, 69.9, 60.4, 49.8, 38.7, 36.5, 34.1, 29.7, 28.4, 28.4, 28.2, 24.3, 22.9. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>34</sub>H<sub>36</sub>BrN<sub>6</sub>NaO<sub>2</sub>P<sup>+</sup>, 693.1713; found, 693.1715.</div></div><div id="sec4_1_1_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> <i>tert</i>-Butyl-4-(2-(3-bromo-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)piperidine-1-carboxylate (<b>5a</b>)</h5><div class="NLM_p last">The titled compound <b>5a</b> was obtained following the procedure described for <b>1a</b> using <i>N</i>-Boc-4-(2-hydroxyethyl)piperidine (0.78 g, 3.4 mmol). Flash column chromatography (PE/EA = 5:1). 0.55 g, 71%, as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.04 (d, <i>J</i> = 4.1 Hz, 1H), 7.92 (dd, <i>J</i> = 12.4, 7.5 Hz, 6H), 7.60–7.55 (m, 3H), 7.49 (dd, <i>J</i> = 7.9, 3.0 Hz, 6H), 4.30 (d, <i>J</i> = 7.3 Hz, 2H), 3.46 (t, <i>J</i> = 9.1 Hz, 2H), 3.36–3.17 (m, 2H), 3.17–2.99 (m, 2H), 2.88–2.82 (m, 1H), 1.90 (d, <i>J</i> = 9.4 Hz, 2H), 1.64 (d, <i>J</i> = 8.7 Hz, 2H), 1.43 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 161.5, 157.7, 155.9, 154.6, 154.6, 144.2, 139.2, 134.9, 134.9, 133.1, 133.1, 107.5, 106.4, 106.4, 106.1, 101.9, 101.1, 101.1, 98.2, 98.2, 97.8, 97.2, 95.2, 79.4, 55.6, 52.3, 50.9, 50.9, 43.6, 43.0, 36.8, 29.7, 28.4, 23.1, 22.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>35</sub>H<sub>38</sub>BrN<sub>6</sub>NaO<sub>2</sub>P<sup>+</sup>, 707.1869; found, 707.1871.</div></div><div id="sec4_1_1_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> <i>tert</i>-Butyl-3-((3-bromo-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate (<b>6a</b>)</h5><div class="NLM_p last">The titled compound <b>6a</b> was obtained following the procedure described for <b>1a</b> using <i>N</i>-Boc-piperidine-3-methanol (0.73 g, 3.4 mmol). Flash column chromatography (PE/EA = 3:1). 1.1 g, 74%, as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.05 (s, 1H), 8.01–7.82 (m, 6H), 7.56 (td, <i>J</i> = 7.3, 1.6 Hz, 3H), 7.47 (td, <i>J</i> = 7.6, 3.1 Hz, 6H), 4.22–4.11 (m, 2H), 3.88 (d, <i>J</i> = 13.6 Hz, 2H), 2.77 (ddd, <i>J</i> = 13.6, 11.2, 2.8 Hz, 1H), 2.67 (s, 1H), 2.22 (s, 1H), 1.68 (td, <i>J</i> = 14.5, 4.1 Hz, 2H), 1.38 (s, <i>J</i> = 64.0 Hz, 9H), 1.30–1.23 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.1, 163.0, 155.8, 154.7, 154.6, 133.4, 133.4, 133.4, 133.34, 133.3, 133.3, 132.2, 132.2, 132.1, 128.9, 128.6, 128.5, 128.5, 128.5, 127.9, 120.6, 107.3, 107.0, 79.3, 60.4, 49.8, 36.5, 28.5, 28.4, 28.2, 24.3, 23.0, 22.7, 22.0. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>34</sub>H<sub>36</sub>BrN<sub>6</sub>NaO<sub>2</sub>P<sup>+</sup>, 693.1713; found, 693.1715.</div></div><div id="sec4_1_1_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> <i>tert</i>-Butyl-4-(2-(3-bromo-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)piperazine-1-carboxylate (<b>7a</b>)</h5><div class="NLM_p last">The titled compound <b>7a</b> was obtained following the procedure described for <b>1a</b> using <i>N</i>-Boc-4-(2-hydroxyethyl)piperazine (0.78 g, 3.4 mmol). Flash column chromatography (PE/EA = 5:1). 0.68 mg, 69%, as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.05 (s, 1H), 7.92 (dd, <i>J</i> = 12.4, 7.7 Hz, 6H), 7.58–7.42 (m, 9H), 4.42 (t, <i>J</i> = 6.9 Hz, 2H), 3.35 (t, <i>J</i> = 5.0 Hz, 4H), 2.87 (t, <i>J</i> = 6.9 Hz, 2H), 2.46 (s, 4H), 1.44 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.1, 155.7, 154.7, 154.5, 154.5, 133.4, 133.4, 133.4, 133.3, 133.3, 133.3, 132.3, 132.2, 132.2, 132.1, 132.1, 128.8, 128.6, 128.6, 128.5, 128.5, 127.8, 120.5, 107.4, 107.2, 79.5, 56.9, 52.8, 51.9, 50.5, 44.5, 44.0, 43.1, 28.4. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>34</sub>H<sub>37</sub>BrN<sub>7</sub>NaO<sub>2</sub>P<sup>+</sup>, 708.1822; found, 708.1824.</div></div><div id="sec4_1_1_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> <i>tert</i>-Butyl-4-(3-(3-bromo-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)piperazine-1-carboxylate (<b>8a</b>)</h5><div class="NLM_p last">The titled compound <b>8a</b> was obtained following the procedure described for <b>1a</b> using <i>tert</i>-butyl-4-(3-hydroxypropyl)piperazine-1-carboxylate (0.83 g, 3.4 mmol). Flash column chromatography (PE/EA = 5:1). 1.1 g, 68%, as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.06 (s, 1H), 7.96–7.90 (m, 6H), 7.55 (td, <i>J</i> = 6.4, 5.7, 1.6 Hz, 3H), 7.46 (ddt, <i>J</i> = 6.7, 5.3, 2.2 Hz, 6H), 4.36 (t, <i>J</i> = 6.9 Hz, 2H), 3.35 (t, <i>J</i> = 5.0 Hz, 4H), 2.38 (s, 2H), 2.31 (d, <i>J</i> = 5.1 Hz, 4H), 2.07 (t, <i>J</i> = 7.0 Hz, 2H), 1.44 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.0, 163.0, 155.7, 154.7, 154.4, 154.3, 133.4, 133.3, 133.3, 132.2, 132.2, 132.1, 132.0, 128.9, 128.6, 128.5, 128.4, 127.9, 120.1, 107.4, 107.2, 79.6, 79.4, 56.2, 55.6, 55.5, 53.5, 52.9, 52.9, 45.5, 28.4, 27.1, 26.7, 22.1, 22.0. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>35</sub>H<sub>39</sub>BrN<sub>7</sub>NaO<sub>2</sub>P<sup>+</sup>, 722.1978; found, 722.1980.</div></div><div id="sec4_1_1_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> <i>tert</i>-Butyl4-(4-(3-bromo-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)piperazine-1-carboxylate (<b>9a</b>)</h5><div class="NLM_p last">The titled compound <b>9a</b> was obtained following the procedure described for <b>1a</b> using <i>tert</i>-Butyl-4-(4-hydroxyButyl)piperazine-1-carboxylate (0.88 g, 3.4 mmol). Flash column chromatography (PE/EA = 3:1). 1.1 g, 71%, as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.05 (d, <i>J</i> = 4.0 Hz, 1H), 7.98–7.86 (m, 6H), 7.60–7.46 (m, 9H), 4.31 (d, <i>J</i> = 5.8 Hz, 2H), 3.48–3.35 (m, 4H), 2.44–2.28 (m, 6H), 1.91 (s, 2H), 1.45 (d, <i>J</i> = 4.1 Hz, 9H), 1.25 (s, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 158.0, 155.7, 154.9, 154.1, 154.1, 153.3, 145.7, 145.7, 136.1, 136.1, 128.5, 125.6, 125.6, 124.7, 122.4, 122.4, 120.9, 120.9, 112.1, 112.1, 103.1, 103.1, 98.5, 98.5, 84.9, 79.3, 50.8, 50.4, 44.7, 43.6, 36.1, 33.5, 31.8, 29.7, 28.5, 25.4. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>36</sub>H<sub>41</sub>BrN<sub>7</sub>NaO<sub>2</sub>P<sup>+</sup>, 736.2135; found, 736.2137.</div></div><div id="sec4_1_1_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> <i>tert</i>-Butyl-4-(6-(3-bromo-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)hexyl)piperazine-1-carboxylate (<b>11a</b>)</h5><div class="NLM_p last">The titled compound <b>11a</b> was obtained following the procedure described for <b>1a</b> using <i>tert</i>-butyl 4-(6-hydroxyhexyl)piperazine-1-carboxylate (0.97 g, 3.4 mmol). Flash column chromatography (PE/EA = 4:1). 1.0 g, 61%, as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.06 (d, <i>J</i> = 2.1 Hz, 1H), 7.97–7.90 (m, 6H), 7.57 (t, <i>J</i> = 7.5 Hz, 3H), 7.48 (t, <i>J</i> = 7.6 Hz, 6H), 4.31–4.25 (m, 2H), 3.42 (t, <i>J</i> = 5.1 Hz, 4H), 2.34 (t, <i>J</i> = 4.9 Hz, 4H), 2.31–2.26 (m, 2H), 1.88 (p, <i>J</i> = 6.6 Hz, 2H), 1.46 (d, <i>J</i> = 2.1 Hz, 11H), 1.35–1.30 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 164.1, 160.2, 155.7, 154.5, 151.6, 135.8, 133.5, 133.4, 133.3, 132.0, 131.9, 131.9, 130.5, 129.2, 128.5, 128.5, 128.4, 128.4, 128.2, 127.5, 107.9, 107.9, 100.4, 100.4, 79.2, 79.2, 58.1, 55.3, 53.2, 52.4, 46.8, 46.8, 41.4, 37.7, 29.6, 26.3, 24.5, 22.7. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>38</sub>H<sub>45</sub>BrN<sub>7</sub>NaO<sub>2</sub>P<sup>+</sup>, 764.2448; found, 764.2450.</div></div><div id="sec4_1_1_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> <i>tert</i>-Butyl-4-(7-(3-bromo-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)heptyl)piperazine-1-carboxylate (<b>12a</b>)</h5><div class="NLM_p last">The titled compound <b>12a</b> was obtained following the procedure described for <b>1a</b> using <i>tert</i>-Butyl-4-(7-hydroxyheptyl)piperazine-1-carboxylate (1.0 g, 3.4 mmol). Flash column chromatography (PE/EA = 6:1). 1.1 g, 61%, as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.06 (s, 1H), 7.97–7.90 (m, 6H), 7.56 (dd, <i>J</i> = 8.1, 6.3 Hz, 3H), 7.47 (dt, <i>J</i> = 7.6, 3.8 Hz, 6H), 4.28 (t, <i>J</i> = 7.2 Hz, 2H), 3.42 (t, <i>J</i> = 4.9 Hz, 4H), 2.35 (t, <i>J</i> = 5.0 Hz, 4H), 2.32–2.26 (m, 2H), 1.88 (t, <i>J</i> = 7.1 Hz, 2H), 1.44 (s, 11H), 1.32 (dd, <i>J</i> = 7.3, 3.2 Hz, 4H), 1.26 (d, <i>J</i> = 7.1 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.1, 163.0, 155.7, 154.8, 154.2, 154.1, 133.4, 133.3, 132.2, 132.2, 132.0, 131.9, 129.0, 128.6, 128.6, 128.5, 128.5, 127.9, 120.1, 120.1, 107.4, 107.1, 79.5, 79.5, 60.4, 60.4, 58.7, 53.0, 53.0, 47.2, 47.20, 43.2, 29.6, 29.1, 28.5, 27.3, 26.7, 26.5, 21.1. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>39</sub>H<sub>47</sub>BrN<sub>7</sub>NaO<sub>2</sub>P<sup>+</sup>, 778.2604; found, 778.2606.</div></div><div id="sec4_1_1_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> <i>tert</i>-Butyl-4-(5-(3-(benzo[<i>d</i>][1,3]dioxol-5-yl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazine-1-carboxylate (<b>13a</b>)</h5><div class="NLM_p last">The titled compound <b>13a</b> was obtained following the procedure described for <b>1b</b> using 3,4-(methylenedioxy)phenylboronic acid (0.15 g, 0.89 mmol). Flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 50:1). 0.36 g, 64%, as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.06–8.05 (m, 1H), 7.99 (dd, <i>J</i> = 8.1, 1.7 Hz, 1H), 7.95–7.90 (m, 1H), 7.89–7.77 (m, 6H), 7.54 (ddt, <i>J</i> = 7.3, 5.3, 1.6 Hz, 3H), 7.49–7.43 (m, 6H), 6.05 (s, 2H), 4.36 (t, <i>J</i> = 7.2 Hz, 2H), 3.40 (t, <i>J</i> = 5.1 Hz, 4H), 2.33 (d, <i>J</i> = 7.1 Hz, 6H), 1.96–1.90 (m, 2H), 1.45 (s, 13H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.9, 155.7, 154.9, 154.7, 154.4, 147.3, 147.3, 147.1, 145.2, 133.4, 133.3, 132.2, 132.2, 132.0, 131.9, 129.3, 128.9, 128.6, 128.6, 128.5, 128.5, 128.4, 128.3, 128.2, 123.7, 110.7, 107.9, 105.5, 105.2, 100.9, 99.9, 92.5, 79.5, 58.5, 58.4, 53.0, 47.1, 46.8, 29.7, 29.6, 28.4, 26.4, 24.7, 24.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>44</sub>H<sub>48</sub>N<sub>7</sub>NaO<sub>4</sub>P<sup>+</sup>, 792.3398; found, 792.3400.</div></div><div id="sec4_1_1_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> <i>tert</i>-Butyl-4-(5-(3-(benzofuran-5-yl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazine-1-carboxylate (<b>14a</b>)</h5><div class="NLM_p last">The titled compound <b>14a</b> was obtained following the procedure described for <b>1b</b> using dibenzo[b,d]furan-2-ylboronic acid (0.14 g, 0.89 mmol). Flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 35:1). 0.35 g, 68%, as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.56 (s, 1H), 7.92–7.88 (m, 6H), 7.63–7.57 (m, 4H), 7.48 (t, <i>J</i> = 3.9 Hz, 6H), 7.32 (dd, <i>J</i> = 7.3, 1.4 Hz, 1H), 7.26–7.22 (m, 1H), 4.45 (t, <i>J</i> = 7.4 Hz, 2H), 4.29 (t, <i>J</i> = 7.2 Hz, 2H), 3.41 (d, <i>J</i> = 5.1 Hz, 6H), 2.34 (d, <i>J</i> = 4.9 Hz, 4H), 2.00 (q, <i>J</i> = 7.6 Hz, 2H), 1.91 (d, <i>J</i> = 7.6 Hz, 2H), 1.53 (s, 2H), 1.45 (d, <i>J</i> = 1.6 Hz, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.8, 155.7, 155.0, 154.9, 154.7, 154.1, 150.3, 136.6, 133.5, 133.4, 133.4, 133.3, 132.3, 132.2, 132.2, 132.2, 129.1, 128.9, 128.9, 128.7, 128.6, 128.6, 128.5, 127.9, 127.9, 124.5, 122.7, 120.9, 120.1, 111.7, 109.4, 79.5, 58.5, 58.4, 52.9, 47.3, 47.1, 29.7, 29.6, 28.4, 26.4, 26.3, 24.6, 24.5, 22.1. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>45</sub>H<sub>48</sub>N<sub>7</sub>NaO<sub>3</sub>P<sup>+</sup>, 788.3443; found, 788.3445.</div></div><div id="sec4_1_1_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> <i>tert</i>-Butyl-4-(5-(3-(4-methoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazine-1-carboxylate (<b>15a</b>)</h5><div class="NLM_p last">The titled compound <b>15a</b> was obtained following the procedure described for <b>1b</b> using benzofuran-5-ylboronic acid (0.14 g, 0.89 mmol). Flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 30:1). 0.37 g, 71%, as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.90 (s, 1H), 7.59 (s, 2H), 7.46 (d, <i>J</i> = 4.8 Hz, 6H), 7.10 (s, 3H), 7.03–7.00 (m, 6H), 6.80 (s, 2H), 3.82 (s, 2H), 3.54 (s, 3H), 2.94 (s, 4H), 1.86 (s, 6H), 1.43 (s, 2H), 1.04 (s, 2H), 0.98 (s, 11H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 164.8, 164.1, 157.6, 156.0, 156.0, 154.5, 154.5, 149.9, 149.9, 142.4, 142.4, 135.4, 135.4, 130.9, 130.9, 127.7, 127.5, 126.7, 126.7, 122.1, 121.7, 121.4, 121.4, 121.0, 119.2, 119.2, 106.8, 98.3, 58.2, 58.2, 53.4, 52.7, 52.7, 47.2, 45.7, 41.9, 29.5, 29.5, 26.2, 26.2, 25.2, 24.5, 24.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>44</sub>H<sub>50</sub>N<sub>7</sub>NaO<sub>3</sub>P<sup>+</sup>, 755.3713; found, 755.3715.</div></div><div id="sec4_1_1_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> <i>tert</i>-Butyl-4-(5-(3-(3-acetamidophenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazine-1-carboxylate (<b>16a</b>)</h5><div class="NLM_p last">The titled compound <b>16a</b> was obtained following the procedure described for <b>1b</b> using (3-acetamidophenyl)boronic acid (0.15 g, 0.89 mmol). Flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 30:1). 0.34 g, 64%, as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.20 (d, <i>J</i> = 7.7 Hz, 1H), 8.08 (s, 1H), 8.04 (dd, <i>J</i> = 4.3, 2.1 Hz, 2H), 7.84–7.78 (m, 6H), 7.55 (td, <i>J</i> = 7.3, 1.7 Hz, 3H), 7.45 (dd, <i>J</i> = 7.9, 3.0 Hz, 6H), 7.42 (d, <i>J</i> = 1.9 Hz, 1H), 7.35 (d, <i>J</i> = 6.2 Hz, 1H), 4.38 (t, <i>J</i> = 7.2 Hz, 2H), 3.39 (t, <i>J</i> = 5.1 Hz, 4H), 2.35–2.27 (m, 6H), 2.05 (s, 3H), 1.98–1.91 (m, 2H), 1.55–1.48 (m, 2H), 1.43 (s, 9H), 1.35 (dd, <i>J</i> = 11.4, 4.4 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 168.2, 163.9, 163.8, 154.9, 154.9, 154.7, 154.7, 154.6, 145.0, 137.6, 134.6, 133.4, 133.3, 132.1, 132.0, 129.2, 128.7, 128.6, 128.5, 128.5, 128.4, 128.4, 128.2, 126.2, 120.4, 119.6, 105.7, 105.5, 105.5, 79.6, 77.4, 58.4, 52.9, 46.9, 29.7, 28.5, 28.5, 28.4, 28.4, 28.4, 26.3, 26.2, 24.7, 24.7, 24.6. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>45</sub>H<sub>51</sub>N8<sub>7</sub>NaO<sub>3</sub>P<sup>+</sup>, 805.3708; found, 805.3710.</div></div><div id="sec4_1_1_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> <i>tert</i>-Butyl-4-(5-(3-(3-(trifluoromethoxy)phenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazine-1-carboxylate (<b>17a</b>)</h5><div class="NLM_p last">The titled compound <b>17a</b> was obtained following the procedure described for <b>1b</b> using (3-(trifluoromethoxy)phenyl)boronic acid (0.18 g, 0.89 mmol). Flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 30:1). 0.38 mg, 68%, as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.43 (dt, <i>J</i> = 7.9, 1.2 Hz, 1H), 8.37 (s, 1H), 7.81 (ddd, <i>J</i> = 12.2, 8.2, 1.3 Hz, 6H), 7.55 (td, <i>J</i> = 6.5, 5.7, 1.5 Hz, 3H), 7.44 (td, <i>J</i> = 7.5, 3.1 Hz, 8H), 4.38 (t, <i>J</i> = 7.2 Hz, 2H), 3.41 (s, 4H), 2.38–2.28 (m, 6H), 1.96 (q, <i>J</i> = 7.5 Hz, 2H), 1.54 (s, 3H), 1.45 (s, 9H), 1.38 (d, <i>J</i> = 7.6 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.9, 163.8, 155.1, 155.0, 154.8, 154.7, 154.6, 154.5, 154.5, 153.3, 149.0, 143.9, 136.1, 133.4, 133.4, 133.3, 133.3, 133.2, 133.2, 133.1, 132.0, 132.0, 129.1, 129.1, 129.0, 128.5, 128.53, 128.4, 128.4, 128.2, 128.2, 128.1, 122.2, 121.9, 119.8, 105.7, 79.5, 58.5, 53.0, 46.9, 29.7, 28.4, 26.3, 24.6. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>44</sub>H<sub>47</sub>F<sub>3</sub>N<sub>7</sub>NaO<sub>3</sub>P<sup>+</sup>, 832.3322; found, 832.3324.</div></div><div id="sec4_1_1_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> <i>tert</i>-Butyl-4-(5-(3-(3,4,5-trimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazine-1-carboxylate (<b>23a</b>)</h5><div class="NLM_p last">The titled compound <b>23a</b> was obtained following the procedure described for <b>1b</b> using (3,4,5-trimethoxyphenyl)boronic acid (0.19 g, 0.89 mmol). Flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 30:1). 0.41 mg, 71%, as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.02 (d, <i>J</i> = 2.0 Hz, 1H), 7.74–7.67 (m, 6H), 7.47 (t, <i>J</i> = 7.6 Hz, 3H), 7.38–7.35 (m, 6H), 7.20 (s, 2H), 4.31 (s, 2H), 3.88 (d, <i>J</i> = 2.0 Hz, 3H), 3.64 (d, <i>J</i> = 2.0 Hz, 6H), 3.35 (s, 4H), 2.27 (d, <i>J</i> = 14.6 Hz, 6H), 1.89 (t, <i>J</i> = 7.6 Hz, 2H), 1.47 (d, <i>J</i> = 8.8 Hz, 2H), 1.37 (s, 9H), 1.31 (d, <i>J</i> = 8.2 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 168.4, 168.3, 163.8, 163.8, 163.8, 154.8, 154.7, 152.7, 152.6, 152.6, 145.9, 137.9, 133.4, 133.3, 133.3, 133.2, 133.2, 132.2, 132.1, 132.1, 132.1, 129.5, 129.2, 128.6, 128.5, 128.2, 107.3, 107.3, 105.6, 105.3, 61.1, 61.1, 58.5, 55.9, 55.9, 53.4, 52.9, 50.9, 46.8, 29.7, 28.4, 28.4, 26.2, 24.7, 24.6, 22.0. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>46</sub>H<sub>54</sub>N<sub>7</sub>NaO<sub>5</sub>P<sup>+</sup>, 838.3811; found, 838.3813.</div></div><div id="sec4_1_1_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> <i>tert</i>-Butyl-4-(5-(3-(3-(trifluoromethyl)phenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazine-1-carboxylate (<b>24a</b>)</h5><div class="NLM_p last">The titled compound <b>24a</b> was obtained following the procedure described for <b>1b</b> using (3-(trifluoromethyl)phenyl)boronic acid (0.17 g, 0.89 mmol). Flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 30:1). 0.35 g, 61%, as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.43 (d, <i>J</i> = 7.9 Hz, 1H), 8.37 (s, 1H), 8.07 (d, <i>J</i> = 2.0 Hz, 1H), 7.85–7.77 (m, 6H), 7.54 (t, <i>J</i> = 7.6 Hz, 3H), 7.44 (t, <i>J</i> = 7.8 Hz, 8H), 4.39 (t, <i>J</i> = 7.5 Hz, 2H), 3.46 (d, <i>J</i> = 2.5 Hz, 2H), 3.40 (d, <i>J</i> = 5.0 Hz, 2H), 2.35 (t, <i>J</i> = 6.1 Hz, 4H), 2.30 (d, <i>J</i> = 7.1 Hz, 2H), 2.00–1.93 (m, 2H), 1.58–1.51 (m, 2H), 1.45 (d, <i>J</i> = 2.2 Hz, 9H), 1.40–1.33 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.9, 163.8, 155.0, 155.0, 154.7, 154.5, 149.0, 144.0, 136.1, 133.4, 133.3, 133.2, 132.1, 132.0, 129.1, 129.0, 128.6, 128.5, 128.4, 128.2, 128.1, 122.2, 122.2, 121.9, 121.9, 119.8, 119.3, 119.3, 105.7, 105.4, 102.1, 100.0, 79.6, 77.3, 58.5, 53.0, 50.7, 46.9, 29.7, 28.4, 26.3, 24.6, 22.1, 22.0. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>44</sub>H<sub>47</sub>F<sub>3</sub>N<sub>7</sub>NaO<sub>2</sub>P<sup>+</sup>, 816.3373; found, 816.3374.</div></div><div id="sec4_1_1_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> <i>tert</i>-Butyl-4-(5-(3-(3-isopropoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazine-1-carboxylate (<b>25a</b>)</h5><div class="NLM_p last">The titled compound <b>25a</b> was obtained following the procedure described for <b>1b</b> using (3-isopropoxyphenyl)boronic acid (0.16 g, 0.89 mmol). Flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 30:1). 0.35 g, 63%, as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.06 (t, <i>J</i> = 5.2 Hz, 1H), 7.93–7.75 (m, 6H), 7.63 (d, <i>J</i> = 6.2 Hz, 1H), 7.54 (q, <i>J</i> = 7.5, 6.5 Hz, 3H), 7.51–7.31 (m, 8H), 6.95 (d, <i>J</i> = 8.3 Hz, 1H), 4.62–4.25 (m, 3H), 3.53–3.30 (m, 6H), 2.31 (dd, <i>J</i> = 16.7, 6.3 Hz, 6H), 1.93 (dt, <i>J</i> = 24.3, 7.3 Hz, 2H), 1.52 (d, <i>J</i> = 8.4 Hz, 11H), 1.24 (dd, <i>J</i> = 6.8, 3.6 Hz, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.8, 157.5, 155.7, 154.7, 154.5, 145.7, 135.3, 134.8, 133.6, 133.4, 133.4, 133.3, 133.3, 132.2, 132.2, 132.0, 131.9, 129.3, 128.9, 128.8, 128.6, 128.4, 128.4, 127.9, 122.6, 116.6, 116.1, 100.0, 79.5, 69.7, 58.5, 58.4, 53.4, 53.0, 47.1, 46.8, 29.7, 29.6, 28.4, 26.4, 26.3, 24.7, 24.5, 24.2, 22.1, 22.0. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>46</sub>H<sub>54</sub>N<sub>7</sub>NaO<sub>3</sub>P<sup>+</sup>, 806.3923; found, 806.3925.</div></div><div id="sec4_1_1_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> <i>tert</i>-Butyl-4-(5-(3-(3-(benzyloxy)-phenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazine-1-carboxylate (<b>26a</b>)</h5><div class="NLM_p last">The titled compound <b>26a</b> was obtained following the procedure described for <b>1b</b> using (3-(benzyloxy)phenyl)boronic acid (0.20 g, 0.89 mmol). Flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 25:1). 0.41 g, 71%, as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.10–7.99 (m, 2H), 7.97–7.76 (m, 8H), 7.67–7.61 (m, 1H), 7.55–7.47 (m, 4H), 7.42 (d, <i>J</i> = 7.7 Hz, 6H), 7.31 (s, 2H), 7.05 (d, <i>J</i> = 8.4 Hz, 1H), 6.94 (s, 1H), 5.00 (d, <i>J</i> = 3.6 Hz, 2H), 4.38 (s, 2H), 3.48–3.38 (m, 4H), 2.34 (t, <i>J</i> = 10.0 Hz, 6H), 1.94 (dt, <i>J</i> = 23.9, 11.1 Hz, 2H), 1.60–1.38 (m, 13H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.9, 163.8, 155.1, 154.8, 154.6, 142.8, 136.1, 133.2, 133.1, 132.1, 132.1, 132.1, 132.0, 1316, 131.3, 131.2, 130.9, 129.6, 129.6, 128.8, 128.6, 128.6, 128.6, 128.5, 128.4, 128.4, 127.8, 127.8, 124.9, 124.8, 122.2, 121.3, 121.3, 121.2, 105.5, 105.2, 79.9, 58.3, 52.8, 46.8, 29.7, 29.5, 28.4, 28.4, 28.3, 25.7, 24.4, 22.7, 22.1, 22.0. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>50</sub>H<sub>54</sub>N<sub>7</sub>NaO<sub>3</sub>P<sup>+</sup>, 854.3918; found, 854.3920.</div></div><div id="sec4_1_1_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> <i>tert</i>-Butyl-4-(5-(3-(2-chloro-5-methoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazine-1-carboxylate (<b>27a</b>)</h5><div class="NLM_p last">The titled compound <b>27a</b> was obtained following the procedure described for <b>1b</b> using (2-chloro-5-methoxyphenyl)boronic acid (0.17 g, 0.89 mmol). Flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 25:1). 0.39 g, 71%, as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.12 (d, <i>J</i> = 3.5 Hz, 1H), 7.71–7.64 (m, 6H), 7.49 (d, <i>J</i> = 7.9 Hz, 3H), 7.40–7.34 (m, 7H), 7.21 (t, <i>J</i> = 2.7 Hz, 1H), 7.01 (dt, <i>J</i> = 8.9, 2.6 Hz, 1H), 4.40 (s, 2H), 3.77 (t, <i>J</i> = 2.5 Hz, 3H), 3.39 (d, <i>J</i> = 5.5 Hz, 4H), 2.37–2.28 (m, 6H), 1.96 (d, <i>J</i> = 8.1 Hz, 2H), 1.61–1.32 (m, 13H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.5, 163.4, 157.8, 157.7, 155.4, 154.7, 154.0, 153.9, 143.3, 143.3, 134.6, 133.3, 133.3, 133.2, 131.9, 131.9, 130.0, 129.2, 128.4, 128.4, 128.4, 128.3, 128.3, 128.2, 126.6, 126.4, 117.0, 115.7, 115.7, 115.6, 79.5, 77.2, 58.5, 58.4, 55.5, 53.0, 47.0, 29.8, 29.7, 28.4, 28.4, 26.4, 24.7, 18.4. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>44</sub>H<sub>49</sub>ClN<sub>7</sub>NaO<sub>3</sub>P<sup>+</sup>, 812.3215; found, 812.3217.</div></div><div id="sec4_1_1_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> <i>tert</i>-Butyl-4-(5-(3-(3,5-bis(trifluoromethyl)phenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazine-1-carboxylate (<b>34a</b>)</h5><div class="NLM_p last">The titled compound <b>34a</b> was obtained following the procedure described for <b>1b</b> using (3,5-bis(trifluoromethyl)phenyl)boronic acid (0.23 g, 0.89 mmol). Flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 35:1). 0.41 g, 69%, as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.75 (s, 2H), 8.08 (s, 1H), 7.87 (s, 1H), 7.74 (dd, <i>J</i> = 12.3, 7.7 Hz, 6H), 7.57–7.51 (m, 3H), 7.42 (td, <i>J</i> = 7.7, 2.9 Hz, 6H), 4.39 (t, <i>J</i> = 7.1 Hz, 2H), 3.47 (d, <i>J</i> = 5.3 Hz, 4H), 2.44 (s, 4H), 2.38 (t, <i>J</i> = 7.7 Hz, 2H), 1.99–1.91 (m, 2H), 1.59 (d, <i>J</i> = 9.6 Hz, 2H), 1.45 (s, 9H), 1.36 (d, <i>J</i> = 7.7 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.9, 163.8, 155.1, 154.8, 154.6, 142.8, 136.1, 133.2, 133.2, 133.2, 133.1, 133.1, 132.1, 132.1, 132.1, 131.6, 131.2, 130.9, 130.6, 129.6, 129.6, 128.8, 128.6, 128.6, 128.5, 128.4, 127.8, 124.9, 122.2, 121.3, 105.5, 105.2, 79.9, 58.3, 52.8, 46.8, 29.5, 28.4, 28.4, 28.3, 28.3, 25.7, 24.4, 22.1, 22.0. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>45</sub>H<sub>46</sub>F<sub>6</sub>N<sub>7</sub>NaO<sub>2</sub>P<sup>+</sup>, 884.3247; found, 884.329.</div></div><div id="sec4_1_1_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> <i>tert</i>-Butyl-4-(5-(3-(3-fluoro-5-(trifluoromethyl)phenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazine-1-carboxylate (<b>35a</b>)</h5><div class="NLM_p last">The titled compound <b>35a</b> was obtained following the procedure described for <b>1b</b> using (3-fluoro-5-(trifluoromethyl)phenyl)boronic acid (0.18 g, 0.89 mmol). Flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 35:1). 0.38 g, 67%, as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.85 (dt, <i>J</i> = 10.0, 1.9 Hz, 1H), 8.32 (s, 1H), 8.06 (s, 1H), 7.84–7.77 (m, 6H), 7.55 (td, <i>J</i> = 7.5, 1.8 Hz, 3H), 7.45 (dt, <i>J</i> = 7.8, 3.9 Hz, 6H), 7.35–7.32 (m, 1H), 4.39 (t, <i>J</i> = 7.2 Hz, 2H), 3.44 (t, <i>J</i> = 5.1 Hz, 2H), 3.40 (s, 2H), 2.34 (t, <i>J</i> = 6.1 Hz, 6H), 1.96 (t, <i>J</i> = 7.5 Hz, 2H), 1.57 (s, 2H), 1.45 (s, 9H), 1.37 (t, <i>J</i> = 7.8 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.9, 163.8, 163.4, 161.0, 155.2, 155.2, 154.7, 154.6, 142.9, 137.4, 137.3, 133.3, 133.2, 132.1, 132.1, 131.7, 129.0, 128.8, 128.6, 128.5, 128.3, 128.0, 121.3, 121.0, 120.8, 120.8, 111.5, 111.3, 105.6, 105.4, 79.6, 79.5, 58.5, 58.2, 53.0, 47.0, 29.6, 28.4, 26.4, 26.2, 24.6, 24.2, 22.1, 22.0. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>44</sub>H<sub>46</sub>F<sub>3</sub>N<sub>7</sub>NaO<sub>2</sub>P<sup>+</sup>, 834.3279; found, 834.3281.</div></div><div id="sec4_1_1_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> <i>tert</i>-Butyl-3-((3-(3,5-dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)azetidine-1-carboxylate (<b>1b</b>)</h5><div class="NLM_p last">To a solution of compound <b>1a</b> (5.0 g, 6.7 mmol), K<sub>2</sub>CO<sub>3</sub> (1.8 g, 13 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (0.80 g, 0.67 mmol) in 1,4-dioxane/H<sub>2</sub>O (9 mL, 3:1) was added compound <b>44</b> (1.6 g, 8.8 mmol) in 1,4-dioxane at room temperature. After stirring at 80 °C for 8 h under a nitrogen atmosphere, the mixture was diluted with EtOAc (10 mL), washed with saturated NaCl solution (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH = 50:1) to afford compound <b>1b</b> (4.3 g, 61%) as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.06 (d, <i>J</i> = 3.2 Hz, 1H), 7.89–7.71 (m, 6H), 7.56–7.40 (m, 11H), 6.70–6.41 (m, 1H), 4.58 (dd, <i>J</i> = 7.3, 3.2 Hz, 2H), 4.11–3.96 (m, 2H), 3.92–3.84 (m, 2H), 3.76 (d, <i>J</i> = 3.1 Hz, 6H), 3.26–3.07 (m, 1H), 1.41 (d, <i>J</i> = 3.1 Hz, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 164.0, 163.4, 160.3, 156.3, 154.8, 154.7, 146.1, 135.6, 133.4, 133.3, 132.3, 132.2, 132.1, 132.0, 132.0, 129.2, 128.6, 128.6, 128.5, 128.5, 128.4, 128.4, 128.17, 127.8, 126.3, 108.2, 107.9, 107.9, 100.6, 79.3, 68.2, 63.8, 55.3, 55.3, 55.0, 50.0, 28.9, 28.4, 28.4, 24.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>40</sub>H<sub>41</sub>N<sub>6</sub>NaO<sub>4</sub>P<sup>+</sup>, 723.2819; found, 723.2822.</div></div><div id="sec4_1_1_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> <i>tert</i>-Butyl-3-((3-(3,5-dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carboxylate (<b>2b</b>)</h5><div class="NLM_p last">The titled compound <b>2b</b> was obtained from <b>2a</b> following the general procedure described for <b>1b</b>. The compound <b>2b</b> (71%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.07 (s, 1H), 7.81 (ddd, <i>J</i> = 12.3, 8.3, 1.3 Hz, 6H), 7.52 (dd, <i>J</i> = 7.4, 1.7 Hz, 3H), 7.47 (d, <i>J</i> = 3.6 Hz, 2H), 7.42 (td, <i>J</i> = 7.7, 3.0 Hz, 6H), 6.57 (t, <i>J</i> = 2.4 Hz, 1H), 4.27 (d, <i>J</i> = 7.3 Hz, 2H), 4.13–3.93 (m, 2H), 3.76 (s, 6H), 2.65 (t, <i>J</i> = 12.9 Hz, 2H), 2.24 (ddp, <i>J</i> = 11.0, 7.2, 3.8 Hz, 1H), 1.67–1.46 (m, 2H), 1.43 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.9, 160.3, 160.3, 155.4, 155.3, 154.8, 154.7, 145.8, 135.7, 133.5, 133.4, 133.4, 133.3, 133.3, 132.2, 132.1, 132.0, 132.0, 132.0, 131.0, 129.2, 128.6, 128.5, 128.5, 128.5, 128.4, 128.3, 128.3, 108.0, 108.0, 105.6, 105.3, 100.5, 79.3, 55.3, 51.9, 36.8, 29.7, 28.5, 22.7, 20.0. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>41</sub>H<sub>43</sub>N<sub>6</sub>NaO<sub>4</sub>P<sup>+</sup>, 737.2976; found, 737.2978.</div></div><div id="sec4_1_1_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> <i>tert</i>-Butyl-4-(3-(3,5-dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate (<b>2b</b>)</h5><div class="NLM_p last">The titled compound <b>3b</b> was obtained from <b>3a</b> following the general procedure described for <b>1b</b>. The compound <b>3b</b> (72%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.06 (s, 1H), 7.81 (ddd, <i>J</i> = 9.6, 6.3, 3.4 Hz, 6H), 7.62–7.36 (m, 11H), 6.57 (dt, <i>J</i> = 4.8, 2.4 Hz, 1H), 4.87 (ddt, <i>J</i> = 12.0, 8.0, 4.1 Hz, 1H), 4.29 (s, 2H), 3.76 (d, <i>J</i> = 3.4 Hz, 6H), 2.95 (s, 2H), 2.39–2.24 (m, 2H), 1.97 (d, <i>J</i> = 12.7 Hz, 2H), 1.47 (q, <i>J</i> = 3.2 Hz, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 157.7, 156.0, 155.8, 155.8, 154.8, 154.8, 154.2, 154.2, 148.6, 148.6, 148.5, 143.9, 143.9, 127.0, 127.0, 122.3, 122.2, 122.2, 109.1, 109.1, 109.0, 109.0, 108.9, 108.9, 101.6, 101.6, 98.2, 79.3, 79.3, 69.3, 68.9, 50.9, 44.7, 44.7, 36.1, 36.1, 33.5, 31.8, 29.7, 28.5, 28.4. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>41</sub>H<sub>43</sub>N<sub>6</sub>NaO<sub>4</sub>P<sup>+</sup>, 737.2976; found, 737.2978.</div></div><div id="sec4_1_1_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> <i>tert</i>-Butyl-4-((3-(3,5-dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate (<b>4b</b>)</h5><div class="NLM_p last">The titled compound <b>4b</b> was obtained from <b>4a</b> following the general procedure described for <b>1b</b>. The compound <b>4b</b> (62%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.06 (s, 1H), 7.81 (tt, <i>J</i> = 8.0, 3.1 Hz, 6H), 7.58–7.51 (m, 3H), 7.49 (q, <i>J</i> = 3.3 Hz, 2H), 7.43 (tt, <i>J</i> = 7.7, 3.5 Hz, 6H), 6.78–6.40 (m, 1H), 4.29 (s, 2H), 3.76 (d, <i>J</i> = 3.2 Hz, 6H), 2.95 (s, 2H), 2.31 (ddq, <i>J</i> = 12.0, 8.2, 4.2 Hz, 2H), 2.05 (d, <i>J</i> = 3.2 Hz, 1H), 1.97 (d, <i>J</i> = 12.8 Hz, 2H), 1.48 (d, <i>J</i> = 3.3 Hz, 9H), 1.26 (td, <i>J</i> = 7.1, 3.3 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.9, 163.9, 160.2, 155.7, 154.8, 154.8, 154.7, 154.5, 145.6, 135.8, 133.4, 133.4, 133.3, 133.3, 132.2, 131.9, 131.9, 129.2, 128.9, 128.6, 128.6, 128.5, 128.5, 128.4, 128.2, 120.1, 107.9, 105.7, 100.5, 79.6, 58.5, 58.4, 55.3, 55.3, 52.9, 47.0, 46.8, 29.7, 29.6, 28.4, 26.3, 24.6. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>42</sub>H<sub>45</sub>N<sub>6</sub>NaO<sub>4</sub>P<sup>+</sup>, 751.3132; found, 751.3135.</div></div><div id="sec4_1_1_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> <i>tert</i>-Butyl-4-(2-(3-(3,5-dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)piperidine-1-carboxylate (<b>5b</b>)</h5><div class="NLM_p last">The titled compound <b>5b</b> was obtained from <b>5a</b> following the general procedure described for <b>1b</b>. The compound <b>5b</b> (67%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.06 (s, 1H), 7.84–7.77 (m, 6H), 7.49 (q, <i>J</i> = 2.9 Hz, 5H), 7.40 (dt, <i>J</i> = 7.7, 3.8 Hz, 6H), 6.56 (t, <i>J</i> = 2.4 Hz, 1H), 4.52 (t, <i>J</i> = 7.0 Hz, 2H), 3.74 (s, 6H), 3.37 (t, <i>J</i> = 5.0 Hz, 4H), 2.93 (t, <i>J</i> = 7.1 Hz, 2H), 2.50 (t, <i>J</i> = 5.0 Hz, 4H), 1.45 (s, 1H), 1.43 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.9, 163.9, 160.2, 160.2, 159.1, 158.4, 156.0, 154.8, 154.7, 154.5, 145.6, 135.8, 135.8, 133.7, 133.4, 133.3, 132.5, 132.0, 132.0, 131.9, 129.5, 129.3, 128.5, 128.4, 128.3, 128.3, 108.0, 107.9, 105.7, 105.4, 100.5, 100.5, 79.6, 58.7, 55.3, 55.3, 52.9, 47.0, 29.8, 29.2, 28.4, 28.4, 28.4, 27.4, 26.7, 26.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>43</sub>H<sub>47</sub>N<sub>6</sub>NaO<sub>4</sub>P<sup>+</sup>, 765.3289; found, 765.3291.</div></div><div id="sec4_1_1_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> <i>tert</i>-Butyl-3-((3-(3,5-dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate (<b>6b</b>)</h5><div class="NLM_p last">The titled compound <b>6b</b> was obtained from <b>6a</b> following the general procedure described for <b>1b</b>. The compound <b>6b</b> (76%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.09–8.05 (m, 1H), 7.96–7.77 (m, 6H), 7.59–7.39 (m, 11H), 6.57 (d, <i>J</i> = 2.1 Hz, 1H), 4.38 (t, <i>J</i> = 7.3 Hz, 2H), 3.76 (d, <i>J</i> = 1.5 Hz, 6H), 3.41 (d, <i>J</i> = 5.5 Hz, 4H), 1.94 (dt, <i>J</i> = 15.1, 7.6 Hz, 1H), 1.55 (p, <i>J</i> = 8.2 Hz, 2H), 1.45 (d, <i>J</i> = 1.5 Hz, 9H), 1.35 (dt, <i>J</i> = 15.1, 7.4 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 168.3, 166.9, 165.5, 161.59, 161.6, 161.5, 157.8, 157.8, 156.0, 155.8, 154.7, 154.7, 144.6, 144.5, 134.8, 127.9, 127.8, 127.8, 127.5, 127.5, 127.5, 119.4, 108.8, 106.4, 106.3, 106.3, 101.3, 101.3, 101.1, 98.2, 55.6, 49.9, 49.7, 49.5, 46.5, 45.7, 45.7, 42.7, 37.4, 29.7, 28.6, 22.7. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>42</sub>H<sub>45</sub>N<sub>6</sub>NaO<sub>4</sub>P<sup>+</sup>, 751.3132; found, 751.3135.</div></div><div id="sec4_1_1_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> <i>tert</i>-Butyl-4-(2-(3-(3,5-dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)piperazine-1-carboxylate (<b>7b</b>)</h5><div class="NLM_p last">The titled compound <b>7b</b> was obtained from <b>7a</b> following the general procedure described for <b>1b</b>. The compound <b>7b</b> (60%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.07 (s, 1H), 7.87–7.77 (m, 6H), 7.51 (td, <i>J</i> = 6.4, 5.4, 2.1 Hz, 5H), 7.41 (dt, <i>J</i> = 7.7, 3.8 Hz, 6H), 6.57 (t, <i>J</i> = 2.4 Hz, 1H), 4.53 (t, <i>J</i> = 7.0 Hz, 2H), 3.75 (s, 6H), 3.38 (t, <i>J</i> = 5.0 Hz, 4H), 2.94 (t, <i>J</i> = 7.1 Hz, 2H), 2.51 (t, <i>J</i> = 5.0 Hz, 4H), 1.44 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.9, 163.8, 160.2, 155.2, 155.2, 154.8, 154.7, 154.6, 145.9, 135.7, 133.4, 133.3, 133.1, 132.1, 132.0, 131.9, 131.9, 129.2, 128.6, 128.5, 128.4, 128.2, 107.9, 105.7, 105.5, 100.5, 90.9, 79.7, 79.5, 77.3, 70.3, 66.0, 62.9, 57.1, 55.3, 53.5, 52.9, 44.3, 43.1, 28.4, 22.1, 22.0. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>42</sub>H<sub>46</sub>N<sub>7</sub>NaO<sub>4</sub>P<sup>+</sup>, 766.3241; found, 766.3246.</div></div><div id="sec4_1_1_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> <i>tert</i>-Butyl-4-(3-(3-(3,5-dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)Bamino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)piperazine-1-carboxylate (<b>8b</b>)</h5><div class="NLM_p last">The titled compound <b>8b</b> was obtained from <b>8a</b> following the general procedure described for <b>1b</b>. The compound <b>8b</b> (74%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.06 (s, 1H), 7.81 (ddt, <i>J</i> = 12.3, 7.0, 1.4 Hz, 6H), 7.53 (td, <i>J</i> = 6.5, 5.7, 1.5 Hz, 3H), 7.49 (d, <i>J</i> = 2.4 Hz, 2H), 7.43 (dt, <i>J</i> = 7.4, 3.6 Hz, 6H), 6.57 (t, <i>J</i> = 2.3 Hz, 1H), 4.44 (t, <i>J</i> = 6.9 Hz, 2H), 3.76 (s, 6H), 3.38 (t, <i>J</i> = 5.1 Hz, 4H), 2.45 (t, <i>J</i> = 7.1 Hz, 2H), 2.36 (m, 4H), 2.19–2.10 (m, 2H), 1.44 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.9, 163.9, 160.2, 154.9, 154.9, 154.9, 154.7, 154.5, 145.7, 135.8, 135.8, 133.5, 133.4, 133.4, 133.3, 133.3, 132.0, 131.9, 129.2, 128.5, 128.4, 128.3, 128.3, 107.9, 107.9, 105.7, 105.5, 100.5, 79.5, 79.5, 60.4, 55.7, 55.3, 52.9, 45.2, 45.2, 28.5, 28.5, 28.4, 28.4, 26.8, 26.7, 21.1. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>43</sub>H<sub>48</sub>N<sub>7</sub>NaO<sub>4</sub>P<sup>+</sup>, 780.3398; found, 780.3400.</div></div><div id="sec4_1_1_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> <i>tert</i>-Butyl-4-(4-(3-(3,5-dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)piperazine-1-carboxylate (<b>9b</b>)</h5><div class="NLM_p last">The titled compound <b>9b</b> was obtained from <b>9a</b> following the general procedure described for <b>1b</b>. The compound <b>9b</b> (74%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.06 (s, 1H), 7.81 (ddt, <i>J</i> = 12.3, 7.0, 1.4 Hz, 6H), 7.53 (ddd, <i>J</i> = 7.3, 5.2, 1.5 Hz, 3H), 7.47 (d, <i>J</i> = 2.4 Hz, 2H), 7.42 (td, <i>J</i> = 7.5, 2.9 Hz, 6H), 6.57 (t, <i>J</i> = 2.4 Hz, 1H), 4.40 (t, <i>J</i> = 7.1 Hz, 2H), 3.76 (s, 6H), 3.40 (d, <i>J</i> = 5.8 Hz, 4H), 2.35 (s, 6H), 1.97 (p, <i>J</i> = 7.1 Hz, 2H), 1.60 (s, 2H), 1.45 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 165.3, 163.9, 160.2, 160.2, 154.8, 154.5, 145.8, 135.7, 133.4, 133.3, 132.0, 132.0, 129.2, 129.2, 128.6, 128.5, 128.5, 128.4, 128.4, 128.2, 128.2, 128.0, 127.2, 127.2, 107.9, 105.7, 105.5, 100.5, 55.3, 55.3, 46.1, 46.1, 44.3, 42.3, 35.9, 35.9, 33.6, 32.6, 31.6, 29.7, 29.7. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>42</sub>H<sub>50</sub>N<sub>7</sub>NaO<sub>4</sub>P<sup>+</sup>, 794.3554; found, 794.3556.</div></div><div id="sec4_1_1_37" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> <i>tert</i>-Butyl-4-(6-(3-(3,5-dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)hexyl)piperazine-1-carboxylate (<b>11b</b>)</h5><div class="NLM_p last">The titled compound <b>11b</b> was obtained from <b>11a</b> following the general procedure described for <b>1b</b>. The compound <b>11b</b> (68%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.06 (s, 1H), 7.81 (ddt, <i>J</i> = 12.3, 7.0, 1.4 Hz, 6H), 7.53 (td, <i>J</i> = 6.5, 5.8, 1.5 Hz, 3H), 7.49–7.38 (m, 9H), 6.56 (t, <i>J</i> = 2.4 Hz, 1H), 4.40 (t, <i>J</i> = 7.1 Hz, 2H), 3.75 (s, 7H), 3.40 (d, <i>J</i> = 6.2 Hz, 4H), 2.35 (s, 6H), 1.97 (q, <i>J</i> = 7.8, 7.1 Hz, 2H), 1.57 (d, <i>J</i> = 20.9 Hz, 3H), 1.44 (s, 11H), 1.29 (s, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 160.2, 156.2, 154.8, 154.8, 154.5, 145.6, 145.0, 144.8, 135.8, 135.8, 133.4, 133.4, 133.3, 132.2, 132.2, 132.1, 132.0, 132.0, 129.3, 128.6, 128.5, 128.5, 128.4, 128.3, 109.0, 108.0, 105.7, 105.5, 100.5, 100.5, 97.6, 85.7, 58.6, 55.3, 54.7, 52.9, 50.8, 46.9, 40.2, 29.7, 29.7, 28.4, 27.1, 26.6, 25.1, 24.2. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>46</sub>H<sub>54</sub>N<sub>7</sub>NaO<sub>4</sub>P<sup>+</sup>, 822.3867; found, 822.3869.</div></div><div id="sec4_1_1_38" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> <i>tert</i>-Butyl-4-(7-(3-(3,5-dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)heptyl)piperazine-1-carboxylate (<b>12b</b>)</h5><div class="NLM_p last">The titled compound <b>12b</b> was obtained from <b>12a</b> following the general procedure described for <b>1b</b>. The compound <b>12b</b> (68%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.07 (s, 1H), 7.81 (ddd, <i>J</i> = 12.2, 7.6, 1.4 Hz, 6H), 7.53 (td, <i>J</i> = 6.5, 5.8, 1.6 Hz, 3H), 7.49 (d, <i>J</i> = 2.4 Hz, 2H), 7.43 (dt, <i>J</i> = 7.7, 3.8 Hz, 6H), 6.57 (t, <i>J</i> = 2.4 Hz, 1H), 4.37 (t, <i>J</i> = 7.3 Hz, 2H), 3.76 (s, 6H), 3.44 (t, <i>J</i> = 5.3 Hz, 4H), 2.38 (s, 4H), 2.32 (s, 2H), 1.93 (t, <i>J</i> = 7.2 Hz, 2H), 1.45 (s, 11H), 1.35 (p, <i>J</i> = 3.1 Hz, 4H), 1.29–1.25 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.9, 163.9, 160.2, 160.2, 154.8, 154.7, 154.5, 154.5, 145.6, 145.6, 135.8, 133.4, 133.3, 133.3, 132.0, 131.9, 131.9, 129.3, 128.5, 128.4, 128.3, 108.1, 107.9, 107.9, 105.7, 105.7, 105.5, 100.5, 100.5, 79.6, 79.6, 58.7, 58.7, 55.3, 55.3, 52.9, 52.9, 47.0, 47.0, 29.8, 29.8, 29.2, 28.4, 27.4, 26.7, 26.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>47</sub>H<sub>56</sub>N<sub>7</sub>NaO<sub>4</sub>P<sup>+</sup>, 836.4024; found, 836.4026.</div></div><div id="sec4_1_1_39" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> 1-(4-(5-(3-(Benzo[d][1,3]dioxol-5-yl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>13b</b>)</h5><div class="NLM_p last">The titled compound <b>13b</b> was obtained from <b>13a</b> following the general procedure described for <b>1c</b>. The compound <b>13b</b> (64%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.05 (s, 1H), 7.99 (dd, <i>J</i> = 8.1, 1.7 Hz, 1H), 7.92 (d, <i>J</i> = 3.6 Hz, 1H), 7.90–7.80 (m, 6H), 7.58–7.42 (m, 9H), 6.54 (ddd, <i>J</i> = 16.8, 10.5, 3.6 Hz, 1H), 6.27 (dd, <i>J</i> = 16.8, 1.9 Hz, 1H), 6.05 (s, 2H), 5.67 (dd, <i>J</i> = 10.5, 2.0 Hz, 1H), 4.44–4.30 (m, 2H), 3.66 (t, <i>J</i> = 5.0 Hz, 2H), 3.52 (d, <i>J</i> = 5.1 Hz, 2H), 2.41 (d, <i>J</i> = 4.8 Hz, 4H), 2.32 (dd, <i>J</i> = 9.1, 5.7 Hz, 2H), 2.00–1.90 (m, 2H), 1.57–1.50 (m, 2H), 1.36 (qd, <i>J</i> = 19.5, 18.4, 10.3 Hz, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.2, 155.7, 154.4, 147.3, 147.1, 145.2, 133.4, 133.3, 132.2, 132.2, 132.0, 132.0, 129.3, 128.9, 128.6, 128.5, 128.5, 128.4, 128.3, 128.2, 127.9, 127.7, 127.5, 123.7, 110.7, 107.9, 105.2, 100.9, 99.9, 77.2, 58.2, 58.1, 53.3, 52.7, 47.0, 46.7, 45.7, 41.8, 29.6, 26.3, 24.5, 24.4. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>42</sub>H<sub>42</sub>N<sub>7</sub>NaO<sub>3</sub>P<sup>+</sup>, 746.2979; found, 746.2981.</div></div><div id="sec4_1_1_40" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> 1-(4-(5-(3-(Benzofuran-5-yl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>14b</b>)</h5><div class="NLM_p last">The titled compound <b>14b</b> was obtained from <b>14a</b> following the general procedure described for <b>1c</b>. The compound <b>14b</b> (68%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.56 (s, 1H), 8.10 (d, <i>J</i> = 1.3 Hz, 1H), 8.06 (d, <i>J</i> = 1.3 Hz, 1H), 7.93–7.89 (m, 6H), 7.59 (ddd, <i>J</i> = 9.2, 7.6, 1.9 Hz, 4H), 7.50–7.48 (m, 6H), 7.32 (d, <i>J</i> = 7.5 Hz, 1H), 7.24 (s, 1H), 6.50 (ddd, <i>J</i> = 10.5, 6.3, 1.4 Hz, 1H), 6.28 (dt, <i>J</i> = 6.3, 1.8 Hz, 1H), 5.65 (dt, <i>J</i> = 6.0, 3.1 Hz, 1H), 4.45 (t, <i>J</i> = 7.3 Hz, 2H), 4.29 (t, <i>J</i> = 7.1 Hz, 2H), 3.68–3.65 (m, 2H), 3.53 (t, <i>J</i> = 5.2 Hz, 2H), 2.39 (s, 4H), 2.32 (s, 2H), 2.00–1.91 (m, 2H), 1.52 (dp, <i>J</i> = 14.7, 7.4 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.2, 155.7, 155.0, 154.9, 150.2, 136.6, 133.5, 133.4, 133.4, 133.3, 133.3, 132.3, 132.3, 132.2, 132.2, 129.1, 128.9, 128.9, 128.7, 128.7, 128.6, 128.6, 128.5, 127.9, 127.7, 127.6, 127.5, 124.5, 122.8, 120.9, 120.2, 111.7, 109.4, 100.0, 58.1, 53.3, 52.7, 47.2, 45.7, 41.9, 29.6, 26.2, 24.4. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>43</sub>H<sub>42</sub>N<sub>7</sub>NaO<sub>2</sub>P<sup>+</sup>, 742.3024; found, 742.3026.</div></div><div id="sec4_1_1_41" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> 1-(4-(5-(3-(4-Methoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>15b</b>)</h5><div class="NLM_p last">The titled compound <b>15b</b> was obtained from <b>15a</b> following the general procedure described for <b>1c</b>. The compound <b>15b</b> (68%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.35 (dd, <i>J</i> = 8.6, 3.7 Hz, 2H), 8.06 (d, <i>J</i> = 3.6 Hz, 1H), 7.82 (ddd, <i>J</i> = 12.0, 7.7, 3.5 Hz, 6H), 7.58–7.39 (m, 9H), 6.98 (dd, <i>J</i> = 8.7, 3.6 Hz, 2H), 6.52 (ddd, <i>J</i> = 17.0, 10.4, 3.7 Hz, 1H), 6.26 (dt, <i>J</i> = 16.7, 2.4 Hz, 1H), 5.66 (dt, <i>J</i> = 10.8, 2.4 Hz, 1H), 4.37 (td, <i>J</i> = 7.3, 3.6 Hz, 2H), 3.90 (d, <i>J</i> = 3.6 Hz, 3H), 3.71–3.61 (m, 2H), 3.50 (q, <i>J</i> = 5.0, 4.3 Hz, 2H), 2.46–2.36 (m, 4H), 2.33 (s, 2H), 1.95 (td, <i>J</i> = 7.9, 3.9 Hz, 2H), 1.61–1.49 (m, 2H), 1.37 (dp, <i>J</i> = 12.9, 4.2 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 164.0, 159.5, 159.0, 154.8, 154.8, 154.5, 145.4, 133.5, 1335, 133.4, 132.2, 132.0, 132.0, 131.2, 129.3, 129.3, 128.6, 128.5, 128.4, 128.3, 127.7, 127.7, 127.5, 126.8, 126.8, 113.5, 113.2, 105.4, 58.7, 58.2, 55.4, 53.5, 53.2, 52.8, 46.7, 45.7, 41.8, 30.1, 29.7, 26.2, 24.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>42</sub>H<sub>44</sub>N<sub>7</sub>NaO<sub>2</sub>P<sup>+</sup>, 732.3181; found, 732.3183.</div></div><div id="sec4_1_1_42" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> <i>N</i>-(4-(1-(5-(4-Acryloylpiperazin-1-yl)pentyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl)acetamide (<b>16b</b>)</h5><div class="NLM_p last">The titled compound <b>16b</b> was obtained from <b>16a</b> following the general procedure described for <b>1c</b>. The compound <b>16b</b> (72%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.19 (d, <i>J</i> = 7.7 Hz, 1H), 8.08 (s, 1H), 8.04 (d, <i>J</i> = 4.7 Hz, 2H), 7.81 (dd, <i>J</i> = 12.3, 7.7 Hz, 6H), 7.55 (t, <i>J</i> = 7.5 Hz, 3H), 7.43 (tt, <i>J</i> = 8.3, 4.2 Hz, 8H), 6.51 (dd, <i>J</i> = 16.8, 10.5 Hz, 1H), 6.25 (d, <i>J</i> = 16.8 Hz, 1H), 5.66 (d, <i>J</i> = 10.6 Hz, 1H), 4.39 (t, <i>J</i> = 7.0 Hz, 2H), 3.73–3.59 (m, 2H), 3.49 (t, <i>J</i> = 4.9 Hz, 2H), 2.37 (dd, <i>J</i> = 10.0, 4.9 Hz, 4H), 2.30 (t, <i>J</i> = 7.5 Hz, 2H), 2.06 (s, 3H), 1.96 (q, <i>J</i> = 7.3 Hz, 2H), 1.50 (t, <i>J</i> = 7.7 Hz, 2H), 1.37 (q, <i>J</i> = 7.7 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 168.2, 165.2, 163.9, 163.8, 154.9, 154.8, 154.6, 145.0, 139.2, 137.6, 134.6, 134.6, 133.4, 133.3, 132.1, 132.0, 129.7, 129.1, 128.7, 128.6, 128.5, 128.4, 128.1, 127.8, 127.4, 126.1, 120.4, 119.6, 105.7, 105.5, 105.5, 58.0, 53.2, 52.5, 46.8, 45.6, 41.8, 41.8, 29.7, 29.5, 25.9, 24.7, 24.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>43</sub>H<sub>45</sub>N<sub>8</sub>NaO<sub>2</sub>P<sup>+</sup>, 7592.3290; found, 759.3292.</div></div><div id="sec4_1_1_43" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> <i>tert</i>-Butyl-4-(5-(3-(3-(trifluoromethoxy)phenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazine-1-carboxylate (<b>17b</b>)</h5><div class="NLM_p last">The titled compound <b>17b</b> was obtained from <b>17a</b> following the general procedure described for <b>1c</b>. The compound <b>17b</b> (71%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.42 (d, <i>J</i> = 7.7 Hz, 1H), 8.36 (s, 1H), 8.07 (s, 1H), 7.87–7.78 (m, 6H), 7.58–7.52 (m, 3H), 7.44 (td, <i>J</i> = 7.8, 3.1 Hz, 8H), 6.51 (dd, <i>J</i> = 16.8, 10.5 Hz, 1H), 6.29 (d, <i>J</i> = 16.7 Hz, 1H), 5.68 (d, <i>J</i> = 10.7 Hz, 1H), 4.39 (s, 2H), 3.70 (s, 2H), 3.55 (s, 2H), 2.45 (s, 6H), 2.02–1.93 (m, 2H), 1.57 (s, 2H), 1.38 (s, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 163.9, 155.2, 154.6, 149.0, 144.1, 143.2, 138.5, 136.1, 133.4, 134.4, 133.3, 133.3, 133.2, 132.2, 132.1, 132.1, 129.1, 129.0, 128.5, 128.5, 128.4, 128.4, 128.2, 128.2, 128.0, 128.0, 122.2, 121.9, 119.8, 119.3, 118.2, 100.0, 58.1, 58.0, 56.2, 53.1, 52.6, 46.8, 29.7, 29.4, 24.3. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>42</sub>H<sub>41</sub>F<sub>3</sub>N<sub>7</sub>NaO<sub>2</sub>P<sup>+</sup>, 786.2898; found, 786.2900.</div></div><div id="sec4_1_1_44" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> 1-(4-(5-(3-(3,4,5-Trimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>23b</b>)</h5><div class="NLM_p last">The titled compound <b>23b</b> was obtained from <b>23a</b> following the general procedure described for <b>1c</b>. The compound <b>23b</b> (70%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.98 (s, 1H), 7.84–7.75 (m, 6H), 7.61 (dd, <i>J</i> = 7.4, 1.8 Hz, 3H), 7.49 (td, <i>J</i> = 7.7, 3.1 Hz, 6H), 7.41 (s, 2H), 6.69 (dd, <i>J</i> = 16.8, 10.6 Hz, 1H), 6.19 (dd, <i>J</i> = 16.7, 1.9 Hz, 1H), 5.74 (dd, <i>J</i> = 10.6, 2.0 Hz, 1H), 4.38 (t, <i>J</i> = 6.8 Hz, 2H), 3.91 (s, 3H), 3.70 (s, 6H), 3.68–3.57 (m, 4H), 2.63 (d, <i>J</i> = 42.4 Hz, 6H), 1.96 (p, <i>J</i> = 7.0 Hz, 2H), 1.61 (s, 2H), 1.35 (d, <i>J</i> = 7.4 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 159.3, 159.3, 157.6, 156.5, 156.5, 155.9, 155.9, 154.7, 153.8, 153.8, 153.0, 141.2, 141.2, 137.9, 137.9, 133.5, 133.5, 127.6, 113.9, 113.9, 110.1, 108.8, 107.6, 107.3, 107.3, 101.1, 99.9, 92.1, 79.6, 77.3, 58.4, 56.4, 55.7, 53.0, 52.9, 50.3, 47.2, 29.7, 29.5, 28.4, 26.2, 24.6, 24.5, 22.6. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>44</sub>H<sub>48</sub>N<sub>7</sub>NaO<sub>4</sub>P<sup>+</sup>, 792.3398; found, 792.3400.</div></div><div id="sec4_1_1_45" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> 1-(4-(5-(3-(3-(Trifluoromethyl)phenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>24b</b>)</h5><div class="NLM_p last">The titled compound <b>24b</b> was obtained from <b>24a</b> following the general procedure described for <b>1c</b>. The compound <b>24b</b> (61%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.43 (t, <i>J</i> = 5.8 Hz, 1H), 8.37 (s, 1H), 8.07 (d, <i>J</i> = 4.2 Hz, 1H), 7.81 (dt, <i>J</i> = 11.7, 5.2 Hz, 6H), 7.55 (q, <i>J</i> = 6.4, 5.5 Hz, 3H), 7.44 (td, <i>J</i> = 8.6, 8.0, 4.2 Hz, 8H), 6.53 (td, <i>J</i> = 11.9, 11.1, 5.8 Hz, 1H), 6.32–6.25 (m, 1H), 5.68 (q, <i>J</i> = 7.9, 6.8 Hz, 1H), 4.39 (d, <i>J</i> = 6.3 Hz, 2H), 3.69 (t, <i>J</i> = 9.8 Hz, 2H), 3.55–3.49 (m, 2H), 2.43 (d, <i>J</i> = 5.4 Hz, 4H), 2.37–2.32 (m, 2H), 1.96 (dt, <i>J</i> = 11.3, 6.0 Hz, 2H), 1.55 (s, 2H), 1.36 (dt, <i>J</i> = 14.6, 7.2 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 163.9, 154.9, 154.5, 149.0, 144.0, 136.1, 133.3, 133.3, 133.2, 133.2, 132.2, 132.1, 132.1, 132.0, 130.0, 129.9, 129.1, 129.0, 128.6, 128.5, 128.4, 128.2, 128.1, 127.9, 127.7, 127.5, 127.4, 122.2, 119.8, 119.3, 105.7, 105.4, 58.1, 53.2, 52.6, 46.9, 29.7, 26.0, 24.5, 24.2, 22.0. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>42</sub>H<sub>41</sub>F<sub>3</sub>N<sub>7</sub>NaOP<sup>+</sup>, 770.2960; found, 770.2962.</div></div><div id="sec4_1_1_46" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> 1-(4-(5-(3-(3-Isopropoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>25b</b>)</h5><div class="NLM_p last">The titled compound <b>25b</b> was obtained from <b>25a</b> following the general procedure described for <b>1c</b>. The compound <b>25b</b> (63%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.06 (s, 1H), 7.86 (ddt, <i>J</i> = 46.2, 12.7, 6.1 Hz, 8H), 7.59–7.43 (m, 9H), 7.34 (q, <i>J</i> = 7.2 Hz, 1H), 6.97 (t, <i>J</i> = 6.2 Hz, 1H), 6.53 (tt, <i>J</i> = 10.5, 5.0 Hz, 1H), 6.26 (dd, <i>J</i> = 16.5, 4.4 Hz, 1H), 5.80–5.57 (m, 1H), 4.61–4.28 (m, 3H), 3.66 (s, 2H), 3.51 (s, 2H), 2.40 (s, 4H), 2.31 (t, <i>J</i> = 6.5 Hz, 2H), 1.98–1.89 (m, 2H), 1.53 (q, <i>J</i> = 8.2 Hz, 2H), 1.37 (t, <i>J</i> = 10.7 Hz, 2H), 1.25 (d, <i>J</i> = 6.1 Hz, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 177.8, 172.7, 165.2, 157.6, 155.7, 154.5, 145.7, 135.3, 133.4, 133.4, 133.3, 133.3, 132.2, 132.0, 131.9, 129.3, 128.9, 128.8, 128.6, 128.5, 128.4, 127.6, 127.6, 122.6, 116.7, 116.0, 100.0, 69.8, 58.2, 58.1, 53.3, 52.7, 47.0, 46.7, 45.7, 41.8, 35.3, 33.1, 29.6, 29.5, 26.2, 24.5, 24.4, 22.1. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>44</sub>H<sub>48</sub>N<sub>7</sub>NaO<sub>2</sub>P<sup>+</sup>, 760.3499; found, 760.3501.</div></div><div id="sec4_1_1_47" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> 1-(4-(5-(3-(3-(Benzyloxy)phenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>26b</b>)</h5><div class="NLM_p last">The titled compound <b>26b</b> was obtained from <b>26a</b> following the general procedure described for <b>1c</b>. The compound <b>26b</b> (65%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 8.01 (s, 1H), 7.98–7.90 (m, 3H), 7.77 (dd, <i>J</i> = 12.6, 7.8 Hz, 6H), 7.67–7.42 (m, 13H), 7.22–7.16 (m, 2H), 6.76–6.69 (m, 1H), 6.30–6.24 (m, 1H), 5.85–5.79 (m, 1H), 4.96 (s, 2H), 4.43 (t, <i>J</i> = 6.7 Hz, 2H), 3.21 (q, <i>J</i> = 7.3 Hz, 6H), 1.99 (dt, <i>J</i> = 14.2, 7.4 Hz, 2H), 1.78 (s, 2H), 1.37 (dd, <i>J</i> = 6.7, 3.8 Hz, 2H), 1.31 (t, <i>J</i> = 7.3 Hz, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.2, 163.7, 158.7, 157.7, 155.9, 155.8, 155.8, 154.3, 154.1, 154.0, 144.1, 144.1, 134.6, 130.5, 130.5, 127.9, 127.8, 127.8, 127.7, 127.7, 127.5, 127.5, 126.5, 120.3, 120.3, 117.2, 116.5, 115.7, 115.7, 114.2, 98.4, 98.3, 71.0, 70.1, 70.1, 58.2, 53.4, 52.8, 52.7, 52.7, 47.0, 45.7, 41.8, 29.7, 29.6, 26.2, 24.5, 22.1. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>48</sub>H<sub>48</sub>N<sub>7</sub>NaO<sub>2</sub>P<sup>+</sup>, 808.3499; found, 808.3501.</div></div><div id="sec4_1_1_48" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> 1-(4-(5-(3-(2-Chloro-5-methoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>27b</b>)</h5><div class="NLM_p last">The titled compound <b>27b</b> was obtained from <b>27a</b> following the general procedure described for <b>1c</b>. The compound <b>27b</b> (63%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 8.01 (d, <i>J</i> = 5.8 Hz, 1H), 7.66 (dd, <i>J</i> = 12.9, 6.9 Hz, 6H), 7.57 (d, <i>J</i> = 6.7 Hz, 3H), 7.51–7.41 (m, 7H), 7.18 (d, <i>J</i> = 4.5 Hz, 2H), 6.72 (dd, <i>J</i> = 15.6, 9.8 Hz, 1H), 6.27–6.18 (m, 1H), 5.77 (d, <i>J</i> = 10.1 Hz, 1H), 4.42–4.35 (m, 2H), 3.80 (d, <i>J</i> = 4.0 Hz, 3H), 3.75 (s, 4H), 2.90 (s, 4H), 2.76 (s, 2H), 1.99 (d, <i>J</i> = 11.4 Hz, 2H), 1.68 (s, 2H), 1.34 (d, <i>J</i> = 19.6 Hz, 2H). <sup>13</sup>C NMR (100 MHz, MeOD): δ 166.0, 163.7, 163.6, 163.6, 159.7, 158.8, 158.4, 158.2, 155.1, 155.0, 153.2, 144.0, 133.8, 132.9, 132.9, 132.8, 132.1, 132.1, 129.9, 128.6, 128.3, 128.3, 128.2, 128.0, 127.6, 126.9, 125.9, 125.9, 117.4, 117.4, 115.3, 115.3, 107.3, 107.1, 57.0, 54.8, 51.7, 46.1, 39.8, 28.8, 24.1, 23.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>42</sub>H<sub>43</sub>ClN<sub>7</sub>NaO<sub>2</sub>P<sup>+</sup>, 766.2797; found, 766.2800.</div></div><div id="sec4_1_1_49" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> 1-(4-(5-(3-(3,5-Bis(trifluoromethyl)phenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>34b</b>)</h5><div class="NLM_p last">The titled compound <b>34b</b> was obtained from <b>34a</b> following the general procedure described for <b>1c</b>. The compound <b>34b</b> (69%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.76 (d, <i>J</i> = 1.6 Hz, 2H), 8.08 (s, 1H), 7.87 (s, 1H), 7.78–7.71 (m, 6H), 7.56–7.50 (m, 3H), 7.42 (td, <i>J</i> = 7.7, 3.1 Hz, 6H), 6.54 (dd, <i>J</i> = 16.8, 10.5 Hz, 1H), 6.27 (dd, <i>J</i> = 16.9, 2.0 Hz, 1H), 5.67 (dd, <i>J</i> = 10.6, 2.0 Hz, 1H), 4.40 (t, <i>J</i> = 7.2 Hz, 2H), 3.67 (s, 2H), 3.58–3.49 (m, 2H), 2.41 (t, <i>J</i> = 5.0 Hz, 4H), 2.33 (t, <i>J</i> = 7.5 Hz, 2H), 1.98 (d, <i>J</i> = 7.5 Hz, 2H), 1.59–1.52 (m, 2H), 1.39 (q, <i>J</i> = 8.2 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 165.2, 163.9, 163.8, 155.1, 154.8, 142.8, 136.2, 133.2, 133.2, 133.1, 132.1, 132.0, 131.6, 131.2, 130.9, 130.6, 129.6, 129.6, 128.8, 128.5, 128.4, 127.8, 127.7, 127.6, 127.5, 124.9, 122.2, 121.2, 105.5, 105.2, 58.2, 53.3, 53.2, 52.7, 47.0, 45.7, 41.8, 39.9, 36.0, 29.6, 26.2, 24.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>43</sub>H<sub>40</sub>F<sub>6</sub>N<sub>7</sub>NaOP<sup>+</sup>, 838.2828; found, 838.2830.</div></div><div id="sec4_1_1_50" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> 1-(4-(5-(3-(3-Fluoro-5-(trifluoromethyl)phenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>35b</b>)</h5><div class="NLM_p last">The titled compound <b>35b</b> was obtained from <b>35a</b> following the general procedure described for <b>1c</b>. The compound <b>35b</b> (64%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.85 (d, <i>J</i> = 10.0 Hz, 1H), 8.31 (s, 1H), 8.06 (s, 1H), 7.80 (dd, <i>J</i> = 12.3, 7.7 Hz, 6H), 7.55 (t, <i>J</i> = 7.5 Hz, 3H), 7.45 (dt, <i>J</i> = 8.0, 4.0 Hz, 6H), 6.53 (dd, <i>J</i> = 16.9, 10.5 Hz, 1H), 6.27 (d, <i>J</i> = 16.8 Hz, 1H), 5.67 (d, <i>J</i> = 10.5 Hz, 1H), 4.39 (t, <i>J</i> = 7.2 Hz, 2H), 3.68 (s, 2H), 3.54 (s, 2H), 2.42 (d, <i>J</i> = 5.9 Hz, 4H), 2.35 (t, <i>J</i> = 7.7 Hz, 2H), 1.96 (t, <i>J</i> = 7.6 Hz, 2H), 1.56 (p, <i>J</i> = 7.7 Hz, 2H), 1.42–1.33 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 163.9, 163.5, 163.4, 161.0, 155.2, 154.6, 142.9, 137.4, 137.3, 133.3, 133.2, 132.1, 132.1, 128.9, 128.8, 128.6, 128.5, 127.9, 127.8, 127.5, 121.3, 121.3, 121.2, 121.2, 121.0, 120.8, 119.1, 115.2, 111.3, 105.6, 105.4, 105.4, 58.2, 53.2, 52.7, 46.9, 45.6, 41.7, 29.5, 26.1, 24.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>42</sub>H<sub>40</sub>F<sub>4</sub>N<sub>7</sub>NaOP<sup>+</sup>, 788.2860; found, 788.2862.</div></div><div id="sec4_1_1_51" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> 1-(3-((3-(3,5-Dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)azetidin-1-yl)prop-2-en-1-one (<b>1c</b>)</h5><div class="NLM_p last">To a solution of compound <b>1b</b> (0.45 g, 0.60 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added TFA (5 mL) at room temperature. After stirring for 30 min, the resulting mixture was concentrated in vacuo to afford a crude. To a solution of crude compound, TEA (98 μL, 0.70 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added <b>46</b> (52 μL, 0.60 mmol) at 0 °C. After stirring at room temperature for 1 h, the mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (5 mL), washed with saturated NaCl solution (15 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH 30:1) to afford compound <b>1c</b> (78 mg, 72%) as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.06 (d, <i>J</i> = 2.8 Hz, 1H), 7.87–7.76 (m, 6H), 7.59–7.42 (m, 11H), 6.58 (d, <i>J</i> = 2.9 Hz, 1H), 6.37–6.12 (m, 2H), 5.68–5.57 (m, 1H), 4.74–4.53 (m, 2H), 4.28–4.22 (m, 2H), 4.18 (t, <i>J</i> = 9.6 Hz, 1H), 4.03–3.98 (m, 1H), 3.76 (d, <i>J</i> = 2.8 Hz, 6H), 3.29 (s, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.7, 163.9, 160.3, 157.8, 155.1, 154.7, 147.7, 146.8, 146.4, 135.4, 135.4, 133.4, 133.3, 132.1, 132.1, 132.0, 131.9, 129.0, 128.5, 128.4, 128.0, 127.3 127.3, 125.8, 125.8, 125.1, 107.9, 105.5, 101.9, 100.6, 55.3, 55.3, 53.6, 52.1, 50.9, 49.2, 29.1, 29.1. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>38</sub>H<sub>35</sub>N<sub>6</sub>NaO<sub>3</sub>P<sup>+</sup>, 677.2400; found, 677.2402.</div></div><div id="sec4_1_1_52" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> 1-(3-((3-(3,5-Dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidin-1-yl)prop-2-en-1-one <b>(2c</b>)</h5><div class="NLM_p last">The titled compound <b>2c</b> was obtained from <b>2b</b> following the general procedure described for <b>1c</b>. The compound <b>2c</b> (66%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.07 (s, 1H), 7.88–7.77 (m, 6H), 7.53 (d, <i>J</i> = 7.6 Hz, 3H), 7.49 (s, 2H), 7.43 (dq, <i>J</i> = 8.0, 4.6, 3.8 Hz, 6H), 6.62–6.48 (m, 2H), 6.24 (d, <i>J</i> = 16.6 Hz, 1H), 5.64 (d, <i>J</i> = 10.3 Hz, 1H), 4.62 (d, <i>J</i> = 13.2 Hz, 1H), 4.44 (s, 2H), 3.95 (d, <i>J</i> = 13.3 Hz, 1H), 3.76 (d, <i>J</i> = 2.7 Hz, 6H), 2.97 (t, <i>J</i> = 13.0 Hz, 1H), 2.58 (t, <i>J</i> = 12.9 Hz, 1H), 1.92–1.88 (m, 2H), 1.57 (s, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.6, 161.8, 161.8, 161.7, 158.0, 156.1, 154.5, 154.5, 144.5, 135.2, 128.2, 128.2, 128.1, 127.6, 127.6, 106.6, 101.4, 101.3, 98.5, 98.5, 77.5, 55.8, 50.5, 46.3, 46.3, 44.9, 44.9, 42.5, 36.1, 33.9, 32.9, 32.2, 31.8, 31.7, 30.0, 29.9, 29.6, 22.9, 14.40. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>41</sub>H<sub>43</sub>N<sub>6</sub>NaO<sub>4</sub>P<sup>+</sup> C<sub>39</sub>H<sub>37</sub>N<sub>6</sub>NaO<sub>3</sub>P<sup>+</sup>, 691.2557; found, 691.2559.</div></div><div id="sec4_1_1_53" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> 1-(4-(3-(3,5-Dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>3c</b>)</h5><div class="NLM_p last">The titled compound <b>3c</b> was obtained from <b>3b</b> following the general procedure described for <b>1c</b>. The compound <b>3c</b> (62%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.05 (s, 1H), 7.81 (dd, <i>J</i> = 12.3, 7.7 Hz, 6H), 7.56–7.51 (m, 3H), 7.49 (d, <i>J</i> = 2.3 Hz, 2H), 7.42 (td, <i>J</i> = 7.7, 2.9 Hz, 6H), 6.65–6.55 (m, 2H), 6.29 (dd, <i>J</i> = 16.8, 1.8 Hz, 1H), 5.70 (dd, <i>J</i> = 10.6, 1.9 Hz, 1H), 4.98 (td, <i>J</i> = 11.1, 10.6, 5.1 Hz, 1H), 4.85–4.73 (m, 1H), 4.16 (d, <i>J</i> = 13.3 Hz, 1H), 3.76 (s, 6H), 3.31 (t, <i>J</i> = 13.1 Hz, 1H), 2.94 (d, <i>J</i> = 12.8 Hz, 1H), 2.34 (d, <i>J</i> = 12.8 Hz, 2H), 2.07 (dd, <i>J</i> = 12.6, 3.9 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 169.8, 165.5, 161.5, 161.5, 158.6, 157.7, 155.6, 153.9, 153.7, 144.3, 144.3, 142.7, 141.2, 141.2, 135.5, 134.9, 134.9, 134.8, 127.9, 127.9, 127.9, 127.6, 127.6, 127.6, 106.3, 106.3, 101.2, 101.2, 98.5, 98.5, 75.6, 74.6, 55.5, 53.9, 53.9, 50.5, 45.1, 41.3, 31.8. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>39</sub>H<sub>37</sub>N<sub>6</sub>NaO<sub>3</sub>P<sup>+</sup>, 691.2557; found, 691.2559.</div></div><div id="sec4_1_1_54" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> 1-(4-(2-(3-(3,5-Dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)piperidin-1-yl)prop-2-en-1-one (<b>5c</b>)</h5><div class="NLM_p last">The titled compound <b>5c</b> was obtained from <b>5b</b> following the general procedure described for <b>1c</b>. The compound <b>5c</b> (62%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.06 (s, 1H), 7.81 (t, <i>J</i> = 10.1 Hz, 6H), 7.53 (d, <i>J</i> = 7.5 Hz, 3H), 7.49 (d, <i>J</i> = 8.8 Hz, 2H), 7.47–7.38 (m, 6H), 6.58 (q, <i>J</i> = 2.3 Hz, 1H), 6.43–6.24 (m, 2H), 5.75–5.54 (m, 1H), 4.56–4.33 (m, 2H), 3.76 (d, <i>J</i> = 2.6 Hz, 6H), 3.71 (d, <i>J</i> = 9.1 Hz, 2H), 3.60–3.44 (m, 2H), 3.46–3.20 (m, 1H), 3.00 (dt, <i>J</i> = 12.6, 6.4 Hz, 1H), 2.05 (s, 1H), 1.64 (s, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 163.9, 163.8, 160.5, 160.3, 154.8, 154.5, 145.8, 135.7, 135.3, 134.8, 133.4, 133.4, 133.3, 133.3, 132.0, 132.0, 129.2, 128.5, 128.5, 128.4, 128.4, 128.2, 128.0, 127.2, 127.2, 108.6, 107.9, 106.0, 105.7, 105.5, 100.5, 55.3, 46.1, 44.3, 42.3, 35.9, 33.6, 32.6, 31.6, 29.7. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>41</sub>H<sub>41</sub>N<sub>6</sub>NaO<sub>3</sub>P<sup>+</sup>, 719.2870; found, 719.2802.</div></div><div id="sec4_1_1_55" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> 1-(3-((3-(3,5-Dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)prop-2-en-1-one (<b>6c</b>)</h5><div class="NLM_p last">The titled compound <b>6c</b> was obtained from <b>6b</b> following the general procedure described for <b>1c</b>. The compound <b>6c</b> (67%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.06 (d, <i>J</i> = 4.5 Hz, 1H), 7.87–7.79 (m, 6H), 7.56–7.36 (m, 11H), 6.69–6.41 (m, 2H), 6.26–6.12 (m, 1H), 5.75–5.40 (m, 1H), 4.32 (q, <i>J</i> = 9.5, 6.0 Hz, 2H), 3.90 (d, <i>J</i> = 34.2 Hz, 1H), 3.76 (s, 6H), 3.11–2.97 (m, 1H), 2.92–2.72 (m, 1H), 2.34 (s, 1H), 1.94–1.72 (m, 3H), 1.45 (s, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 158.0, 155.6, 155.6, 154.9, 154.1, 145.7, 136.1, 136.1, 136.1, 128.5, 128.5, 128.5, 125.6, 125.6, 125.6, 125.6, 124.7, 122.36, 122.36, 122.4, 122.3, 120.9, 120.9, 120.9, 112.1, 112.1, 112.1, 103.1, 103.1, 103.1, 98.5, 98.5, 50.8, 44.66, 44.7, 36.1, 36.1, 33.5, 31.8, 28.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>40</sub>H<sub>39</sub>N<sub>6</sub>NaO<sub>3</sub>P<sup>+</sup>, 705.2713; found, 705.2715.</div></div><div id="sec4_1_1_56" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> 1-(4-(2-(3-(3,5-Dimethoxyphenyl)-4-((triphenyl-λ5-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)piperazin-1-yl)prop-2-en-1-one (<b>7c</b>)</h5><div class="NLM_p last">The titled compound <b>7c</b> was obtained from <b>7b</b> following the general procedure described for <b>1c</b>. The compound <b>7c</b> (67%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.06 (s, 1H), 7.80 (ddd, <i>J</i> = 12.3, 8.2, 1.4 Hz, 6H), 7.58–7.48 (m, 3H), 7.48 (d, <i>J</i> = 2.3 Hz, 2H), 7.47–7.37 (m, 6H), 6.61–6.47 (m, 2H), 6.25 (dt, <i>J</i> = 16.7, 1.5 Hz, 1H), 5.66 (dt, <i>J</i> = 10.6, 1.5 Hz, 1H), 4.53 (t, <i>J</i> = 6.9 Hz, 2H), 3.76 (d, <i>J</i> = 1.1 Hz, 6H), 3.64 (s, 2H), 3.50 (s, 2H), 2.96 (t, <i>J</i> = 6.9 Hz, 2H), 2.57 (s, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 169.4, 165.3, 161.5, 157.6, 155.7, 154.6, 144.4, 140.6, 135.0, 133.4, 130.6, 127.8, 127.4, 126.5, 116.4, 111.5, 106.3, 101.1, 98.3, 95.3, 92.6, 82.5, 76.9, 68.6, 67.5, 63.2, 61.7, 56.7, 55.5, 53.1, 52.5, 47.7, 46.5, 45.7, 44.4, 44.4, 41.9, 29.7, 25.5, 24.8. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>40</sub>H<sub>40</sub>N<sub>7</sub>NaO<sub>3</sub>P<sup>+</sup>, 720.2822; found, 720.2827.</div></div><div id="sec4_1_1_57" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> 1-(4-(3-(3-(3,5-Dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)piperazin-1-yl)prop-2-en-1-one (<b>8c</b>)</h5><div class="NLM_p last">The titled compound <b>8c</b> was obtained from <b>8b</b> following the general procedure described for <b>1c</b>. The compound <b>8c</b> (65%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.10 (s, 1H), 7.80 (ddd, <i>J</i> = 12.3, 8.3, 1.4 Hz, 6H), 7.54 (ddd, <i>J</i> = 7.3, 5.1, 1.5 Hz, 3H), 7.44 (qd, <i>J</i> = 7.2, 2.8 Hz, 8H), 6.66–6.49 (m, 2H), 6.26 (dd, <i>J</i> = 16.8, 1.9 Hz, 1H), 5.68 (dd, <i>J</i> = 10.5, 1.9 Hz, 1H), 4.46 (s, 2H), 3.76 (s, 6H), 3.67 (s, 2H), 3.56 (d, <i>J</i> = 13.0 Hz, 2H), 2.51 (d, <i>J</i> = 17.1 Hz, 6H), 2.25–2.13 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.2, 161.5, 161.5, 157.7, 157.7, 155.6, 155.6, 154.3, 154.3, 144.3, 144.29, 134.9, 134.9, 128.0, 128.0, 127.9, 127.4, 127.3, 127.3, 127.2, 106.33, 106.3, 101.1, 99.5, 98.3, 55.6, 55.4, 55.4, 53.2, 52.5, 52.5, 45.4, 45.3, 45.3, 41.6, 29.7, 29.7, 29.7, 26.5, 26.5, 22.7. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>41</sub>H<sub>42</sub>N<sub>7</sub>NaO<sub>3</sub>P<sup>+</sup>, 734.2979; found, 734.2981.</div></div><div id="sec4_1_1_58" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> 1-(4-(4-(3-(3,5-Dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)piperazin-1-yl)prop-2-en-1-one (<b>9c</b>)</h5><div class="NLM_p last">The titled compound <b>9c</b> was obtained from <b>9b</b> following the general procedure described for <b>1c</b>. The compound <b>9c</b> (65%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.07 (s, 1H), 7.81 (ddt, <i>J</i> = 12.2, 7.0, 1.3 Hz, 6H), 7.56–7.39 (m, 11H), 6.61–6.50 (m, 2H), 6.32–6.24 (m, 1H), 5.68 (ddd, <i>J</i> = 10.6, 6.4, 2.0 Hz, 1H), 4.37 (t, <i>J</i> = 7.3 Hz, 2H), 3.76 (s, 6H), 3.68 (s, 2H), 3.56 (d, <i>J</i> = 13.3 Hz, 2H), 2.41 (s, 4H), 2.30 (s, 2H), 1.98–1.88 (m, 2H), 1.45–1.31 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 161.6, 161.5, 161.5, 157.7, 157.7, 155.9, 155.8, 155.8, 154.2, 154.2, 144.0, 144.0, 143.8, 135.2, 127.9, 127.8, 127.8, 127.5, 127.5, 106.4, 101.1, 98.3, 58.5, 58.5, 55.6, 55.6, 53.4, 52.7, 47.2, 47.2, 46.9, 45.7, 41.8, 29.7, 29.7, 29.0, 29.0, 27.3, 27.3, 26.6, 26.6. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>42</sub>H<sub>44</sub>N<sub>7</sub>NaO<sub>3</sub>P<sup>+</sup>, 748.3135; found, 748.3136.</div></div><div id="sec4_1_1_59" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> 1-(4-(5-(3-(3,5-Dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>10c</b>)</h5><div class="NLM_p last">The titled compound <b>10c</b> was obtained from compound <b>45</b> following the general procedure described for <b>1c</b>. The compound <b>10c</b> (60%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.06 (s, 1H), 7.80 (dd, <i>J</i> = 11.7, 8.1 Hz, 6H), 7.52 (d, <i>J</i> = 7.3 Hz, 3H), 7.48 (s, 2H), 7.45–7.37 (m, 6H), 6.56 (s, 1H), 6.55–6.47 (m, 1H), 6.26 (d, <i>J</i> = 16.8 Hz, 1H), 5.66 (d, <i>J</i> = 10.5 Hz, 1H), 4.39 (d, <i>J</i> = 6.8 Hz, 2H), 3.75 (s, 6H), 3.64 (s, 2H), 3.48 (d, <i>J</i> = 12.1 Hz, 2H), 2.38 (s, 4H), 2.31 (d, <i>J</i> = 7.1 Hz, 2H), 1.96 (d, <i>J</i> = 6.4 Hz, 2H), 1.52 (s, 2H), 1.37 (s, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 187.4, 165.3, 164.0, 160.2, 159.8, 154.8, 154.8, 154.5, 145.6, 135.8, 133.4, 133.3, 132.0, 129.2, 128.6, 128.5, 128.4, 128.3, 128.3, 127.7, 127.6, 107.9, 105.7, 105.5, 100.4, 99.9, 70.6, 60.3, 58.2, 55.3, 53.5, 53.3, 46.8, 45.7, 41.9, 31.6, 29.7, 29.1, 28.4, 26.3, 24.6, 22.7, 20.6. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>43</sub>H<sub>46</sub>N<sub>7</sub>NaO<sub>3</sub>P<sup>+</sup>, 762.3292; found, 762.3294.</div></div><div id="sec4_1_1_60" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> 1-(4-(6-(3-(3,5-Dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)hexyl)piperazin-1-yl)prop-2-en-1-one (<b>11c</b>)</h5><div class="NLM_p last">The titled compound <b>11c</b> was obtained from <b>11b</b> following the general procedure described for <b>1c</b>. The compound <b>11c</b> (65%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.09 (s, 1H), 7.78 (s, 6H), 7.55 (d, <i>J</i> = 7.5 Hz, 3H), 7.42 (t, <i>J</i> = 7.7 Hz, 8H), 6.57 (s, 2H), 6.30 (d, <i>J</i> = 16.0 Hz, 1H), 5.72 (s, 1H), 4.39 (s, 2H), 3.75 (s, 6H), 3.49 (s, 4H), 2.43 (s, 4H), 1.96 (s, 4H), 1.38 (s, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 165.3, 162.3, 161.5, 161.5, 157.7, 157.7, 156.2, 155.6, 155.6, 154.1, 154.1, 153.1, 151.1, 150.5, 144.6, 144.1, 144.1, 135.0, 129.3, 128.5, 127.5, 127.0, 123.4, 119.9, 118.1, 106.4, 104.9, 101.1, 98.3, 98.3, 77.4, 58.1, 55.6, 52.9, 52.3, 50.7, 47.0, 29.7, 29.5, 26.7, 26.3, 25.3, 22.4. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>44</sub>H<sub>48</sub>N<sub>7</sub>NaO<sub>3</sub>P<sup>+</sup>, 776.3448; found, 776.3450.</div></div><div id="sec4_1_1_61" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> 1-(4-(7-(3-(3,5-Dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)heptyl)piperazin-1-yl)prop-2-en-1-one (<b>12c</b>)</h5><div class="NLM_p last">The titled compound <b>12c</b> was obtained from 1<b>2b</b> following the general procedure described for <b>1c</b>. The compound <b>12c</b> (65%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.27 (s, 1H), 7.69 (dd, <i>J</i> = 12.8, 7.7 Hz, 6H), 7.63–7.58 (m, 3H), 7.46 (dt, <i>J</i> = 11.1, 5.5 Hz, 6H), 7.21 (s, 2H), 6.59 (d, <i>J</i> = 2.4 Hz, 1H), 6.49 (dd, <i>J</i> = 16.8, 10.5 Hz, 1H), 6.34 (d, <i>J</i> = 16.7 Hz, 1H), 5.83–5.73 (m, 1H), 4.41 (t, <i>J</i> = 7.2 Hz, 2H), 3.72 (s, 6H), 3.12 (qd, <i>J</i> = 7.2, 4.2 Hz, 2H), 2.96 (dd, <i>J</i> = 11.2, 5.6 Hz, 2H), 1.98–1.85 (m, 2H), 1.71 (s, 2H), 1.47–1.06 (m, 12H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 166.5, 163.4, 163.1, 161.4, 161.4, 149.6, 149.0, 145.4, 135.1, 134.2, 134.1, 134.1, 131.1, 130.1, 130.0, 130.0, 127.8, 127.0, 126.7, 119.0, 119.0, 116.1, 116.1, 108.9, 108.9, 106.4, 106.4, 106.2, 102.2, 102.2, 58.1, 56.3, 56.3, 52.4, 49.1, 46.6, 43.7, 39.9, 30.1, 29.8, 28.9, 27.1, 26.7, 26.2, 24.1. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>45</sub>H<sub>50</sub>N<sub>7</sub>NaO<sub>3</sub>P<sup>+</sup>, 790.3605; found, 790.3607.</div></div><div id="sec4_1_1_62" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> 1-(3-((4-Amino-3-(3,5-dimethoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)azetidin-1-yl)prop-2-en-1-one (<b>1</b>)</h5><div class="NLM_p last">To a solution of compound <b>1c</b> (0.10 g, 0.20 mmol) in THF (0.5 mL) was added AcOH/THF/H<sub>2</sub>O (3 mL, 3:1:2) at room temperature. After stirring for 18 h, the mixture was washed by saturated NaHCO<sub>3</sub> to pH∼7. The mixture was extracted with EtOAc, and the combined organic phases were dried and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH = 15:1) to afford compound <b>1</b> (1.2 g, 60%) as a yellow solid. mp 182–184 °C; IR (KBr): 3341, 3201, 2953, 2737, 1695, 1331, 1074 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.38 (s, 1H), 6.80 (d, <i>J</i> = 2.3 Hz, 2H), 6.57 (t, <i>J</i> = 2.3 Hz, 1H), 6.33 (dd, <i>J</i> = 17.0, 1.9 Hz, 1H), 6.17 (dd, <i>J</i> = 17.0, 10.3 Hz, 1H), 5.76–5.57 (m, 3H), 4.76–4.61 (m, 2H), 4.38–4.14 (m, 3H), 4.02 (dd, <i>J</i> = 10.5, 5.5 Hz, 1H), 3.87 (s, 6H), 3.49–3.25 (m, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.7, 161.6, 157.8, 156.2, 154.7, 144.7, 134.8, 127.4, 127.2, 125.7, 106.3, 101.2, 98.4, 55.6, 53.5, 50.8, 49.4, 32.7, 29.1, 27.9. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>20</sub>H<sub>22</sub>N<sub>6</sub>NaO<sub>3</sub><sup>+</sup>, 417.1646; found, 417.1648. HPLC purity: 99.5%.</div></div><div id="sec4_1_1_63" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> 1-(3-((4-Amino-3-(3,5-dimethoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidin-1-yl)prop-2-en-1-one (<b>2</b>)</h5><div class="NLM_p last">The titled compound <b>2</b> was obtained from <b>2c</b> following the general procedure described for <b>1</b>. The compound <b>2</b> (66%) was a white solid. mp 197–199 °C; IR (KBr): 3305, 3207, 2977, 2561, 1774, 1462, 974 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.38 (s, 1H), 6.81 (d, <i>J</i> = 2.2 Hz, 2H), 6.62–6.54 (m, 2H), 6.25 (dd, <i>J</i> = 16.9, 2.0 Hz, 1H), 5.76 (s, 2H), 5.66 (dd, <i>J</i> = 10.6, 2.0 Hz, 1H), 4.65 (d, <i>J</i> = 13.3 Hz, 1H), 4.49 (t, <i>J</i> = 7.2 Hz, 2H), 3.99 (d, <i>J</i> = 13.7 Hz, 1H), 3.86 (s, 6H), 3.00 (t, <i>J</i> = 12.6 Hz, 1H), 2.64–2.52 (m, 1H), 1.97–1.94 (m, 1H), 1.91 (s, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 164.5, 161.5, 158.0, 156.0, 154.6, 144.6, 134.9, 128.5, 127.5, 106.4, 101.3, 98.3, 55.6, 50.0, 49.1, 45.7, 45.2, 39.9, 37.7, 29.6, 27.9. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>21</sub>H<sub>24</sub>N<sub>6</sub>NaO<sub>3</sub><sup>+</sup>, 431.1802; found, 431.1804. HPLC purity: 100.0%.</div></div><div id="sec4_1_1_64" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> 1-(4-(4-Amino-3-(3,5-dimethoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>3</b>)</h5><div class="NLM_p last">The titled compound <b>3</b> was obtained from <b>3c</b> following the general procedure described for <b>1</b>. The compound <b>3</b> (64%) was a yellow solid. mp 185–187 °C; IR (KBr): 3309, 3305, 2911, 2715, 1608, 1382, 1077 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.38 (s, 1H), 6.80 (d, <i>J</i> = 2.2 Hz, 2H), 6.67–6.51 (m, 2H), 6.31 (dd, <i>J</i> = 16.8, 1.8 Hz, 1H), 5.84–5.63 (m, 3H), 5.05 (tt, <i>J</i> = 11.3, 4.2 Hz, 1H), 4.85 (d, <i>J</i> = 13.4 Hz, 1H), 4.20 (d, <i>J</i> = 13.9 Hz, 1H), 3.86 (s, 6H), 3.33 (t, <i>J</i> = 12.7 Hz, 1H), 3.02–2.85 (m, 1H), 2.34 (t, <i>J</i> = 11.8 Hz, 2H), 2.11 (d, <i>J</i> = 13.0 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 161.5, 157.8, 155.8, 154.7, 154.3, 144.1, 135.1, 132.1, 131.6, 106.3, 101.1, 100.0, 98.3, 79.6, 55.7, 55.6, 52.9, 45.5, 29.7, 28.4, 26.8. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>21</sub>H<sub>24</sub>N<sub>6</sub>NaO<sub>3</sub><sup>+</sup>, 431.1802; found, 431.1805. HPLC purity: 100.0%.</div></div><div id="sec4_1_1_65" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> 1-(4-((4-Amino-3-(3,5-dimethoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)prop-2-en-1-one (<b>4</b>)</h5><div class="NLM_p last">The titled compound <b>20</b> was obtained following the procedure described for <b>1</b>. The compound <b>3</b> (64%) was a yellow solid. mp 195–197 °C; IR (KBr): 3314, 3306, 2971, 2714, 1596, 1381, 1377 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.34 (s, 1H), 6.80 (d, <i>J</i> = 2.3 Hz, 2H), 6.57–6.49 (m, 2H), 6.23 (d, <i>J</i> = 16.8 Hz, 1H), 5.89 (s, 2H), 5.64 (d, <i>J</i> = 10.6 Hz, 1H), 4.65 (d, <i>J</i> = 13.3 Hz, 1H), 4.33 (d, <i>J</i> = 7.1 Hz, 2H), 3.97 (d, <i>J</i> = 13.8 Hz, 1H), 3.85 (s, 6H), 3.00 (t, <i>J</i> = 12.9 Hz, 1H), 2.62 (t, <i>J</i> = 12.9 Hz, 1H), 2.33 (d, <i>J</i> = 11.0 Hz, 1H), 1.66 (d, <i>J</i> = 16.3 Hz, 3H), 1.33 (td, <i>J</i> = 14.3, 7.5 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.4, 161.5, 161.5, 157.9, 156.0, 154.7, 144.3, 134.9, 127.9, 127.9, 127.4, 106.4, 101.1, 99.9, 98.2, 55.6, 51.9, 45.6, 41.8, 36.8, 30.5, 29.4. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>26</sub>N<sub>6</sub>NaO<sub>3</sub><sup>+</sup>, 445.1959; found, 445.1961. HPLC purity: 99.6%.</div></div><div id="sec4_1_1_66" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90"> 1-(4-(2-(4-Amino-3-(3,5-dimethoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)piperidin-1-yl)prop-2-en-1-one (<b>5</b>)</h5><div class="NLM_p last">The titled compound <b>5</b> was obtained from <b>5c</b> following the general procedure described for <b>1</b>. The compound <b>5</b> (67%) was a yellow solid. mp 201–203 °C; IR (KBr): 3213, 3201, 2951, 2733, 1794, 1162, 1106 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.38 (d, <i>J</i> = 1.1 Hz, 1H), 6.81 (d, <i>J</i> = 2.3 Hz, 2H), 6.57 (d, <i>J</i> = 2.4 Hz, 1H), 6.44–6.36 (m, 2H), 5.68 (dd, <i>J</i> = 9.6, 2.7 Hz, 1H), 4.50 (dd, <i>J</i> = 12.8, 6.9 Hz, 2H), 3.87 (s, 7H), 3.80–3.72 (m, 2H), 3.72–3.65 (m, 1H), 3.57–3.47 (m, 2H), 3.01 (d, <i>J</i> = 7.3 Hz, 1H), 1.65 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 166.3, 162.5, 162.3, 158.7, 156.8, 155.2, 145.2, 136.0, 128.9, 128.4, 107.4, 107.2, 102.1, 99.3, 56.6, 47.0, 45.6, 43.2, 36.9, 34.6, 33.5, 32.6, 30.7. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>28</sub>N<sub>6</sub>NaO<sub>3</sub><sup>+</sup>, 459.2115; found, 459.2115. HPLC purity: 100.0%.</div></div><div id="sec4_1_1_67" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> 1-(3-((4-Amino-3-(3,5-dimethoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)prop-2-en-1-one (<b>6</b>)</h5><div class="NLM_p last">The titled compound <b>6</b> was obtained from <b>6c</b> following the general procedure described for <b>1</b>. The compound <b>6</b> (58%) was a yellow solid. mp 190–193 °C; IR (KBr): 3331, 3206, 2971, 2712, 1595, 1381, 1097 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.39–8.33 (m, 1H), 6.93–6.75 (m, 2H), 6.63–6.46 (m, 2H), 6.21 (dd, <i>J</i> = 16.9, 8.7 Hz, 1H), 5.99 (s, 2H), 5.61 (dd, <i>J</i> = 32.0, 10.5 Hz, 1H), 4.53–4.27 (m, 3H), 3.86 (s, 6H), 3.07 (dt, <i>J</i> = 23.7, 12.4 Hz, 1H), 2.81 (dt, <i>J</i> = 44.0, 12.0 Hz, 1H), 2.35 (s, 1H), 1.93 (s, 1H), 1.58–1.29 (m, 2H), 1.26 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.2, 161.5, 161.5, 158.0, 155.7, 154.3, 144.2, 135.1, 127.7, 127.5, 106.4, 106.3, 101.1, 98.3, 55.5, 55.4, 53.3, 52.7, 45.7, 45.4, 41.9, 26.8. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>26</sub>N<sub>6</sub>NaO<sub>3</sub><sup>+</sup>, 445.1959; found, 445.1961. HPLC purity: 99.9%.</div></div><div id="sec4_1_1_68" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> 1-(4-(2-(4-Amino-3-(3,5-dimethoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)piperazin-1-yl)prop-2-en-1-one (<b>7</b>)</h5><div class="NLM_p last">The titled compound <b>7</b> was obtained from <b>7c</b> following the general procedure described for <b>1</b>. The compound <b>7</b> (70%) was a yellow solid. mp 192–194 °C; IR (KBr): 3411, 3377, 2715, 1536, 1071, 1066, 960 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.36 (s, 1H), 6.80 (d, <i>J</i> = 2.3 Hz, 2H), 6.60–6.47 (m, 2H), 6.26 (dd, <i>J</i> = 16.8, 1.9 Hz, 1H), 5.67 (dd, <i>J</i> = 10.5, 1.9 Hz, 1H), 4.57 (t, <i>J</i> = 6.7 Hz, 2H), 3.85 (s, 6H), 3.62 (s, 2H), 3.49 (s, 2H), 2.96 (t, <i>J</i> = 6.7 Hz, 2H), 2.56 (t, <i>J</i> = 5.0 Hz, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 161.5, 157.4, 155.1, 154.5, 144.6, 134.8, 127.9, 127.4, 106.3, 101.2, 98.2, 95.6, 56.7, 55.6, 52.6, 50.9, 45.6, 44.4, 41.8, 31.9, 29.1. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>27</sub>N<sub>7</sub>NaO<sub>3</sub><sup>+</sup>, 460.2068; found, 460.2072. HPLC purity: 98.8%.</div></div><div id="sec4_1_1_69" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> 1-(4-(3-(4-Amino-3-(3,5-dimethoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)piperazin-1-yl)prop-2-en-1-one (<b>8</b>)</h5><div class="NLM_p last">The titled compound <b>8</b> was obtained from <b>8c</b> following the general procedure described for <b>1</b>. The compound <b>8</b> (67%) was a yellow solid. mp 207–209 °C; IR (KBr): 3114, 3107, 2957, 2931, 1714, 1312, 904 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.36 (s, 1H), 6.81 (d, <i>J</i> = 2.3 Hz, 2H), 6.58–6.50 (m, 2H), 5.88 (s, 2H), 5.69 (dd, <i>J</i> = 10.5, 1.9 Hz, 1H), 4.52 (t, <i>J</i> = 6.9 Hz, 2H), 3.86 (s, 6H), 3.69 (d, <i>J</i> = 6.9 Hz, 2H), 3.57 (s, 2H), 2.51 (dt, <i>J</i> = 10.8, 6.0 Hz, 6H), 2.21 (p, <i>J</i> = 7.0 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 160.3, 154.4, 133.4, 133.3, 132.2, 132.1, 132.0, 129.0, 128.6, 128.6, 128.4, 128.1, 127.3, 127.3, 107.9, 100.5, 55.4, 55.3, 53.1, 52.5, 45.2, 26.4. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>29</sub>N<sub>7</sub>NaO<sub>3</sub><sup>+</sup>, 474.2224; found, 474.2226. HPLC purity: 99.9%.</div></div><div id="sec4_1_1_70" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> 1-(4-(4-(4-Amino-3-(3,5-dimethoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)piperazin-1-yl)prop-2-en-1-one (<b>9</b>)</h5><div class="NLM_p last">The titled compound <b>9</b> was obtained from <b>9c</b> following the general procedure described for <b>1</b>. The compound <b>9</b> (66%) was a yellow solid. mp 218–219 °C; IR (KBr): 3304, 3107, 2911, 2509, 1977, 1712, 1430 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.40–8.36 (m, 1H), 6.81 (dd, <i>J</i> = 3.2, 2.0 Hz, 2H), 6.54 (ddd, <i>J</i> = 17.4, 8.7, 4.1 Hz, 2H), 6.28 (dt, <i>J</i> = 16.9, 2.5 Hz, 1H), 5.72–5.66 (m, 1H), 5.61 (s, 2H), 4.46 (s, 2H), 3.89–3.82 (m, 6H), 3.67 (s, 2H), 3.54 (s, 2H), 2.41 (s, 6H), 2.01 (s, 2H), 1.56 (s, 2H). <sup>13</sup>C NMR (100 MHz, MeOD): δ 169.4, 166.0, 152.2, 151.70, 147.6, 145.9, 132.7, 128.5, 126.6, 106.2, 106.1, 101.5, 101.4, 96.5, 56.6, 54.7, 53.5, 51.1, 40.5, 39.1, 38.5, 35.2, 28.3, 22.7. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>31</sub>N<sub>7</sub>NaO<sub>3</sub><sup>+</sup>, 488.2381; found, 488.2383. HPLC purity: 99.9%.</div></div><div id="sec4_1_1_71" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> 1-(4-(5-(4-Amino-3-(3,5-dimethoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>10</b>)</h5><div class="NLM_p last">The titled compound <b>10</b> was obtained from <b>10c</b> following the general procedure described for <b>1</b>. The compound <b>10</b> (70%) was a yellow solid. mp 236–238 °C; IR (KBr): 3410, 2941, 2715, 1384, 1204, 1157, 1061, 1039 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.38 (s, 1H), 6.82–6.80 (m, 2H), 6.58–6.55 (m, 1H), 6.53 (d, <i>J</i> = 10.4 Hz, 1H), 6.27 (d, <i>J</i> = 16.7 Hz, 1H), 5.68 (d, <i>J</i> = 10.6 Hz, 1H), 5.61 (s, 2H), 4.43 (s, 2H), 3.86 (s, 6H), 3.67 (s, 2H), 3.53 (s, 2H), 2.42–2.38 (m, 4H), 2.34–2.30 (m, 2H), 2.02–1.96 (m, 2H), 1.54 (d, <i>J</i> = 7.4 Hz, 2H), 1.39 (d, <i>J</i> = 6.9 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 161.6, 157.7, 155.9, 154.3, 144.0, 135.1, 127.7, 127.5, 106.4, 101.1, 100.0, 98.3, 58.2, 55.6, 53.4, 52.7, 47.1, 45.7, 41.8, 40.5, 29.6, 29.3, 26.2, 24.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>33</sub>N<sub>7</sub>NaO<sub>3</sub><sup>+</sup>, 502.2537; found, 502.2539. HPLC purity: 99.6%.</div></div><div id="sec4_1_1_72" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> 1-(4-(6-(4-Amino-3-(3,5-dimethoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)hexyl)piperazin-1-yl)prop-2-en-1-one (<b>11</b>)</h5><div class="NLM_p last">The titled compound <b>11</b> was obtained from <b>11c</b> following the general procedure described for <b>1</b>. The compound <b>11</b> (70%) was a yellow solid. mp 241–243 °C; IR (KBr): 3110, 2887, 2725, 1608, 1154, 1057, 1034, 997 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.34 (d, <i>J</i> = 1.3 Hz, 1H), 6.81 (dd, <i>J</i> = 2.3, 1.3 Hz, 2H), 6.61–6.52 (m, 2H), 6.29 (dt, <i>J</i> = 16.9, 1.6 Hz, 1H), 6.00 (s, 2H), 5.69 (dt, <i>J</i> = 10.5, 1.6 Hz, 1H), 4.43 (t, <i>J</i> = 7.3 Hz, 2H), 3.86 (d, <i>J</i> = 1.3 Hz, 6H), 3.69 (t, <i>J</i> = 5.0 Hz, 2H), 3.56 (t, <i>J</i> = 4.9 Hz, 2H), 2.42 (t, <i>J</i> = 5.0 Hz, 4H), 2.33 (t, <i>J</i> = 7.6 Hz, 2H), 1.97 (t, <i>J</i> = 7.2 Hz, 2H), 1.54–1.45 (m, 2H), 1.38 (t, <i>J</i> = 4.3 Hz, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 161.5, 157.8, 155.3, 154.1, 144.2, 135.0, 127.9, 127.5, 127.5, 106.4, 106.4, 101.1, 98.2, 58.3, 55.6, 55.6, 53.4, 52.7, 47.2, 45.7, 41.8, 29.7, 27.0, 26.6, 26.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>26</sub>H<sub>35</sub>N<sub>7</sub>NaO<sub>3</sub><sup>+</sup>, 516.2694; found, 516.2696. HPLC purity: 99.6%.</div></div><div id="sec4_1_1_73" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97"> 1-(4-(7-(4-Amino-3-(3,5-dimethoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)heptyl)piperazin-1-yl)prop-2-en-1-one (<b>12</b>)</h5><div class="NLM_p last">The titled compound <b>12</b> was obtained from <b>12c</b> following the general procedure described for <b>1</b>. The compound <b>12</b> (66%) was a yellow solid. mp 256–258 °C; IR (KBr): 3449, 3106, 2608, 2154, 1857, 1638, 1097 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.38 (d, <i>J</i> = 2.8 Hz, 1H), 6.82 (t, <i>J</i> = 2.5 Hz, 2H), 6.62–6.50 (m, 2H), 6.33–6.23 (m, 1H), 5.77–5.56 (m, 3H), 4.42 (s, 2H), 3.86 (d, <i>J</i> = 2.8 Hz, 6H), 3.70 (s, 2H), 3.57 (s, 2H), 2.50–2.37 (m, 4H), 2.33 (s, 2H), 1.96 (s, 2H), 1.47 (s, 2H), 1.33 (d, <i>J</i> = 27.0 Hz, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 161.6, 157.8, 154.4, 153.8, 144.5, 134.8, 128.4, 127.5, 127.1, 125.9, 106.4, 101.2, 98.1, 58.1, 55.6, 53.0, 52.3, 47.2, 44.7, 40.9, 29.7, 29.4, 28.8, 27.0, 26.5, 22.7. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>27</sub>H<sub>37</sub>N<sub>7</sub>NaO<sub>3</sub><sup>+</sup>, 530.2850; found, 530.2852. HPLC purity: 99.7%.</div></div><div id="sec4_1_1_74" class="NLM_sec NLM_sec_level_4"><div id="ac_i98" class="anchor-spacer"></div><h5 class="article-section__title" id="_i98"> 1-(4-(5-(4-Amino-3-(benzo[<i>d</i>][1,3]dioxol-5-yl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>13</b>)</h5><div class="NLM_p last">The titled compound <b>13</b> was obtained from <b>13b</b> following the general procedure described for <b>1</b>. The compound <b>13</b>(69%) was a white liquid. mp 238–240 °C; IR (KBr): 3324, 3317, 1980, 1765, 1341, 1016, 974 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.36 (s, 1H), 7.16 (d, <i>J</i> = 2.7 Hz, 1H), 6.97 (d, <i>J</i> = 7.9 Hz, 1H), 6.62–6.49 (m, 1H), 6.28 (dd, <i>J</i> = 16.9, 2.0 Hz, 1H), 6.06 (s, 2H), 5.86–5.65 (m, 3H), 4.42 (t, <i>J</i> = 7.2 Hz, 2H), 3.70 (d, <i>J</i> = 7.5 Hz, 2H), 3.55 (t, <i>J</i> = 5.1 Hz, 2H), 2.43 (t, <i>J</i> = 4.9 Hz, 4H), 2.35 (t, <i>J</i> = 7.6 Hz, 2H), 1.99 (td, <i>J</i> = 16.9, 15.0, 9.4 Hz, 2H), 1.79–1.14 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.2, 157.8, 155.7, 154.2, 148.6, 148.5, 143.8, 127.4, 127.1, 122.1, 109.0, 108.9, 101.6, 101.5, 98.2, 58.1, 53.3, 52.7, 46.9, 45.6, 41.7, 29.5, 26.1, 24.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>29</sub>N<sub>7</sub>NaO<sub>3</sub><sup>+</sup>, 4860.2224; found, 4860.2226. HPLC purity: 99.6%.</div></div><div id="sec4_1_1_75" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> 1-(4-(5-(4-Amino-3-(benzofuran-5-yl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>14</b>)</h5><div class="NLM_p last">The titled compound <b>14</b> was obtained from <b>14b</b> following the general procedure described for <b>1</b>. The compound <b>14</b>(65%) was a white liquid. mp 244–246 °C; IR (KBr): 3115, 1669, 1596, 1434, 1384, 1204, 1157 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.39 (s, 1H), 7.68 (dd, <i>J</i> = 7.3, 1.5 Hz, 1H), 7.59–7.55 (m, 1H), 7.40–7.32 (m, 3H), 6.53 (dd, <i>J</i> = 16.8, 10.6 Hz, 1H), 6.28 (dd, <i>J</i> = 16.9, 1.9 Hz, 1H), 5.68 (dd, <i>J</i> = 10.6, 2.0 Hz, 1H), 4.46 (t, <i>J</i> = 7.2 Hz, 2H), 3.69 (s, 2H), 3.55 (s, 2H), 2.44 (s, 4H), 2.36 (t, <i>J</i> = 7.6 Hz, 2H), 2.01 (p, <i>J</i> = 7.4 Hz, 2H), 1.57 (q, <i>J</i> = 7.6 Hz, 2H), 1.44–1.36 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 163.8, 157.6, 156.0 154.4, 149.5, 134.7, 128.3, 127.8, 127.4, 125.1, 124.0, 121.7, 111.0, 104.3, 97.9, 58.1, 53.3, 52.7, 47.3, 45.6, 41.7, 29.5, 26.1, 24.4. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>29</sub>N<sub>7</sub>NaO<sub>2</sub><sup>+</sup>, 482.2269; found, 482.2271. HPLC purity: 99.7%.</div></div><div id="sec4_1_1_76" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100"> 1-(4-(5-(4-Amino-3-(4-methoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>15</b>)</h5><div class="NLM_p last">The titled compound <b>15</b> was obtained from <b>15b</b> following the general procedure described for <b>1</b>. The compound <b>15</b> (65%) was a white liquid. mp 191–193 °C; IR (KBr): 3101, 2611, 1695, 1604, 1184, 1106, 957 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, MeOD): δ 8.24 (s, 1H), 7.61 (d, <i>J</i> = 8.6 Hz, 2H), 7.18–7.06 (m, 2H), 6.82–6.64 (m, 1H), 6.19 (dd, <i>J</i> = 16.7, 2.0 Hz, 1H), 5.74 (dd, <i>J</i> = 10.6, 1.9 Hz, 1H), 4.41 (t, <i>J</i> = 6.8 Hz, 2H), 3.88 (s, 3H), 3.62 (s, 4H), 2.48 (s, 4H), 2.39 (s, 2H), 1.96 (q, <i>J</i> = 7.3 Hz, 2H), 1.60–1.52 (m, 2H), 1.35 (q, <i>J</i> = 7.9 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 157.7, 155.9, 155.9, 154.4, 143.6, 140.4, 133.9, 132.5, 129.6, 127.8, 126.7, 125.9, 124.7, 64.1, 58.2, 53.4, 52.7, 48.6, 47.1, 29.5, 26.0, 24.5, 15.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>31</sub>N<sub>7</sub>NaO<sub>2</sub><sup>+</sup>, 472.2426; found, 472.2428. HPLC purity: 100.0%.</div></div><div id="sec4_1_1_77" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101"> <i>N</i>-(4-(1-(5-(4-Acryloylpiperazin-1-yl)pentyl)-4-amino-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl)acetamide (<b>16</b>)</h5><div class="NLM_p last">The titled compound <b>16</b> was obtained from <b>16b</b> following the general procedure described for <b>1</b>. The compound <b>16</b> (61%) was a white liquid. mp 194–196 °C; IR (KBr): 3107, 2758, 1795, 1704, 1351, 1066, 997 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, MeOD): δ 8.24 (d, <i>J</i> = 1.3 Hz, 1H), 8.01 (s, 1H), 7.54–7.43 (m, 3H), 6.72 (dd, <i>J</i> = 16.9, 10.7 Hz, 1H), 6.18 (dt, <i>J</i> = 16.8, 1.7 Hz, 1H), 5.73 (dt, <i>J</i> = 10.6, 1.7 Hz, 1H), 4.43 (t, <i>J</i> = 6.7 Hz, 2H), 3.60 (q, <i>J</i> = 6.7, 4.6 Hz, 4H), 2.46 (d, <i>J</i> = 5.2 Hz, 4H), 2.37 (t, <i>J</i> = 7.6 Hz, 2H), 2.16 (d, <i>J</i> = 1.4 Hz, 3H), 1.97 (t, <i>J</i> = 7.4 Hz, 2H), 1.57 (dd, <i>J</i> = 11.0, 4.7 Hz, 2H), 1.34 (p, <i>J</i> = 7.6 Hz, 2H). <sup>13</sup>C NMR (100 MHz, MeOD): δ 170.6, 165.9, 158.4, 155.4, 153.8, 144.4, 139.14, 133.2, 129.6, 127.3, 127.3, 123.7, 120.4, 120.1, 100.0, 97.6, 57.6, 52.8, 52.3, 45.0, 41.3, 28.9, 25.3, 23.9, 22.4. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>32</sub>N<sub>8</sub>NaO<sub>2</sub><sup>+</sup>, 472.2426; found, 472.2428. HPLC purity: 99.6%.</div></div><div id="sec4_1_1_78" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102"> 1-(4-(5-(4-Amino-3-(3-(trifluoromethoxy)phenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>17</b>)</h5><div class="NLM_p last">The titled compound <b>17</b> was obtained from <b>17b</b> following the general procedure described for <b>1</b>. The compound <b>17</b> (61%) was a white liquid. mp 206–208 °C; IR (KBr): 3111, 2957, 2795, 1974, 1630, 1264, 1017 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, MeOD): δ 8.27 (s, 1H), 7.70 (t, <i>J</i> = 7.6 Hz, 1H), 7.63 (d, <i>J</i> = 10.6 Hz, 1H), 7.49–7.42 (m, 1H), 7.35 (dd, <i>J</i> = 7.8, 5.3 Hz, 1H), 6.73 (dd, <i>J</i> = 16.8, 10.7 Hz, 1H), 6.18 (dd, <i>J</i> = 16.8, 1.9 Hz, 1H), 5.73 (dd, <i>J</i> = 10.7, 2.0 Hz, 1H), 4.44 (t, <i>J</i> = 6.8 Hz, 2H), 3.61 (d, <i>J</i> = 5.4 Hz, 4H), 2.50–2.37 (m, 4H), 2.35 (d, <i>J</i> = 7.7 Hz, 2H), 1.99 (q, <i>J</i> = 7.1 Hz, 2H), 1.59–1.55 (m, 2H), 1.35 (s, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 166.2, 158.5, 156.8, 155.4, 150.6, 143.3, 136.3, 131.8, 128.6, 128.4, 127.6, 122.3, 121.9, 120.1, 99.2, 59.1, 54.3, 53.6, 48.1, 46.6, 42.8, 30.4, 27.1, 25.4. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>28</sub>F<sub>3</sub>N<sub>7</sub>NaO<sub>2</sub><sup>+</sup>, 526.2143; found, 526.2145. HPLC purity: 100.0%.</div></div><div id="sec4_1_1_79" class="NLM_sec NLM_sec_level_4"><div id="ac_i103" class="anchor-spacer"></div><h5 class="article-section__title" id="_i103"> 1-(4-(5-(4-Amino-3-(naphthalen-2-yl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>18</b>)</h5><div class="NLM_p last">The titled compound <b>18</b> was obtained following the procedure described for <b>1</b>. The compound <b>18</b> (65%) was a white solid. mp 221–223 °C; IR (KBr): 3301, 3100, 2850, 1900, 1680, 1450, 744 cm<sup>–1</sup>. 1H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.41 (s, 1H), 8.17 (s, 1H), 8.03 (d, <i>J</i> = 8.4 Hz, 1H), 7.94 (dq, <i>J</i> = 6.5, 3.8 Hz, 2H), 7.82 (dd, <i>J</i> = 8.4, 1.7 Hz, 1H), 7.58 (dt, <i>J</i> = 6.3, 3.5 Hz, 2H), 6.51 (dd, <i>J</i> = 16.8, 10.5 Hz, 1H), 6.27 (dd, <i>J</i> = 16.8, 1.9 Hz, 1H), 5.74–5.53 (m, 3H), 4.49 (t, <i>J</i> = 7.2 Hz, 2H), 3.68 (s, 2H), 3.52 (s, 2H), 2.38 (dt, <i>J</i> = 28.0, 6.2 Hz, 6H), 2.03 (p, <i>J</i> = 7.5 Hz, 2H), 1.58 (p, <i>J</i> = 7.7 Hz, 2H), 1.40 (q, <i>J</i> = 7.5 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ168.1, 166.2, 157.9, 155.9, 144.2, 133.4, 133.3, 131.0, 129.4, 128.3, 128.2, 127.9, 127.7, 127.0, 126.9, 125.8, 60.8, 58.2, 53.2, 52.8, 47.1, 45.5, 41.6, 32.2, 29.6, 26.3, 24.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>27</sub>H<sub>31</sub>N<sub>7</sub>NaO<sup>+</sup>, 492.2482; found, 492.2484. HPLC purity: 97.7%.</div></div><div id="sec4_1_1_80" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> 1-(4-(5-(4-Amino-3-(4-methylnaphthalen-1-yl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>19</b>)</h5><div class="NLM_p last">The titled compound <b>19</b> was obtained following the procedure described for <b>1</b>. The compound <b>19</b> (67%) was a white solid. mp 223–225 °C; IR (KBr): 3443, 3100, 1685, 1644, 1500, 1450, 662 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.38 (s, 1H), 8.11 (d, <i>J</i> = 8.4 Hz, 1H), 7.92 (d, <i>J</i> = 8.2 Hz, 1H), 7.67–7.43 (m, 4H), 6.53 (dd, <i>J</i> = 16.8, 10.5 Hz, 1H), 6.27 (dd, <i>J</i> = 16.8, 1.9 Hz, 1H), 5.68 (dd, <i>J</i> = 10.5, 2.0 Hz, 1H), 4.51 (t, <i>J</i> = 7.2 Hz, 2H), 3.67 (t, <i>J</i> = 5.3 Hz, 2H), 3.52 (t, <i>J</i> = 4.9 Hz, 2H), 2.78 (s, 3H), 2.49–2.31 (m, 6H), 2.05 (t, <i>J</i> = 7.5 Hz, 2H), 1.58 (s, 2H), 1.43 (t, <i>J</i> = 7.5 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 157.7, 156.0, 153.9, 142.7, 136.5, 133.1, 133.0, 131.6, 128.3, 128.1, 127.8, 127.5, 126.9, 126.5, 126.4, 125.8, 124.7, 100.3, 58.2, 53.4, 52.8, 47.1, 45.7, 41.8, 29.6, 26.3, 24.6. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>28</sub>H<sub>33</sub>N<sub>7</sub>NaO<sup>+</sup>, 506.2639; found, 506.2640. HPLC purity: 100.0%.</div></div><div id="sec4_1_1_81" class="NLM_sec NLM_sec_level_4"><div id="ac_i105" class="anchor-spacer"></div><h5 class="article-section__title" id="_i105"> 1-(4-(5-(4-Amino-3-(4-bromonaphthalen-1-yl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>20</b>)</h5><div class="NLM_p last">The titled compound <b>20</b> was obtained following the procedure described for <b>1</b>. The compound <b>20</b> (61%) was a yellow solid. mp 247–249 °C; IR (KBr): 3030, 1680, 1620, 1455, 1299, 810, 575 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.32 (d, <i>J</i> = 7.8 Hz, 2H), 7.86 (dd, <i>J</i> = 9.4, 7.9 Hz, 2H), 7.65–7.60 (m, 1H), 7.51 (ddd, <i>J</i> = 8.3, 6.8, 1.3 Hz, 1H), 7.44 (d, <i>J</i> = 7.6 Hz, 1H), 6.46 (dd, <i>J</i> = 16.8, 10.5 Hz, 1H), 6.22 (dd, <i>J</i> = 16.8, 1.9 Hz, 1H), 5.64 (d, <i>J</i> = 10.4 Hz, 1H), 4.46 (d, <i>J</i> = 6.9 Hz, 2H), 3.68–3.52 (m, 4H), 2.51–2.33 (m, 6H), 2.12–2.03 (m, 2H), 1.61–1.55 (m, 2H), 1.37 (d, <i>J</i> = 8.5 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 157.7, 155.8, 154.9, 154.2, 148.6, 148.5, 143.9, 143.9, 127.0, 122.3, 122.2, 122.2, 109.1, 109.0, 108.9, 101.6, 101.5, 98.2, 50.9, 44.7, 44.7, 36.1, 33.5, 31.8, 29.7, 28.5, 28.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>27</sub>H<sub>30</sub>BrN<sub>7</sub>NaO<sup>+</sup>, 570.1587; found, 570.1589. HPLC purity: 99.4%.</div></div><div id="sec4_1_1_82" class="NLM_sec NLM_sec_level_4"><div id="ac_i106" class="anchor-spacer"></div><h5 class="article-section__title" id="_i106"> 1-(4-(5-(4-Amino-3-(2,5-dimethoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>21</b>)</h5><div class="NLM_p last">The titled compound <b>21</b> was obtained following the procedure described for <b>1</b>. The compound <b>21</b> (64%) was a yellow solid. mp 233–235 °C; IR (KBr): 3020, 2960, 1680, 1600, 1580, 1450, 850, 760 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.34 (s, 1H), 7.06 (d, <i>J</i> = 2.2 Hz, 1H), 7.00 (s, 2H), 6.60–6.49 (m, 1H), 6.27 (dt, <i>J</i> = 16.8, 1.7 Hz, 1H), 5.67 (s, 3H), 4.43 (t, <i>J</i> = 7.3 Hz, 2H), 3.80 (dd, <i>J</i> = 11.0, 1.3 Hz, 6H), 3.67 (s, 2H), 3.54 (t, <i>J</i> = 5.0 Hz, 2H), 2.41 (t, <i>J</i> = 5.1 Hz, 4H), 2.34 (t, <i>J</i> = 7.6 Hz, 2H), 2.02–1.95 (m, 2H), 1.44–1.35 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 158.4, 155.5, 154.4, 153.9, 150.5, 140.8, 127.8, 127.5, 123.1, 117.1, 116.1, 113.4, 100.6, 58.2, 56.7, 55.8, 53.3, 52.7, 47.1, 45.6, 41.8, 29.5, 26.2, 24.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>33</sub>N<sub>7</sub>NaO<sub>3</sub><sup>+</sup>, 502.2537; found, 502.2539. HPLC purity: 97.0%.</div></div><div id="sec4_1_1_83" class="NLM_sec NLM_sec_level_4"><div id="ac_i107" class="anchor-spacer"></div><h5 class="article-section__title" id="_i107"> 1-(4-(5-(4-Amino-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>22</b>)</h5><div class="NLM_p last">The titled compound <b>22</b> was obtained following the procedure described for <b>1</b>. The compound <b>22</b> (61%) was a yellow solid. mp 234–235 °C; IR (KBr): 3050, 2877, 1680, 1600, 1566, 1260, 922, 760cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.29 (s, 1H), 7.18–7.11 (m, 2H), 6.95 (t, <i>J</i> = 6.0 Hz, 1H), 6.47 (dd, <i>J</i> = 16.6, 11.1 Hz, 1H), 6.22 (d, <i>J</i> = 17.4 Hz, 1H), 5.91–5.53 (m, 3H), 4.36 (d, <i>J</i> = 6.2 Hz, 2H), 3.89 (d, <i>J</i> = 3.8 Hz, 6H), 3.60 (d, <i>J</i> = 51.6 Hz, 4H), 2.39 (d, <i>J</i> = 31.7 Hz, 6H), 1.93 (s, 2H), 1.55 (s, 2H), 1.33 (s, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 157.9, 155.6, 154.2, 149.9, 149.7, 144.2, 128.1, 127.3, 125.8, 120.8, 111.7, 111.5, 98.3, 58.1, 56.1, 53.2, 52.6, 46.9, 45.3, 41.4, 29.5, 25.8, 24.5, 21.4. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>33</sub>N<sub>7</sub>NaO<sub>3</sub><sup>+</sup>, 502.2537; found, 502.2538. HPLC purity: 99.9%.</div></div><div id="sec4_1_1_84" class="NLM_sec NLM_sec_level_4"><div id="ac_i108" class="anchor-spacer"></div><h5 class="article-section__title" id="_i108"> 1-(4-(5-(4-Amino-3-(3,4,5-trimethoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>23</b>)</h5><div class="NLM_p last">The titled compound <b>23</b> was obtained from <b>23b</b> following the general procedure described for <b>1</b>. The compound <b>23</b> (68%) was a white liquid. mp 241–243 °C; IR (KBr): 3311, 3125, 2870, 2207, 1730, 1263, 1013 cm <sup>–1</sup>.<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.30 (s, 1H), 6.82 (d, <i>J</i> = 1.3 Hz, 2H), 6.47 (ddd, <i>J</i> = 16.8, 10.5, 1.3 Hz, 1H), 6.19 (dt, <i>J</i> = 16.8, 1.6 Hz, 1H), 5.87 (s, 2H), 5.60 (dt, <i>J</i> = 10.5, 1.6 Hz, 1H), 4.36 (t, <i>J</i> = 7.3 Hz, 2H), 3.86 (d, <i>J</i> = 1.3 Hz, 6H), 3.83 (d, <i>J</i> = 1.3 Hz, 3H), 3.60 (t, <i>J</i> = 5.0 Hz, 2H), 3.47 (t, <i>J</i> = 5.0 Hz, 2H), 2.33 (t, <i>J</i> = 5.1 Hz, 4H), 2.27 (d, <i>J</i> = 7.5 Hz, 2H), 1.93 (q, <i>J</i> = 7.6 Hz, 2H), 1.49 (t, <i>J</i> = 7.6 Hz, 2H), 1.33 (d, <i>J</i> = 7.6 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.2, 158.0, 155.8, 154.2, 153.9, 144.1, 138.8, 128.6, 128.6, 128.4, 127.7, 127.5, 105.6, 98.3, 61.0, 58.2, 56.3, 53.4, 52.7, 47.0, 45.7, 41.9, 29.7, 29.6, 26.3, 24.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>26</sub>H<sub>35</sub>N<sub>7</sub>NaO<sub>4</sub><sup>+</sup>, 532.2643; found, 536.2645. HPLC purity: 99.7%.</div></div><div id="sec4_1_1_85" class="NLM_sec NLM_sec_level_4"><div id="ac_i109" class="anchor-spacer"></div><h5 class="article-section__title" id="_i109"> 1-(4-(5-(4-Amino-3-(3-(trifluoromethyl)phenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>24</b>)</h5><div class="NLM_p last">The titled compound <b>24</b> was obtained from <b>24b</b> following the general procedure described for <b>1</b>. The compound <b>24</b> (68%) was a white liquid. mp 211–213 °C; IR (KBr): 2994, 2912, 2714, 2107, 1930, 1563, 913 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.37 (s, 1H), 7.68–7.54 (m, 3H), 7.33 (d, <i>J</i> = 6.5 Hz, 1H), 6.59–6.47 (m, 1H), 6.25 (dd, <i>J</i> = 16.8, 4.6 Hz, 1H), 5.95–5.59 (m, 3H), 4.43 (d, <i>J</i> = 6.6 Hz, 2H), 3.64 (d, <i>J</i> = 9.2 Hz, 2H), 3.52 (s, 2H), 2.39 (d, <i>J</i> = 5.7 Hz, 4H), 2.32 (d, <i>J</i> = 7.3 Hz, 2H), 1.98 (q, <i>J</i> = 7.1 Hz, 2H), 1.56 (s, 2H), 1.42–1.32 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 157.7, 155.8, 154.5, 149.8, 142.5, 135.3, 130.9, 127.7, 127.5, 126.7, 121.4, 121.4, 121.0, 98.3, 58.1, 53.4, 52.7, 47.2, 45.7, 41.9, 29.7, 26.2, 24.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>28</sub>F<sub>3</sub>N<sub>7</sub>NaO<sup>+</sup>, 510.2205; found, 510.2207. HPLC purity: 100.0%.</div></div><div id="sec4_1_1_86" class="NLM_sec NLM_sec_level_4"><div id="ac_i110" class="anchor-spacer"></div><h5 class="article-section__title" id="_i110"> 1-(4-(5-(4-Amino-3-(3-isopropoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>25</b>)</h5><div class="NLM_p last">The titled compound <b>25</b> was obtained from <b>25b</b> following the general procedure described for <b>1</b>. The compound <b>25</b> (65%) was a white liquid. mp 231–233 °C; IR (KBr): 2976, 2941, 2774, 2206, 1937, 1663, 873 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.15 (d, <i>J</i> = 1.2 Hz, 1H), 7.36 (t, <i>J</i> = 7.9 Hz, 1H), 7.11 (dd, <i>J</i> = 8.2, 5.0 Hz, 2H), 7.00–6.95 (m, 1H), 6.70–6.60 (m, 1H), 6.09 (dt, <i>J</i> = 16.8, 1.6 Hz, 1H), 5.64 (dt, <i>J</i> = 10.6, 1.6 Hz, 1H), 4.60 (q, <i>J</i> = 6.0 Hz, 1H), 4.32 (t, <i>J</i> = 6.8 Hz, 2H), 3.53 (t, <i>J</i> = 6.3 Hz, 4H), 2.38 (s, 4H), 2.30 (t, <i>J</i> = 7.6 Hz, 2H), 1.87 (d, <i>J</i> = 7.1 Hz, 2H), 1.48 (t, <i>J</i> = 7.8 Hz, 2H), 1.25 (dd, <i>J</i> = 6.0, 1.3 Hz, 6H), 1.22 (d, <i>J</i> = 7.4 Hz, 2H). <sup>13</sup>C NMR (100 MHz, MeOD): δ 166.0, 158.6, 158.5, 155.4, 153.7, 144.7, 134.0, 130.2, 127.3, 127.3, 120.1, 116.4, 115.5, 100.0, 97.6, 69.9, 57.6, 52.8, 52.3, 46.4, 45.0, 41.3, 28.9, 25.2, 23.9, 21.0. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>26</sub>H<sub>35</sub>N<sub>7</sub>NaO<sub>2</sub><sup>+</sup>, 500.2744; found, 500.2747. HPLC purity: 97.9%.</div></div><div id="sec4_1_1_87" class="NLM_sec NLM_sec_level_4"><div id="ac_i111" class="anchor-spacer"></div><h5 class="article-section__title" id="_i111"> 1-(4-(5-(4-Amino-3-(3-(benzyloxy)phenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>26</b>)</h5><div class="NLM_p last">The titled compound <b>26</b> was obtained from <b>26b</b> following the general procedure described for <b>1</b>. The compound <b>26</b> (65%) was a white liquid. mp 275–277 °C; IR (KBr): 2775, 2794, 2111, 2106, 1573, 1763, 977 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.37 (s, 1H), 7.49–7.27 (m, 8H), 7.11 (d, <i>J</i> = 8.5 Hz, 1H), 6.54 (dd, <i>J</i> = 16.8, 10.4 Hz, 1H), 6.28 (d, <i>J</i> = 16.8 Hz, 1H), 5.69 (d, <i>J</i> = 10.4 Hz, 1H), 5.43 (s, 2H), 5.17 (s, 2H), 4.44 (t, <i>J</i> = 7.4 Hz, 2H), 3.62 (d, <i>J</i> = 49.9 Hz, 4H), 2.39 (d, <i>J</i> = 27.3 Hz, 6H), 2.03–1.93 (m, 2H), 1.38 (s, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 159.4, 157.7, 155.4, 154.2, 144.1, 136.6, 134.5, 133.3, 130.6, 128.7, 128.1, 127.7, 127.5, 127.4, 120.9, 116.0, 114.5, 98.2, 70.0, 58.1, 53.3, 52.7, 47.1, 45.7, 41.8, 29.5, 26.2, 24.5, 21.2. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>30</sub>H<sub>35</sub>N<sub>7</sub>NaO<sub>2</sub><sup>+</sup>, 548.2744; found, 548.2747. HPLC purity: 100.0%.</div></div><div id="sec4_1_1_88" class="NLM_sec NLM_sec_level_4"><div id="ac_i112" class="anchor-spacer"></div><h5 class="article-section__title" id="_i112"> 1-(4-(5-(4-Amino-3-(2-chloro-5-methoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>27</b>)</h5><div class="NLM_p last">The titled compound <b>27</b> was obtained from <b>27b</b> following the general procedure described for <b>1</b>. The compound <b>27</b> (65%) was a white liquid. mp 241–243 °C; IR (KBr): 2915, 2864, 2201, 1894, 1771, 1703, 907 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.35 (d, <i>J</i> = 4.2 Hz, 1H), 7.43 (s, 1H), 6.99 (dq, <i>J</i> = 19.8, 3.2 Hz, 2H), 6.53 (ddd, <i>J</i> = 15.6, 10.7, 3.9 Hz, 1H), 6.25 (dd, <i>J</i> = 16.9, 3.9 Hz, 1H), 5.80–5.22 (m, 3H), 4.45 (t, <i>J</i> = 6.5 Hz, 2H), 3.82 (d, <i>J</i> = 4.9 Hz, 3H), 3.68–3.63 (m, 2H), 3.51 (s, 2H), 2.39 (d, <i>J</i> = 5.4 Hz, 4H), 2.31 (q, <i>J</i> = 6.2, 5.4 Hz, 2H), 1.99 (q, <i>J</i> = 6.8 Hz, 2H), 1.53 (q, <i>J</i> = 7.1 Hz, 2H), 1.42–1.28 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 158.6, 157.7, 155.9, 153.8, 141.1, 132.6, 131.1, 127.7, 127.5, 124.7, 116.9, 99.9, 70.5, 58.2, 55.7, 53.4, 52.7, 47.1, 45.7, 41.9, 29.5, 26.2, 24.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>30</sub>ClN<sub>7</sub>NaO<sub>2</sub><sup>+</sup>, 506.2042; found, 506.2044. HPLC purity: 95.5%.</div></div><div id="sec4_1_1_89" class="NLM_sec NLM_sec_level_4"><div id="ac_i113" class="anchor-spacer"></div><h5 class="article-section__title" id="_i113"> 1-(4-(5-(4-Amino-3-(4-fluorophenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>28</b>)</h5><div class="NLM_p last">The titled compound <b>28</b> was obtained following the procedure described for <b>1</b>. The compound <b>28</b> (64%) was a yellow solid. mp 234–235 °C; IR (KBr): 3050, 2877, 1680, 1600, 1566, 1260, 922, 760 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.39 (d, <i>J</i> = 2.2 Hz, 1H), 7.02 (s, 2H), 6.75–6.71 (m, 1H), 6.58–6.51 (m, 1H), 6.27 (d, <i>J</i> = 15.0 Hz, 1H), 5.68 (d, <i>J</i> = 10.5 Hz, 1H), 5.56 (s, 2H), 4.44 (s, 2H), 3.61 (d, <i>J</i> = 50.8 Hz, 4H), 2.42 (s, 6H), 1.99 (t, <i>J</i> = 7.7 Hz, 2H), 1.56 (d, <i>J</i> = 8.5 Hz, 2H), 1.39 (d, <i>J</i> = 7.4 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 168.1, 166.1, 157.7, 155.9, 154.3, 143.1, 131.1, 130.3, 130.2, 129.4, 128.3, 116.6, 116.4, 98.3, 60.8, 58.1, 53.2, 52.7, 47.0, 32.2, 29.7, 29.5, 24.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>28</sub>FN<sub>7</sub>NaO<sup>+</sup>, 460.2232; found, 460.2234. HPLC purity: 96.0%.</div></div><div id="sec4_1_1_90" class="NLM_sec NLM_sec_level_4"><div id="ac_i114" class="anchor-spacer"></div><h5 class="article-section__title" id="_i114"> 1-(4-(5-(4-Amino-3-(3-fluoro-4-hydroxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>29</b>)</h5><div class="NLM_p last">The titled compound <b>29</b> was obtained following the procedure described for <b>1</b>. The compound <b>29</b> (68%) was a yellow solid. mp 192–194 °C; IR (KBr): 3583, 3033, 1580, 1420, 1260, 1100, 755 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.34 (s, 1H), 7.80–7.64 (m, 2H), 7.30–7.23 (m, 2H), 6.55 (dd, <i>J</i> = 16.8, 10.5 Hz, 1H), 6.28 (dd, <i>J</i> = 16.8, 2.0 Hz, 1H), 5.69 (dd, <i>J</i> = 10.5, 1.9 Hz, 1H), 4.44 (t, <i>J</i> = 7.2 Hz, 2H), 3.68 (t, <i>J</i> = 5.1 Hz, 2H), 3.54 (t, <i>J</i> = 5.0 Hz, 2H), 2.47–2.29 (m, 6H), 1.99 (p, <i>J</i> = 7.4 Hz, 2H), 1.40 (qd, <i>J</i> = 7.6, 2.5 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 191.6, 167.5, 165.3, 162.6, 158.3, 157.3, 157.3, 156.6, 156.5, 154.1, 129.3, 128.5, 127.3, 117.2, 100.3, 99.9, 70.3, 57.9, 53.2, 52.5, 47.3, 31.9, 29.7, 29.3, 24.2. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>): δ −138.1. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>28</sub>FN<sub>7</sub>NaO<sub>2</sub><sup>+</sup>, 476.2181; found, 476.2183. HPLC purity: 99.5%.</div></div><div id="sec4_1_1_91" class="NLM_sec NLM_sec_level_4"><div id="ac_i115" class="anchor-spacer"></div><h5 class="article-section__title" id="_i115"> 1-(4-(5-(4-Amino-3-(6-methoxynaphthalen-2-yl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>30</b>)</h5><div class="NLM_p last">The titled compound <b>30</b> was obtained following the procedure described for <b>1</b>. The compound <b>30</b> (66%) was a yellow solid. mp 244–246 °C; IR (KBr): 3050, 2988, 2640, 1611, 1490, 1030, 933 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.37 (s, 1H), 8.08 (d, <i>J</i> = 1.7 Hz, 1H), 7.91 (d, <i>J</i> = 8.4 Hz, 1H), 7.83 (d, <i>J</i> = 8.9 Hz, 1H), 7.77 (dd, <i>J</i> = 8.4, 1.8 Hz, 1H), 7.26–7.20 (m, 2H), 6.51 (dd, <i>J</i> = 16.8, 10.5 Hz, 1H), 6.27 (dd, <i>J</i> = 16.8, 2.0 Hz, 1H), 6.03–5.59 (m, 3H), 4.47 (t, <i>J</i> = 7.2 Hz, 2H), 3.97 (s, 3H), 3.69 (s, 2H), 3.54 (s, 2H), 2.50–2.33 (m, 6H), 2.06–1.97 (m, 2H), 1.59 (p, <i>J</i> = 7.7 Hz, 2H), 1.47–1.36 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 158.5, 157.9, 155.5, 154.3, 144.5, 134.6, 129.7, 128.9, 128.2, 128.1, 127.8, 127.5, 127.4, 126.3, 119.9, 105.8, 98.5, 58.1, 55.4, 53.3, 52.7, 47.0, 45.5, 41.7, 29.6, 26.1, 24.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>28</sub>H<sub>33</sub>N<sub>7</sub>NaO<sub>2</sub><sup>+</sup>, 520.2588; found, 520.2590. HPLC purity: 99.6%.</div></div><div id="sec4_1_1_92" class="NLM_sec NLM_sec_level_4"><div id="ac_i116" class="anchor-spacer"></div><h5 class="article-section__title" id="_i116"> 1-(4-(5-(4-Amino-3-(4-nitrophenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>31</b>)</h5><div class="NLM_p last">The titled compound <b>31</b> was obtained following the procedure described for <b>1</b>. The compound <b>31</b> (64%) was a yellow solid. mp 233–235 °C; IR (KBr): 3014, 2894, 2842, 1674, 1571, 1365, 1104 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.45–8.36 (m, 3H), 7.92 (d, <i>J</i> = 8.8 Hz, 2H), 6.54 (dd, <i>J</i> = 16.8, 10.5 Hz, 1H), 6.27 (dd, <i>J</i> = 16.9, 2.0 Hz, 1H), 5.90–5.63 (m, 3H), 4.48 (t, <i>J</i> = 7.2 Hz, 2H), 3.67 (s, 2H), 3.59–3.50 (m, 2H), 2.42 (t, <i>J</i> = 5.1 Hz, 4H), 2.35 (dd, <i>J</i> = 8.5, 6.5 Hz, 2H), 2.01 (p, <i>J</i> = 7.6 Hz, 2H), 1.63–1.55 (m, 2H), 1.41 (dt, <i>J</i> = 11.4, 6.8 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 157.6, 155.9, 154.7, 148.0, 141.7, 139.6, 129.2, 127.8, 127.7, 127.5, 124.6, 98.4, 77.2, 58.1, 53.4, 52.7, 47.4, 45.7, 41.8, 29.7, 26.2, 24.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>28</sub>N<sub>8</sub>NaO<sub>3</sub><sup>+</sup>, 487.2177; found, 487.2179. HPLC purity: 99.3%.</div></div><div id="sec4_1_1_93" class="NLM_sec NLM_sec_level_4"><div id="ac_i117" class="anchor-spacer"></div><h5 class="article-section__title" id="_i117"> 1-(4-(5-(4-Amino-3-(4-nitrophenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>31</b>)</h5><div class="NLM_p last">The titled compound <b>31</b> was obtained following the procedure described for <b>1</b>. The compound <b>31</b> (64%) was a yellow solid. mp 217–219 °C; IR (KBr): 3111, 2894, 1695, 1603, 1525, 1450, 900, 774 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.28 (s, 1H), 7.38 (d, <i>J</i> = 8.8 Hz, 1H), 6.99–6.90 (m, 2H), 6.48 (dd, <i>J</i> = 16.8, 10.5 Hz, 1H), 6.21 (dd, <i>J</i> = 16.8, 1.9 Hz, 1H), 5.62 (dd, <i>J</i> = 10.5, 1.9 Hz, 1H), 4.39 (t, <i>J</i> = 7.1 Hz, 2H), 3.77 (s, 3H), 3.62 (s, 2H), 3.49 (t, <i>J</i> = 5.1 Hz, 2H), 2.33 (dt, <i>J</i> = 36.0, 6.2 Hz, 6H), 1.96–1.84 (m, 2H), 1.50 (p, <i>J</i> = 7.6 Hz, 2H), 1.30 (qd, <i>J</i> = 10.9, 9.6, 4.7 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 158.6, 157.7, 155.6, 153.7, 141.2, 132.5, 131.1, 127.9, 127.4, 124.7, 116.9, 116.9, 99.9, 58.1, 55.7, 53.3, 52.7, 47.1, 45.5, 41.7, 29.5, 26.0, 24.5. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>): δ −115.1. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>30</sub>FN<sub>7</sub>NaO<sub>2</sub><sup>+</sup>, 490.2337; found, 490.2339. HPLC purity: 98.4%.</div></div><div id="sec4_1_1_94" class="NLM_sec NLM_sec_level_4"><div id="ac_i118" class="anchor-spacer"></div><h5 class="article-section__title" id="_i118"> 1-(4-(5-(4-Amino-3-(4-nitrophenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>31</b>)</h5><div class="NLM_p last">The titled compound <b>31</b> was obtained following the procedure described for <b>1</b>. The compound <b>33</b> (64%) was a yellow solid. mp 211–213 °C; IR (KBr): 3033, 2900, 1520, 1480, 977, 828, 650 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.24 (s, 1H), 7.45 (d, <i>J</i> = 7.6 Hz, 2H), 7.20 (s, 1H), 6.49–6.34 (m, 1H), 6.13 (dd, <i>J</i> = 16.9, 2.0 Hz, 1H), 5.69–5.50 (m, 2H), 4.30 (t, <i>J</i> = 7.3 Hz, 2H), 3.53 (s, 2H), 3.39 (s, 2H), 2.23 (dt, <i>J</i> = 31.8, 6.2 Hz, 6H), 1.85 (p, <i>J</i> = 7.6 Hz, 2H), 1.42 (p, <i>J</i> = 7.7 Hz, 2H), 1.25 (q, <i>J</i> = 7.8 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 157.7, 155.9, 154.5, 149.9, 142.4, 135.4, 130.9, 127.8, 127.5, 126.7, 121.4, 121.0, 98.3, 58.1, 53.4, 52.7, 47.2, 45.7, 41.8, 29.5, 26.2, 24.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>27</sub>F<sub>2</sub>N<sub>7</sub>NaO<sup>+</sup>, 478.2137; found, 478.2139. HPLC purity: 98.2%.</div></div><div id="sec4_1_1_95" class="NLM_sec NLM_sec_level_4"><div id="ac_i119" class="anchor-spacer"></div><h5 class="article-section__title" id="_i119"> 1-(4-(5-(4-Amino-3-(3,5-bis(trifluoromethyl)phenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>34</b>)</h5><div class="NLM_p last">The titled compound <b>34</b> was obtained from <b>34b</b> following the general procedure described for <b>1</b>. The compound <b>34</b> (68%) was a white liquid. mp 274–276 °C; IR (KBr): 3301, 3020, 2997, 1680, 1654, 1430, 1140 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.44 (s, 1H), 8.20 (s, 2H), 7.99 (s, 1H), 6.61–6.51 (m, 1H), 6.28 (d, <i>J</i> = 17.0 Hz, 1H), 5.69 (d, <i>J</i> = 10.6 Hz, 1H), 4.48 (t, <i>J</i> = 7.0 Hz, 2H), 3.64 (s, 4H), 2.39 (d, <i>J</i> = 26.1 Hz, 6H), 2.05–1.99 (m, 2H), 1.78 (s, 2H), 1.38 (dd, <i>J</i> = 23.0, 12.9 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 157.5, 156.0, 154.8, 140.9, 135.5, 133.2, 132.9, 132.6, 128.5, 127.8, 127.5, 124.4, 122.5, 121.7, 98.4, 58.1, 53.4, 52.7, 47.35 45.7, 41.8, 29.5, 26.2, 24.5. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>): δ −87.6. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>27</sub>F<sub>6</sub>N<sub>7</sub>NaO<sup>+</sup>, 578.2073; found, 578.2075. HPLC purity: 99.0%.</div></div><div id="sec4_1_1_96" class="NLM_sec NLM_sec_level_4"><div id="ac_i120" class="anchor-spacer"></div><h5 class="article-section__title" id="_i120"> 1-(4-(5-(4-Amino-3-(3-fluoro-5-(trifluoromethyl)phenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)prop-2-en-1-one (<b>35</b>)</h5><div class="NLM_p last">The titled compound <b>35</b> was obtained from <b>35b</b> following the general procedure described for <b>1</b>. The compound <b>35</b> (68%) was a white solid. mp 251–253 °C; IR (KBr): 3104, 2842, 2714, 1997, 1583, 1430, 985 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.34 (s, 1H), 7.78 (s, 1H), 7.62 (dt, <i>J</i> = 8.7, 1.9 Hz, 1H), 7.43 (dt, <i>J</i> = 8.4, 2.0 Hz, 1H), 6.52 (dd, <i>J</i> = 16.8, 10.5 Hz, 1H), 6.25 (dd, <i>J</i> = 16.9, 1.9 Hz, 1H), 6.03 (s, 1H), 5.66 (dd, <i>J</i> = 10.5, 1.9 Hz, 1H), 4.44 (t, <i>J</i> = 7.2 Hz, 2H), 3.59 (dt, <i>J</i> = 50.6, 5.0 Hz, 4H), 2.47–2.30 (m, 6H), 1.98 (q, <i>J</i> = 7.5 Hz, 2H), 1.54 (q, <i>J</i> = 7.7 Hz, 2H), 1.37 (q, <i>J</i> = 8.2 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.3, 161.6, 157.7, 155.5, 154.5, 141.5, 136.6, 127.8, 127.4, 121.1, 121.0, 118.1, 113.2, 98.2, 58.1, 53.3, 52.6, 47.3, 45.6, 41.8, 29.7, 29.5, 26.1, 24.5, 21.4. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>27</sub>F<sub>4</sub>N<sub>7</sub>NaO<sup>+</sup>, 528.2105; found, 528.2107. HPLC purity: 98.4%.</div></div><div id="sec4_1_1_97" class="NLM_sec NLM_sec_level_4"><div id="ac_i121" class="anchor-spacer"></div><h5 class="article-section__title" id="_i121"> (<i>E</i>)-1-(4-(5-(4-Amino-3-(3,5-dimethoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)-4,4,4-trifluorobut-2-en-1-one (<b>36</b>)</h5><div class="NLM_p last">The titled compound <b>36</b> was obtained following the procedure described for <b>1.</b> The compound <b>36</b> (68%) was a white solid. mp 261–263 °C; IR (KBr): 3401, 3200, 2975, 2843, 1590, 1245, 1140, 975 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.32 (s, 1H), 6.92 (dt, <i>J</i> = 15.4, 2.1 Hz, 1H), 6.78 (d, <i>J</i> = 2.3 Hz, 2H), 6.73–6.64 (m, 1H), 6.52 (t, <i>J</i> = 2.3 Hz, 1H), 4.40 (t, <i>J</i> = 7.2 Hz, 2H), 3.82 (s, 6H), 3.65 (t, <i>J</i> = 5.2 Hz, 2H), 3.50 (t, <i>J</i> = 5.0 Hz, 2H), 2.40 (q, <i>J</i> = 4.7 Hz, 4H), 2.32 (t, <i>J</i> = 7.5 Hz, 2H), 1.96 (p, <i>J</i> = 7.4 Hz, 2H), 1.52 (q, <i>J</i> = 7.6 Hz, 2H), 1.36 (q, <i>J</i> = 8.2 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 162.3, 161.8, 158.1, 155.8, 154.3, 144.4, 135.3, 129.7, 129.4, 128.0, 127.9, 121.4, 106.6, 101.3, 98.5, 58.3, 55.8, 53.5, 52.7, 47.3, 46.2, 42.5, 29.9, 29.8, 26.4, 24.7. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>): δ −65.0. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>26</sub>H<sub>32</sub>F<sub>3</sub>N<sub>7</sub>NaO<sub>3</sub><sup>+</sup>, 570.2411; found, 570.2413. HPLC purity: 99.1%.</div></div><div id="sec4_1_1_98" class="NLM_sec NLM_sec_level_4"><div id="ac_i122" class="anchor-spacer"></div><h5 class="article-section__title" id="_i122"> (<i>E</i>)-1-(4-(5-(4-Amino-3-(3,5-bis(trifluoromethyl)phenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)-4,4,4-trifluorobut-2-en-1-one (<b>37</b>)</h5><div class="NLM_p last">The titled compound <b>37</b> was obtained following the procedure described for <b>1</b>. The compound <b>37</b> (69%) was a white solid. mp 283–285 °C; IR (KBr): 3304, 3002, 2987, 1667, 1654, 1350, 975 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.41 (d, <i>J</i> = 2.5 Hz, 1H), 7.80 (s, 1H), 7.64 (d, <i>J</i> = 8.8 Hz, 1H), 7.45 (d, <i>J</i> = 8.3 Hz, 1H), 6.94 (d, <i>J</i> = 15.4 Hz, 1H), 6.81–6.64 (m, 1H), 5.57 (s, 2H), 4.57–4.41 (m, 2H), 3.62 (d, <i>J</i> = 60.7 Hz, 4H), 2.62–2.26 (m, 6H), 2.00 (p, <i>J</i> = 7.9 Hz, 2H), 1.64–1.53 (m, 2H), 1.40 (dd, <i>J</i> = 15.3, 7.3 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 164.1, 162.1, 157.4, 155.9, 154.7, 141.3, 136.6, 136.6, 129.2, 127.7, 127.7, 121.0, 121.0, 118.7, 113.4, 113.2, 98.2, 58.0, 53.3, 52.5, 47.2, 45.9, 42.2, 29.7, 26.1, 24.5. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>): δ −62.8, −65.0. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>26</sub>H<sub>26</sub>F<sub>9</sub>N<sub>7</sub>NaO<sup>+</sup>, 646.1947; found, 646.1947. HPLC purity: 99.0%.</div></div><div id="sec4_1_1_99" class="NLM_sec NLM_sec_level_4"><div id="ac_i123" class="anchor-spacer"></div><h5 class="article-section__title" id="_i123"> (<i>E</i>)-1-(4-(5-(4-Amino-3-(3-fluoro-5-(trifluoromethyl)phenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)-4,4,4-trifluorobut-2-en-1-one (<b>38</b>)</h5><div class="NLM_p last">The titled compound <b>38</b> was obtained following the procedure described for <b>1.</b> The compound <b>38</b> (67%) was a white solid. mp 271–272 °C; IR (KBr): 3301, 3111, 2987, 1680, 1554, 1250, 795 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.43 (d, <i>J</i> = 2.3 Hz, 1H), 8.20 (s, 2H), 7.99 (s, 1H), 6.94 (d, <i>J</i> = 15.5 Hz, 1H), 6.71 (dq, <i>J</i> = 14.2, 6.7 Hz, 1H), 4.48 (t, <i>J</i> = 7.0 Hz, 2H), 3.69 (s, 2H), 3.54 (s, 2H), 2.41 (d, <i>J</i> = 31.2 Hz, 6H), 2.01 (t, <i>J</i> = 7.6 Hz, 2H), 1.59 (s, 2H), 1.48–1.27 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 162.0, 155.2, 154.6, 142.9, 133.2, 132.1, 132.1, 129.4, 129.0, 128.6, 128.5, 127.9, 121.3, 120.8, 111.6, 105.6, 58.1, 53.3, 52.6, 46.9, 46.0, 42.3, 29.5, 26.3, 24.5, 22.1. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>): δ −63.6, −66.0, −109.1. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>26</sub>H<sub>26</sub>F<sub>9</sub>N<sub>7</sub>NaO<sup>+</sup>, 646.1947; found, 646.1947. HPLC purity: 99.3%.</div></div><div id="sec4_1_1_100" class="NLM_sec NLM_sec_level_4"><div id="ac_i124" class="anchor-spacer"></div><h5 class="article-section__title" id="_i124"> (<i>E</i>)-1-(4-(5-(4-Amino-3-(3,5-dimethoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)-4-(dimethylamino)but-2-en-1-one (<b>39</b>)</h5><div class="NLM_p last">The titled compound <b>39</b> was obtained following the procedure described for <b>1</b>. The compound <b>39</b> (68%) was a white solid. mp 267–268 °C; IR (KBr): 3301, 3100, 2963, 2843, 1680, 1554, 1245, 910 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.24 (s, 1H), 6.77 (d, <i>J</i> = 2.2 Hz, 2H), 6.63–6.55 (m, 3H), 4.32 (t, <i>J</i> = 6.9 Hz, 2H), 3.80 (s, 6H), 3.46 (s, 4H), 3.12–3.07 (m, 2H), 2.31–2.21 (m, 6H), 2.19 (s, 6H), 1.85 (p, <i>J</i> = 7.2 Hz, 2H), 1.49–1.41 (m, 2H), 1.25 (d, <i>J</i> = 7.6 Hz, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 164.3, 161.4, 161.3, 158.5, 156.1, 154.5, 154.5, 143.8, 141.3, 135.3, 123.4, 106.6, 106.6, 101.2, 101.2, 97.6, 60.0, 57.8, 55.8, 53.6, 52.8, 46.6, 45.5, 45.1, 41.8, 29.3, 25.9, 24.3. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>28</sub>H<sub>40</sub>N<sub>8</sub>NaO<sub>3</sub><sup>+</sup>, 559.3116; found, 559.3118. HPLC purity: 98.6%.</div></div><div id="sec4_1_1_101" class="NLM_sec NLM_sec_level_4"><div id="ac_i125" class="anchor-spacer"></div><h5 class="article-section__title" id="_i125"> (<i>E</i>)-1-(4-(5-(4-Amino-3-(3,5-dimethoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)but-2-en-1-one (<b>40</b>)</h5><div class="NLM_p last">The titled compound <b>40</b> was obtained following the procedure described for <b>1</b>. The compound <b>40</b> (68%) was a white solid. mp 267–268 °C; IR (KBr): 3333, 3100, 2972, 2843, 1680, 1245, 1140, 675 cm <sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.31 (s, 1H), 6.88–6.73 (m, 3H), 6.52 (t, <i>J</i> = 2.3 Hz, 1H), 6.20 (dq, <i>J</i> = 15.0, 1.7 Hz, 1H), 4.39 (t, <i>J</i> = 7.2 Hz, 2H), 3.82 (s, 6H), 3.62 (d, <i>J</i> = 8.1 Hz, 2H), 3.56–3.43 (m, 2H), 2.36 (t, <i>J</i> = 5.1 Hz, 4H), 2.29 (dd, <i>J</i> = 8.7, 6.4 Hz, 2H), 2.01–1.91 (m, 2H), 1.83 (dd, <i>J</i> = 6.9, 1.7 Hz, 3H), 1.52 (t, <i>J</i> = 7.6 Hz, 2H), 1.36 (ddd, <i>J</i> = 15.3, 9.1, 5.4 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.5, 161.5, 158.0, 155.7, 154.1, 144.1, 141.5, 135.1, 121.4, 119.9, 106.4, 101.1, 98.2, 60.4, 58.2, 55.5, 53.5, 53.4, 52.8, 47.0, 45.5, 41.8, 29.6, 26.2, 24.5, 18.2. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>26</sub>H<sub>35</sub>N<sub>7</sub>NaO<sub>3</sub><sup>+</sup>, 516.2694; found, 516.2696. HPLC purity: 94.8%.</div></div><div id="sec4_1_1_102" class="NLM_sec NLM_sec_level_4"><div id="ac_i126" class="anchor-spacer"></div><h5 class="article-section__title" id="_i126"> <i>tert</i>-Butyl-4-(5-(3-bromo-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazine-1-carboxylate (<b>43</b>)</h5><div class="NLM_p last">The titled compound <b>43</b> was obtained following the procedure described for <b>1a</b> using compound <b>42</b> (0.93 g, 3.4 mmol). Flash column chromatography (PE/EA = 3:1). 1.1 g, 63%, as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.05 (s, 1H), 7.92 (dd, <i>J</i> = 12.3, 7.6 Hz, 6H), 7.56 (t, <i>J</i> = 7.0 Hz, 3H), 7.47 (t, <i>J</i> = 6.5 Hz, 6H), 4.28 (t, <i>J</i> = 7.0 Hz, 2H), 3.41 (s, 4H), 2.30 (dd, <i>J</i> = 17.9, 10.3 Hz, 6H), 1.88 (dd, <i>J</i> = 14.5, 7.1 Hz, 2H), 1.53–1.43 (m, 11H), 1.32 (d, <i>J</i> = 7.4 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.1, 163.0, 155.8, 155.8, 155.7, 154.7, 154.2, 154.1, 153.5, 153.49, 133.3, 132.2, 132.2, 128.9, 128.6, 128.6, 128.5, 120.2, 107.1, 107.1, 100.0, 79.6, 70.6, 58.4, 58.4, 52.9, 52.8, 47.1, 47.1, 29.7, 29.6, 28.4, 26.2, 24.5, 24.5, 22.7, 21.7. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>37</sub>H<sub>43</sub>BrN<sub>7</sub>NaO<sub>2</sub>P<sup>+</sup>, 750.2291; found, 750.2293.</div></div><div id="sec4_1_1_103" class="NLM_sec NLM_sec_level_4"><div id="ac_i127" class="anchor-spacer"></div><h5 class="article-section__title" id="_i127"> <i>tert</i>-Butyl-4-(5-(3-(3,5-dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazine-1-carboxylate (<b>45</b>)</h5><div class="NLM_p last">The titled compound <b>45</b> was obtained from <b>43</b> following the general procedure described for <b>1b</b>. The compound <b>45</b> (70%) was a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.06 (s, 1H), 7.93–7.78 (m, 6H), 7.55–7.50 (m, 3H), 7.48 (s, 2H), 7.41 (t, <i>J</i> = 6.5 Hz, 6H), 6.56 (s, 1H), 4.37 (t, <i>J</i> = 7.1 Hz, 2H), 3.75 (s, 6H), 3.41 (s, 4H), 2.37–2.29 (m, 6H), 1.98–1.88 (m, 2H), 1.56–1.50 (m, 2H), 1.44 (s, 9H), 1.39–1.33 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.9, 163.9, 155.7, 154.8, 154.8, 154.7, 154.7, 154.5, 145.6, 135.8, 133.4, 133.3, 132.2, 131.9, 131.9, 129.3, 128.9, 128.6, 128.5, 128.4, 128.3, 127.9, 120.1, 107.9, 107.6, 107.4, 107.2, 105.7, 105.4, 100.5, 79.6, 58.5, 58.4, 52.9, 47.0, 46.8, 43.8, 42.9, 29.7, 29.6, 28.4, 28.2, 26.3, 24.6, 24.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>45</sub>H<sub>52</sub>N<sub>7</sub>NaO<sub>4</sub>P<sup>+</sup>, 808.3711; found, 808.3713.</div></div><div id="sec4_1_1_104" class="NLM_sec NLM_sec_level_4"><div id="ac_i128" class="anchor-spacer"></div><h5 class="article-section__title" id="_i128"> (<i>E</i>)-1-(4-(5-(3-(3,5-Dimethoxyphenyl)-4-((triphenyl-λ<sup>5</sup>-phosphaneylidene)amino)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)pentyl)piperazin-1-yl)-4,4,4-trifluorobut-2-en-1-one (<b>47</b>)</h5><div class="NLM_p last">To a solution of compound <b>45</b> (0.83 g, 1.1 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) was added TFA (1.5 mL) at room temperature. After stirring for 30 min, the resulting mixture was concentrated in vacuo to afford a crude. To a solution of crude compound, TEA (0.31 mL, 2.2 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added <b>46</b> (0.21 g, 1.3 mmol) at 0 °C. After stirring at room temperature for 1 h, the mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (10 mL), washed with saturated NaCl solution (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH = 20:1) to afford compound <b>47</b> (0.53 g, 59%) as a yellow liquid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.00 (s, 1H), 7.74 (ddt, <i>J</i> = 12.2, 7.0, 1.4 Hz, 6H), 7.50–7.43 (m, 3H), 7.41 (d, <i>J</i> = 2.3 Hz, 2H), 7.35 (td, <i>J</i> = 7.7, 3.0 Hz, 6H), 6.86 (dq, <i>J</i> = 15.3, 2.0 Hz, 1H), 6.63 (dq, <i>J</i> = 15.4, 6.6 Hz, 1H), 6.50 (t, <i>J</i> = 2.3 Hz, 1H), 4.32 (t, <i>J</i> = 7.2 Hz, 2H), 3.69 (s, 6H), 3.60 (d, <i>J</i> = 5.5 Hz, 2H), 3.42 (s, 2H), 2.39–2.22 (m, 6H), 1.89 (t, <i>J</i> = 7.6 Hz, 2H), 1.51–1.42 (m, 2H), 1.30 (t, <i>J</i> = 7.2 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 162.8, 160.9, 159.2, 159.2, 154.1, 153.8, 153.5, 144.6, 134.7, 132.4, 132.4, 132.4, 132.4, 132.3, 132.3, 130.9, 130.9, 130.9, 128.4, 128.19, 128.1, 127.4, 127.4, 127.4, 127.3, 127.3, 127.3, 127.2, 126.8, 126.7, 120.1, 106.9, 106.9, 99.3, 57.0, 54.2, 52.2, 51.5, 45.7, 44.9, 41.2, 28.6, 25.2, 23.4. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>44</sub>H<sub>45</sub>F<sub>3</sub>N<sub>7</sub>NaO<sub>3</sub>P<sup>+</sup>, 830.3166; found, 830.3168.</div></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i129" class="anchor-spacer"></div><h3 class="article-section__title" id="_i129"> Cell Lines and Cell Culture</h3><div class="NLM_p last">NCI-H1581 and SNU-16 were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured according to the instructions. Other cells were purchased form Institute of Basic Medicine, Chinese Academy of Medical Sciences, and cultured according to the instructions.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i130" class="anchor-spacer"></div><h3 class="article-section__title" id="_i130"> Protein Purification</h3><div class="NLM_p last">Protein preparation was performed with some modifications to that described in previously published protocols.<a onclick="showRef(event, 'ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30">(28−30)</a> The kinase domain of human FGFR1 (residues 459–765), FGFR2 (residues 458–768), FGFR3 (K650E, residues 450–758), and FGFR4 (residues 445–753) was subcloned into modified pET-28a vector, which contains a Ulp protease-cleavable <i>N</i>-terminal 6×histidine tag. The recombinant FGFR-KD was co-expressed with human PTP1B in <i>Escherichia coli</i> BL21 (DE3). The colony was inoculated into the LB culture with 50 μg/mL kanamycin and 100 μg/mL ampicillin and induced with 0.5 mM isopropyl β-d-1-thiogalactopyranoside at 16 °C for 18 h when the culture grew to OD600 0.8. Cells were harvested by centrifugation at 4000 rpm for 15 min. For his-tagged FGFR purification, the cell pellets were re-suspended in buffer A (20 mM Tris-HCl, pH 8.0, 500 mM NaCl, 5% glycerol) and disrupted by a high-pressure homogenizer AH-1500 (ATS Engineering Limited) at 800 bar. After centrifugation at 12,000 rpm for 40 min, the lysate supernatants were then loaded onto a 1 mL Ni-NTA column pre-equilibrated with buffer A. After resin washing with buffer A containing 20 mM imidazole, the <i>N</i>-terminal histidine tag was cleaved with the addition of Ulp protease overnight at 4 °C. Untagged FGFRs were eluted with buffer A and finally purified by anion exchange chromatography (Resource Q 1 mL, GE Healthcare). Peak fractions were concentrated and stored at −80 °C for later use.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i131" class="anchor-spacer"></div><h3 class="article-section__title" id="_i131"> Kinase Inhibition Assay</h3><div class="NLM_p last">The kinase activities of FGFR1, FGFR2, FGFR3, and FGFR4 were assessed using the HTRF method, which is conducted by Sichuan Greentech Bioscience Co. Ltd.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i132" class="anchor-spacer"></div><h3 class="article-section__title" id="_i132"> Kinase Panel Assay</h3><div class="NLM_p last">Kinase panel assays were conducted by Wuxi PharmaTech Co. Ltd.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i133" class="anchor-spacer"></div><h3 class="article-section__title" id="_i133"> Western Blotting Experiments</h3><div class="NLM_p last">NCI-H1581 and SNU-16 (2 × 10<sup>5</sup> per well) were seeded in 6-well culture plates, treated with compound <b>36</b> at indicated concentrations for 12 h and lysed in RIPA lysis buffer supplemented with protease inhibitors (cocktail/PMSF (phenylmethanesulfonyl fluoride)) and a dephosphorylase inhibitor (NaF). The protein concentration was measured with a BCA protein assay kit (Beyotime Biotechnology, P0012). Equal amounts of proteins were electrophoresed by SDS-PAGE (8–15%) under denaturing conditions and transferred onto the PDVF (polyvinylidene fluoride) membranes (Millipore Corporation, IPVH00010). Membranes were blocked in 5% non-fat milk (BD Difco, 232100) and then incubated with primary antibodies. After being washed, the membranes were incubated with secondary antibodies and detected using a Luminescent Image Analyzer LSA 4000 (GE, Fairfield, CO, USA).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i134" class="anchor-spacer"></div><h3 class="article-section__title" id="_i134"> Cell Proliferation Assay</h3><div class="NLM_p last">Cell counting kit (CCK)-8 assay was used to assess the drug sensitivity to different cancer cell lines. Cells were seeded in 96-well plates at 2–2.5 × 10<sup>3</sup> cells/well in a final volume of 100 μL. Then, compound <b>36</b> was added at different concentrations after 24 h post-plating and incubated for another 96 h. The concentrations required to inhibit growth by 50% (IC<sub>50</sub>) were calculated with GraphPad Prizm7.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i135" class="anchor-spacer"></div><h3 class="article-section__title" id="_i135"> PK Study</h3><div class="NLM_p last">Sprague-Dawley male rats (220–350 g) were purchased from Academy of Military Medical Sciences (Beijing, China). For a single dose PK study of compound <b>36</b>, six rats were divided into two groups: (A) PO of compound <b>36</b> (5 mg/kg) and (B) IV of compound <b>36</b> (5 mg/kg). For IV study, 200 μL of blood was collected from different rats at 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 4 h, 6 h, and 8 h. For PO study, 200 μL of blood was collected from different rats at 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 4 h, 6 h, and 8 h. Blood samples were treated with heparin to prevent coagulation. Blood samples were centrifuged for 10 min at 13,000 rpm in a desktop centrifuge to collect plasma. 50 μL of plasma samples were combined with 200 μL of internal standard (buspirone, 100 ng/mL) in MeOH/H<sub>2</sub>O (1:1, v/v) and centrifuged at 15,000 rpm for 10 min at 4 °C. The supernatant (100 μL) was collected and mixed with five parts of 50% MeOH/water. The plasma drug concentration was determined by LC/MS–MS. Summary of the LC/MS–MS method is provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.1c00174/suppl_file/jm1c00174_si_001.csv" class="ext-link">Supporting Information</a>. The processed plasma concentration–time data were analyzed using non-compartmental analysis.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i136" class="anchor-spacer"></div><h3 class="article-section__title" id="_i136"> Animal Study</h3><div class="NLM_p last">The animal studies were approved by the Institutional Review Board of Nankai University. All animal studies were conducted according to protocols approved by the Animal Ethics Committee of Nankai University. A total volume of 0.1 mL of PBS containing 5.0 × 10<sup>6</sup> NCI-H1581 and SNU-16 cells was injected subcutaneously into 6 weeks old female BALB/c Nude mice, respectively. All mice were kept in a specific pathogen-free environment. When the tumor volume reached about 80–100 mm<sup>3</sup>, the mice were randomly divided to vehicle control and compound <b>36</b> (50 or 100 mg/kg/d, p.o., <i>n</i> = 6 for each group) and were treated as per dose mentioned above. Tumor volume and mice weight were measured each day after the initiation of the treatment. Mice were executed, and tumors were harvested on day 26 or after 40 days, respectively.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i137" class="anchor-spacer"></div><h3 class="article-section__title" id="_i137"> Statistical Analysis</h3><div class="NLM_p last">All statistical analyses were conducted using GraphPad Prizm7 software. Statistically significant differences were determined by Student’s <i>t</i> test, and <i>P</i> values less than 0.05 were considered statistically significant in all cases.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i138"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00174" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46746" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46746" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00174?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00174</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings of all test compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00174/suppl_file/jm1c00174_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">PDB file is for the Supporting Information (Figure S4) (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00174/suppl_file/jm1c00174_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Copies of <sup>1</sup>H/<sup>13</sup>C NMR spectrum of all compounds and intermediates (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00174/suppl_file/jm1c00174_si_003.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00174/suppl_file/jm1c00174_si_001.csv">jm1c00174_si_001.csv (2.77 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00174/suppl_file/jm1c00174_si_002.pdb">jm1c00174_si_002.pdb (753.92 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00174/suppl_file/jm1c00174_si_003.pdf">jm1c00174_si_003.pdf (13.04 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00174" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74700" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74700" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mingming Wei</span> - <span class="hlFld-Affiliation affiliation">The State Key Laboratory
of Medicinal
Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#472a2e29202a2e2920342f2229203032077671746924282a"><span class="__cf_email__" data-cfemail="066b6f68616b6f6861756e6368617173463730352865696b">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guang Yang</span> - <span class="hlFld-Affiliation affiliation">The State Key Laboratory
of Medicinal
Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-1773-9392" title="Orcid link">https://orcid.org/0000-0002-1773-9392</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#bbfccedad5dc95c2dad5dcfbd5dad5d0dad295dedfce95d8d5"><span class="__cf_email__" data-cfemail="0a4d7f6b646d24736b646d4a646b64616b63246f6e7f246964">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cheng Yang</span> - <span class="hlFld-Affiliation affiliation">The State Key Laboratory
of Medicinal
Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e2a18a878c85cc9b838c85a28c838c89838bcc878697cc818c"><span class="__cf_email__" data-cfemail="54173c313a337a2d353a33143a353a3f353d7a3130217a373a">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yujiao Wei</span> - <span class="hlFld-Affiliation affiliation">The State Key Laboratory
of Medicinal
Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanting Tang</span> - <span class="hlFld-Affiliation affiliation">The State Key Laboratory
of Medicinal
Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yunyun Zhou</span> - <span class="hlFld-Affiliation affiliation">The State Key Laboratory
of Medicinal
Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuyu Yang</span> - <span class="hlFld-Affiliation affiliation">The State Key Laboratory
of Medicinal
Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yetong Cui</span> - <span class="hlFld-Affiliation affiliation">The State Key Laboratory
of Medicinal
Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xuan Wang</span> - <span class="hlFld-Affiliation affiliation">The State Key Laboratory
of Medicinal
Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yubo Wang</span> - <span class="hlFld-Affiliation affiliation">The State Key Laboratory
of Medicinal
Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yulin Liu</span> - <span class="hlFld-Affiliation affiliation">The State Key Laboratory
of Medicinal
Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ning Liu</span> - <span class="hlFld-Affiliation affiliation">The State Key Laboratory
of Medicinal
Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qianqian Wang</span> - <span class="hlFld-Affiliation affiliation">The State Key Laboratory
of Medicinal
Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chong Li</span> - <span class="hlFld-Affiliation affiliation">The State Key Laboratory
of Medicinal
Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hao Ruan</span> - <span class="hlFld-Affiliation affiliation">The State Key Laboratory
of Medicinal
Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Honggang Zhou</span> - <span class="hlFld-Affiliation affiliation">The State Key Laboratory
of Medicinal
Chemical Biology, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.W. and Y.T. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i140">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18504" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18504" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the Fundamental Research Funds for the Central Universities, the Nankai University (735–63201240), the National Natural Science Foundation of China (NSFC, nos 82003186 and 82073691), and the Key Research and Development Program of Tianjin City (no. 19YFZCSY00160).</p></div><div class="postAsapNotesSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="postAsapNotesSection">Note Added After ASAP Publication</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32280" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32280" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This paper was published on June 15, 2021. Due to production error, the Table 1 graphic was missing. The corrected version was reposted on June 22, 2021.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">Cys</td><td class="NLM_def"><p class="first last">cysteine</p></td></tr><tr><td class="NLM_term">FGFR</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half inhibit concentration</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small cell lung cancer</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">p.o.</td><td class="NLM_def"><p class="first last">intragastric administration</p></td></tr><tr><td class="NLM_term">RTKs</td><td class="NLM_def"><p class="first last">receptor tyrosine kinases</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationships</p></td></tr><tr><td class="NLM_term">TKIs</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitors</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i142">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87623" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87623" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 30 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grose, R.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor signalling: from development to cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1038/nrc2780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1038%2Fnrc2780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=20094046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=116-129&author=N.+Turnerauthor=R.+Grose&title=Fibroblast+growth+factor+signalling%3A+from+development+to+cancer&doi=10.1038%2Fnrc2780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor signalling: from development to cancer</span></div><div class="casAuthors">Turner, Nicholas; Grose, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-129</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) and their receptors control a wide range of biol. functions, regulating cellular proliferation, survival, migration and differentiation.  Although targeting FGF signalling as a cancer therapeutic target has lagged behind that of other receptor tyrosine kinases, there is now substantial evidence for the importance of FGF signalling in the pathogenesis of diverse tumor types, and clin. reagents that specifically target the FGFs or FGF receptors are being developed.  Although FGF signalling can drive tumorigenesis, in different contexts FGF signalling can mediate tumor protective functions; the identification of the mechanisms that underlie these differential effects will be important to understand how FGF signalling can be most appropriately therapeutically targeted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUBfz6uAu97bVg90H21EOLACvtfcHk0liDEsZ79S2suQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D&md5=7963bc75c149981560dffc8d91b4aaf1</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2780%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DGrose%26aufirst%3DR.%26atitle%3DFibroblast%2520growth%2520factor%2520signalling%253A%2520from%2520development%2520to%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D116%26epage%3D129%26doi%3D10.1038%2Fnrc2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carter, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fearon, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grose, R. P.</span></span> <span> </span><span class="NLM_article-title">Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1016/j.tcb.2014.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1016%2Fj.tcb.2014.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=25467007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2jtL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=221-233&author=E.+P.+Carterauthor=A.+E.+Fearonauthor=R.+P.+Grose&title=Careless+talk+costs+lives%3A+fibroblast+growth+factor+receptor+signalling+and+the+consequences+of+pathway+malfunction&doi=10.1016%2Fj.tcb.2014.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction</span></div><div class="casAuthors">Carter, Edward P.; Fearon, Abbie E.; Grose, Richard P.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">221-233</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Since its discovery 40 years ago, fibroblast growth factor (FGF) receptor (FGFR) signalling has been found to regulate fundamental cellular behaviors in a wide range of cell types.  FGFRs regulate development, homeostasis, and repair and are implicated in many disorders and diseases; and indeed, there is extensive potential for severe consequences, be they developmental, homeostatic, or oncogenic, should FGF-FGFR signalling go awry, so careful control of the pathway is critically important.  In this review, we discuss the recent developments in the FGF field, highlighting how FGFR signalling works in normal cells, how it can go wrong, how frequently it is compromised, and how it is being targeted therapeutically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJuJ0uV7rBFbVg90H21EOLACvtfcHk0liDEsZ79S2suQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2jtL%252FL&md5=d184f8f455ae220c2265070479309dee</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2014.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2014.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DE.%2BP.%26aulast%3DFearon%26aufirst%3DA.%2BE.%26aulast%3DGrose%26aufirst%3DR.%2BP.%26atitle%3DCareless%2520talk%2520costs%2520lives%253A%2520fibroblast%2520growth%2520factor%2520receptor%2520signalling%2520and%2520the%2520consequences%2520of%2520pathway%2520malfunction%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2015%26volume%3D25%26spage%3D221%26epage%3D233%26doi%3D10.1016%2Fj.tcb.2014.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Touat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ileana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postel-Vinay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">André, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span> <span> </span><span class="NLM_article-title">Targeting FGFR signaling in cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2684</span>– <span class="NLM_lpage">2694</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-14-2329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F1078-0432.CCR-14-2329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=26078430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVajurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2684-2694&author=M.+Touatauthor=E.+Ileanaauthor=S.+Postel-Vinayauthor=F.+Andr%C3%A9author=J.-C.+Soria&title=Targeting+FGFR+signaling+in+cancer&doi=10.1158%2F1078-0432.ccr-14-2329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting FGFR Signaling in Cancer</span></div><div class="casAuthors">Touat, Mehdi; Ileana, Ecaterina; Postel-Vinay, Sophie; Andre, Fabrice; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2684-2694</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor signaling pathway (FGFR signaling) is an evolutionary conserved signaling cascade that regulates several basic biol. processes, including tissue development, angiogenesis, and tissue regeneration.  Substantial evidence indicates that aberrant FGFR signaling is involved in the pathogenesis of cancer.  Recent developments of deep sequencing technologies have allowed the discovery of frequent mol. alterations in components of FGFR signaling among several solid tumor types.  Moreover, compelling preclin. models have demonstrated the oncogenic potential of these aberrations in driving tumor growth, promoting angiogenesis, and conferring resistance mechanisms to anticancer therapies.  Recently, the field of FGFR targeting has exponentially progressed thanks to the development of novel agents inhibiting FGFs or FGFRs, which had manageable safety profiles in early-phase trials.  Promising treatment efficacy has been obsd. in different types of malignancies, particularly in tumors harboring aberrant FGFR signaling, thus offering novel therapeutic opportunities in the era of precision medicine.  The most exciting challenges now focus on selecting patients who are most likely to benefit from these agents, increasing the efficacy of therapies with the development of novel potent compds. and combination strategies, and overcoming toxicities assocd. with FGFR inhibitors.  After examn. of the basic and translational research studies that validated the oncogenic potential of aberrant FGFR signaling, this review focuses on recent data from clin. trials evaluating FGFR targeting therapies and discusses the challenges and perspectives for the development of these agents.  Clin Cancer Res; 21(12); 2684-94. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSZpKbvUn0hrVg90H21EOLACvtfcHk0liDEsZ79S2suQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVajurfP&md5=3dbb11de3f3a7d25d3b4ccb56400fd4d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2329%26sid%3Dliteratum%253Aachs%26aulast%3DTouat%26aufirst%3DM.%26aulast%3DIleana%26aufirst%3DE.%26aulast%3DPostel-Vinay%26aufirst%3DS.%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26aulast%3DSoria%26aufirst%3DJ.-C.%26atitle%3DTargeting%2520FGFR%2520signaling%2520in%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2684%26epage%3D2694%26doi%3D10.1158%2F1078-0432.ccr-14-2329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dieci, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnedos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">264</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.cd-12-0362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F2159-8290.CD-12-0362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=23418312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVOktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=264-279&author=M.+V.+Dieciauthor=M.+Arnedosauthor=F.+Andreauthor=J.+C.+Soria&title=Fibroblast+growth+factor+receptor+inhibitors+as+a+cancer+treatment%3A+from+a+biologic+rationale+to+medical+perspectives&doi=10.1158%2F2159-8290.cd-12-0362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives</span></div><div class="casAuthors">Dieci, Maria Vittoria; Arnedos, Monica; Andre, Fabrice; Soria, Jean Charles</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">264-279</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling pathway plays a fundamental role in many physiol. processes, including embryogenesis, adult tissue homeostasis, and wound healing, by orchestrating angiogenesis.  Ligand-independent and ligand-dependent activation have been implicated in a broad range of human malignancies and promote cancer progression in tumors driven by FGF/FGFR oncogenic mutations or amplifications, tumor neoangiogenesis, and targeted treatment resistance, thereby supporting a strong rationale for anti-FGF/FGFR agent development.  Efforts are being pursued to develop selective approaches for use against this pathway by optimizing the management of emerging, class-specific toxicity profiles and correctly designing clin. trials to address these different issues.  Significance: FGF/FGFR pathway deregulations are increasingly recognized across different human cancers.  Understanding the mechanisms at the basis of these alterations and their multiple roles in cancer promotion and drug resistance is a fundamental step for further implementation of targeted therapies and research strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6bibZKwamTLVg90H21EOLACvtfcHk0liIInN-iFyf0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVOktL4%253D&md5=0e694a7641aa83c1540f745576f04bfa</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0362%26sid%3Dliteratum%253Aachs%26aulast%3DDieci%26aufirst%3DM.%2BV.%26aulast%3DArnedos%26aufirst%3DM.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DFibroblast%2520growth%2520factor%2520receptor%2520inhibitors%2520as%2520a%2520cancer%2520treatment%253A%2520from%2520a%2520biologic%2520rationale%2520to%2520medical%2520perspectives%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D264%26epage%3D279%26doi%3D10.1158%2F2159-8290.cd-12-0362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grose, R.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor signalling: from development to cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1038/nrc2780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1038%2Fnrc2780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=20094046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=116-129&author=N.+Turnerauthor=R.+Grose&title=Fibroblast+growth+factor+signalling%3A+from+development+to+cancer&doi=10.1038%2Fnrc2780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor signalling: from development to cancer</span></div><div class="casAuthors">Turner, Nicholas; Grose, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-129</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) and their receptors control a wide range of biol. functions, regulating cellular proliferation, survival, migration and differentiation.  Although targeting FGF signalling as a cancer therapeutic target has lagged behind that of other receptor tyrosine kinases, there is now substantial evidence for the importance of FGF signalling in the pathogenesis of diverse tumor types, and clin. reagents that specifically target the FGFs or FGF receptors are being developed.  Although FGF signalling can drive tumorigenesis, in different contexts FGF signalling can mediate tumor protective functions; the identification of the mechanisms that underlie these differential effects will be important to understand how FGF signalling can be most appropriately therapeutically targeted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUBfz6uAu97bVg90H21EOLACvtfcHk0liIInN-iFyf0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D&md5=7963bc75c149981560dffc8d91b4aaf1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc2780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2780%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DGrose%26aufirst%3DR.%26atitle%3DFibroblast%2520growth%2520factor%2520signalling%253A%2520from%2520development%2520to%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D116%26epage%3D129%26doi%3D10.1038%2Fnrc2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miduturu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stransky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodous, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooijmans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shutes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzi, T.</span></span> <span> </span><span class="NLM_article-title">First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.cd-14-1029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F2159-8290.CD-14-1029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=25776529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVSrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=424-437&author=M.+Hagelauthor=C.+Miduturuauthor=M.+Sheetsauthor=N.+Rubinauthor=W.+Wengauthor=N.+Stranskyauthor=N.+Bifulcoauthor=J.+L.+Kimauthor=B.+Hodousauthor=N.+Brooijmansauthor=A.+Shutesauthor=C.+Winterauthor=C.+Lengauerauthor=N.+E.+Kohlauthor=T.+Guzi&title=First+selective+small+molecule+inhibitor+of+FGFR4+for+the+treatment+of+hepatocellular+carcinomas+with+an+activated+FGFR4+signaling+pathway&doi=10.1158%2F2159-8290.cd-14-1029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway</span></div><div class="casAuthors">Hagel, Margit; Miduturu, Chandra; Sheets, Michael; Rubin, Nooreen; Weng, Weifan; Stransky, Nicolas; Bifulco, Neil; Kim, Joseph L.; Hodous, Brian; Brooijmans, Natasja; Shutes, Adam; Winter, Christopher; Lengauer, Christoph; Kohl, Nancy E.; Guzi, Timothy</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">424-437</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HCC cells with FGF19 gene amplification or overexpression and an intact FGFR4 signaling pathway are sensitive to potent and selective FGFR4 inhibition by the small mol. BLU9931 in vitro and in xenograft models.  Aberrant signaling through the fibroblast growth factor 19 (FGF19)/fibroblast growth factor receptor 4 (FGFR 4) signaling complex has been shown to cause hepatocellular carcinoma (HCC) in mice and has been implicated to play a similar role in humans.  We have developed BLU9931, a potent and irreversible small-mol. inhibitor of FGFR4, as a targeted therapy to treat patients with HCC whose tumors have an activated FGFR4 signaling pathway.  BLU9931 is exquisitely selective for FGFR4 vs. other FGFR family members and all other kinases.  BLU9931 shows remarkable antitumor activity in mice bearing an HCC tumor xenograft that overexpresses FGF19 due to amplification as well as a liver tumor xenograft that overexpresses FGF19 mRNA but lacks FGF19 amplification.  Approx. one third of patients with HCC whose tumors express FGF19 together with FGFR4 and its coreceptor klotho β (KLB) could potentially respond to treatment with an FGFR4 inhibitor.  These findings are the first demonstration of a therapeutic strategy that targets a subset of patients with HCC.  Significance: This article documents the discovery of BLU9931, a novel irreversible kinase inhibitor that specifically targets FGFR4 while sparing all other FGFR paralogs and demonstrates exquisite kinome selectivity.  BLU9931 is efficacious in tumors with an intact FGFR4 signaling pathway that includes FGF19, FGFR4, and KLB.  BLU9931 is the first FGFR4-selective mol. for the treatment of patients with HCC with aberrant FGFR4 signaling.  Cancer Discov; 5(4); 424-37. cpr2015 AACR.  See related commentary by Packer and Pollock, p. 355 This article is highlighted in the In This Issue feature, p.  333.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqcHNr-1ZnG7Vg90H21EOLACvtfcHk0liIInN-iFyf0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVSrtL8%253D&md5=4a69439aee01a3c090c14851a785362e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-1029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-1029%26sid%3Dliteratum%253Aachs%26aulast%3DHagel%26aufirst%3DM.%26aulast%3DMiduturu%26aufirst%3DC.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DRubin%26aufirst%3DN.%26aulast%3DWeng%26aufirst%3DW.%26aulast%3DStransky%26aufirst%3DN.%26aulast%3DBifulco%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DHodous%26aufirst%3DB.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DShutes%26aufirst%3DA.%26aulast%3DWinter%26aufirst%3DC.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DKohl%26aufirst%3DN.%2BE.%26aulast%3DGuzi%26aufirst%3DT.%26atitle%3DFirst%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520FGFR4%2520for%2520the%2520treatment%2520of%2520hepatocellular%2520carcinomas%2520with%2520an%2520activated%2520FGFR4%2520signaling%2520pathway%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D424%26epage%3D437%26doi%3D10.1158%2F2159-8290.cd-14-1029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Babina, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span> <span> </span><span class="NLM_article-title">Advances and challenges in targeting FGFR signalling in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1038/nrc.2017.8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1038%2Fnrc.2017.8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=28303906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Ont7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=318-332&author=I.+S.+Babinaauthor=N.+C.+Turner&title=Advances+and+challenges+in+targeting+FGFR+signalling+in+cancer&doi=10.1038%2Fnrc.2017.8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Advances and challenges in targeting FGFR signalling in cancer</span></div><div class="casAuthors">Babina, Irina S.; Turner, Nicholas C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">318-332</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate numerous cellular processes.  Deregulation of FGFR signalling is obsd. in a subset of many cancers, making activated FGFRs a highly promising potential therapeutic target supported by multiple preclin. studies.  However, early-phase clin. trials have produced mixed results with FGFR-targeted cancer therapies, revealing substantial complexity to targeting aberrant FGFR signalling.  In this Review, we discuss the increasing understanding of the differences between diverse mechanisms of oncogenic activation of FGFR, and the factors that det. response and resistance to FGFR targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKkSMehfBbyLVg90H21EOLACvtfcHk0lip6ATcUkO7Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Ont7g%253D&md5=ed8f0ad426859a07930f7c0c2d2a9b71</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2017.8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2017.8%26sid%3Dliteratum%253Aachs%26aulast%3DBabina%26aufirst%3DI.%2BS.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26atitle%3DAdvances%2520and%2520challenges%2520in%2520targeting%2520FGFR%2520signalling%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D318%26epage%3D332%26doi%3D10.1038%2Fnrc.2017.8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renhowe, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machajewski, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jazan, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonios-McCrea, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapointe, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feucht, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warne, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heise, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aardalen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wernette-Hammond, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A. L.</span></span> <span> </span><span class="NLM_article-title">Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1021/jm800790t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800790t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1Sl" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=278-292&author=P.+A.+Renhoweauthor=S.+Pecchiauthor=C.+M.+Shaferauthor=T.+D.+Machajewskiauthor=E.+M.+Jazanauthor=C.+Taylorauthor=W.+Antonios-McCreaauthor=C.+M.+McBrideauthor=K.+Frazierauthor=M.+Wiesmannauthor=G.+R.+Lapointeauthor=P.+H.+Feuchtauthor=R.+L.+Warneauthor=C.+C.+Heiseauthor=D.+Menezesauthor=K.+Aardalenauthor=H.+Yeauthor=M.+Heauthor=V.+Leauthor=J.+Voraauthor=J.+M.+Jansenauthor=M.+E.+Wernette-Hammondauthor=A.+L.+Harris&title=Design%2C+structure-activity+relationships+and+in+vivo+characterization+of+4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones%3A+a+novel+class+of+receptor+tyrosine+kinase+inhibitors&doi=10.1021%2Fjm800790t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Structure-Activity Relationships and in Vivo Characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A Novel Class of Receptor Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Renhowe, Paul A.; Pecchi, Sabina; Shafer, Cynthia M.; Machajewski, Timothy D.; Jazan, Elisa M.; Taylor, Clarke; Antonios-McCrea, William; McBride, Christopher M.; Frazier, Kelly; Wiesmann, Marion; Lapointe, Gena R.; Feucht, Paul H.; Warne, Robert L.; Heise, Carla C.; Menezes, Daniel; Aardalen, Kimberly; Ye, Helen; He, Molly; Le, Vincent; Vora, Jayesh; Jansen, Johanna M.; Wernette-Hammond, Mary Ellen; Harris, Alex L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-292</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The inhibition of key receptor tyrosine kinases (RTKs) that are implicated in tumor vasculature formation and maintenance, as well as tumor progression and metastasis, has been a major focus in oncol. research over the last several years.  Many potent small mol. inhibitors of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) kinases have been evaluated.  More recently, compds. that act through the complex inhibition of multiple kinase targets have been reported and may exhibit improved clin. efficacy.  We report herein a series of potent, orally efficacious 4-amino-3-benzimidazol-2-ylhydroquinolin-2-one analogs as inhibitors of VEGF, PDGF, and fibroblast growth factor (FGF) receptor tyrosine kinases.  Compds. in this class, such as TKI258 (I), are reversible ATP-competitive inhibitors of VEGFR-2, FGFR-1, and PDGFRβ with IC50 values <0.1 μM.  On the basis of its favorable in vitro and in vivo properties, compd. I was selected for clin. evaluation and is currently in phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUf3qVBfCr87Vg90H21EOLACvtfcHk0lgX7CP8BxxGkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1Sl&md5=f20f564bb7dacb5a450a29dae9e04b50</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm800790t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800790t%26sid%3Dliteratum%253Aachs%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26aulast%3DMachajewski%26aufirst%3DT.%2BD.%26aulast%3DJazan%26aufirst%3DE.%2BM.%26aulast%3DTaylor%26aufirst%3DC.%26aulast%3DAntonios-McCrea%26aufirst%3DW.%26aulast%3DMcBride%26aufirst%3DC.%2BM.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DLapointe%26aufirst%3DG.%2BR.%26aulast%3DFeucht%26aufirst%3DP.%2BH.%26aulast%3DWarne%26aufirst%3DR.%2BL.%26aulast%3DHeise%26aufirst%3DC.%2BC.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DAardalen%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DV.%26aulast%3DVora%26aufirst%3DJ.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DWernette-Hammond%26aufirst%3DM.%2BE.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26atitle%3DDesign%252C%2520structure-activity%2520relationships%2520and%2520in%2520vivo%2520characterization%2520of%25204-amino-3-benzimidazol-2-ylhydroquinolin-2-ones%253A%2520a%2520novel%2520class%2520of%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D278%26epage%3D292%26doi%3D10.1021%2Fjm800790t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bello, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarlato, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berndt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valbusa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Incalci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalletti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giavazzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camboni, G.</span></span> <span> </span><span class="NLM_article-title">E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1396</span>– <span class="NLM_lpage">1405</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-10-2700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F0008-5472.CAN-10-2700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=21212416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFSjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1396-1405&author=E.+Belloauthor=G.+Colellaauthor=V.+Scarlatoauthor=P.+Olivaauthor=A.+Berndtauthor=G.+Valbusaauthor=S.+C.+Serraauthor=M.+D%E2%80%99Incalciauthor=E.+Cavallettiauthor=R.+Giavazziauthor=G.+Damiaauthor=G.+Camboni&title=E-3810+is+a+potent+dual+inhibitor+of+VEGFR+and+FGFR+that+exerts+antitumor+activity+in+multiple+preclinical+models&doi=10.1158%2F0008-5472.can-10-2700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models</span></div><div class="casAuthors">Bello, Ezia; Colella, Gennaro; Scarlato, Valentina; Oliva, Paolo; Berndt, Alexander; Valbusa, Giovanni; Serra, Sonia Colombo; D'Incalci, Maurizio; Cavalletti, Ennio; Giavazzi, Raffaella; Damia, Giovanna; Camboni, Gabriella</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1396-1405</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tumor angiogenesis is a degenerate process regulated by a complex network of proangiogenic factors.  Existing antiangiogenic drugs used in clinic are characterized by selectivity for specific factors.  Antiangiogenic properties might be improved in drugs that target multiple factors and thereby address the inherent mechanistic degeneracy in angiogenesis.  Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) family members and their cognate receptors are key players in promoting tumor angiogenesis.  Here we report the pharmacol. profile of E-3810, a novel dual inhibitor of the VEGF and FGF receptors.  E-3810 potently and selectively inhibited VEGF receptor (VEGFR)-1, -2, and -3 and FGF receptor (FGFR)-1 and -2 kinases in the nanomolar range.  Ligand-dependent phosphorylation of VEGFR-2 and FGFR-1 was suppressed along with human vascular endothelial cell growth at nanomolar concns.  In contrast, E-3810 lacked cytotoxic effects on cancer cell lines under millimolar concns.  In a variety of tumor xenograft models, including early- or late-stage s.c. and orthotopic models, E-3810 exhibited striking antitumor properties at well-tolerated oral doses administered daily.  We found that E-3810 remained active in tumors rendered nonresponsive to the general kinase inhibitor sunitinib resulting from a previous cycle of sunitinib treatment.  In Matrigel plug assays performed in nude mice, E-3810 inhibited basic FGF-induced angiogenesis and reduced blood vessel d. as assessed by histol. anal.  Dynamic contrast-enhanced magnetic resonance imaging anal. confirmed that E-3810 reduced the distribution of angiogenesis-sensitive contrast agents after only 5 days of treatment.  Taken together, our findings identify E-3810 as a potent antiangiogenic small mol. with a favorable pharmacokinetic profile and broad spectrum antitumor activity, providing a strong rationale for its clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0BsK0BmeJzLVg90H21EOLACvtfcHk0lgX7CP8BxxGkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFSjsbs%253D&md5=ec3692b0d962aa0f035425a293dfb3e6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2700%26sid%3Dliteratum%253Aachs%26aulast%3DBello%26aufirst%3DE.%26aulast%3DColella%26aufirst%3DG.%26aulast%3DScarlato%26aufirst%3DV.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DBerndt%26aufirst%3DA.%26aulast%3DValbusa%26aufirst%3DG.%26aulast%3DSerra%26aufirst%3DS.%2BC.%26aulast%3DD%25E2%2580%2599Incalci%26aufirst%3DM.%26aulast%3DCavalletti%26aufirst%3DE.%26aulast%3DGiavazzi%26aufirst%3DR.%26aulast%3DDamia%26aufirst%3DG.%26aulast%3DCamboni%26aufirst%3DG.%26atitle%3DE-3810%2520is%2520a%2520potent%2520dual%2520inhibitor%2520of%2520VEGFR%2520and%2520FGFR%2520that%2520exerts%2520antitumor%2520activity%2520in%2520multiple%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D1396%26epage%3D1405%26doi%3D10.1158%2F0008-5472.can-10-2700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colbatzky, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handschuh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann-Lintz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tontsch-Grunt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilberg, F.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6- methoxycarbonyl-substituted indolinone (BIBF 1120)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4466</span>– <span class="NLM_lpage">4480</span>, <span class="refDoi"> DOI: 10.1021/jm900431g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900431g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntFygsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4466-4480&author=G.+J.+Rothauthor=A.+Heckelauthor=F.+Colbatzkyauthor=S.+Handschuhauthor=J.+Kleyauthor=T.+Lehmann-Lintzauthor=R.+Lotzauthor=U.+Tontsch-Gruntauthor=R.+Walterauthor=F.+Hilberg&title=Design%2C+synthesis%2C+and+evaluation+of+indolinones+as+triple+angiokinase+inhibitors+and+the+discovery+of+a+highly+specific+6-+methoxycarbonyl-substituted+indolinone+%28BIBF+1120%29&doi=10.1021%2Fjm900431g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Indolinones as Triple Angiokinase Inhibitors and the Discovery of a Highly Specific 6-Methoxycarbonyl-Substituted Indolinone (BIBF 1120)</span></div><div class="casAuthors">Roth, Gerald J.; Heckel, Armin; Colbatzky, Florian; Handschuh, Sandra; Kley, Jorg; Lehmann-Lintz, Thorsten; Lotz, Ralf; Tontsch-Grunt, Ulrike; Walter, Rainer; Hilberg, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4466-4480</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of tumor angiogenesis through blockade of the vascular endothelial growth factor (VEGF) signaling pathway is a new treatment modality in oncol.  Preclin. findings suggest that blockade of addnl. pro-angiogenic kinases, such as fibroblast and platelet-derived growth factor receptors (FGFR and PDGFR), may improve the efficacy of pharmacol. cancer treatment.  Indolinones substituted in position 6 were identified as selective inhibitors of VEGF-, PDGF-, and FGF-receptor kinases.  In particular, 6-methoxycarbonyl-substituted indolinones showed a highly favorable selectivity profile.  Optimization identified potent inhibitors of VEGF-related endothelial cell proliferation with addnl. efficacy on pericyctes and smooth muscle cells.  In contrast, no direct inhibition of tumor cell proliferation was obsd.  Compds. 2 (BIBF 1000) and 3 (BIBF 1120) are orally available and display encouraging efficacy in in vivo tumor models while being well tolerated.  The triple angiokinase inhibitor 3 (I) is currently in phase III clin. trials for the treatment of nonsmall cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvvcX-_HYCS7Vg90H21EOLACvtfcHk0lgX7CP8BxxGkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntFygsL4%253D&md5=1b8af461631ae3117520fc4811130bb3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm900431g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900431g%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DHeckel%26aufirst%3DA.%26aulast%3DColbatzky%26aufirst%3DF.%26aulast%3DHandschuh%26aufirst%3DS.%26aulast%3DKley%26aufirst%3DJ.%26aulast%3DLehmann-Lintz%26aufirst%3DT.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DWalter%26aufirst%3DR.%26aulast%3DHilberg%26aufirst%3DF.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520indolinones%2520as%2520triple%2520angiokinase%2520inhibitors%2520and%2520the%2520discovery%2520of%2520a%2520highly%2520specific%25206-%2520methoxycarbonyl-substituted%2520indolinone%2520%2528BIBF%25201120%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4466%26epage%3D4480%26doi%3D10.1021%2Fjm900431g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gozgit, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span> <span> </span><span class="NLM_article-title">Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-11-0450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F1535-7163.MCT-11-0450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=22238366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=690-699&author=J.+M.+Gozgitauthor=M.+J.+Wongauthor=L.+Moranauthor=S.+Wardwellauthor=Q.+K.+Mohemmadauthor=N.+I.+Narasimhanauthor=W.+C.+Shakespeareauthor=F.+Wangauthor=T.+Clacksonauthor=V.+M.+Rivera&title=Ponatinib+%28AP24534%29%2C+a+multitargeted+pan-FGFR+inhibitor+with+activity+in+multiple+FGFR-amplified+or+mutated+cancer+models&doi=10.1158%2F1535-7163.mct-11-0450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models</span></div><div class="casAuthors">Gozgit, Joseph M.; Wong, Matthew J.; Moran, Lauren; Wardwell, Scott; Mohemmad, Qurish K.; Narasimhan, Narayana I.; Shakespeare, William C.; Wang, Frank; Clackson, Tim; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">690-699</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Members of the fibroblast growth factor receptor family of kinases (FGFR1-4) are dysregulated in multiple cancers.  Ponatinib (AP24534) is an oral multitargeted tyrosine kinase inhibitor being explored in a pivotal phase II trial in patients with chronic myelogenous leukemia due to its potent activity against BCR-ABL.  Ponatinib has also been shown to inhibit the in vitro kinase activity of all four FGFRs, prompting us to examine its potential as an FGFR inhibitor.  In Ba/F3 cells engineered to express activated FGFR1-4, ponatinib potently inhibited FGFR-mediated signaling and viability with IC50 values <40 nmol/L, with substantial selectivity over parental Ba/F3 cells.  In a panel of 14 cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon) and contg. FGFRs dysregulated by a variety of mechanisms, ponatinib inhibited FGFR-mediated signaling with IC50 values <40 nmol/L and inhibited cell growth with GI50 (concn. needed to reduce the growth of treated cells to half that of untreated cells) values of 7 to 181 nmol/L.  Daily oral dosing of ponatinib (10-30 mg/kg) to mice reduced tumor growth and inhibited signaling in all three tumor models examd.  Importantly, the potency of ponatinib in these models is similar to that previously obsd. in BCR-ABL-driven models and plasma levels of ponatinib that exceed the IC50 values for FGFR1-4 inhibition can be sustained in patients.  These results show that ponatinib is a potent pan-FGFR inhibitor and provide strong rationale for its evaluation in patients with FGFR-driven cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4-w5b7EPxLLVg90H21EOLACvtfcHk0lhWsV-xKno3kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKis70%253D&md5=771979af1fba727510e073d19335ef5a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0450%26sid%3Dliteratum%253Aachs%26aulast%3DGozgit%26aufirst%3DJ.%2BM.%26aulast%3DWong%26aufirst%3DM.%2BJ.%26aulast%3DMoran%26aufirst%3DL.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DPonatinib%2520%2528AP24534%2529%252C%2520a%2520multitargeted%2520pan-FGFR%2520inhibitor%2520with%2520activity%2520in%2520multiple%2520FGFR-amplified%2520or%2520mutated%2520cancer%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D690%26epage%3D699%26doi%3D10.1158%2F1535-7163.mct-11-0450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavine, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilgour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span> <span> </span><span class="NLM_article-title">AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">2045</span>– <span class="NLM_lpage">2056</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-11-3034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F0008-5472.CAN-11-3034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=22369928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1Wgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=2045-2056&author=P.+R.+Gavineauthor=L.+Mooneyauthor=E.+Kilgourauthor=A.+P.+Thomasauthor=K.+Al-Kadhimiauthor=S.+Beckauthor=C.+Rooneyauthor=T.+Colemanauthor=D.+Bakerauthor=M.+J.+Mellorauthor=A.+N.+Brooksauthor=T.+Klinowska&title=AZD4547%3A+an+orally+bioavailable%2C+potent%2C+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+tyrosine+kinase+family&doi=10.1158%2F0008-5472.can-11-3034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family</span></div><div class="casAuthors">Gavine, Paul R.; Mooney, Lorraine; Kilgour, Elaine; Thomas, Andrew P.; Al-Kadhimi, Katherine; Beck, Sarah; Rooney, Claire; Coleman, Tanya; Baker, Dawn; Mellor, Martine J.; Brooks, A. Nigel; Klinowska, Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2045-2056</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor (FGF) signaling axis is increasingly implicated in tumorigenesis and chemoresistance.  Several small-mol. FGF receptor (FGFR) kinase inhibitors are currently in clin. development; however, the predominant activity of the most advanced of these agents is against the kinase insert domain receptor (KDR), which compromises the FGFR selectivity.  Here, we report the pharmacol. profile of AZD4547, a novel and selective inhibitor of the FGFR1, 2, and 3 tyrosine kinases.  AZD4547 inhibited recombinant FGFR kinase activity in vitro and suppressed FGFR signaling and growth in tumor cell lines with deregulated FGFR expression.  In a representative FGFR-driven human tumor xenograft model, oral administration of AZD4547 was well tolerated and resulted in potent dose-dependent antitumor activity, consistent with plasma exposure and pharmacodynamic modulation of tumor FGFR.  Importantly, at efficacious doses, no evidence of anti-KDR-related effects were obsd., confirming the in vivo FGFR selectivity of AZD4547.  Taken together, our findings show that AZD4547 is a novel selective small-mol. inhibitor of FGFR with potent antitumor activity against FGFR-deregulated tumors in preclin. models.  AZD4547 is under clin. investigation for the treatment of FGFR-dependent tumors.  Cancer Res; 72(8); 2045-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnpExryJc9xbVg90H21EOLACvtfcHk0lhWsV-xKno3kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1Wgsrs%253D&md5=cba90ad8f9b9e51cd10288868bbcc85e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3034%26sid%3Dliteratum%253Aachs%26aulast%3DGavine%26aufirst%3DP.%2BR.%26aulast%3DMooney%26aufirst%3DL.%26aulast%3DKilgour%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DBeck%26aufirst%3DS.%26aulast%3DRooney%26aufirst%3DC.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DBaker%26aufirst%3DD.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DBrooks%26aufirst%3DA.%2BN.%26aulast%3DKlinowska%26aufirst%3DT.%26atitle%3DAZD4547%253A%2520an%2520orally%2520bioavailable%252C%2520potent%252C%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520family%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D2045%26epage%3D2056%26doi%3D10.1158%2F0008-5472.can-11-3034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guagnano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spanka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Douget, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brueggen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghausen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drueckes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graus Porta, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7066</span>– <span class="NLM_lpage">7083</span>, <span class="refDoi"> DOI: 10.1021/jm2006222</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2006222" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7066-7083&author=V.+Guagnanoauthor=P.+Furetauthor=C.+Spankaauthor=V.+Bordasauthor=M.+Le+Dougetauthor=C.+Stammauthor=J.+Brueggenauthor=M.+R.+Jensenauthor=C.+Schnellauthor=H.+Schmidauthor=M.+Wartmannauthor=J.+Berghausenauthor=P.+Drueckesauthor=A.+Zimmerlinauthor=D.+Bussiereauthor=J.+Murrayauthor=D.+Graus+Porta&title=Discovery+of+3-%282%2C6-dichloro-3%2C5-dimethoxy-phenyl%29-1-%7B6-%5B4-%284-ethyl-piperazin-1-yl%29-phenylamino%5D-pyrimidin-4-yl%7D-1-methyl-urea+%28NVP-BGJ398%29%2C+a+potent+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+family+of+receptor+tyrosine+kinase&doi=10.1021%2Fjm2006222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase</span></div><div class="casAuthors">Guagnano, Vito; Furet, Pascal; Spanka, Carsten; Bordas, Vincent; Le Douget, Mickael; Stamm, Christelle; Brueggen, Josef; Jensen, Michael R.; Schnell, Christian; Schmid, Herbert; Wartmann, Markus; Berghausen, Joerg; Drueckes, Peter; Zimmerlin, Alfred; Bussiere, Dirksen; Murray, Jeremy; Graus Porta, Diana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7066-7083</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of N-aryl-N'-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring.  On the basis of its in vitro profile, compd. 1h (NVP-BGJ398) was selected for in vivo evaluation and showed significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3.  These results support the potential therapeutic use of 1h as a new anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSC1v0A_6I_bVg90H21EOLACvtfcHk0lhWsV-xKno3kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvK&md5=f9a2d742294cd3814e872bdd8add1ffa</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm2006222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2006222%26sid%3Dliteratum%253Aachs%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DSpanka%26aufirst%3DC.%26aulast%3DBordas%26aufirst%3DV.%26aulast%3DLe%2BDouget%26aufirst%3DM.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DSchmid%26aufirst%3DH.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DBerghausen%26aufirst%3DJ.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DGraus%2BPorta%26aufirst%3DD.%26atitle%3DDiscovery%2520of%25203-%25282%252C6-dichloro-3%252C5-dimethoxy-phenyl%2529-1-%257B6-%255B4-%25284-ethyl-piperazin-1-yl%2529-phenylamino%255D-pyrimidin-4-yl%257D-1-methyl-urea%2520%2528NVP-BGJ398%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520family%2520of%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7066%26epage%3D7083%26doi%3D10.1021%2Fjm2006222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zia-Ebrahimi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloem, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-b.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D. J.</span></span> <span> </span><span class="NLM_article-title">A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2200</span>– <span class="NLM_lpage">2210</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-11-0306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F1535-7163.MCT-11-0306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=21900693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2200-2210&author=G.+Zhaoauthor=W.-y.+Liauthor=D.+Chenauthor=J.+R.+Henryauthor=H.-Y.+Liauthor=Z.+Chenauthor=M.+Zia-Ebrahimiauthor=L.+Bloemauthor=Y.+Zhaiauthor=K.+Hussauthor=S.-b.+Pengauthor=D.+J.+McCann&title=A+novel%2C+selective+inhibitor+of+fibroblast+growth+factor+receptors+that+shows+a+potent+broad+spectrum+of+antitumor+activity+in+several+tumor+xenograft+models&doi=10.1158%2F1535-7163.mct-11-0306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models</span></div><div class="casAuthors">Zhao, Genshi; Li, Wei-ying; Chen, Daohong; Henry, James R.; Li, Hong-Yu; Chen, Zhaogen; Zia-Ebrahimi, Mohammad; Bloem, Laura; Zhai, Yan; Huss, Karen; Peng, Sheng-bin; McCann, Denis J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2200-2210</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor receptors (FGFR) are tyrosine kinases that are present in many types of endothelial and tumor cells and play an important role in tumor cell growth, survival, and migration as well as in maintaining tumor angiogenesis.  Overexpression of FGFRs or aberrant regulation of their activities has been implicated in many forms of human malignancies.  Therefore, targeting FGFRs represents an attractive strategy for development of cancer treatment options by simultaneously inhibiting tumor cell growth, survival, and migration as well as tumor angiogenesis.  Here, we describe a potent, selective, small-mol. FGFR inhibitor, (R)-(E)-2-(4-(2-(5-(1-(3,5-Dichloropyridin-4-yl)ethoxy)-1H-indazol-3yl)vinyl)-1H-pyrazol-1-yl)ethanol, designated as LY2874455.  This mol. is active against all 4 FGFRs, with a similar potency in biochem. assays.  It exhibits a potent activity against FGF/FGFR-mediated signaling in several cancer cell lines and shows an excellent broad spectrum of antitumor activity in several tumor xenograft models representing the major FGF/FGFR relevant tumor histologies including lung, gastric, and bladder cancers and multiple myeloma, and with a well-defined pharmacokinetic/pharmacodynamic relationship.  LY2874455 also exhibits a 6- to 9-fold in vitro and in vivo selectivity on inhibition of FGF- over VEGF-mediated target signaling in mice.  Furthermore, LY2874455 did not show VEGF receptor 2-mediated toxicities such as hypertension at efficacious doses.  Currently, this mol. is being evaluated for its potential use in the clinic.  Mol Cancer Ther; 10(11); 2200-10.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLrzAyZQK_grVg90H21EOLACvtfcHk0ljZYmIeURJyCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7N&md5=eaf08fd213a836f48da2055e01bd9c29</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0306%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DW.-y.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DLi%26aufirst%3DH.-Y.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZia-Ebrahimi%26aufirst%3DM.%26aulast%3DBloem%26aufirst%3DL.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DHuss%26aufirst%3DK.%26aulast%3DPeng%26aufirst%3DS.-b.%26aulast%3DMcCann%26aufirst%3DD.%2BJ.%26atitle%3DA%2520novel%252C%2520selective%2520inhibitor%2520of%2520fibroblast%2520growth%2520factor%2520receptors%2520that%2520shows%2520a%2520potent%2520broad%2520spectrum%2520of%2520antitumor%2520activity%2520in%2520several%2520tumor%2520xenograft%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2200%26epage%3D2210%26doi%3D10.1158%2F1535-7163.mct-11-0306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perera, T. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jovcheva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mevellec, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vialard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lange, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhulst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulussen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van De Ven, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freyne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squires, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilissen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platero, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkera, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angibaud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquerre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, M. V.</span></span> <span> </span><span class="NLM_article-title">Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1010</span>– <span class="NLM_lpage">1020</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-16-0589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F1535-7163.MCT-16-0589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=28341788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=1010-1020&author=T.+P.+S.+Pereraauthor=E.+Jovchevaauthor=L.+Mevellecauthor=J.+Vialardauthor=D.+De+Langeauthor=T.+Verhulstauthor=C.+Paulussenauthor=K.+Van+De+Venauthor=P.+Kingauthor=E.+Freyneauthor=D.+C.+Reesauthor=M.+Squiresauthor=G.+Saxtyauthor=M.+Pageauthor=C.+W.+Murrayauthor=R.+Gilissenauthor=G.+Wardauthor=N.+T.+Thompsonauthor=D.+R.+Newellauthor=N.+Chengauthor=L.+Xieauthor=J.+Yangauthor=S.+J.+Plateroauthor=J.+D.+Karkeraauthor=C.+Moyauthor=P.+Angibaudauthor=S.+Laquerreauthor=M.+V.+Lorenzi&title=Discovery+and+pharmacological+characterization+of+JNJ-42756493+%28erdafitinib%29%2C+a+functionally+selective+small-molecule+FGFR+family+inhibitor&doi=10.1158%2F1535-7163.mct-16-0589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor</span></div><div class="casAuthors">Perera, Timothy P. S.; Jovcheva, Eleonora; Mevellec, Laurence; Vialard, Jorge; De Lange, Desiree; Verhulst, Tinne; Paulussen, Caroline; Van De Ven, Kelly; King, Peter; Freyne, Eddy; Rees, David C.; Squires, Matthew; Saxty, Gordon; Page, Martin; Murray, Christopher W.; Gilissen, Ron; Ward, George; Thompson, Neil T.; Newell, David R.; Cheng, Na; Xie, Liang; Yang, Jennifer; Platero, Suso J.; Karkera, Jayaprakash D.; Moy, Christopher; Angibaud, Patrick; Laquerre, Sylvie; Lorenzi, Matthew V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1010-1020</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Fibroblast growth factor (FGF) signaling plays crit. roles in key biol. processes ranging from embryogenesis to wound healing and has strong links to several hallmarks of cancer.  Genetic alterations in FGF receptor (FGFR) family members are assocd. with increased tumor growth, metastasis, angiogenesis, and decreased survival.  JNJ-42756493, erdafitinib, is an orally active small mol. with potent tyrosine kinase inhibitory activity against all four FGFR family members and selectivity vs. other highly related kinases.  JNJ-42756493 shows rapid uptake into the lysosomal compartment of cells in culture, which is assocd. with prolonged inhibition of FGFR signaling, possibly due to sustained release of the inhibitor.  In xenografts from human tumor cell lines or patient-derived tumor tissue with activating FGFR alterations, JNJ-42756493 administration results in potent and dose-dependent antitumor activity accompanied by pharmacodynamic modulation of phospho-FGFR and phospho-ERK in tumors.  The results of the current study provide a strong rationale for the clin. investigation of JNJ-42756493 in patients with tumors harboring FGFR pathway alterations.  Mol Cancer Ther; 16(6); 1010-20. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhJZ2AgFcI6LVg90H21EOLACvtfcHk0ljZYmIeURJyCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht7g%253D&md5=2cae21f09ad519925ab2a3c760284b02</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0589%26sid%3Dliteratum%253Aachs%26aulast%3DPerera%26aufirst%3DT.%2BP.%2BS.%26aulast%3DJovcheva%26aufirst%3DE.%26aulast%3DMevellec%26aufirst%3DL.%26aulast%3DVialard%26aufirst%3DJ.%26aulast%3DDe%2BLange%26aufirst%3DD.%26aulast%3DVerhulst%26aufirst%3DT.%26aulast%3DPaulussen%26aufirst%3DC.%26aulast%3DVan%2BDe%2BVen%26aufirst%3DK.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DFreyne%26aufirst%3DE.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DSquires%26aufirst%3DM.%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DPage%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DGilissen%26aufirst%3DR.%26aulast%3DWard%26aufirst%3DG.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DPlatero%26aufirst%3DS.%2BJ.%26aulast%3DKarkera%26aufirst%3DJ.%2BD.%26aulast%3DMoy%26aufirst%3DC.%26aulast%3DAngibaud%26aufirst%3DP.%26aulast%3DLaquerre%26aufirst%3DS.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26atitle%3DDiscovery%2520and%2520pharmacological%2520characterization%2520of%2520JNJ-42756493%2520%2528erdafitinib%2529%252C%2520a%2520functionally%2520selective%2520small-molecule%2520FGFR%2520family%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D1010%26epage%3D1020%26doi%3D10.1158%2F1535-7163.mct-16-0589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abou-Alfa, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahai, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollebecque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaccaro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melisi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Rajabi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borad, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallinson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catenacci, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Cutsem, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lihou, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Féliz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, A.</span></span> <span> </span><span class="NLM_article-title">Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.1016/s1470-2045(20)30109-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1016%2FS1470-2045%2820%2930109-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=32203698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsFehu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=671-684&author=G.+K.+Abou-Alfaauthor=V.+Sahaiauthor=A.+Hollebecqueauthor=G.+Vaccaroauthor=D.+Melisiauthor=R.+Al-Rajabiauthor=A.+S.+Paulsonauthor=M.+J.+Boradauthor=A.+G.+Gallinsonauthor=D.-Y.+Ohauthor=E.+Dotanauthor=D.+V.+Catenacciauthor=E.+Van+Cutsemauthor=T.+Jiauthor=C.+F.+Lihouauthor=H.+Zhenauthor=L.+F%C3%A9lizauthor=A.+Vogel&title=Pemigatinib+for+previously+treated%2C+locally+advanced+or+metastatic+cholangiocarcinoma%3A+a+multicentre%2C+open-label%2C+phase+2+study&doi=10.1016%2Fs1470-2045%2820%2930109-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study</span></div><div class="casAuthors">Abou-Alfa, Ghassan K.; Sahai, Vaibhav; Hollebecque, Antoine; Vaccaro, Gina; Melisi, Davide; Al-Rajabi, Raed; Paulson, Andrew S.; Borad, Mitesh J.; Gallinson, David; Murphy, Adrian G.; Oh, Do-Youn; Dotan, Efrat; Catenacci, Daniel V.; Van Cutsem, Eric; Ji, Tao; Lihou, Christine F.; Zhen, Huiling; Feliz, Luis; Vogel, Arndt</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">671-684</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the pathogenesis of cholangiocarcinoma.  Pemigatinib is a selective, potent, oral inhibitor of FGFR1, 2, and 3.  This study evaluated the safety and antitumor activity of pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma with and without FGFR2 fusions or rearrangements.  In this multicentre, open-label, single-arm, multicohort, phase 2 study (FIGHT-202), patients aged 18 years or older with disease progression following at least one previous treatment and an Eastern Cooperative Oncol. Group (ECOG) performance status of 0-2 recruited from 146 academic or community-based sites in the USA, Europe, the Middle East, and Asia were assigned to one of three cohorts: patients with FGFR2 fusions or rearrangements, patients with other FGF/FGFR alterations, or patients with no FGF/FGFR alterations.  All enrolled patients received a starting dose of 13·5 mg oral pemigatinib once daily (21-day cycle; 2 wk on, 1 wk off) until disease progression, unacceptable toxicity, withdrawal of consent, or physician decision.  The primary endpoint was the proportion of patients who achieved an objective response among those with FGFR2 fusions or rearrangements, assessed centrally in all patients who received at least one dose of pemigatinib.  This study is registered with ClinicalTrials.gov, NCT02924376, and enrolment is completed.  Between Jan 17, 2017, and March 22, 2019, 146 patients were enrolled: 107 with FGFR2 fusions or rearrangements, 20 with other FGF/FGFR alterations, 18 with no FGF/FGFR alterations, and one with an undetd. FGF/FGFR alteration.  The median follow-up was 17·8 mo (IQR 11·6-21·3). 38 (35·5% [95% CI 26·5-45·4]) patients with FGFR2 fusions or rearrangements achieved an objective response (three complete responses and 35 partial responses).  Overall, hyperphosphatemia was the most common all-grade adverse event irresp. of cause (88 [60%] of 146 patients).  Ninty three (64%) patients had a grade 3 or worse adverse event (irresp. of cause); the most frequent were hypophosphatemia (18 [12%]), arthralgia (nine [6%]), stomatitis (eight [5%]), hyponatremia (eight [5%]), abdominal pain (seven [5%]), and fatigue (seven [5%]). 65 (45%) patients had serious adverse events; the most frequent were abdominal pain (seven [5%]), pyrexia (seven [5%]), cholangitis (five [3%]), and pleural effusion (five [3%]).  Overall, 71 (49%) patients died during the study, most frequently because of disease progression (61 [42%]); no deaths were deemed to be treatment related.  These data support the therapeutic potential of pemigatinib in previously treated patients with cholangiocarcinoma who have FGFR2 fusions or rearrangements.Incyte Corporation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr28ylbW5yBxLVg90H21EOLACvtfcHk0ljD8j_TH_rAlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsFehu7g%253D&md5=872884a01e01dad2c7864709d6da57e0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2820%2930109-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252820%252930109-1%26sid%3Dliteratum%253Aachs%26aulast%3DAbou-Alfa%26aufirst%3DG.%2BK.%26aulast%3DSahai%26aufirst%3DV.%26aulast%3DHollebecque%26aufirst%3DA.%26aulast%3DVaccaro%26aufirst%3DG.%26aulast%3DMelisi%26aufirst%3DD.%26aulast%3DAl-Rajabi%26aufirst%3DR.%26aulast%3DPaulson%26aufirst%3DA.%2BS.%26aulast%3DBorad%26aufirst%3DM.%2BJ.%26aulast%3DGallinson%26aufirst%3DA.%2BG.%26aulast%3DOh%26aufirst%3DD.-Y.%26aulast%3DDotan%26aufirst%3DE.%26aulast%3DCatenacci%26aufirst%3DD.%2BV.%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3DJi%26aufirst%3DT.%26aulast%3DLihou%26aufirst%3DC.%2BF.%26aulast%3DZhen%26aufirst%3DH.%26aulast%3DF%25C3%25A9liz%26aufirst%3DL.%26aulast%3DVogel%26aufirst%3DA.%26atitle%3DPemigatinib%2520for%2520previously%2520treated%252C%2520locally%2520advanced%2520or%2520metastatic%2520cholangiocarcinoma%253A%2520a%2520multicentre%252C%2520open-label%252C%2520phase%25202%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2020%26volume%3D21%26spage%3D671%26epage%3D684%26doi%3D10.1016%2Fs1470-2045%2820%2930109-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verstraete, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debucquoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonnissen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dok, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isebaert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haustermans, K.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">946</span>– <span class="NLM_lpage">957</span>, <span class="refDoi"> DOI: 10.1186/s12885-015-2000-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1186%2Fs12885-015-2000-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=26675289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVGlsL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=946-957&author=M.+Verstraeteauthor=A.+Debucquoyauthor=A.+Gonnissenauthor=R.+Dokauthor=S.+Isebaertauthor=E.+Devosauthor=W.+McBrideauthor=K.+Haustermans&title=In+vitro+and+in+vivo+evaluation+of+the+radiosensitizing+effect+of+a+selective+FGFR+inhibitor+%28JNJ-42756493%29+for+rectal+cancer&doi=10.1186%2Fs12885-015-2000-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer</span></div><div class="casAuthors">Verstraete, Maud; Debucquoy, Annelies; Gonnissen, Annelies; Dok, Ruveyda; Isebaert, Sofie; Devos, Ellen; McBride, William; Haustermans, Karin</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">946/1-946/11</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: We examd. the anti-tumor effect and radiosensitizing potential of a small mol. inhibitor of fibroblast growth factor receptor (FGFR) in colorectal cancer (CRC) in vitro and in vivo.  Methods: Effects of in vitro drug treatment on cell survival, proliferation, FGFR signaling, cell cycle distribution, apoptosis and radiosensitivity were assessed using various CRC cell lines with FGFR wild type (Caco2 and HCA7) and FGFR2 amplification (HCT116, NCI-H716).  In vivo tumor responses to FGFR inhibition with and without radiation therapy were evaluated by growth delay assays in two colorectal xenograft mouse models (NMRI nu/nu mice injected with NCI-H716 or CaCo2 cells).  Mechanistic studies were conducted using Western blot anal., immunohistochem. and qPCR.  Results: In the tested cell lines, the FGFR inhibitor (JNJ-42756493) was effective in vitro and in vivo in CRC tumors with highest expression of FGFR2 (NCI-H716).  In vitro, cell proliferation in this line was decreased, assocd. with increased apoptotic death and decreased cell survival.  In vivo, growth of NCI-H716 tumors was delayed by 5 days by drug treatment alone, although when drug delivery was stopped the relative tumor vol. increased compared to control.  The FGFR inhibitor did not radiosensitize NCI-H716 tumors either in vitro or in vivo.  Conclusions: Among tested CRC cell lines, the growth inhibitory activity of this FGFR inhibitor was evident in cell lines with high constitutive FGFR2 expression, suggesting that FGFR addiction may provide a window for therapeutic intervention, though caution is advised.  Preclin. study with NCI-H716 and Caco2 tumor demonstrated that continued presence of drug could be essential for tumor growth control, esp. in cells with aberrant FGFR expression.  In the tested set-up, the inhibitor showed no radiosensitizing effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwHbaZgWuLqLVg90H21EOLACvtfcHk0ljD8j_TH_rAlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVGlsL%252FM&md5=e500f8b61e02249fdb052b88affc427d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2Fs12885-015-2000-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-015-2000-8%26sid%3Dliteratum%253Aachs%26aulast%3DVerstraete%26aufirst%3DM.%26aulast%3DDebucquoy%26aufirst%3DA.%26aulast%3DGonnissen%26aufirst%3DA.%26aulast%3DDok%26aufirst%3DR.%26aulast%3DIsebaert%26aufirst%3DS.%26aulast%3DDevos%26aufirst%3DE.%26aulast%3DMcBride%26aufirst%3DW.%26aulast%3DHaustermans%26aufirst%3DK.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%2520the%2520radiosensitizing%2520effect%2520of%2520a%2520selective%2520FGFR%2520inhibitor%2520%2528JNJ-42756493%2529%2520for%2520rectal%2520cancer%26jtitle%3DBMC%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D946%26epage%3D957%26doi%3D10.1186%2Fs12885-015-2000-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">A structure-guided approach to creating covalent FGFR inhibitors</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1016%2Fj.chembiol.2010.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=20338520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=285-295&author=W.+Zhouauthor=W.+Hurauthor=U.+McDermottauthor=A.+Duttauthor=W.+Xianauthor=S.+B.+Ficarroauthor=J.+Zhangauthor=S.+V.+Sharmaauthor=J.+Bruggeauthor=M.+Meyersonauthor=J.+Settlemanauthor=N.+S.+Gray&title=A+structure-guided+approach+to+creating+covalent+FGFR+inhibitors&doi=10.1016%2Fj.chembiol.2010.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Guided Approach to Creating Covalent FGFR Inhibitors</span></div><div class="casAuthors">Zhou, Wenjun; Hur, Wooyoung; McDermott, Ultan; Dutt, Amit; Xian, Wa; Ficarro, Scott B.; Zhang, Jianming; Sharma, Sreenath V.; Brugge, Joan; Meyerson, Matthew; Settleman, Jeffrey; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-295</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The fibroblast growth factor receptor tyrosine kinases (FGFR1, 2, 3, and 4) represent promising therapeutic targets in a no. of cancers.  We have developed the first potent and selective irreversible inhibitor of FGFR1, 2, 3, and 4, which we named FIIN-1 that forms a covalent bond with cysteine 486 located in the P loop of the FGFR1 ATP binding site.  We demonstrated that the inhibitor potently inhibits Tel-FGFR1-transformed Ba/F3 cells (EC50 = 14 nM) as well as numerous FGFR-dependent cancer cell lines.  A biotin-derivatized version of the inhibitor, FIIN-1-biotin, was shown to covalently label FGFR1 at Cys486.  FIIN-1 is a useful probe of FGFR-dependent cellular phenomena and may provide a starting point of the development of therapeutically relevant irreversible inhibitors of wild-type and drug-resistant forms of FGFR kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqxMZh8QQP47Vg90H21EOLACvtfcHk0ljD8j_TH_rAlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D&md5=0b7b084a073b1c6f30f38565a0e4db81</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DDutt%26aufirst%3DA.%26aulast%3DXian%26aufirst%3DW.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBrugge%26aufirst%3DJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520structure-guided%2520approach%2520to%2520creating%2520covalent%2520FGFR%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D285%26epage%3D295%26doi%3D10.1016%2Fj.chembiol.2010.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanizaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aref, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, J. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>, <span class="NLM_elocation-id">E4869</span> <span class="refDoi"> DOI: 10.1073/pnas.1403438111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1073%2Fpnas.1403438111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=25349422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVWmsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&author=L.+Tanauthor=J.+Wangauthor=J.+Tanizakiauthor=Z.+Huangauthor=A.+R.+Arefauthor=M.+Rusanauthor=S.+J.+Zhuauthor=Y.+Zhangauthor=D.+Ercanauthor=R.+G.+Liaoauthor=M.+Capellettiauthor=W.+Zhouauthor=W.+Hurauthor=N.+Kimauthor=T.+Simauthor=S.+Gaudetauthor=D.+A.+Barbieauthor=J.+R.+J.+Yehauthor=C.+H.+Yunauthor=P.+S.+Hammermanauthor=M.+Mohammadiauthor=P.+A.+Janneauthor=N.+S.+Gray&title=Development+of+covalent+inhibitors+that+can+overcome+resistance+to+first-generation+FGFR+kinase+inhibitors&doi=10.1073%2Fpnas.1403438111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors</span></div><div class="casAuthors">Tan, Li; Wang, Jun; Tanizaki, Junko; Huang, Zhifeng; Aref, Amir R.; Rusan, Maria; Zhu, Su-Jie; Zhang, Yiyun; Ercan, Dalia; Liao, Rachel G.; Capelletti, Marzia; Zhou, Wenjun; Hur, Wooyoung; Kim, NamDoo; Sim, Taebo; Gaudet, Suzanne; Barbie, David A.; Yeh, Jing-Ruey Joanna; Yun, Cai-Hong; Hammerman, Peter S.; Mohammadi, Moosa; Janne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">E4869-E4877</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The human FGF receptors (FGFRs) play crit. roles in various human cancers, and several FGFR inhibitors are currently under clin. investigation.  Resistance usually results from selection for mutant kinases that are impervious to the action of the drug or from up-regulation of compensatory signaling pathways.  Preclin. studies have demonstrated that resistance to FGFR inhibitors can be acquired through mutations in the FGFR gatekeeper residue, as clin. obsd. for FGFR4 in embryonal rhabdomyosarcoma and neuroendocrine breast carcinomas.  Here the authors report on the use of a structure-based drug design to develop two selective, next-generation covalent FGFR inhibitors, the FGFR irreversible inhibitors I and II.  To our knowledge, I and II are the first inhibitors that can potently inhibit the proliferation of cells dependent upon the gatekeeper mutants of FGFR1 or FGFR2, which confer resistance to first-generation clin. FGFR inhibitors such as NVP-BGJ398 and AZD4547.  Because of the conformational flexibility of the reactive acrylamide substituent, II has the unprecedented ability to inhibit both the EGF receptor (EGFR) and FGFR covalently by targeting two distinct cysteine residues.  The authors report the cocrystal structure of FGFR4 with I, which unexpectedly exhibits a "DFG-out" covalent binding mode.  The structural basis for dual FGFR and EGFR targeting by FIIN3 also is illustrated by crystal structures of II bound with FGFR4 V550L and EGFR L858R.  These results have important implications for the design of covalent FGFR inhibitors that can overcome clin. resistance and provide the first example, to the knowledge, of a kinase inhibitor that covalently targets cysteines located in different positions within the ATP-binding pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmCbTDKPA32LVg90H21EOLACvtfcHk0lizlGKWpuTCqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVWmsL%252FP&md5=fd4a7eac1e0c17e7c9f2651dd2d76ac7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1403438111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1403438111%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTanizaki%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAref%26aufirst%3DA.%2BR.%26aulast%3DRusan%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DLiao%26aufirst%3DR.%2BG.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DGaudet%26aufirst%3DS.%26aulast%3DBarbie%26aufirst%3DD.%2BA.%26aulast%3DYeh%26aufirst%3DJ.%2BR.%2BJ.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520covalent%2520inhibitors%2520that%2520can%2520overcome%2520resistance%2520to%2520first-generation%2520FGFR%2520kinase%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2014%26volume%3D111%26doi%3D10.1073%2Fpnas.1403438111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. K.</span></span> <span> </span><span class="NLM_article-title">Covalent targeting of fibroblast growth factor receptor inhibits metastatic breast cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2096</span>– <span class="NLM_lpage">2106</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-16-0136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F1535-7163.MCT-16-0136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=27371729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVCnsLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2096-2106&author=W.+S.+Brownauthor=L.+Tanauthor=A.+Smithauthor=N.+S.+Grayauthor=M.+K.+Wendt&title=Covalent+targeting+of+fibroblast+growth+factor+receptor+inhibits+metastatic+breast+cancer&doi=10.1158%2F1535-7163.mct-16-0136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer</span></div><div class="casAuthors">Brown, Wells S.; Tan, Li; Smith, Andrew; Gray, Nathanael S.; Wendt, Michael K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2096-2106</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Therapeutic targeting of late-stage breast cancer is limited by an inadequate understanding of how tumor cell signaling evolves during metastatic progression and by the currently available small mol. inhibitors capable of targeting these processes.  Herein, we demonstrate that both β3 integrin and fibroblast growth factor receptor-1 (FGFR1) are part of an epithelial-mesenchymal transition (EMT) program that is required to facilitate metastatic outgrowth in response to fibroblast growth factor-2 (FGF2).  Mechanistically, β3 integrin phys. disrupts an interaction between FGFR1 and E-cadherin, leading to a dramatic redistribution of FGFR1 subcellular localization, enhanced FGF2 signaling and increased three-dimensional (3D) outgrowth of metastatic breast cancer cells.  This ability of β3 integrin to drive FGFR signaling requires the enzymic activity of focal adhesion kinase (FAK).  Consistent with these mechanistic data, we demonstrate that FGFR, β3 integrin, and FAK constitute a mol. signature capable of predicting decreased survival of patients with the basal-like subtype of breast cancer.  Importantly, covalent targeting of a conserved cysteine in the P-loop of FGFR1-4 with our newly developed small mol., FIIN-4, more effectively blocks 3D metastatic outgrowth as compared with currently available FGFR inhibitors.  In vivo application of FIIN-4 potently inhibited the growth of metastatic, patient-derived breast cancer xenografts and murine-derived metastases growing within the pulmonary microenvironment.  Overall, the current studies demonstrate that FGFR1 works in concert with other EMT effector mols. to drive aberrant downstream signaling, and that these events can be effectively targeted using our novel therapeutics for the treatment of the most aggressive forms of breast cancer.  Mol Cancer Ther; 15(9); 2096-106. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQFBxSpCHYZ7Vg90H21EOLACvtfcHk0lizlGKWpuTCqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVCnsLvI&md5=f58566c7181197b10a9dcc3c203ef13e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0136%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DW.%2BS.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWendt%26aufirst%3DM.%2BK.%26atitle%3DCovalent%2520targeting%2520of%2520fibroblast%2520growth%2520factor%2520receptor%2520inhibits%2520metastatic%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D2096%26epage%3D2106%26doi%3D10.1158%2F1535-7163.mct-16-0136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brameld, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venetsanakos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaStant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughhead, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karr, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerritsen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span> <span> </span><span class="NLM_article-title">Discovery of the irreversible covalent FGFR inhibitor 8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the treatment of solid tumors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6516</span>– <span class="NLM_lpage">6527</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00360</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00360" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVykt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6516-6527&author=K.+A.+Brameldauthor=T.+D.+Owensauthor=E.+Vernerauthor=E.+Venetsanakosauthor=J.+M.+Bradshawauthor=V.+T.+Phanauthor=D.+Tamauthor=K.+Leungauthor=J.+Shuauthor=J.+LaStantauthor=D.+G.+Loughheadauthor=T.+Tonauthor=D.+E.+Karrauthor=M.+E.+Gerritsenauthor=D.+M.+Goldsteinauthor=J.+O.+Funk&title=Discovery+of+the+irreversible+covalent+FGFR+inhibitor+8-%283-%284-acryloylpiperazin-1-yl%29propyl%29-6-%282%2C6-dichloro-3%2C5-dimethoxyphenyl%29-2-%28methylamino%29pyrido%5B2%2C3-d%5Dpyrimidin-7%288H%29-one+%28PRN1371%29+for+the+treatment+of+solid+tumors&doi=10.1021%2Facs.jmedchem.7b00360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors</span></div><div class="casAuthors">Brameld, Ken A.; Owens, Timothy D.; Verner, Erik; Venetsanakos, Eleni; Bradshaw, J. Michael; Phan, Vernon T.; Tam, Danny; Leung, Kwan; Shu, Jin; LaStant, Jacob; Loughhead, David G.; Ton, Tony; Karr, Dane E.; Gerritsen, Mary E.; Goldstein, David M.; Funk, Jens Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6516-6527</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors.  Clin. validation of FGFR as a therapeutic target has been demonstrated in bladder, liver, lung, breast, and gastric cancers.  Our goal was to develop an irreversible covalent inhibitor of FGFR1-4 for use in oncol. indications.  An irreversible covalent binding mechanism imparts many desirable pharmacol. benefits including high potency, selectivity, and prolonged target inhibition.  Herein we report the structure-based design, medicinal chem. optimization, and unique ADME assays of our irreversible covalent drug discovery program which culminated in the discovery of compd. 34 (PRN1371), a highly selective and potent FGFR1-4 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpklTuvm1niy7Vg90H21EOLACvtfcHk0lizlGKWpuTCqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVykt7fK&md5=987069b645d5e0e36ccda5e5c81520b9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00360%26sid%3Dliteratum%253Aachs%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DVenetsanakos%26aufirst%3DE.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DPhan%26aufirst%3DV.%2BT.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLeung%26aufirst%3DK.%26aulast%3DShu%26aufirst%3DJ.%26aulast%3DLaStant%26aufirst%3DJ.%26aulast%3DLoughhead%26aufirst%3DD.%2BG.%26aulast%3DTon%26aufirst%3DT.%26aulast%3DKarr%26aufirst%3DD.%2BE.%26aulast%3DGerritsen%26aufirst%3DM.%2BE.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26atitle%3DDiscovery%2520of%2520the%2520irreversible%2520covalent%2520FGFR%2520inhibitor%25208-%25283-%25284-acryloylpiperazin-1-yl%2529propyl%2529-6-%25282%252C6-dichloro-3%252C5-dimethoxyphenyl%2529-2-%2528methylamino%2529pyrido%255B2%252C3-d%255Dpyrimidin-7%25288H%2529-one%2520%2528PRN1371%2529%2520for%2520the%2520treatment%2520of%2520solid%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6516%26epage%3D6527%26doi%3D10.1021%2Facs.jmedchem.7b00360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of a Series of Pyrazolo[3,4-d]pyridazinone Compounds as the Novel Covalent Fibroblast Growth Factor Receptor Inhibitors by the Rational Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7473</span>– <span class="NLM_lpage">7488</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00510</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00510" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVemu77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7473-7488&author=Y.+Wangauthor=Y.+Daiauthor=X.+Wuauthor=F.+Liauthor=B.+Liuauthor=C.+Liauthor=Q.+Liuauthor=Y.+Zhouauthor=B.+Wangauthor=M.+Zhuauthor=R.+Cuiauthor=X.+Tanauthor=Z.+Xiongauthor=J.+Liuauthor=M.+Tanauthor=Y.+Xuauthor=M.+Gengauthor=H.+Jiangauthor=H.+Liuauthor=J.+Aiauthor=M.+Zheng&title=Discovery+and+Development+of+a+Series+of+Pyrazolo%5B3%2C4-d%5Dpyridazinone+Compounds+as+the+Novel+Covalent+Fibroblast+Growth+Factor+Receptor+Inhibitors+by+the+Rational+Drug+Design&doi=10.1021%2Facs.jmedchem.9b00510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of a Series of Pyrazolo[3,4-d]pyridazinone Compounds as the Novel Covalent Fibroblast Growth Factor Receptor Inhibitors by the Rational Drug Design</span></div><div class="casAuthors">Wang, Yulan; Dai, Yang; Wu, Xiaowei; Li, Fei; Liu, Bo; Li, Chunpu; Liu, Qiufeng; Zhou, Yuanyang; Wang, Bao; Zhu, Mingrui; Cui, Rongrong; Tan, Xiaoqin; Xiong, Zhaoping; Liu, Jia; Tan, Minjia; Xu, Yechun; Geng, Meiyu; Jiang, Hualiang; Liu, Hong; Ai, Jing; Zheng, Mingyue</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7473-7488</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Alterations of fibroblast growth factor receptors (FGFRs) play key roles in numerous cancer progression and development, which makes FGFRs attractive targets in the cancer therapy.  In the present study, based on a newly devised FGFR target-specific scoring function, a novel FGFR inhibitor hit was identified through virtual screening.  Hit-to-lead optimization was then performed by integrating mol. docking and site-of-metab. predictions with an array of in vitro evaluations and X-ray cocrystal structure detn., leading to a covalent FGFR inhibitor 15, which showed a highly selective and potent FGFR inhibition profile.  Pharmacokinetic assessment, protein kinase profiling, and hERG inhibition evaluation were also conducted, and they confirmed the value of 15 as a lead for further investigation.  Overall, this study exemplifies the importance of the integrative use of computational methods and exptl. techniques in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKNbodkitt5rVg90H21EOLACvtfcHk0lj0DV5s3hyofA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVemu77L&md5=80943e14d5d126f05f7d66a88208f109</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00510%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DCui%26aufirst%3DR.%26aulast%3DTan%26aufirst%3DX.%26aulast%3DXiong%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520a%2520Series%2520of%2520Pyrazolo%255B3%252C4-d%255Dpyridazinone%2520Compounds%2520as%2520the%2520Novel%2520Covalent%2520Fibroblast%2520Growth%2520Factor%2520Receptor%2520Inhibitors%2520by%2520the%2520Rational%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7473%26epage%3D7488%26doi%3D10.1021%2Facs.jmedchem.9b00510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9085</span>– <span class="NLM_lpage">9104</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01843</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01843" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9085-9104&author=Y.+Wangauthor=L.+Liauthor=J.+Fanauthor=Y.+Daiauthor=A.+Jiangauthor=M.+Gengauthor=J.+Aiauthor=W.+Duan&title=Discovery+of+Potent+Irreversible+Pan-Fibroblast+Growth+Factor+Receptor+%28FGFR%29+Inhibitors&doi=10.1021%2Facs.jmedchem.7b01843"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors</span></div><div class="casAuthors">Wang, Yuming; Li, Lijun; Fan, Jun; Dai, Yang; Jiang, Alan; Geng, Meiyu; Ai, Jing; Duan, Wenhu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9085-9104</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fibroblast growth factor receptors (FGFR1-4) are promising therapeutic targets in many cancers.  With the resurgence of interest in irreversible inhibitors, efforts have been directed to the discovery of irreversible FGFR inhibitors.  Currently, several selective irreversible inhibitors are being evaluated in clin. trials that could covalently target a conserved cysteine in the P-loop of FGFR.  In this article, the authors used a structure-guided approach that is rationalized by a computer-aided simulation to discover the novel and irreversible pan-FGFR inhibitor, 9g ((S)-1-(3-(4-amino-5-(7-methoxy-5-methylbenzo[b]thien-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one), which provided superior FGFR in vitro activities and decent selectivity over VEGFR2 (vascular endothelia growth factor receptor 2).  In in vivo studies, 9g displayed clear antitumor activities in NCI-H1581 and SNU-16 xenograft mice models.  Addnl., the dilg. method confirmed the irreversible binding of 9g to FGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcoke3wblah7Vg90H21EOLACvtfcHk0lj0DV5s3hyofA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGjt7k%253D&md5=5dc4652a87384819f60325e7dc9425f1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01843%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DA.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DDuan%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520Potent%2520Irreversible%2520Pan-Fibroblast%2520Growth%2520Factor%2520Receptor%2520%2528FGFR%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9085%26epage%3D9104%26doi%3D10.1021%2Facs.jmedchem.7b01843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guise, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taghipouran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yosaatmadja, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashoorzadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paik, W.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squire, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">543</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.04.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1016%2Fj.ejmech.2017.04.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=28521156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvFGnt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2017&pages=531-543&author=X.+Liauthor=C.+P.+Guiseauthor=R.+Taghipouranauthor=Y.+Yosaatmadjaauthor=A.+Ashoorzadehauthor=W.-K.+Paikauthor=C.+J.+Squireauthor=S.+Jiangauthor=J.+Luoauthor=Y.+Xuauthor=Z.-C.+Tuauthor=X.+Luauthor=X.+Renauthor=A.+V.+Pattersonauthor=J.+B.+Smaillauthor=K.+Ding&title=2-Oxo-3%2C+4-dihydropyrimido%5B4%2C+5-d%5Dpyrimidinyl+derivatives+as+new+irreversible+pan+fibroblast+growth+factor+receptor+%28FGFR%29+inhibitors&doi=10.1016%2Fj.ejmech.2017.04.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors</span></div><div class="casAuthors">Li, Xueqiang; Guise, Christopher P.; Taghipouran, Rana; Yosaatmadja, Yuliana; Ashoorzadeh, Amir; Paik, Woo-Kyong; Squire, Christopher J.; Jiang, Shuang; Luo, Jinfeng; Xu, Yong; Tu, Zheng-Chao; Lu, Xiaoyun; Ren, Xiaomei; Patterson, Adam V.; Smaill, Jeff B.; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">531-543</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivs. were designed and synthesized as new irreversible inhibitors of the FGFR family.  One of the most promising compds. (E)-3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(1-(4-(dimethylamino)but-2-enoyl)piperidin-4-yl)-7-(phenylamino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one potently inhibited FGFR1/2/3 with IC50 values of 1.06, 0.84 and 5.38 nM, resp., whereas its potency against FGFR4 was diminished by an order of magnitude.  The above compd. strongly suppresses the proliferation of FGFR1-amplified H520 non-small cell lung cancer cells, FGFR2-amplified SUM52 breast cancer cells and FGFR3-amplified SW780 bladder cancer cells with low nanomolar IC50 values, but was significantly less potent against four FGFR-neg. cancer cell lines, with low micromolar IC50 values and it may serve as a promising new lead for further anticancer drug discovery.  Biol. investigation also confirmed the irreversible binding of the mol. with the FGFR1-3 target kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpifDjwM_tfWrVg90H21EOLACvtfcHk0lib49bFJt1sIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvFGnt7s%253D&md5=fc772aaa0de716325a0b73f1a0f8504d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.04.049%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DGuise%26aufirst%3DC.%2BP.%26aulast%3DTaghipouran%26aufirst%3DR.%26aulast%3DYosaatmadja%26aufirst%3DY.%26aulast%3DAshoorzadeh%26aufirst%3DA.%26aulast%3DPaik%26aufirst%3DW.-K.%26aulast%3DSquire%26aufirst%3DC.%2BJ.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.-C.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DDing%26aufirst%3DK.%26atitle%3D2-Oxo-3%252C%25204-dihydropyrimido%255B4%252C%25205-d%255Dpyrimidinyl%2520derivatives%2520as%2520new%2520irreversible%2520pan%2520fibroblast%2520growth%2520factor%2520receptor%2520%2528FGFR%2529%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D135%26spage%3D531%26epage%3D543%26doi%3D10.1016%2Fj.ejmech.2017.04.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamarca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barriuso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valle, J. W.</span></span> <span> </span><span class="NLM_article-title">Molecular targeted therapies: Ready for “prime time” in biliary tract cancer</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">170</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2020.03.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1016%2Fj.jhep.2020.03.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=32171892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvFKkurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2020&pages=170-185&author=A.+Lamarcaauthor=J.+Barriusoauthor=M.+G.+McNamaraauthor=J.+W.+Valle&title=Molecular+targeted+therapies%3A+Ready+for+%E2%80%9Cprime+time%E2%80%9D+in+biliary+tract+cancer&doi=10.1016%2Fj.jhep.2020.03.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular targeted therapies: Ready for "prime time" in biliary tract cancer</span></div><div class="casAuthors">Lamarca, Angela; Barriuso, Jorge; McNamara, Mairead G.; Valle, Juan W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">170-185</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The prognosis for patients with biliary tract cancers (cholangiocarcinoma and gallbladder cancer) is poor, while the incidence of these cancers is increasing.  Most patients are diagnosed with advanced disease when treatment options are limited to palliative approaches, mainly focused on chemotherapy.  In recent years, novel treatment targets of relevance to biliary tract cancers, mainly present in patients with intrahepatic cholangiocarcinoma, have been identified and are rapidly changing the field.  These include fibroblast growth factor receptor (FGFR) fusions and isocitrate dehydrogenase (IDH)-1 and -2 mutations which are each present in around 10-20% of patients with intrahepatic cholangiocarcinoma.  In addn., inhibition of other pathways/mols. is currently being explored, including human epidermal growth factor receptor (HER) family members, the Wnt pathway, neurotropic tyrosine kinase receptor (NTRK) fusions and BRAF mutations.  The IDH1 inhibitor ivosidenib has already been tested in a phase III clin. trial in pretreated cholangiocarcinoma and showed benefit in terms of progression-free survival.  Multiple FGFR inhibitors have consistently shown high response rates in phase II/III trials, esp. for patients harbouring FGFR2 fusions.  This review provides an overview of the status of targeted therapies in biliary tract cancers.  Detailed discussion regarding current clin. development of IDH and FGFR inhibitors is provided, with an overview of current caveats and future steps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1V9T0WhgFfrVg90H21EOLACvtfcHk0lib49bFJt1sIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvFKkurc%253D&md5=129aa59899f6b5e8034d004a54c71ff0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2020.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2020.03.007%26sid%3Dliteratum%253Aachs%26aulast%3DLamarca%26aufirst%3DA.%26aulast%3DBarriuso%26aufirst%3DJ.%26aulast%3DMcNamara%26aufirst%3DM.%2BG.%26aulast%3DValle%26aufirst%3DJ.%2BW.%26atitle%3DMolecular%2520targeted%2520therapies%253A%2520Ready%2520for%2520%25E2%2580%259Cprime%2520time%25E2%2580%259D%2520in%2520biliary%2520tract%2520cancer%26jtitle%3DJ.%2520Hepatol.%26date%3D2020%26volume%3D73%26spage%3D170%26epage%3D185%26doi%3D10.1016%2Fj.jhep.2020.03.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sootome, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiiwa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujioka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohsawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funabashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yashiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonekura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, H.</span></span> <span> </span><span class="NLM_article-title">Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">4986</span>– <span class="NLM_lpage">4997</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-19-2568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F0008-5472.CAN-19-2568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=32973082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis1eksr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=4986-4997&author=H.+Sootomeauthor=H.+Fujitaauthor=K.+Itoauthor=H.+Ochiiwaauthor=Y.+Fujiokaauthor=K.+Itoauthor=A.+Miuraauthor=T.+Sagaraauthor=S.+Itoauthor=H.+Ohsawaauthor=S.+Otsukiauthor=K.+Funabashiauthor=M.+Yashiroauthor=K.+Matsuoauthor=K.+Yonekuraauthor=H.+Hirai&title=Futibatinib+Is+a+Novel+Irreversible+FGFR+1%E2%80%934+Inhibitor+That+Shows+Selective+Antitumor+Activity+against+FGFR-Deregulated+Tumors&doi=10.1158%2F0008-5472.can-19-2568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors</span></div><div class="casAuthors">Sootome, Hiroshi; Fujita, Hidenori; Ito, Kenjiro; Ochiiwa, Hiroaki; Fujioka, Yayoi; Ito, Kimihiro; Miura, Akihiro; Sagara, Takeshi; Ito, Satoru; Ohsawa, Hirokazu; Otsuki, Sachie; Funabashi, Kaoru; Yashiro, Masakazu; Matsuo, Kenichi; Yonekura, Kazuhiko; Hirai, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4986-4997</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">FGFR signaling is deregulated in many human cancers, and FGFR is considered a valid target in FGFR-deregulated tumors.  Here, we examine the preclin. profile of futibatinib (TAS-120; 1-[(3S)-[4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3, 4-d] pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one), a structurally novel, irreversible FGFR1-4 inhibitor.  Among a panel of 296 human kinases, futibatinib selectively inhibited FGFR1-4 with IC50 values of 1.4 to 3.7 nmol/L.  Futibatinib covalently bound the FGFR kinase domain, inhibiting FGFR phosphorylation and, in turn, downstream signaling in FGFR-deregulated tumor cell lines.  Futibatinib exhibited potent, selective growth inhibition of several tumor cell lines (gastric, lung, multiple myeloma, bladder, endometrial, and breast) harboring various FGFR genomic aberrations.  Oral administration of futibatinib led to significant dose-dependent tumor redn. in various FGFR-driven human tumor xenograft models, and tumor redn. was assocd. with sustained FGFR inhibition, which was proportional to the administered dose.  The frequency of appearance of drug-resistant clones was lower with futibatinib than a reversible ATP-competitive FGFR inhibitor, and futibatinib inhibited several drug-resistant FGFR2 mutants, including the FGFR2 V565I/L gatekeeper mutants, with greater potency than any reversible FGFR inhibitors tested (IC50, 1.3-50.6 nmol/L).  These results indicate that futibatinib is a novel orally available, potent, selective, and irreversible inhibitor of FGFR1-4 with a broad spectrum of antitumor activity in cell lines and xenograft models.  These findings provide a strong rationale for testing futibatinib in patients with tumors oncogenically driven by FGFR genomic aberrations, with phase I to III trials ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1IKddHEsSKrVg90H21EOLACvtfcHk0lib49bFJt1sIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis1eksr7P&md5=f78d398f8453192a67a572483e509a99</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-19-2568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-19-2568%26sid%3Dliteratum%253Aachs%26aulast%3DSootome%26aufirst%3DH.%26aulast%3DFujita%26aufirst%3DH.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DOchiiwa%26aufirst%3DH.%26aulast%3DFujioka%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DMiura%26aufirst%3DA.%26aulast%3DSagara%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DS.%26aulast%3DOhsawa%26aufirst%3DH.%26aulast%3DOtsuki%26aufirst%3DS.%26aulast%3DFunabashi%26aufirst%3DK.%26aulast%3DYashiro%26aufirst%3DM.%26aulast%3DMatsuo%26aufirst%3DK.%26aulast%3DYonekura%26aufirst%3DK.%26aulast%3DHirai%26aufirst%3DH.%26atitle%3DFutibatinib%2520Is%2520a%2520Novel%2520Irreversible%2520FGFR%25201%25E2%2580%25934%2520Inhibitor%2520That%2520Shows%2520Selective%2520Antitumor%2520Activity%2520against%2520FGFR-Deregulated%2520Tumors%26jtitle%3DCancer%2520Res.%26date%3D2020%26volume%3D80%26spage%3D4986%26epage%3D4997%26doi%3D10.1158%2F0008-5472.can-19-2568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venetsanakos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brameld, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaStant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karr, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerritsen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span> <span> </span><span class="NLM_article-title">The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2668</span>– <span class="NLM_lpage">2676</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-17-0309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F1535-7163.MCT-17-0309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=28978721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWhsL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=2668-2676&author=E.+Venetsanakosauthor=K.+A.+Brameldauthor=V.+T.+Phanauthor=E.+Vernerauthor=T.+D.+Owensauthor=Y.+Xingauthor=D.+Tamauthor=J.+LaStantauthor=K.+Leungauthor=D.+E.+Karrauthor=R.+J.+Hillauthor=M.+E.+Gerritsenauthor=D.+M.+Goldsteinauthor=J.+O.+Funkauthor=J.+M.+Bradshaw&title=The+Irreversible+Covalent+Fibroblast+Growth+Factor+Receptor+Inhibitor+PRN1371+Exhibits+Sustained+Inhibition+of+FGFR+after+Drug+Clearance&doi=10.1158%2F1535-7163.mct-17-0309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance</span></div><div class="casAuthors">Venetsanakos, Eleni; Brameld, Ken A.; Phan, Vernon T.; Verner, Erik; Owens, Timothy D.; Xing, Yan; Tam, Danny; La Stant, Jacob; Leung, Kwan; Karr, Dane E.; Hill, Ronald J.; Gerritsen, Mary E.; Goldstein, David M.; Funk, Jens Oliver; Bradshaw, J. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2668-2676</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">An increasing no. of cancers are known to harbor mutations, translocations, or amplifications in the fibroblast growth factor receptor (FGFR) family of kinases.  The FGFR inhibitors evaluated in clin. trials to date have shown promise at treating these cancers.  Here, we describe PRN1371, an irreversible covalent inhibitor of FGFR1-4 targeting a cysteine within the kinase active site.  PRN1371 demonstrated strong FGFR potency and excellent kinome-wide selectivity in a no. of biochem. and cellular assays, including in various cancer cell lines exhibiting FGFR alterations.  Furthermore, PRN1371 maintained FGFR inhibition in vivo, not only when circulating drug levels were high but also after the drug had been cleared from circulation, indicating the possibility of sustained FGFR inhibition in the clinic without the need for continuous drug exposure.  Durable tumor regression was also obtained in multiple tumor xenografts and patient-derived tumor xenograft models and was sustained even using an intermittent dosing strategy that provided drug holidays.  PRN1371 is currently under clin. investigation for treatment of patients with solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzKzxYYE-2ZbVg90H21EOLACvtfcHk0ljnnAGHup6pjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWhsL7J&md5=72f3af90d5e9a2f4060e5d0e4c8b99f9</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0309%26sid%3Dliteratum%253Aachs%26aulast%3DVenetsanakos%26aufirst%3DE.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DPhan%26aufirst%3DV.%2BT.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DXing%26aufirst%3DY.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLaStant%26aufirst%3DJ.%26aulast%3DLeung%26aufirst%3DK.%26aulast%3DKarr%26aufirst%3DD.%2BE.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGerritsen%26aufirst%3DM.%2BE.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520Irreversible%2520Covalent%2520Fibroblast%2520Growth%2520Factor%2520Receptor%2520Inhibitor%2520PRN1371%2520Exhibits%2520Sustained%2520Inhibition%2520of%2520FGFR%2520after%2520Drug%2520Clearance%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D2668%26epage%3D2676%26doi%3D10.1158%2F1535-7163.mct-17-0309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yosaatmadja, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squire, C. J.</span></span> <span> </span><span class="NLM_article-title">The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1107/s1399004714027539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1107%2FS1399004714027539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=25760602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFalu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=525-533&author=Y.+Yosaatmadjaauthor=A.+V.+Pattersonauthor=J.+B.+Smaillauthor=C.+J.+Squire&title=The+1.65+%C3%85+resolution+structure+of+the+complex+of+AZD4547+with+the+kinase+domain+of+FGFR1+displays+exquisite+molecular+recognition&doi=10.1107%2Fs1399004714027539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition</span></div><div class="casAuthors">Yosaatmadja, Yuliana; Patterson, Adam Vorn; Smaill, Jeff Bruce; Squire, Christopher John</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">525-533</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">1399-0047</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The fibroblast growth factor receptor (FGFR) family are expressed widely in normal tissues and play a role in tissue repair, inflammation, angiogenesis and development.  However, aberrant signalling through this family can lead to cellular proliferation, evasion of apoptosis and induction of angiogenesis, which is implicated in the development of many cancers and also in drug resistance.  The high frequency of FGFR amplification or mutation in multiple cancer types is such that this family has been targeted for the discovery of novel, selective drug compds., with one of the most recently discovered being AZD4547, a subnanomolar (IC50) FGFR1 inhibitor developed by AstraZeneca and currently in clin. trials.  The 1.65 Å resoln. crystal structure of AZD4547 bound to the kinase domain of FGFR1 has been detd. and reveals extensive drug-protein interactions, an integral network of water mols. and the tight closure of the FGFR1 P-loop to form a long, narrow crevice in which the AZD4547 mol. binds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjQbdbZHvbhbVg90H21EOLACvtfcHk0ljnnAGHup6pjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFalu7Y%253D&md5=e7afc5e7d14f6879fee79b998a46e0b4</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1107%2FS1399004714027539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS1399004714027539%26sid%3Dliteratum%253Aachs%26aulast%3DYosaatmadja%26aufirst%3DY.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DSquire%26aufirst%3DC.%2BJ.%26atitle%3DThe%25201.65%2520%25C3%2585%2520resolution%2520structure%2520of%2520the%2520complex%2520of%2520AZD4547%2520with%2520the%2520kinase%2520domain%2520of%2520FGFR1%2520displays%2520exquisite%2520molecular%2520recognition%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2015%26volume%3D71%26spage%3D525%26epage%3D533%26doi%3D10.1107%2Fs1399004714027539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e0162491</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0162491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1371%2Fjournal.pone.0162491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=27618313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFKjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&author=D.+Wuauthor=M.+Guoauthor=M.+A.+Philipsauthor=L.+Quauthor=L.+Jiangauthor=J.+Liauthor=X.+Chenauthor=Z.+Chenauthor=L.+Chenauthor=Y.+Chen&title=Crystal+Structure+of+the+FGFR4%2FLY2874455+Complex+Reveals+Insights+into+the+Pan-FGFR+Selectivity+of+LY2874455&doi=10.1371%2Fjournal.pone.0162491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the FGFR4/LY2874455 complex reveals insights into the pan-FGFR selectivity of LY2874455</span></div><div class="casAuthors">Wu, Daichao; Guo, Ming; Philips, Michael A.; Qu, Lingzhi; Jiang, Longying; Li, Jun; Chen, Xiaojuan; Chen, Zhuchu; Chen, Lin; Chen, Yongheng</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0162491/1-e0162491/11</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Aberrant FGFR4 signaling has been documented abundantly in various human cancers.  The majority of FGFR inhibitors display significantly reduced potency toward FGFR4 compared to FGFR1-3.  However, LY2874455 has similar inhibition potency for FGFR1-4 with IC50 less than 6.4 nM.  To date, there is no published crystal structure of LY2874455 in complex with any kinase.  To better understand the pan-FGFR selectivity of LY2874455, we have detd. the crystal structure of the FGFR4 kinase domain bound to LY2874455 at a resoln. of 2.35 Å.  LY2874455, a type I inhibitor for FGFR4, binds to the ATP-binding pocket of FGFR4 in a DFG-in active conformation with three hydrogen bonds and a no. of van derWaals contacts.  After alignment of the kinase domain sequence of 4 FGFRs, and superposition of the ATP binding pocket of 4 FGFRs, our structural analyses reveal that the interactions of LY2874455 to FGFR4 are largely conserved in 4 FGFRs, explaining at least partly, the broad inhibitory activity of LY2874455 toward 4 FGFRs.  Consequently, our studies reveal new insights into the pan-FGFR selectivity of LY2874455 and provide a structural basis for developing novel FGFR inhibitors that target FGFR1-4 broadly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquH9zGVO6xArVg90H21EOLACvtfcHk0ljnnAGHup6pjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFKjt74%253D&md5=444e0d350dac9196672923565b10f2ba</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0162491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0162491%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DPhilips%26aufirst%3DM.%2BA.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520FGFR4%252FLY2874455%2520Complex%2520Reveals%2520Insights%2520into%2520the%2520Pan-FGFR%2520Selectivity%2520of%2520LY2874455%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26doi%3D10.1371%2Fjournal.pone.0162491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yosaatmadja, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyukina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleditch, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squire, C. J.</span></span> <span> </span><span class="NLM_article-title">Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1180</span>– <span class="NLM_lpage">1186</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00196</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00196" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlams7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1180-1186&author=X.+Linauthor=Y.+Yosaatmadjaauthor=M.+Kalyukinaauthor=M.+J.+Middleditchauthor=Z.+Zhangauthor=X.+Luauthor=K.+Dingauthor=A.+V.+Pattersonauthor=J.+B.+Smaillauthor=C.+J.+Squire&title=Rotational+Freedom%2C+Steric+Hindrance%2C+and+Protein+Dynamics+Explain+BLU554+Selectivity+for+the+Hinge+Cysteine+of+FGFR4&doi=10.1021%2Facsmedchemlett.9b00196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4</span></div><div class="casAuthors">Lin, Xiaojing; Yosaatmadja, Yuliana; Kalyukina, Maria; Middleditch, Martin J.; Zhang, Zhen; Lu, Xiaoyun; Ding, Ke; Patterson, Adam V.; Smaill, Jeff B.; Squire, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1180-1186</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aberration in FGFR4 signaling drives carcinogenesis and progression in a subset of hepatocellular carcinoma (HCC) patients, thereby making FGFR4 an attractive mol. target for this disease.  Selective FGFR4 inhibition can be achieved through covalently targeting a poorly conserved cysteine residue in the FGFR4 kinase domain.  We report mass spectrometry assays and cocrystal structures of FGFR4 in covalent complex with the clin. candidate BLU554 and with a series of four structurally related inhibitors that define the inherent reactivity and selectivity profile of these mols.  We further reveal the structure of FGFR1 with one of our inhibitors and show that off-target covalent binding can occur through an alternative conformation that supports targeting of a cysteine conserved in all members of the FGFR family.  Collectively, we propose that rotational freedom, steric hindrance, and protein dynamics explain the exceptional selectivity profile of BLU554 for targeting FGFR4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqag7zwpLVc7bVg90H21EOLACvtfcHk0liahRvsfh1OGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlams7vN&md5=43f32bb16bbb3dd3873f8d7a16730a3e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00196%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DX.%26aulast%3DYosaatmadja%26aufirst%3DY.%26aulast%3DKalyukina%26aufirst%3DM.%26aulast%3DMiddleditch%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DSquire%26aufirst%3DC.%2BJ.%26atitle%3DRotational%2520Freedom%252C%2520Steric%2520Hindrance%252C%2520and%2520Protein%2520Dynamics%2520Explain%2520BLU554%2520Selectivity%2520for%2520the%2520Hinge%2520Cysteine%2520of%2520FGFR4%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1180%26epage%3D1186%26doi%3D10.1021%2Facsmedchemlett.9b00196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/medium/jm1c00174_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00174&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/medium/jm1c00174_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Design of the irreversible inhibitors based on the structure of the ATP-binding pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00174&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/medium/jm1c00174_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>36</b> inhibits FGFR signaling pathways. Phosphorylation of FGFRs, PLCγ, AKT1/2/3, and ERK1/2 was evaluated by western blotting in NCI-H1581 (A) and SNU-16 (B) cells treated with compound <b>36</b> for 12 h. β-Actin was used as control proteins.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00174&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/medium/jm1c00174_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>36</b> covalently binds to the C491 residue of FGFR2. (A,B) MS spectrums of recombinant human FGFR2 without or with incubation of compound <b>36</b>, respectively. (C,D) MS/MS analysis of recombinant human FGFR2 without or with incubation of compound <b>36</b>, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00174&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/medium/jm1c00174_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Plasma concentration–time curves for compound <b>36</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00174&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/medium/jm1c00174_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>36</b> suppresses tumor growth in xenograft mouse models. In the NCI-H1581 or SNU-16 xenograft model treated with compound <b>36</b> for indicated concentrations (<i>n</i> = 6), tumor volume (A,D) and body weight (C,F) changes during the treatment and (B,E) weights of tumor tissues from the three groups on the terminated days. Data are presented as means ± SEM; ****<i>P</i> < 0.0001, Student’s <i>t</i>-test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00174&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/medium/jm1c00174_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound <b>36</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00174/20210629/images/large/jm1c00174_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00174&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i142">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56668" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56668" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 30 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grose, R.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor signalling: from development to cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1038/nrc2780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1038%2Fnrc2780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=20094046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=116-129&author=N.+Turnerauthor=R.+Grose&title=Fibroblast+growth+factor+signalling%3A+from+development+to+cancer&doi=10.1038%2Fnrc2780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor signalling: from development to cancer</span></div><div class="casAuthors">Turner, Nicholas; Grose, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-129</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) and their receptors control a wide range of biol. functions, regulating cellular proliferation, survival, migration and differentiation.  Although targeting FGF signalling as a cancer therapeutic target has lagged behind that of other receptor tyrosine kinases, there is now substantial evidence for the importance of FGF signalling in the pathogenesis of diverse tumor types, and clin. reagents that specifically target the FGFs or FGF receptors are being developed.  Although FGF signalling can drive tumorigenesis, in different contexts FGF signalling can mediate tumor protective functions; the identification of the mechanisms that underlie these differential effects will be important to understand how FGF signalling can be most appropriately therapeutically targeted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUBfz6uAu97bVg90H21EOLACvtfcHk0ljIf9ctpygPOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D&md5=7963bc75c149981560dffc8d91b4aaf1</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2780%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DGrose%26aufirst%3DR.%26atitle%3DFibroblast%2520growth%2520factor%2520signalling%253A%2520from%2520development%2520to%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D116%26epage%3D129%26doi%3D10.1038%2Fnrc2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carter, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fearon, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grose, R. P.</span></span> <span> </span><span class="NLM_article-title">Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1016/j.tcb.2014.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1016%2Fj.tcb.2014.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=25467007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2jtL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=221-233&author=E.+P.+Carterauthor=A.+E.+Fearonauthor=R.+P.+Grose&title=Careless+talk+costs+lives%3A+fibroblast+growth+factor+receptor+signalling+and+the+consequences+of+pathway+malfunction&doi=10.1016%2Fj.tcb.2014.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction</span></div><div class="casAuthors">Carter, Edward P.; Fearon, Abbie E.; Grose, Richard P.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">221-233</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Since its discovery 40 years ago, fibroblast growth factor (FGF) receptor (FGFR) signalling has been found to regulate fundamental cellular behaviors in a wide range of cell types.  FGFRs regulate development, homeostasis, and repair and are implicated in many disorders and diseases; and indeed, there is extensive potential for severe consequences, be they developmental, homeostatic, or oncogenic, should FGF-FGFR signalling go awry, so careful control of the pathway is critically important.  In this review, we discuss the recent developments in the FGF field, highlighting how FGFR signalling works in normal cells, how it can go wrong, how frequently it is compromised, and how it is being targeted therapeutically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJuJ0uV7rBFbVg90H21EOLACvtfcHk0ljIf9ctpygPOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2jtL%252FL&md5=d184f8f455ae220c2265070479309dee</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2014.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2014.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DE.%2BP.%26aulast%3DFearon%26aufirst%3DA.%2BE.%26aulast%3DGrose%26aufirst%3DR.%2BP.%26atitle%3DCareless%2520talk%2520costs%2520lives%253A%2520fibroblast%2520growth%2520factor%2520receptor%2520signalling%2520and%2520the%2520consequences%2520of%2520pathway%2520malfunction%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2015%26volume%3D25%26spage%3D221%26epage%3D233%26doi%3D10.1016%2Fj.tcb.2014.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Touat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ileana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postel-Vinay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">André, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span> <span> </span><span class="NLM_article-title">Targeting FGFR signaling in cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2684</span>– <span class="NLM_lpage">2694</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-14-2329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F1078-0432.CCR-14-2329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=26078430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVajurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2684-2694&author=M.+Touatauthor=E.+Ileanaauthor=S.+Postel-Vinayauthor=F.+Andr%C3%A9author=J.-C.+Soria&title=Targeting+FGFR+signaling+in+cancer&doi=10.1158%2F1078-0432.ccr-14-2329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting FGFR Signaling in Cancer</span></div><div class="casAuthors">Touat, Mehdi; Ileana, Ecaterina; Postel-Vinay, Sophie; Andre, Fabrice; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2684-2694</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor signaling pathway (FGFR signaling) is an evolutionary conserved signaling cascade that regulates several basic biol. processes, including tissue development, angiogenesis, and tissue regeneration.  Substantial evidence indicates that aberrant FGFR signaling is involved in the pathogenesis of cancer.  Recent developments of deep sequencing technologies have allowed the discovery of frequent mol. alterations in components of FGFR signaling among several solid tumor types.  Moreover, compelling preclin. models have demonstrated the oncogenic potential of these aberrations in driving tumor growth, promoting angiogenesis, and conferring resistance mechanisms to anticancer therapies.  Recently, the field of FGFR targeting has exponentially progressed thanks to the development of novel agents inhibiting FGFs or FGFRs, which had manageable safety profiles in early-phase trials.  Promising treatment efficacy has been obsd. in different types of malignancies, particularly in tumors harboring aberrant FGFR signaling, thus offering novel therapeutic opportunities in the era of precision medicine.  The most exciting challenges now focus on selecting patients who are most likely to benefit from these agents, increasing the efficacy of therapies with the development of novel potent compds. and combination strategies, and overcoming toxicities assocd. with FGFR inhibitors.  After examn. of the basic and translational research studies that validated the oncogenic potential of aberrant FGFR signaling, this review focuses on recent data from clin. trials evaluating FGFR targeting therapies and discusses the challenges and perspectives for the development of these agents.  Clin Cancer Res; 21(12); 2684-94. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSZpKbvUn0hrVg90H21EOLACvtfcHk0ljIf9ctpygPOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVajurfP&md5=3dbb11de3f3a7d25d3b4ccb56400fd4d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2329%26sid%3Dliteratum%253Aachs%26aulast%3DTouat%26aufirst%3DM.%26aulast%3DIleana%26aufirst%3DE.%26aulast%3DPostel-Vinay%26aufirst%3DS.%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26aulast%3DSoria%26aufirst%3DJ.-C.%26atitle%3DTargeting%2520FGFR%2520signaling%2520in%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2684%26epage%3D2694%26doi%3D10.1158%2F1078-0432.ccr-14-2329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dieci, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnedos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">264</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.cd-12-0362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F2159-8290.CD-12-0362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=23418312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVOktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=264-279&author=M.+V.+Dieciauthor=M.+Arnedosauthor=F.+Andreauthor=J.+C.+Soria&title=Fibroblast+growth+factor+receptor+inhibitors+as+a+cancer+treatment%3A+from+a+biologic+rationale+to+medical+perspectives&doi=10.1158%2F2159-8290.cd-12-0362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives</span></div><div class="casAuthors">Dieci, Maria Vittoria; Arnedos, Monica; Andre, Fabrice; Soria, Jean Charles</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">264-279</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling pathway plays a fundamental role in many physiol. processes, including embryogenesis, adult tissue homeostasis, and wound healing, by orchestrating angiogenesis.  Ligand-independent and ligand-dependent activation have been implicated in a broad range of human malignancies and promote cancer progression in tumors driven by FGF/FGFR oncogenic mutations or amplifications, tumor neoangiogenesis, and targeted treatment resistance, thereby supporting a strong rationale for anti-FGF/FGFR agent development.  Efforts are being pursued to develop selective approaches for use against this pathway by optimizing the management of emerging, class-specific toxicity profiles and correctly designing clin. trials to address these different issues.  Significance: FGF/FGFR pathway deregulations are increasingly recognized across different human cancers.  Understanding the mechanisms at the basis of these alterations and their multiple roles in cancer promotion and drug resistance is a fundamental step for further implementation of targeted therapies and research strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6bibZKwamTLVg90H21EOLACvtfcHk0lhxlFrs14PSJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVOktL4%253D&md5=0e694a7641aa83c1540f745576f04bfa</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0362%26sid%3Dliteratum%253Aachs%26aulast%3DDieci%26aufirst%3DM.%2BV.%26aulast%3DArnedos%26aufirst%3DM.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DFibroblast%2520growth%2520factor%2520receptor%2520inhibitors%2520as%2520a%2520cancer%2520treatment%253A%2520from%2520a%2520biologic%2520rationale%2520to%2520medical%2520perspectives%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D264%26epage%3D279%26doi%3D10.1158%2F2159-8290.cd-12-0362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grose, R.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor signalling: from development to cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1038/nrc2780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1038%2Fnrc2780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=20094046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=116-129&author=N.+Turnerauthor=R.+Grose&title=Fibroblast+growth+factor+signalling%3A+from+development+to+cancer&doi=10.1038%2Fnrc2780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor signalling: from development to cancer</span></div><div class="casAuthors">Turner, Nicholas; Grose, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-129</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) and their receptors control a wide range of biol. functions, regulating cellular proliferation, survival, migration and differentiation.  Although targeting FGF signalling as a cancer therapeutic target has lagged behind that of other receptor tyrosine kinases, there is now substantial evidence for the importance of FGF signalling in the pathogenesis of diverse tumor types, and clin. reagents that specifically target the FGFs or FGF receptors are being developed.  Although FGF signalling can drive tumorigenesis, in different contexts FGF signalling can mediate tumor protective functions; the identification of the mechanisms that underlie these differential effects will be important to understand how FGF signalling can be most appropriately therapeutically targeted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUBfz6uAu97bVg90H21EOLACvtfcHk0lhxlFrs14PSJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D&md5=7963bc75c149981560dffc8d91b4aaf1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc2780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2780%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DGrose%26aufirst%3DR.%26atitle%3DFibroblast%2520growth%2520factor%2520signalling%253A%2520from%2520development%2520to%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D116%26epage%3D129%26doi%3D10.1038%2Fnrc2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miduturu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stransky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodous, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooijmans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shutes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzi, T.</span></span> <span> </span><span class="NLM_article-title">First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.cd-14-1029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F2159-8290.CD-14-1029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=25776529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVSrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=424-437&author=M.+Hagelauthor=C.+Miduturuauthor=M.+Sheetsauthor=N.+Rubinauthor=W.+Wengauthor=N.+Stranskyauthor=N.+Bifulcoauthor=J.+L.+Kimauthor=B.+Hodousauthor=N.+Brooijmansauthor=A.+Shutesauthor=C.+Winterauthor=C.+Lengauerauthor=N.+E.+Kohlauthor=T.+Guzi&title=First+selective+small+molecule+inhibitor+of+FGFR4+for+the+treatment+of+hepatocellular+carcinomas+with+an+activated+FGFR4+signaling+pathway&doi=10.1158%2F2159-8290.cd-14-1029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway</span></div><div class="casAuthors">Hagel, Margit; Miduturu, Chandra; Sheets, Michael; Rubin, Nooreen; Weng, Weifan; Stransky, Nicolas; Bifulco, Neil; Kim, Joseph L.; Hodous, Brian; Brooijmans, Natasja; Shutes, Adam; Winter, Christopher; Lengauer, Christoph; Kohl, Nancy E.; Guzi, Timothy</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">424-437</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HCC cells with FGF19 gene amplification or overexpression and an intact FGFR4 signaling pathway are sensitive to potent and selective FGFR4 inhibition by the small mol. BLU9931 in vitro and in xenograft models.  Aberrant signaling through the fibroblast growth factor 19 (FGF19)/fibroblast growth factor receptor 4 (FGFR 4) signaling complex has been shown to cause hepatocellular carcinoma (HCC) in mice and has been implicated to play a similar role in humans.  We have developed BLU9931, a potent and irreversible small-mol. inhibitor of FGFR4, as a targeted therapy to treat patients with HCC whose tumors have an activated FGFR4 signaling pathway.  BLU9931 is exquisitely selective for FGFR4 vs. other FGFR family members and all other kinases.  BLU9931 shows remarkable antitumor activity in mice bearing an HCC tumor xenograft that overexpresses FGF19 due to amplification as well as a liver tumor xenograft that overexpresses FGF19 mRNA but lacks FGF19 amplification.  Approx. one third of patients with HCC whose tumors express FGF19 together with FGFR4 and its coreceptor klotho β (KLB) could potentially respond to treatment with an FGFR4 inhibitor.  These findings are the first demonstration of a therapeutic strategy that targets a subset of patients with HCC.  Significance: This article documents the discovery of BLU9931, a novel irreversible kinase inhibitor that specifically targets FGFR4 while sparing all other FGFR paralogs and demonstrates exquisite kinome selectivity.  BLU9931 is efficacious in tumors with an intact FGFR4 signaling pathway that includes FGF19, FGFR4, and KLB.  BLU9931 is the first FGFR4-selective mol. for the treatment of patients with HCC with aberrant FGFR4 signaling.  Cancer Discov; 5(4); 424-37. cpr2015 AACR.  See related commentary by Packer and Pollock, p. 355 This article is highlighted in the In This Issue feature, p.  333.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqcHNr-1ZnG7Vg90H21EOLACvtfcHk0lhxlFrs14PSJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVSrtL8%253D&md5=4a69439aee01a3c090c14851a785362e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-1029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-1029%26sid%3Dliteratum%253Aachs%26aulast%3DHagel%26aufirst%3DM.%26aulast%3DMiduturu%26aufirst%3DC.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DRubin%26aufirst%3DN.%26aulast%3DWeng%26aufirst%3DW.%26aulast%3DStransky%26aufirst%3DN.%26aulast%3DBifulco%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DHodous%26aufirst%3DB.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DShutes%26aufirst%3DA.%26aulast%3DWinter%26aufirst%3DC.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DKohl%26aufirst%3DN.%2BE.%26aulast%3DGuzi%26aufirst%3DT.%26atitle%3DFirst%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520FGFR4%2520for%2520the%2520treatment%2520of%2520hepatocellular%2520carcinomas%2520with%2520an%2520activated%2520FGFR4%2520signaling%2520pathway%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D424%26epage%3D437%26doi%3D10.1158%2F2159-8290.cd-14-1029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Babina, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span> <span> </span><span class="NLM_article-title">Advances and challenges in targeting FGFR signalling in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1038/nrc.2017.8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1038%2Fnrc.2017.8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=28303906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Ont7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=318-332&author=I.+S.+Babinaauthor=N.+C.+Turner&title=Advances+and+challenges+in+targeting+FGFR+signalling+in+cancer&doi=10.1038%2Fnrc.2017.8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Advances and challenges in targeting FGFR signalling in cancer</span></div><div class="casAuthors">Babina, Irina S.; Turner, Nicholas C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">318-332</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate numerous cellular processes.  Deregulation of FGFR signalling is obsd. in a subset of many cancers, making activated FGFRs a highly promising potential therapeutic target supported by multiple preclin. studies.  However, early-phase clin. trials have produced mixed results with FGFR-targeted cancer therapies, revealing substantial complexity to targeting aberrant FGFR signalling.  In this Review, we discuss the increasing understanding of the differences between diverse mechanisms of oncogenic activation of FGFR, and the factors that det. response and resistance to FGFR targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKkSMehfBbyLVg90H21EOLACvtfcHk0li6UREjkqe0Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Ont7g%253D&md5=ed8f0ad426859a07930f7c0c2d2a9b71</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2017.8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2017.8%26sid%3Dliteratum%253Aachs%26aulast%3DBabina%26aufirst%3DI.%2BS.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26atitle%3DAdvances%2520and%2520challenges%2520in%2520targeting%2520FGFR%2520signalling%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D318%26epage%3D332%26doi%3D10.1038%2Fnrc.2017.8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renhowe, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machajewski, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jazan, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonios-McCrea, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapointe, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feucht, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warne, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heise, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aardalen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wernette-Hammond, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A. L.</span></span> <span> </span><span class="NLM_article-title">Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1021/jm800790t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800790t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1Sl" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=278-292&author=P.+A.+Renhoweauthor=S.+Pecchiauthor=C.+M.+Shaferauthor=T.+D.+Machajewskiauthor=E.+M.+Jazanauthor=C.+Taylorauthor=W.+Antonios-McCreaauthor=C.+M.+McBrideauthor=K.+Frazierauthor=M.+Wiesmannauthor=G.+R.+Lapointeauthor=P.+H.+Feuchtauthor=R.+L.+Warneauthor=C.+C.+Heiseauthor=D.+Menezesauthor=K.+Aardalenauthor=H.+Yeauthor=M.+Heauthor=V.+Leauthor=J.+Voraauthor=J.+M.+Jansenauthor=M.+E.+Wernette-Hammondauthor=A.+L.+Harris&title=Design%2C+structure-activity+relationships+and+in+vivo+characterization+of+4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones%3A+a+novel+class+of+receptor+tyrosine+kinase+inhibitors&doi=10.1021%2Fjm800790t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Structure-Activity Relationships and in Vivo Characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A Novel Class of Receptor Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Renhowe, Paul A.; Pecchi, Sabina; Shafer, Cynthia M.; Machajewski, Timothy D.; Jazan, Elisa M.; Taylor, Clarke; Antonios-McCrea, William; McBride, Christopher M.; Frazier, Kelly; Wiesmann, Marion; Lapointe, Gena R.; Feucht, Paul H.; Warne, Robert L.; Heise, Carla C.; Menezes, Daniel; Aardalen, Kimberly; Ye, Helen; He, Molly; Le, Vincent; Vora, Jayesh; Jansen, Johanna M.; Wernette-Hammond, Mary Ellen; Harris, Alex L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-292</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The inhibition of key receptor tyrosine kinases (RTKs) that are implicated in tumor vasculature formation and maintenance, as well as tumor progression and metastasis, has been a major focus in oncol. research over the last several years.  Many potent small mol. inhibitors of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) kinases have been evaluated.  More recently, compds. that act through the complex inhibition of multiple kinase targets have been reported and may exhibit improved clin. efficacy.  We report herein a series of potent, orally efficacious 4-amino-3-benzimidazol-2-ylhydroquinolin-2-one analogs as inhibitors of VEGF, PDGF, and fibroblast growth factor (FGF) receptor tyrosine kinases.  Compds. in this class, such as TKI258 (I), are reversible ATP-competitive inhibitors of VEGFR-2, FGFR-1, and PDGFRβ with IC50 values <0.1 μM.  On the basis of its favorable in vitro and in vivo properties, compd. I was selected for clin. evaluation and is currently in phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUf3qVBfCr87Vg90H21EOLACvtfcHk0li6UREjkqe0Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1Sl&md5=f20f564bb7dacb5a450a29dae9e04b50</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm800790t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800790t%26sid%3Dliteratum%253Aachs%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26aulast%3DMachajewski%26aufirst%3DT.%2BD.%26aulast%3DJazan%26aufirst%3DE.%2BM.%26aulast%3DTaylor%26aufirst%3DC.%26aulast%3DAntonios-McCrea%26aufirst%3DW.%26aulast%3DMcBride%26aufirst%3DC.%2BM.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DLapointe%26aufirst%3DG.%2BR.%26aulast%3DFeucht%26aufirst%3DP.%2BH.%26aulast%3DWarne%26aufirst%3DR.%2BL.%26aulast%3DHeise%26aufirst%3DC.%2BC.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DAardalen%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DV.%26aulast%3DVora%26aufirst%3DJ.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DWernette-Hammond%26aufirst%3DM.%2BE.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26atitle%3DDesign%252C%2520structure-activity%2520relationships%2520and%2520in%2520vivo%2520characterization%2520of%25204-amino-3-benzimidazol-2-ylhydroquinolin-2-ones%253A%2520a%2520novel%2520class%2520of%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D278%26epage%3D292%26doi%3D10.1021%2Fjm800790t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bello, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarlato, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berndt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valbusa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Incalci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalletti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giavazzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camboni, G.</span></span> <span> </span><span class="NLM_article-title">E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1396</span>– <span class="NLM_lpage">1405</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-10-2700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F0008-5472.CAN-10-2700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=21212416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFSjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1396-1405&author=E.+Belloauthor=G.+Colellaauthor=V.+Scarlatoauthor=P.+Olivaauthor=A.+Berndtauthor=G.+Valbusaauthor=S.+C.+Serraauthor=M.+D%E2%80%99Incalciauthor=E.+Cavallettiauthor=R.+Giavazziauthor=G.+Damiaauthor=G.+Camboni&title=E-3810+is+a+potent+dual+inhibitor+of+VEGFR+and+FGFR+that+exerts+antitumor+activity+in+multiple+preclinical+models&doi=10.1158%2F0008-5472.can-10-2700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models</span></div><div class="casAuthors">Bello, Ezia; Colella, Gennaro; Scarlato, Valentina; Oliva, Paolo; Berndt, Alexander; Valbusa, Giovanni; Serra, Sonia Colombo; D'Incalci, Maurizio; Cavalletti, Ennio; Giavazzi, Raffaella; Damia, Giovanna; Camboni, Gabriella</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1396-1405</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tumor angiogenesis is a degenerate process regulated by a complex network of proangiogenic factors.  Existing antiangiogenic drugs used in clinic are characterized by selectivity for specific factors.  Antiangiogenic properties might be improved in drugs that target multiple factors and thereby address the inherent mechanistic degeneracy in angiogenesis.  Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) family members and their cognate receptors are key players in promoting tumor angiogenesis.  Here we report the pharmacol. profile of E-3810, a novel dual inhibitor of the VEGF and FGF receptors.  E-3810 potently and selectively inhibited VEGF receptor (VEGFR)-1, -2, and -3 and FGF receptor (FGFR)-1 and -2 kinases in the nanomolar range.  Ligand-dependent phosphorylation of VEGFR-2 and FGFR-1 was suppressed along with human vascular endothelial cell growth at nanomolar concns.  In contrast, E-3810 lacked cytotoxic effects on cancer cell lines under millimolar concns.  In a variety of tumor xenograft models, including early- or late-stage s.c. and orthotopic models, E-3810 exhibited striking antitumor properties at well-tolerated oral doses administered daily.  We found that E-3810 remained active in tumors rendered nonresponsive to the general kinase inhibitor sunitinib resulting from a previous cycle of sunitinib treatment.  In Matrigel plug assays performed in nude mice, E-3810 inhibited basic FGF-induced angiogenesis and reduced blood vessel d. as assessed by histol. anal.  Dynamic contrast-enhanced magnetic resonance imaging anal. confirmed that E-3810 reduced the distribution of angiogenesis-sensitive contrast agents after only 5 days of treatment.  Taken together, our findings identify E-3810 as a potent antiangiogenic small mol. with a favorable pharmacokinetic profile and broad spectrum antitumor activity, providing a strong rationale for its clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0BsK0BmeJzLVg90H21EOLACvtfcHk0li6UREjkqe0Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFSjsbs%253D&md5=ec3692b0d962aa0f035425a293dfb3e6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2700%26sid%3Dliteratum%253Aachs%26aulast%3DBello%26aufirst%3DE.%26aulast%3DColella%26aufirst%3DG.%26aulast%3DScarlato%26aufirst%3DV.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DBerndt%26aufirst%3DA.%26aulast%3DValbusa%26aufirst%3DG.%26aulast%3DSerra%26aufirst%3DS.%2BC.%26aulast%3DD%25E2%2580%2599Incalci%26aufirst%3DM.%26aulast%3DCavalletti%26aufirst%3DE.%26aulast%3DGiavazzi%26aufirst%3DR.%26aulast%3DDamia%26aufirst%3DG.%26aulast%3DCamboni%26aufirst%3DG.%26atitle%3DE-3810%2520is%2520a%2520potent%2520dual%2520inhibitor%2520of%2520VEGFR%2520and%2520FGFR%2520that%2520exerts%2520antitumor%2520activity%2520in%2520multiple%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D1396%26epage%3D1405%26doi%3D10.1158%2F0008-5472.can-10-2700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colbatzky, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handschuh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann-Lintz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tontsch-Grunt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilberg, F.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6- methoxycarbonyl-substituted indolinone (BIBF 1120)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4466</span>– <span class="NLM_lpage">4480</span>, <span class="refDoi"> DOI: 10.1021/jm900431g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900431g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntFygsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4466-4480&author=G.+J.+Rothauthor=A.+Heckelauthor=F.+Colbatzkyauthor=S.+Handschuhauthor=J.+Kleyauthor=T.+Lehmann-Lintzauthor=R.+Lotzauthor=U.+Tontsch-Gruntauthor=R.+Walterauthor=F.+Hilberg&title=Design%2C+synthesis%2C+and+evaluation+of+indolinones+as+triple+angiokinase+inhibitors+and+the+discovery+of+a+highly+specific+6-+methoxycarbonyl-substituted+indolinone+%28BIBF+1120%29&doi=10.1021%2Fjm900431g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Indolinones as Triple Angiokinase Inhibitors and the Discovery of a Highly Specific 6-Methoxycarbonyl-Substituted Indolinone (BIBF 1120)</span></div><div class="casAuthors">Roth, Gerald J.; Heckel, Armin; Colbatzky, Florian; Handschuh, Sandra; Kley, Jorg; Lehmann-Lintz, Thorsten; Lotz, Ralf; Tontsch-Grunt, Ulrike; Walter, Rainer; Hilberg, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4466-4480</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of tumor angiogenesis through blockade of the vascular endothelial growth factor (VEGF) signaling pathway is a new treatment modality in oncol.  Preclin. findings suggest that blockade of addnl. pro-angiogenic kinases, such as fibroblast and platelet-derived growth factor receptors (FGFR and PDGFR), may improve the efficacy of pharmacol. cancer treatment.  Indolinones substituted in position 6 were identified as selective inhibitors of VEGF-, PDGF-, and FGF-receptor kinases.  In particular, 6-methoxycarbonyl-substituted indolinones showed a highly favorable selectivity profile.  Optimization identified potent inhibitors of VEGF-related endothelial cell proliferation with addnl. efficacy on pericyctes and smooth muscle cells.  In contrast, no direct inhibition of tumor cell proliferation was obsd.  Compds. 2 (BIBF 1000) and 3 (BIBF 1120) are orally available and display encouraging efficacy in in vivo tumor models while being well tolerated.  The triple angiokinase inhibitor 3 (I) is currently in phase III clin. trials for the treatment of nonsmall cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvvcX-_HYCS7Vg90H21EOLACvtfcHk0lhPFmtaS4TImw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntFygsL4%253D&md5=1b8af461631ae3117520fc4811130bb3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm900431g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900431g%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DHeckel%26aufirst%3DA.%26aulast%3DColbatzky%26aufirst%3DF.%26aulast%3DHandschuh%26aufirst%3DS.%26aulast%3DKley%26aufirst%3DJ.%26aulast%3DLehmann-Lintz%26aufirst%3DT.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DWalter%26aufirst%3DR.%26aulast%3DHilberg%26aufirst%3DF.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520indolinones%2520as%2520triple%2520angiokinase%2520inhibitors%2520and%2520the%2520discovery%2520of%2520a%2520highly%2520specific%25206-%2520methoxycarbonyl-substituted%2520indolinone%2520%2528BIBF%25201120%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4466%26epage%3D4480%26doi%3D10.1021%2Fjm900431g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gozgit, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span> <span> </span><span class="NLM_article-title">Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-11-0450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F1535-7163.MCT-11-0450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=22238366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=690-699&author=J.+M.+Gozgitauthor=M.+J.+Wongauthor=L.+Moranauthor=S.+Wardwellauthor=Q.+K.+Mohemmadauthor=N.+I.+Narasimhanauthor=W.+C.+Shakespeareauthor=F.+Wangauthor=T.+Clacksonauthor=V.+M.+Rivera&title=Ponatinib+%28AP24534%29%2C+a+multitargeted+pan-FGFR+inhibitor+with+activity+in+multiple+FGFR-amplified+or+mutated+cancer+models&doi=10.1158%2F1535-7163.mct-11-0450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models</span></div><div class="casAuthors">Gozgit, Joseph M.; Wong, Matthew J.; Moran, Lauren; Wardwell, Scott; Mohemmad, Qurish K.; Narasimhan, Narayana I.; Shakespeare, William C.; Wang, Frank; Clackson, Tim; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">690-699</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Members of the fibroblast growth factor receptor family of kinases (FGFR1-4) are dysregulated in multiple cancers.  Ponatinib (AP24534) is an oral multitargeted tyrosine kinase inhibitor being explored in a pivotal phase II trial in patients with chronic myelogenous leukemia due to its potent activity against BCR-ABL.  Ponatinib has also been shown to inhibit the in vitro kinase activity of all four FGFRs, prompting us to examine its potential as an FGFR inhibitor.  In Ba/F3 cells engineered to express activated FGFR1-4, ponatinib potently inhibited FGFR-mediated signaling and viability with IC50 values <40 nmol/L, with substantial selectivity over parental Ba/F3 cells.  In a panel of 14 cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon) and contg. FGFRs dysregulated by a variety of mechanisms, ponatinib inhibited FGFR-mediated signaling with IC50 values <40 nmol/L and inhibited cell growth with GI50 (concn. needed to reduce the growth of treated cells to half that of untreated cells) values of 7 to 181 nmol/L.  Daily oral dosing of ponatinib (10-30 mg/kg) to mice reduced tumor growth and inhibited signaling in all three tumor models examd.  Importantly, the potency of ponatinib in these models is similar to that previously obsd. in BCR-ABL-driven models and plasma levels of ponatinib that exceed the IC50 values for FGFR1-4 inhibition can be sustained in patients.  These results show that ponatinib is a potent pan-FGFR inhibitor and provide strong rationale for its evaluation in patients with FGFR-driven cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4-w5b7EPxLLVg90H21EOLACvtfcHk0lhPFmtaS4TImw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKis70%253D&md5=771979af1fba727510e073d19335ef5a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0450%26sid%3Dliteratum%253Aachs%26aulast%3DGozgit%26aufirst%3DJ.%2BM.%26aulast%3DWong%26aufirst%3DM.%2BJ.%26aulast%3DMoran%26aufirst%3DL.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DPonatinib%2520%2528AP24534%2529%252C%2520a%2520multitargeted%2520pan-FGFR%2520inhibitor%2520with%2520activity%2520in%2520multiple%2520FGFR-amplified%2520or%2520mutated%2520cancer%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D690%26epage%3D699%26doi%3D10.1158%2F1535-7163.mct-11-0450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavine, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilgour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span> <span> </span><span class="NLM_article-title">AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">2045</span>– <span class="NLM_lpage">2056</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-11-3034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F0008-5472.CAN-11-3034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=22369928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1Wgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=2045-2056&author=P.+R.+Gavineauthor=L.+Mooneyauthor=E.+Kilgourauthor=A.+P.+Thomasauthor=K.+Al-Kadhimiauthor=S.+Beckauthor=C.+Rooneyauthor=T.+Colemanauthor=D.+Bakerauthor=M.+J.+Mellorauthor=A.+N.+Brooksauthor=T.+Klinowska&title=AZD4547%3A+an+orally+bioavailable%2C+potent%2C+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+tyrosine+kinase+family&doi=10.1158%2F0008-5472.can-11-3034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family</span></div><div class="casAuthors">Gavine, Paul R.; Mooney, Lorraine; Kilgour, Elaine; Thomas, Andrew P.; Al-Kadhimi, Katherine; Beck, Sarah; Rooney, Claire; Coleman, Tanya; Baker, Dawn; Mellor, Martine J.; Brooks, A. Nigel; Klinowska, Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2045-2056</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor (FGF) signaling axis is increasingly implicated in tumorigenesis and chemoresistance.  Several small-mol. FGF receptor (FGFR) kinase inhibitors are currently in clin. development; however, the predominant activity of the most advanced of these agents is against the kinase insert domain receptor (KDR), which compromises the FGFR selectivity.  Here, we report the pharmacol. profile of AZD4547, a novel and selective inhibitor of the FGFR1, 2, and 3 tyrosine kinases.  AZD4547 inhibited recombinant FGFR kinase activity in vitro and suppressed FGFR signaling and growth in tumor cell lines with deregulated FGFR expression.  In a representative FGFR-driven human tumor xenograft model, oral administration of AZD4547 was well tolerated and resulted in potent dose-dependent antitumor activity, consistent with plasma exposure and pharmacodynamic modulation of tumor FGFR.  Importantly, at efficacious doses, no evidence of anti-KDR-related effects were obsd., confirming the in vivo FGFR selectivity of AZD4547.  Taken together, our findings show that AZD4547 is a novel selective small-mol. inhibitor of FGFR with potent antitumor activity against FGFR-deregulated tumors in preclin. models.  AZD4547 is under clin. investigation for the treatment of FGFR-dependent tumors.  Cancer Res; 72(8); 2045-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnpExryJc9xbVg90H21EOLACvtfcHk0lgBHGUh0--RjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1Wgsrs%253D&md5=cba90ad8f9b9e51cd10288868bbcc85e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3034%26sid%3Dliteratum%253Aachs%26aulast%3DGavine%26aufirst%3DP.%2BR.%26aulast%3DMooney%26aufirst%3DL.%26aulast%3DKilgour%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DBeck%26aufirst%3DS.%26aulast%3DRooney%26aufirst%3DC.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DBaker%26aufirst%3DD.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DBrooks%26aufirst%3DA.%2BN.%26aulast%3DKlinowska%26aufirst%3DT.%26atitle%3DAZD4547%253A%2520an%2520orally%2520bioavailable%252C%2520potent%252C%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520family%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D2045%26epage%3D2056%26doi%3D10.1158%2F0008-5472.can-11-3034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guagnano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spanka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Douget, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brueggen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghausen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drueckes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graus Porta, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7066</span>– <span class="NLM_lpage">7083</span>, <span class="refDoi"> DOI: 10.1021/jm2006222</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2006222" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7066-7083&author=V.+Guagnanoauthor=P.+Furetauthor=C.+Spankaauthor=V.+Bordasauthor=M.+Le+Dougetauthor=C.+Stammauthor=J.+Brueggenauthor=M.+R.+Jensenauthor=C.+Schnellauthor=H.+Schmidauthor=M.+Wartmannauthor=J.+Berghausenauthor=P.+Drueckesauthor=A.+Zimmerlinauthor=D.+Bussiereauthor=J.+Murrayauthor=D.+Graus+Porta&title=Discovery+of+3-%282%2C6-dichloro-3%2C5-dimethoxy-phenyl%29-1-%7B6-%5B4-%284-ethyl-piperazin-1-yl%29-phenylamino%5D-pyrimidin-4-yl%7D-1-methyl-urea+%28NVP-BGJ398%29%2C+a+potent+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+family+of+receptor+tyrosine+kinase&doi=10.1021%2Fjm2006222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase</span></div><div class="casAuthors">Guagnano, Vito; Furet, Pascal; Spanka, Carsten; Bordas, Vincent; Le Douget, Mickael; Stamm, Christelle; Brueggen, Josef; Jensen, Michael R.; Schnell, Christian; Schmid, Herbert; Wartmann, Markus; Berghausen, Joerg; Drueckes, Peter; Zimmerlin, Alfred; Bussiere, Dirksen; Murray, Jeremy; Graus Porta, Diana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7066-7083</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of N-aryl-N'-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring.  On the basis of its in vitro profile, compd. 1h (NVP-BGJ398) was selected for in vivo evaluation and showed significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3.  These results support the potential therapeutic use of 1h as a new anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSC1v0A_6I_bVg90H21EOLACvtfcHk0lgBHGUh0--RjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvK&md5=f9a2d742294cd3814e872bdd8add1ffa</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm2006222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2006222%26sid%3Dliteratum%253Aachs%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DSpanka%26aufirst%3DC.%26aulast%3DBordas%26aufirst%3DV.%26aulast%3DLe%2BDouget%26aufirst%3DM.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DSchmid%26aufirst%3DH.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DBerghausen%26aufirst%3DJ.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DGraus%2BPorta%26aufirst%3DD.%26atitle%3DDiscovery%2520of%25203-%25282%252C6-dichloro-3%252C5-dimethoxy-phenyl%2529-1-%257B6-%255B4-%25284-ethyl-piperazin-1-yl%2529-phenylamino%255D-pyrimidin-4-yl%257D-1-methyl-urea%2520%2528NVP-BGJ398%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520family%2520of%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7066%26epage%3D7083%26doi%3D10.1021%2Fjm2006222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zia-Ebrahimi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloem, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-b.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D. J.</span></span> <span> </span><span class="NLM_article-title">A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2200</span>– <span class="NLM_lpage">2210</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-11-0306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F1535-7163.MCT-11-0306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=21900693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2200-2210&author=G.+Zhaoauthor=W.-y.+Liauthor=D.+Chenauthor=J.+R.+Henryauthor=H.-Y.+Liauthor=Z.+Chenauthor=M.+Zia-Ebrahimiauthor=L.+Bloemauthor=Y.+Zhaiauthor=K.+Hussauthor=S.-b.+Pengauthor=D.+J.+McCann&title=A+novel%2C+selective+inhibitor+of+fibroblast+growth+factor+receptors+that+shows+a+potent+broad+spectrum+of+antitumor+activity+in+several+tumor+xenograft+models&doi=10.1158%2F1535-7163.mct-11-0306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models</span></div><div class="casAuthors">Zhao, Genshi; Li, Wei-ying; Chen, Daohong; Henry, James R.; Li, Hong-Yu; Chen, Zhaogen; Zia-Ebrahimi, Mohammad; Bloem, Laura; Zhai, Yan; Huss, Karen; Peng, Sheng-bin; McCann, Denis J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2200-2210</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor receptors (FGFR) are tyrosine kinases that are present in many types of endothelial and tumor cells and play an important role in tumor cell growth, survival, and migration as well as in maintaining tumor angiogenesis.  Overexpression of FGFRs or aberrant regulation of their activities has been implicated in many forms of human malignancies.  Therefore, targeting FGFRs represents an attractive strategy for development of cancer treatment options by simultaneously inhibiting tumor cell growth, survival, and migration as well as tumor angiogenesis.  Here, we describe a potent, selective, small-mol. FGFR inhibitor, (R)-(E)-2-(4-(2-(5-(1-(3,5-Dichloropyridin-4-yl)ethoxy)-1H-indazol-3yl)vinyl)-1H-pyrazol-1-yl)ethanol, designated as LY2874455.  This mol. is active against all 4 FGFRs, with a similar potency in biochem. assays.  It exhibits a potent activity against FGF/FGFR-mediated signaling in several cancer cell lines and shows an excellent broad spectrum of antitumor activity in several tumor xenograft models representing the major FGF/FGFR relevant tumor histologies including lung, gastric, and bladder cancers and multiple myeloma, and with a well-defined pharmacokinetic/pharmacodynamic relationship.  LY2874455 also exhibits a 6- to 9-fold in vitro and in vivo selectivity on inhibition of FGF- over VEGF-mediated target signaling in mice.  Furthermore, LY2874455 did not show VEGF receptor 2-mediated toxicities such as hypertension at efficacious doses.  Currently, this mol. is being evaluated for its potential use in the clinic.  Mol Cancer Ther; 10(11); 2200-10.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLrzAyZQK_grVg90H21EOLACvtfcHk0lgBHGUh0--RjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7N&md5=eaf08fd213a836f48da2055e01bd9c29</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0306%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DW.-y.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DLi%26aufirst%3DH.-Y.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZia-Ebrahimi%26aufirst%3DM.%26aulast%3DBloem%26aufirst%3DL.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DHuss%26aufirst%3DK.%26aulast%3DPeng%26aufirst%3DS.-b.%26aulast%3DMcCann%26aufirst%3DD.%2BJ.%26atitle%3DA%2520novel%252C%2520selective%2520inhibitor%2520of%2520fibroblast%2520growth%2520factor%2520receptors%2520that%2520shows%2520a%2520potent%2520broad%2520spectrum%2520of%2520antitumor%2520activity%2520in%2520several%2520tumor%2520xenograft%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2200%26epage%3D2210%26doi%3D10.1158%2F1535-7163.mct-11-0306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perera, T. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jovcheva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mevellec, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vialard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lange, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhulst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulussen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van De Ven, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freyne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squires, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilissen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platero, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkera, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angibaud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquerre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, M. V.</span></span> <span> </span><span class="NLM_article-title">Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1010</span>– <span class="NLM_lpage">1020</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-16-0589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F1535-7163.MCT-16-0589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=28341788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=1010-1020&author=T.+P.+S.+Pereraauthor=E.+Jovchevaauthor=L.+Mevellecauthor=J.+Vialardauthor=D.+De+Langeauthor=T.+Verhulstauthor=C.+Paulussenauthor=K.+Van+De+Venauthor=P.+Kingauthor=E.+Freyneauthor=D.+C.+Reesauthor=M.+Squiresauthor=G.+Saxtyauthor=M.+Pageauthor=C.+W.+Murrayauthor=R.+Gilissenauthor=G.+Wardauthor=N.+T.+Thompsonauthor=D.+R.+Newellauthor=N.+Chengauthor=L.+Xieauthor=J.+Yangauthor=S.+J.+Plateroauthor=J.+D.+Karkeraauthor=C.+Moyauthor=P.+Angibaudauthor=S.+Laquerreauthor=M.+V.+Lorenzi&title=Discovery+and+pharmacological+characterization+of+JNJ-42756493+%28erdafitinib%29%2C+a+functionally+selective+small-molecule+FGFR+family+inhibitor&doi=10.1158%2F1535-7163.mct-16-0589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor</span></div><div class="casAuthors">Perera, Timothy P. S.; Jovcheva, Eleonora; Mevellec, Laurence; Vialard, Jorge; De Lange, Desiree; Verhulst, Tinne; Paulussen, Caroline; Van De Ven, Kelly; King, Peter; Freyne, Eddy; Rees, David C.; Squires, Matthew; Saxty, Gordon; Page, Martin; Murray, Christopher W.; Gilissen, Ron; Ward, George; Thompson, Neil T.; Newell, David R.; Cheng, Na; Xie, Liang; Yang, Jennifer; Platero, Suso J.; Karkera, Jayaprakash D.; Moy, Christopher; Angibaud, Patrick; Laquerre, Sylvie; Lorenzi, Matthew V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1010-1020</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Fibroblast growth factor (FGF) signaling plays crit. roles in key biol. processes ranging from embryogenesis to wound healing and has strong links to several hallmarks of cancer.  Genetic alterations in FGF receptor (FGFR) family members are assocd. with increased tumor growth, metastasis, angiogenesis, and decreased survival.  JNJ-42756493, erdafitinib, is an orally active small mol. with potent tyrosine kinase inhibitory activity against all four FGFR family members and selectivity vs. other highly related kinases.  JNJ-42756493 shows rapid uptake into the lysosomal compartment of cells in culture, which is assocd. with prolonged inhibition of FGFR signaling, possibly due to sustained release of the inhibitor.  In xenografts from human tumor cell lines or patient-derived tumor tissue with activating FGFR alterations, JNJ-42756493 administration results in potent and dose-dependent antitumor activity accompanied by pharmacodynamic modulation of phospho-FGFR and phospho-ERK in tumors.  The results of the current study provide a strong rationale for the clin. investigation of JNJ-42756493 in patients with tumors harboring FGFR pathway alterations.  Mol Cancer Ther; 16(6); 1010-20. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhJZ2AgFcI6LVg90H21EOLACvtfcHk0lhfry0eX_Z_5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht7g%253D&md5=2cae21f09ad519925ab2a3c760284b02</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0589%26sid%3Dliteratum%253Aachs%26aulast%3DPerera%26aufirst%3DT.%2BP.%2BS.%26aulast%3DJovcheva%26aufirst%3DE.%26aulast%3DMevellec%26aufirst%3DL.%26aulast%3DVialard%26aufirst%3DJ.%26aulast%3DDe%2BLange%26aufirst%3DD.%26aulast%3DVerhulst%26aufirst%3DT.%26aulast%3DPaulussen%26aufirst%3DC.%26aulast%3DVan%2BDe%2BVen%26aufirst%3DK.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DFreyne%26aufirst%3DE.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DSquires%26aufirst%3DM.%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DPage%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DGilissen%26aufirst%3DR.%26aulast%3DWard%26aufirst%3DG.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DPlatero%26aufirst%3DS.%2BJ.%26aulast%3DKarkera%26aufirst%3DJ.%2BD.%26aulast%3DMoy%26aufirst%3DC.%26aulast%3DAngibaud%26aufirst%3DP.%26aulast%3DLaquerre%26aufirst%3DS.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26atitle%3DDiscovery%2520and%2520pharmacological%2520characterization%2520of%2520JNJ-42756493%2520%2528erdafitinib%2529%252C%2520a%2520functionally%2520selective%2520small-molecule%2520FGFR%2520family%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D1010%26epage%3D1020%26doi%3D10.1158%2F1535-7163.mct-16-0589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abou-Alfa, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahai, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollebecque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaccaro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melisi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Rajabi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borad, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallinson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catenacci, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Cutsem, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lihou, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Féliz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, A.</span></span> <span> </span><span class="NLM_article-title">Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.1016/s1470-2045(20)30109-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1016%2FS1470-2045%2820%2930109-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=32203698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsFehu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=671-684&author=G.+K.+Abou-Alfaauthor=V.+Sahaiauthor=A.+Hollebecqueauthor=G.+Vaccaroauthor=D.+Melisiauthor=R.+Al-Rajabiauthor=A.+S.+Paulsonauthor=M.+J.+Boradauthor=A.+G.+Gallinsonauthor=D.-Y.+Ohauthor=E.+Dotanauthor=D.+V.+Catenacciauthor=E.+Van+Cutsemauthor=T.+Jiauthor=C.+F.+Lihouauthor=H.+Zhenauthor=L.+F%C3%A9lizauthor=A.+Vogel&title=Pemigatinib+for+previously+treated%2C+locally+advanced+or+metastatic+cholangiocarcinoma%3A+a+multicentre%2C+open-label%2C+phase+2+study&doi=10.1016%2Fs1470-2045%2820%2930109-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study</span></div><div class="casAuthors">Abou-Alfa, Ghassan K.; Sahai, Vaibhav; Hollebecque, Antoine; Vaccaro, Gina; Melisi, Davide; Al-Rajabi, Raed; Paulson, Andrew S.; Borad, Mitesh J.; Gallinson, David; Murphy, Adrian G.; Oh, Do-Youn; Dotan, Efrat; Catenacci, Daniel V.; Van Cutsem, Eric; Ji, Tao; Lihou, Christine F.; Zhen, Huiling; Feliz, Luis; Vogel, Arndt</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">671-684</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the pathogenesis of cholangiocarcinoma.  Pemigatinib is a selective, potent, oral inhibitor of FGFR1, 2, and 3.  This study evaluated the safety and antitumor activity of pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma with and without FGFR2 fusions or rearrangements.  In this multicentre, open-label, single-arm, multicohort, phase 2 study (FIGHT-202), patients aged 18 years or older with disease progression following at least one previous treatment and an Eastern Cooperative Oncol. Group (ECOG) performance status of 0-2 recruited from 146 academic or community-based sites in the USA, Europe, the Middle East, and Asia were assigned to one of three cohorts: patients with FGFR2 fusions or rearrangements, patients with other FGF/FGFR alterations, or patients with no FGF/FGFR alterations.  All enrolled patients received a starting dose of 13·5 mg oral pemigatinib once daily (21-day cycle; 2 wk on, 1 wk off) until disease progression, unacceptable toxicity, withdrawal of consent, or physician decision.  The primary endpoint was the proportion of patients who achieved an objective response among those with FGFR2 fusions or rearrangements, assessed centrally in all patients who received at least one dose of pemigatinib.  This study is registered with ClinicalTrials.gov, NCT02924376, and enrolment is completed.  Between Jan 17, 2017, and March 22, 2019, 146 patients were enrolled: 107 with FGFR2 fusions or rearrangements, 20 with other FGF/FGFR alterations, 18 with no FGF/FGFR alterations, and one with an undetd. FGF/FGFR alteration.  The median follow-up was 17·8 mo (IQR 11·6-21·3). 38 (35·5% [95% CI 26·5-45·4]) patients with FGFR2 fusions or rearrangements achieved an objective response (three complete responses and 35 partial responses).  Overall, hyperphosphatemia was the most common all-grade adverse event irresp. of cause (88 [60%] of 146 patients).  Ninty three (64%) patients had a grade 3 or worse adverse event (irresp. of cause); the most frequent were hypophosphatemia (18 [12%]), arthralgia (nine [6%]), stomatitis (eight [5%]), hyponatremia (eight [5%]), abdominal pain (seven [5%]), and fatigue (seven [5%]). 65 (45%) patients had serious adverse events; the most frequent were abdominal pain (seven [5%]), pyrexia (seven [5%]), cholangitis (five [3%]), and pleural effusion (five [3%]).  Overall, 71 (49%) patients died during the study, most frequently because of disease progression (61 [42%]); no deaths were deemed to be treatment related.  These data support the therapeutic potential of pemigatinib in previously treated patients with cholangiocarcinoma who have FGFR2 fusions or rearrangements.Incyte Corporation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr28ylbW5yBxLVg90H21EOLACvtfcHk0lgiHfa3e_ybFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsFehu7g%253D&md5=872884a01e01dad2c7864709d6da57e0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2820%2930109-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252820%252930109-1%26sid%3Dliteratum%253Aachs%26aulast%3DAbou-Alfa%26aufirst%3DG.%2BK.%26aulast%3DSahai%26aufirst%3DV.%26aulast%3DHollebecque%26aufirst%3DA.%26aulast%3DVaccaro%26aufirst%3DG.%26aulast%3DMelisi%26aufirst%3DD.%26aulast%3DAl-Rajabi%26aufirst%3DR.%26aulast%3DPaulson%26aufirst%3DA.%2BS.%26aulast%3DBorad%26aufirst%3DM.%2BJ.%26aulast%3DGallinson%26aufirst%3DA.%2BG.%26aulast%3DOh%26aufirst%3DD.-Y.%26aulast%3DDotan%26aufirst%3DE.%26aulast%3DCatenacci%26aufirst%3DD.%2BV.%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3DJi%26aufirst%3DT.%26aulast%3DLihou%26aufirst%3DC.%2BF.%26aulast%3DZhen%26aufirst%3DH.%26aulast%3DF%25C3%25A9liz%26aufirst%3DL.%26aulast%3DVogel%26aufirst%3DA.%26atitle%3DPemigatinib%2520for%2520previously%2520treated%252C%2520locally%2520advanced%2520or%2520metastatic%2520cholangiocarcinoma%253A%2520a%2520multicentre%252C%2520open-label%252C%2520phase%25202%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2020%26volume%3D21%26spage%3D671%26epage%3D684%26doi%3D10.1016%2Fs1470-2045%2820%2930109-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verstraete, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debucquoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonnissen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dok, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isebaert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haustermans, K.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">946</span>– <span class="NLM_lpage">957</span>, <span class="refDoi"> DOI: 10.1186/s12885-015-2000-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1186%2Fs12885-015-2000-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=26675289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVGlsL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=946-957&author=M.+Verstraeteauthor=A.+Debucquoyauthor=A.+Gonnissenauthor=R.+Dokauthor=S.+Isebaertauthor=E.+Devosauthor=W.+McBrideauthor=K.+Haustermans&title=In+vitro+and+in+vivo+evaluation+of+the+radiosensitizing+effect+of+a+selective+FGFR+inhibitor+%28JNJ-42756493%29+for+rectal+cancer&doi=10.1186%2Fs12885-015-2000-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer</span></div><div class="casAuthors">Verstraete, Maud; Debucquoy, Annelies; Gonnissen, Annelies; Dok, Ruveyda; Isebaert, Sofie; Devos, Ellen; McBride, William; Haustermans, Karin</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">946/1-946/11</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: We examd. the anti-tumor effect and radiosensitizing potential of a small mol. inhibitor of fibroblast growth factor receptor (FGFR) in colorectal cancer (CRC) in vitro and in vivo.  Methods: Effects of in vitro drug treatment on cell survival, proliferation, FGFR signaling, cell cycle distribution, apoptosis and radiosensitivity were assessed using various CRC cell lines with FGFR wild type (Caco2 and HCA7) and FGFR2 amplification (HCT116, NCI-H716).  In vivo tumor responses to FGFR inhibition with and without radiation therapy were evaluated by growth delay assays in two colorectal xenograft mouse models (NMRI nu/nu mice injected with NCI-H716 or CaCo2 cells).  Mechanistic studies were conducted using Western blot anal., immunohistochem. and qPCR.  Results: In the tested cell lines, the FGFR inhibitor (JNJ-42756493) was effective in vitro and in vivo in CRC tumors with highest expression of FGFR2 (NCI-H716).  In vitro, cell proliferation in this line was decreased, assocd. with increased apoptotic death and decreased cell survival.  In vivo, growth of NCI-H716 tumors was delayed by 5 days by drug treatment alone, although when drug delivery was stopped the relative tumor vol. increased compared to control.  The FGFR inhibitor did not radiosensitize NCI-H716 tumors either in vitro or in vivo.  Conclusions: Among tested CRC cell lines, the growth inhibitory activity of this FGFR inhibitor was evident in cell lines with high constitutive FGFR2 expression, suggesting that FGFR addiction may provide a window for therapeutic intervention, though caution is advised.  Preclin. study with NCI-H716 and Caco2 tumor demonstrated that continued presence of drug could be essential for tumor growth control, esp. in cells with aberrant FGFR expression.  In the tested set-up, the inhibitor showed no radiosensitizing effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwHbaZgWuLqLVg90H21EOLACvtfcHk0lgiHfa3e_ybFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVGlsL%252FM&md5=e500f8b61e02249fdb052b88affc427d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2Fs12885-015-2000-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-015-2000-8%26sid%3Dliteratum%253Aachs%26aulast%3DVerstraete%26aufirst%3DM.%26aulast%3DDebucquoy%26aufirst%3DA.%26aulast%3DGonnissen%26aufirst%3DA.%26aulast%3DDok%26aufirst%3DR.%26aulast%3DIsebaert%26aufirst%3DS.%26aulast%3DDevos%26aufirst%3DE.%26aulast%3DMcBride%26aufirst%3DW.%26aulast%3DHaustermans%26aufirst%3DK.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%2520the%2520radiosensitizing%2520effect%2520of%2520a%2520selective%2520FGFR%2520inhibitor%2520%2528JNJ-42756493%2529%2520for%2520rectal%2520cancer%26jtitle%3DBMC%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D946%26epage%3D957%26doi%3D10.1186%2Fs12885-015-2000-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">A structure-guided approach to creating covalent FGFR inhibitors</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1016%2Fj.chembiol.2010.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=20338520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=285-295&author=W.+Zhouauthor=W.+Hurauthor=U.+McDermottauthor=A.+Duttauthor=W.+Xianauthor=S.+B.+Ficarroauthor=J.+Zhangauthor=S.+V.+Sharmaauthor=J.+Bruggeauthor=M.+Meyersonauthor=J.+Settlemanauthor=N.+S.+Gray&title=A+structure-guided+approach+to+creating+covalent+FGFR+inhibitors&doi=10.1016%2Fj.chembiol.2010.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Guided Approach to Creating Covalent FGFR Inhibitors</span></div><div class="casAuthors">Zhou, Wenjun; Hur, Wooyoung; McDermott, Ultan; Dutt, Amit; Xian, Wa; Ficarro, Scott B.; Zhang, Jianming; Sharma, Sreenath V.; Brugge, Joan; Meyerson, Matthew; Settleman, Jeffrey; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-295</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The fibroblast growth factor receptor tyrosine kinases (FGFR1, 2, 3, and 4) represent promising therapeutic targets in a no. of cancers.  We have developed the first potent and selective irreversible inhibitor of FGFR1, 2, 3, and 4, which we named FIIN-1 that forms a covalent bond with cysteine 486 located in the P loop of the FGFR1 ATP binding site.  We demonstrated that the inhibitor potently inhibits Tel-FGFR1-transformed Ba/F3 cells (EC50 = 14 nM) as well as numerous FGFR-dependent cancer cell lines.  A biotin-derivatized version of the inhibitor, FIIN-1-biotin, was shown to covalently label FGFR1 at Cys486.  FIIN-1 is a useful probe of FGFR-dependent cellular phenomena and may provide a starting point of the development of therapeutically relevant irreversible inhibitors of wild-type and drug-resistant forms of FGFR kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqxMZh8QQP47Vg90H21EOLACvtfcHk0lgiHfa3e_ybFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D&md5=0b7b084a073b1c6f30f38565a0e4db81</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DDutt%26aufirst%3DA.%26aulast%3DXian%26aufirst%3DW.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBrugge%26aufirst%3DJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520structure-guided%2520approach%2520to%2520creating%2520covalent%2520FGFR%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D285%26epage%3D295%26doi%3D10.1016%2Fj.chembiol.2010.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanizaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aref, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, J. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>, <span class="NLM_elocation-id">E4869</span> <span class="refDoi"> DOI: 10.1073/pnas.1403438111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1073%2Fpnas.1403438111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=25349422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVWmsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&author=L.+Tanauthor=J.+Wangauthor=J.+Tanizakiauthor=Z.+Huangauthor=A.+R.+Arefauthor=M.+Rusanauthor=S.+J.+Zhuauthor=Y.+Zhangauthor=D.+Ercanauthor=R.+G.+Liaoauthor=M.+Capellettiauthor=W.+Zhouauthor=W.+Hurauthor=N.+Kimauthor=T.+Simauthor=S.+Gaudetauthor=D.+A.+Barbieauthor=J.+R.+J.+Yehauthor=C.+H.+Yunauthor=P.+S.+Hammermanauthor=M.+Mohammadiauthor=P.+A.+Janneauthor=N.+S.+Gray&title=Development+of+covalent+inhibitors+that+can+overcome+resistance+to+first-generation+FGFR+kinase+inhibitors&doi=10.1073%2Fpnas.1403438111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors</span></div><div class="casAuthors">Tan, Li; Wang, Jun; Tanizaki, Junko; Huang, Zhifeng; Aref, Amir R.; Rusan, Maria; Zhu, Su-Jie; Zhang, Yiyun; Ercan, Dalia; Liao, Rachel G.; Capelletti, Marzia; Zhou, Wenjun; Hur, Wooyoung; Kim, NamDoo; Sim, Taebo; Gaudet, Suzanne; Barbie, David A.; Yeh, Jing-Ruey Joanna; Yun, Cai-Hong; Hammerman, Peter S.; Mohammadi, Moosa; Janne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">E4869-E4877</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The human FGF receptors (FGFRs) play crit. roles in various human cancers, and several FGFR inhibitors are currently under clin. investigation.  Resistance usually results from selection for mutant kinases that are impervious to the action of the drug or from up-regulation of compensatory signaling pathways.  Preclin. studies have demonstrated that resistance to FGFR inhibitors can be acquired through mutations in the FGFR gatekeeper residue, as clin. obsd. for FGFR4 in embryonal rhabdomyosarcoma and neuroendocrine breast carcinomas.  Here the authors report on the use of a structure-based drug design to develop two selective, next-generation covalent FGFR inhibitors, the FGFR irreversible inhibitors I and II.  To our knowledge, I and II are the first inhibitors that can potently inhibit the proliferation of cells dependent upon the gatekeeper mutants of FGFR1 or FGFR2, which confer resistance to first-generation clin. FGFR inhibitors such as NVP-BGJ398 and AZD4547.  Because of the conformational flexibility of the reactive acrylamide substituent, II has the unprecedented ability to inhibit both the EGF receptor (EGFR) and FGFR covalently by targeting two distinct cysteine residues.  The authors report the cocrystal structure of FGFR4 with I, which unexpectedly exhibits a "DFG-out" covalent binding mode.  The structural basis for dual FGFR and EGFR targeting by FIIN3 also is illustrated by crystal structures of II bound with FGFR4 V550L and EGFR L858R.  These results have important implications for the design of covalent FGFR inhibitors that can overcome clin. resistance and provide the first example, to the knowledge, of a kinase inhibitor that covalently targets cysteines located in different positions within the ATP-binding pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmCbTDKPA32LVg90H21EOLACvtfcHk0lgJ1tZ3OQ3t5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVWmsL%252FP&md5=fd4a7eac1e0c17e7c9f2651dd2d76ac7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1403438111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1403438111%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTanizaki%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAref%26aufirst%3DA.%2BR.%26aulast%3DRusan%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DLiao%26aufirst%3DR.%2BG.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DGaudet%26aufirst%3DS.%26aulast%3DBarbie%26aufirst%3DD.%2BA.%26aulast%3DYeh%26aufirst%3DJ.%2BR.%2BJ.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520covalent%2520inhibitors%2520that%2520can%2520overcome%2520resistance%2520to%2520first-generation%2520FGFR%2520kinase%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2014%26volume%3D111%26doi%3D10.1073%2Fpnas.1403438111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. K.</span></span> <span> </span><span class="NLM_article-title">Covalent targeting of fibroblast growth factor receptor inhibits metastatic breast cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2096</span>– <span class="NLM_lpage">2106</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-16-0136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F1535-7163.MCT-16-0136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=27371729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVCnsLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2096-2106&author=W.+S.+Brownauthor=L.+Tanauthor=A.+Smithauthor=N.+S.+Grayauthor=M.+K.+Wendt&title=Covalent+targeting+of+fibroblast+growth+factor+receptor+inhibits+metastatic+breast+cancer&doi=10.1158%2F1535-7163.mct-16-0136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer</span></div><div class="casAuthors">Brown, Wells S.; Tan, Li; Smith, Andrew; Gray, Nathanael S.; Wendt, Michael K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2096-2106</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Therapeutic targeting of late-stage breast cancer is limited by an inadequate understanding of how tumor cell signaling evolves during metastatic progression and by the currently available small mol. inhibitors capable of targeting these processes.  Herein, we demonstrate that both β3 integrin and fibroblast growth factor receptor-1 (FGFR1) are part of an epithelial-mesenchymal transition (EMT) program that is required to facilitate metastatic outgrowth in response to fibroblast growth factor-2 (FGF2).  Mechanistically, β3 integrin phys. disrupts an interaction between FGFR1 and E-cadherin, leading to a dramatic redistribution of FGFR1 subcellular localization, enhanced FGF2 signaling and increased three-dimensional (3D) outgrowth of metastatic breast cancer cells.  This ability of β3 integrin to drive FGFR signaling requires the enzymic activity of focal adhesion kinase (FAK).  Consistent with these mechanistic data, we demonstrate that FGFR, β3 integrin, and FAK constitute a mol. signature capable of predicting decreased survival of patients with the basal-like subtype of breast cancer.  Importantly, covalent targeting of a conserved cysteine in the P-loop of FGFR1-4 with our newly developed small mol., FIIN-4, more effectively blocks 3D metastatic outgrowth as compared with currently available FGFR inhibitors.  In vivo application of FIIN-4 potently inhibited the growth of metastatic, patient-derived breast cancer xenografts and murine-derived metastases growing within the pulmonary microenvironment.  Overall, the current studies demonstrate that FGFR1 works in concert with other EMT effector mols. to drive aberrant downstream signaling, and that these events can be effectively targeted using our novel therapeutics for the treatment of the most aggressive forms of breast cancer.  Mol Cancer Ther; 15(9); 2096-106. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQFBxSpCHYZ7Vg90H21EOLACvtfcHk0lgJ1tZ3OQ3t5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVCnsLvI&md5=f58566c7181197b10a9dcc3c203ef13e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0136%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DW.%2BS.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWendt%26aufirst%3DM.%2BK.%26atitle%3DCovalent%2520targeting%2520of%2520fibroblast%2520growth%2520factor%2520receptor%2520inhibits%2520metastatic%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D2096%26epage%3D2106%26doi%3D10.1158%2F1535-7163.mct-16-0136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brameld, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venetsanakos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaStant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughhead, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karr, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerritsen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span> <span> </span><span class="NLM_article-title">Discovery of the irreversible covalent FGFR inhibitor 8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the treatment of solid tumors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6516</span>– <span class="NLM_lpage">6527</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00360</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00360" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVykt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6516-6527&author=K.+A.+Brameldauthor=T.+D.+Owensauthor=E.+Vernerauthor=E.+Venetsanakosauthor=J.+M.+Bradshawauthor=V.+T.+Phanauthor=D.+Tamauthor=K.+Leungauthor=J.+Shuauthor=J.+LaStantauthor=D.+G.+Loughheadauthor=T.+Tonauthor=D.+E.+Karrauthor=M.+E.+Gerritsenauthor=D.+M.+Goldsteinauthor=J.+O.+Funk&title=Discovery+of+the+irreversible+covalent+FGFR+inhibitor+8-%283-%284-acryloylpiperazin-1-yl%29propyl%29-6-%282%2C6-dichloro-3%2C5-dimethoxyphenyl%29-2-%28methylamino%29pyrido%5B2%2C3-d%5Dpyrimidin-7%288H%29-one+%28PRN1371%29+for+the+treatment+of+solid+tumors&doi=10.1021%2Facs.jmedchem.7b00360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors</span></div><div class="casAuthors">Brameld, Ken A.; Owens, Timothy D.; Verner, Erik; Venetsanakos, Eleni; Bradshaw, J. Michael; Phan, Vernon T.; Tam, Danny; Leung, Kwan; Shu, Jin; LaStant, Jacob; Loughhead, David G.; Ton, Tony; Karr, Dane E.; Gerritsen, Mary E.; Goldstein, David M.; Funk, Jens Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6516-6527</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors.  Clin. validation of FGFR as a therapeutic target has been demonstrated in bladder, liver, lung, breast, and gastric cancers.  Our goal was to develop an irreversible covalent inhibitor of FGFR1-4 for use in oncol. indications.  An irreversible covalent binding mechanism imparts many desirable pharmacol. benefits including high potency, selectivity, and prolonged target inhibition.  Herein we report the structure-based design, medicinal chem. optimization, and unique ADME assays of our irreversible covalent drug discovery program which culminated in the discovery of compd. 34 (PRN1371), a highly selective and potent FGFR1-4 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpklTuvm1niy7Vg90H21EOLACvtfcHk0lh8tx1Pl8M3cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVykt7fK&md5=987069b645d5e0e36ccda5e5c81520b9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00360%26sid%3Dliteratum%253Aachs%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DVenetsanakos%26aufirst%3DE.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DPhan%26aufirst%3DV.%2BT.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLeung%26aufirst%3DK.%26aulast%3DShu%26aufirst%3DJ.%26aulast%3DLaStant%26aufirst%3DJ.%26aulast%3DLoughhead%26aufirst%3DD.%2BG.%26aulast%3DTon%26aufirst%3DT.%26aulast%3DKarr%26aufirst%3DD.%2BE.%26aulast%3DGerritsen%26aufirst%3DM.%2BE.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26atitle%3DDiscovery%2520of%2520the%2520irreversible%2520covalent%2520FGFR%2520inhibitor%25208-%25283-%25284-acryloylpiperazin-1-yl%2529propyl%2529-6-%25282%252C6-dichloro-3%252C5-dimethoxyphenyl%2529-2-%2528methylamino%2529pyrido%255B2%252C3-d%255Dpyrimidin-7%25288H%2529-one%2520%2528PRN1371%2529%2520for%2520the%2520treatment%2520of%2520solid%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6516%26epage%3D6527%26doi%3D10.1021%2Facs.jmedchem.7b00360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of a Series of Pyrazolo[3,4-d]pyridazinone Compounds as the Novel Covalent Fibroblast Growth Factor Receptor Inhibitors by the Rational Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7473</span>– <span class="NLM_lpage">7488</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00510</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00510" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVemu77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7473-7488&author=Y.+Wangauthor=Y.+Daiauthor=X.+Wuauthor=F.+Liauthor=B.+Liuauthor=C.+Liauthor=Q.+Liuauthor=Y.+Zhouauthor=B.+Wangauthor=M.+Zhuauthor=R.+Cuiauthor=X.+Tanauthor=Z.+Xiongauthor=J.+Liuauthor=M.+Tanauthor=Y.+Xuauthor=M.+Gengauthor=H.+Jiangauthor=H.+Liuauthor=J.+Aiauthor=M.+Zheng&title=Discovery+and+Development+of+a+Series+of+Pyrazolo%5B3%2C4-d%5Dpyridazinone+Compounds+as+the+Novel+Covalent+Fibroblast+Growth+Factor+Receptor+Inhibitors+by+the+Rational+Drug+Design&doi=10.1021%2Facs.jmedchem.9b00510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of a Series of Pyrazolo[3,4-d]pyridazinone Compounds as the Novel Covalent Fibroblast Growth Factor Receptor Inhibitors by the Rational Drug Design</span></div><div class="casAuthors">Wang, Yulan; Dai, Yang; Wu, Xiaowei; Li, Fei; Liu, Bo; Li, Chunpu; Liu, Qiufeng; Zhou, Yuanyang; Wang, Bao; Zhu, Mingrui; Cui, Rongrong; Tan, Xiaoqin; Xiong, Zhaoping; Liu, Jia; Tan, Minjia; Xu, Yechun; Geng, Meiyu; Jiang, Hualiang; Liu, Hong; Ai, Jing; Zheng, Mingyue</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7473-7488</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Alterations of fibroblast growth factor receptors (FGFRs) play key roles in numerous cancer progression and development, which makes FGFRs attractive targets in the cancer therapy.  In the present study, based on a newly devised FGFR target-specific scoring function, a novel FGFR inhibitor hit was identified through virtual screening.  Hit-to-lead optimization was then performed by integrating mol. docking and site-of-metab. predictions with an array of in vitro evaluations and X-ray cocrystal structure detn., leading to a covalent FGFR inhibitor 15, which showed a highly selective and potent FGFR inhibition profile.  Pharmacokinetic assessment, protein kinase profiling, and hERG inhibition evaluation were also conducted, and they confirmed the value of 15 as a lead for further investigation.  Overall, this study exemplifies the importance of the integrative use of computational methods and exptl. techniques in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKNbodkitt5rVg90H21EOLACvtfcHk0lh8tx1Pl8M3cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVemu77L&md5=80943e14d5d126f05f7d66a88208f109</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00510%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DCui%26aufirst%3DR.%26aulast%3DTan%26aufirst%3DX.%26aulast%3DXiong%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520a%2520Series%2520of%2520Pyrazolo%255B3%252C4-d%255Dpyridazinone%2520Compounds%2520as%2520the%2520Novel%2520Covalent%2520Fibroblast%2520Growth%2520Factor%2520Receptor%2520Inhibitors%2520by%2520the%2520Rational%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7473%26epage%3D7488%26doi%3D10.1021%2Facs.jmedchem.9b00510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9085</span>– <span class="NLM_lpage">9104</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01843</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01843" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9085-9104&author=Y.+Wangauthor=L.+Liauthor=J.+Fanauthor=Y.+Daiauthor=A.+Jiangauthor=M.+Gengauthor=J.+Aiauthor=W.+Duan&title=Discovery+of+Potent+Irreversible+Pan-Fibroblast+Growth+Factor+Receptor+%28FGFR%29+Inhibitors&doi=10.1021%2Facs.jmedchem.7b01843"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors</span></div><div class="casAuthors">Wang, Yuming; Li, Lijun; Fan, Jun; Dai, Yang; Jiang, Alan; Geng, Meiyu; Ai, Jing; Duan, Wenhu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9085-9104</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fibroblast growth factor receptors (FGFR1-4) are promising therapeutic targets in many cancers.  With the resurgence of interest in irreversible inhibitors, efforts have been directed to the discovery of irreversible FGFR inhibitors.  Currently, several selective irreversible inhibitors are being evaluated in clin. trials that could covalently target a conserved cysteine in the P-loop of FGFR.  In this article, the authors used a structure-guided approach that is rationalized by a computer-aided simulation to discover the novel and irreversible pan-FGFR inhibitor, 9g ((S)-1-(3-(4-amino-5-(7-methoxy-5-methylbenzo[b]thien-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one), which provided superior FGFR in vitro activities and decent selectivity over VEGFR2 (vascular endothelia growth factor receptor 2).  In in vivo studies, 9g displayed clear antitumor activities in NCI-H1581 and SNU-16 xenograft mice models.  Addnl., the dilg. method confirmed the irreversible binding of 9g to FGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcoke3wblah7Vg90H21EOLACvtfcHk0lh8tx1Pl8M3cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGjt7k%253D&md5=5dc4652a87384819f60325e7dc9425f1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01843%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DA.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DDuan%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520Potent%2520Irreversible%2520Pan-Fibroblast%2520Growth%2520Factor%2520Receptor%2520%2528FGFR%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9085%26epage%3D9104%26doi%3D10.1021%2Facs.jmedchem.7b01843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guise, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taghipouran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yosaatmadja, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashoorzadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paik, W.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squire, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">543</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.04.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1016%2Fj.ejmech.2017.04.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=28521156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvFGnt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2017&pages=531-543&author=X.+Liauthor=C.+P.+Guiseauthor=R.+Taghipouranauthor=Y.+Yosaatmadjaauthor=A.+Ashoorzadehauthor=W.-K.+Paikauthor=C.+J.+Squireauthor=S.+Jiangauthor=J.+Luoauthor=Y.+Xuauthor=Z.-C.+Tuauthor=X.+Luauthor=X.+Renauthor=A.+V.+Pattersonauthor=J.+B.+Smaillauthor=K.+Ding&title=2-Oxo-3%2C+4-dihydropyrimido%5B4%2C+5-d%5Dpyrimidinyl+derivatives+as+new+irreversible+pan+fibroblast+growth+factor+receptor+%28FGFR%29+inhibitors&doi=10.1016%2Fj.ejmech.2017.04.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors</span></div><div class="casAuthors">Li, Xueqiang; Guise, Christopher P.; Taghipouran, Rana; Yosaatmadja, Yuliana; Ashoorzadeh, Amir; Paik, Woo-Kyong; Squire, Christopher J.; Jiang, Shuang; Luo, Jinfeng; Xu, Yong; Tu, Zheng-Chao; Lu, Xiaoyun; Ren, Xiaomei; Patterson, Adam V.; Smaill, Jeff B.; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">531-543</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivs. were designed and synthesized as new irreversible inhibitors of the FGFR family.  One of the most promising compds. (E)-3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(1-(4-(dimethylamino)but-2-enoyl)piperidin-4-yl)-7-(phenylamino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one potently inhibited FGFR1/2/3 with IC50 values of 1.06, 0.84 and 5.38 nM, resp., whereas its potency against FGFR4 was diminished by an order of magnitude.  The above compd. strongly suppresses the proliferation of FGFR1-amplified H520 non-small cell lung cancer cells, FGFR2-amplified SUM52 breast cancer cells and FGFR3-amplified SW780 bladder cancer cells with low nanomolar IC50 values, but was significantly less potent against four FGFR-neg. cancer cell lines, with low micromolar IC50 values and it may serve as a promising new lead for further anticancer drug discovery.  Biol. investigation also confirmed the irreversible binding of the mol. with the FGFR1-3 target kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpifDjwM_tfWrVg90H21EOLACvtfcHk0liJUNE6Kmjq_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvFGnt7s%253D&md5=fc772aaa0de716325a0b73f1a0f8504d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.04.049%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DGuise%26aufirst%3DC.%2BP.%26aulast%3DTaghipouran%26aufirst%3DR.%26aulast%3DYosaatmadja%26aufirst%3DY.%26aulast%3DAshoorzadeh%26aufirst%3DA.%26aulast%3DPaik%26aufirst%3DW.-K.%26aulast%3DSquire%26aufirst%3DC.%2BJ.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.-C.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DDing%26aufirst%3DK.%26atitle%3D2-Oxo-3%252C%25204-dihydropyrimido%255B4%252C%25205-d%255Dpyrimidinyl%2520derivatives%2520as%2520new%2520irreversible%2520pan%2520fibroblast%2520growth%2520factor%2520receptor%2520%2528FGFR%2529%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D135%26spage%3D531%26epage%3D543%26doi%3D10.1016%2Fj.ejmech.2017.04.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamarca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barriuso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valle, J. W.</span></span> <span> </span><span class="NLM_article-title">Molecular targeted therapies: Ready for “prime time” in biliary tract cancer</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">170</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2020.03.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1016%2Fj.jhep.2020.03.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=32171892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvFKkurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2020&pages=170-185&author=A.+Lamarcaauthor=J.+Barriusoauthor=M.+G.+McNamaraauthor=J.+W.+Valle&title=Molecular+targeted+therapies%3A+Ready+for+%E2%80%9Cprime+time%E2%80%9D+in+biliary+tract+cancer&doi=10.1016%2Fj.jhep.2020.03.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular targeted therapies: Ready for "prime time" in biliary tract cancer</span></div><div class="casAuthors">Lamarca, Angela; Barriuso, Jorge; McNamara, Mairead G.; Valle, Juan W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">170-185</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The prognosis for patients with biliary tract cancers (cholangiocarcinoma and gallbladder cancer) is poor, while the incidence of these cancers is increasing.  Most patients are diagnosed with advanced disease when treatment options are limited to palliative approaches, mainly focused on chemotherapy.  In recent years, novel treatment targets of relevance to biliary tract cancers, mainly present in patients with intrahepatic cholangiocarcinoma, have been identified and are rapidly changing the field.  These include fibroblast growth factor receptor (FGFR) fusions and isocitrate dehydrogenase (IDH)-1 and -2 mutations which are each present in around 10-20% of patients with intrahepatic cholangiocarcinoma.  In addn., inhibition of other pathways/mols. is currently being explored, including human epidermal growth factor receptor (HER) family members, the Wnt pathway, neurotropic tyrosine kinase receptor (NTRK) fusions and BRAF mutations.  The IDH1 inhibitor ivosidenib has already been tested in a phase III clin. trial in pretreated cholangiocarcinoma and showed benefit in terms of progression-free survival.  Multiple FGFR inhibitors have consistently shown high response rates in phase II/III trials, esp. for patients harbouring FGFR2 fusions.  This review provides an overview of the status of targeted therapies in biliary tract cancers.  Detailed discussion regarding current clin. development of IDH and FGFR inhibitors is provided, with an overview of current caveats and future steps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1V9T0WhgFfrVg90H21EOLACvtfcHk0liJUNE6Kmjq_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvFKkurc%253D&md5=129aa59899f6b5e8034d004a54c71ff0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2020.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2020.03.007%26sid%3Dliteratum%253Aachs%26aulast%3DLamarca%26aufirst%3DA.%26aulast%3DBarriuso%26aufirst%3DJ.%26aulast%3DMcNamara%26aufirst%3DM.%2BG.%26aulast%3DValle%26aufirst%3DJ.%2BW.%26atitle%3DMolecular%2520targeted%2520therapies%253A%2520Ready%2520for%2520%25E2%2580%259Cprime%2520time%25E2%2580%259D%2520in%2520biliary%2520tract%2520cancer%26jtitle%3DJ.%2520Hepatol.%26date%3D2020%26volume%3D73%26spage%3D170%26epage%3D185%26doi%3D10.1016%2Fj.jhep.2020.03.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sootome, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiiwa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujioka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohsawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funabashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yashiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonekura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, H.</span></span> <span> </span><span class="NLM_article-title">Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">4986</span>– <span class="NLM_lpage">4997</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-19-2568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F0008-5472.CAN-19-2568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=32973082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis1eksr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=4986-4997&author=H.+Sootomeauthor=H.+Fujitaauthor=K.+Itoauthor=H.+Ochiiwaauthor=Y.+Fujiokaauthor=K.+Itoauthor=A.+Miuraauthor=T.+Sagaraauthor=S.+Itoauthor=H.+Ohsawaauthor=S.+Otsukiauthor=K.+Funabashiauthor=M.+Yashiroauthor=K.+Matsuoauthor=K.+Yonekuraauthor=H.+Hirai&title=Futibatinib+Is+a+Novel+Irreversible+FGFR+1%E2%80%934+Inhibitor+That+Shows+Selective+Antitumor+Activity+against+FGFR-Deregulated+Tumors&doi=10.1158%2F0008-5472.can-19-2568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors</span></div><div class="casAuthors">Sootome, Hiroshi; Fujita, Hidenori; Ito, Kenjiro; Ochiiwa, Hiroaki; Fujioka, Yayoi; Ito, Kimihiro; Miura, Akihiro; Sagara, Takeshi; Ito, Satoru; Ohsawa, Hirokazu; Otsuki, Sachie; Funabashi, Kaoru; Yashiro, Masakazu; Matsuo, Kenichi; Yonekura, Kazuhiko; Hirai, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4986-4997</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">FGFR signaling is deregulated in many human cancers, and FGFR is considered a valid target in FGFR-deregulated tumors.  Here, we examine the preclin. profile of futibatinib (TAS-120; 1-[(3S)-[4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3, 4-d] pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one), a structurally novel, irreversible FGFR1-4 inhibitor.  Among a panel of 296 human kinases, futibatinib selectively inhibited FGFR1-4 with IC50 values of 1.4 to 3.7 nmol/L.  Futibatinib covalently bound the FGFR kinase domain, inhibiting FGFR phosphorylation and, in turn, downstream signaling in FGFR-deregulated tumor cell lines.  Futibatinib exhibited potent, selective growth inhibition of several tumor cell lines (gastric, lung, multiple myeloma, bladder, endometrial, and breast) harboring various FGFR genomic aberrations.  Oral administration of futibatinib led to significant dose-dependent tumor redn. in various FGFR-driven human tumor xenograft models, and tumor redn. was assocd. with sustained FGFR inhibition, which was proportional to the administered dose.  The frequency of appearance of drug-resistant clones was lower with futibatinib than a reversible ATP-competitive FGFR inhibitor, and futibatinib inhibited several drug-resistant FGFR2 mutants, including the FGFR2 V565I/L gatekeeper mutants, with greater potency than any reversible FGFR inhibitors tested (IC50, 1.3-50.6 nmol/L).  These results indicate that futibatinib is a novel orally available, potent, selective, and irreversible inhibitor of FGFR1-4 with a broad spectrum of antitumor activity in cell lines and xenograft models.  These findings provide a strong rationale for testing futibatinib in patients with tumors oncogenically driven by FGFR genomic aberrations, with phase I to III trials ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1IKddHEsSKrVg90H21EOLACvtfcHk0liJUNE6Kmjq_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis1eksr7P&md5=f78d398f8453192a67a572483e509a99</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-19-2568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-19-2568%26sid%3Dliteratum%253Aachs%26aulast%3DSootome%26aufirst%3DH.%26aulast%3DFujita%26aufirst%3DH.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DOchiiwa%26aufirst%3DH.%26aulast%3DFujioka%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DMiura%26aufirst%3DA.%26aulast%3DSagara%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DS.%26aulast%3DOhsawa%26aufirst%3DH.%26aulast%3DOtsuki%26aufirst%3DS.%26aulast%3DFunabashi%26aufirst%3DK.%26aulast%3DYashiro%26aufirst%3DM.%26aulast%3DMatsuo%26aufirst%3DK.%26aulast%3DYonekura%26aufirst%3DK.%26aulast%3DHirai%26aufirst%3DH.%26atitle%3DFutibatinib%2520Is%2520a%2520Novel%2520Irreversible%2520FGFR%25201%25E2%2580%25934%2520Inhibitor%2520That%2520Shows%2520Selective%2520Antitumor%2520Activity%2520against%2520FGFR-Deregulated%2520Tumors%26jtitle%3DCancer%2520Res.%26date%3D2020%26volume%3D80%26spage%3D4986%26epage%3D4997%26doi%3D10.1158%2F0008-5472.can-19-2568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venetsanakos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brameld, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaStant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karr, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerritsen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span> <span> </span><span class="NLM_article-title">The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2668</span>– <span class="NLM_lpage">2676</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-17-0309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1158%2F1535-7163.MCT-17-0309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=28978721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWhsL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=2668-2676&author=E.+Venetsanakosauthor=K.+A.+Brameldauthor=V.+T.+Phanauthor=E.+Vernerauthor=T.+D.+Owensauthor=Y.+Xingauthor=D.+Tamauthor=J.+LaStantauthor=K.+Leungauthor=D.+E.+Karrauthor=R.+J.+Hillauthor=M.+E.+Gerritsenauthor=D.+M.+Goldsteinauthor=J.+O.+Funkauthor=J.+M.+Bradshaw&title=The+Irreversible+Covalent+Fibroblast+Growth+Factor+Receptor+Inhibitor+PRN1371+Exhibits+Sustained+Inhibition+of+FGFR+after+Drug+Clearance&doi=10.1158%2F1535-7163.mct-17-0309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance</span></div><div class="casAuthors">Venetsanakos, Eleni; Brameld, Ken A.; Phan, Vernon T.; Verner, Erik; Owens, Timothy D.; Xing, Yan; Tam, Danny; La Stant, Jacob; Leung, Kwan; Karr, Dane E.; Hill, Ronald J.; Gerritsen, Mary E.; Goldstein, David M.; Funk, Jens Oliver; Bradshaw, J. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2668-2676</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">An increasing no. of cancers are known to harbor mutations, translocations, or amplifications in the fibroblast growth factor receptor (FGFR) family of kinases.  The FGFR inhibitors evaluated in clin. trials to date have shown promise at treating these cancers.  Here, we describe PRN1371, an irreversible covalent inhibitor of FGFR1-4 targeting a cysteine within the kinase active site.  PRN1371 demonstrated strong FGFR potency and excellent kinome-wide selectivity in a no. of biochem. and cellular assays, including in various cancer cell lines exhibiting FGFR alterations.  Furthermore, PRN1371 maintained FGFR inhibition in vivo, not only when circulating drug levels were high but also after the drug had been cleared from circulation, indicating the possibility of sustained FGFR inhibition in the clinic without the need for continuous drug exposure.  Durable tumor regression was also obtained in multiple tumor xenografts and patient-derived tumor xenograft models and was sustained even using an intermittent dosing strategy that provided drug holidays.  PRN1371 is currently under clin. investigation for treatment of patients with solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzKzxYYE-2ZbVg90H21EOLACvtfcHk0liCuCqyfnyL4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWhsL7J&md5=72f3af90d5e9a2f4060e5d0e4c8b99f9</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0309%26sid%3Dliteratum%253Aachs%26aulast%3DVenetsanakos%26aufirst%3DE.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DPhan%26aufirst%3DV.%2BT.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DXing%26aufirst%3DY.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLaStant%26aufirst%3DJ.%26aulast%3DLeung%26aufirst%3DK.%26aulast%3DKarr%26aufirst%3DD.%2BE.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGerritsen%26aufirst%3DM.%2BE.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520Irreversible%2520Covalent%2520Fibroblast%2520Growth%2520Factor%2520Receptor%2520Inhibitor%2520PRN1371%2520Exhibits%2520Sustained%2520Inhibition%2520of%2520FGFR%2520after%2520Drug%2520Clearance%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D2668%26epage%3D2676%26doi%3D10.1158%2F1535-7163.mct-17-0309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yosaatmadja, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squire, C. J.</span></span> <span> </span><span class="NLM_article-title">The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1107/s1399004714027539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1107%2FS1399004714027539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=25760602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFalu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=525-533&author=Y.+Yosaatmadjaauthor=A.+V.+Pattersonauthor=J.+B.+Smaillauthor=C.+J.+Squire&title=The+1.65+%C3%85+resolution+structure+of+the+complex+of+AZD4547+with+the+kinase+domain+of+FGFR1+displays+exquisite+molecular+recognition&doi=10.1107%2Fs1399004714027539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition</span></div><div class="casAuthors">Yosaatmadja, Yuliana; Patterson, Adam Vorn; Smaill, Jeff Bruce; Squire, Christopher John</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">525-533</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">1399-0047</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The fibroblast growth factor receptor (FGFR) family are expressed widely in normal tissues and play a role in tissue repair, inflammation, angiogenesis and development.  However, aberrant signalling through this family can lead to cellular proliferation, evasion of apoptosis and induction of angiogenesis, which is implicated in the development of many cancers and also in drug resistance.  The high frequency of FGFR amplification or mutation in multiple cancer types is such that this family has been targeted for the discovery of novel, selective drug compds., with one of the most recently discovered being AZD4547, a subnanomolar (IC50) FGFR1 inhibitor developed by AstraZeneca and currently in clin. trials.  The 1.65 Å resoln. crystal structure of AZD4547 bound to the kinase domain of FGFR1 has been detd. and reveals extensive drug-protein interactions, an integral network of water mols. and the tight closure of the FGFR1 P-loop to form a long, narrow crevice in which the AZD4547 mol. binds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjQbdbZHvbhbVg90H21EOLACvtfcHk0liCuCqyfnyL4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFalu7Y%253D&md5=e7afc5e7d14f6879fee79b998a46e0b4</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1107%2FS1399004714027539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS1399004714027539%26sid%3Dliteratum%253Aachs%26aulast%3DYosaatmadja%26aufirst%3DY.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DSquire%26aufirst%3DC.%2BJ.%26atitle%3DThe%25201.65%2520%25C3%2585%2520resolution%2520structure%2520of%2520the%2520complex%2520of%2520AZD4547%2520with%2520the%2520kinase%2520domain%2520of%2520FGFR1%2520displays%2520exquisite%2520molecular%2520recognition%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2015%26volume%3D71%26spage%3D525%26epage%3D533%26doi%3D10.1107%2Fs1399004714027539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e0162491</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0162491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=10.1371%2Fjournal.pone.0162491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=27618313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFKjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&author=D.+Wuauthor=M.+Guoauthor=M.+A.+Philipsauthor=L.+Quauthor=L.+Jiangauthor=J.+Liauthor=X.+Chenauthor=Z.+Chenauthor=L.+Chenauthor=Y.+Chen&title=Crystal+Structure+of+the+FGFR4%2FLY2874455+Complex+Reveals+Insights+into+the+Pan-FGFR+Selectivity+of+LY2874455&doi=10.1371%2Fjournal.pone.0162491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the FGFR4/LY2874455 complex reveals insights into the pan-FGFR selectivity of LY2874455</span></div><div class="casAuthors">Wu, Daichao; Guo, Ming; Philips, Michael A.; Qu, Lingzhi; Jiang, Longying; Li, Jun; Chen, Xiaojuan; Chen, Zhuchu; Chen, Lin; Chen, Yongheng</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0162491/1-e0162491/11</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Aberrant FGFR4 signaling has been documented abundantly in various human cancers.  The majority of FGFR inhibitors display significantly reduced potency toward FGFR4 compared to FGFR1-3.  However, LY2874455 has similar inhibition potency for FGFR1-4 with IC50 less than 6.4 nM.  To date, there is no published crystal structure of LY2874455 in complex with any kinase.  To better understand the pan-FGFR selectivity of LY2874455, we have detd. the crystal structure of the FGFR4 kinase domain bound to LY2874455 at a resoln. of 2.35 Å.  LY2874455, a type I inhibitor for FGFR4, binds to the ATP-binding pocket of FGFR4 in a DFG-in active conformation with three hydrogen bonds and a no. of van derWaals contacts.  After alignment of the kinase domain sequence of 4 FGFRs, and superposition of the ATP binding pocket of 4 FGFRs, our structural analyses reveal that the interactions of LY2874455 to FGFR4 are largely conserved in 4 FGFRs, explaining at least partly, the broad inhibitory activity of LY2874455 toward 4 FGFRs.  Consequently, our studies reveal new insights into the pan-FGFR selectivity of LY2874455 and provide a structural basis for developing novel FGFR inhibitors that target FGFR1-4 broadly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquH9zGVO6xArVg90H21EOLACvtfcHk0liCuCqyfnyL4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFKjt74%253D&md5=444e0d350dac9196672923565b10f2ba</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0162491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0162491%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DPhilips%26aufirst%3DM.%2BA.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520FGFR4%252FLY2874455%2520Complex%2520Reveals%2520Insights%2520into%2520the%2520Pan-FGFR%2520Selectivity%2520of%2520LY2874455%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26doi%3D10.1371%2Fjournal.pone.0162491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yosaatmadja, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyukina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleditch, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squire, C. J.</span></span> <span> </span><span class="NLM_article-title">Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1180</span>– <span class="NLM_lpage">1186</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00196</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00196" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlams7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1180-1186&author=X.+Linauthor=Y.+Yosaatmadjaauthor=M.+Kalyukinaauthor=M.+J.+Middleditchauthor=Z.+Zhangauthor=X.+Luauthor=K.+Dingauthor=A.+V.+Pattersonauthor=J.+B.+Smaillauthor=C.+J.+Squire&title=Rotational+Freedom%2C+Steric+Hindrance%2C+and+Protein+Dynamics+Explain+BLU554+Selectivity+for+the+Hinge+Cysteine+of+FGFR4&doi=10.1021%2Facsmedchemlett.9b00196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4</span></div><div class="casAuthors">Lin, Xiaojing; Yosaatmadja, Yuliana; Kalyukina, Maria; Middleditch, Martin J.; Zhang, Zhen; Lu, Xiaoyun; Ding, Ke; Patterson, Adam V.; Smaill, Jeff B.; Squire, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1180-1186</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aberration in FGFR4 signaling drives carcinogenesis and progression in a subset of hepatocellular carcinoma (HCC) patients, thereby making FGFR4 an attractive mol. target for this disease.  Selective FGFR4 inhibition can be achieved through covalently targeting a poorly conserved cysteine residue in the FGFR4 kinase domain.  We report mass spectrometry assays and cocrystal structures of FGFR4 in covalent complex with the clin. candidate BLU554 and with a series of four structurally related inhibitors that define the inherent reactivity and selectivity profile of these mols.  We further reveal the structure of FGFR1 with one of our inhibitors and show that off-target covalent binding can occur through an alternative conformation that supports targeting of a cysteine conserved in all members of the FGFR family.  Collectively, we propose that rotational freedom, steric hindrance, and protein dynamics explain the exceptional selectivity profile of BLU554 for targeting FGFR4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqag7zwpLVc7bVg90H21EOLACvtfcHk0liJ7cs3qJTHAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlams7vN&md5=43f32bb16bbb3dd3873f8d7a16730a3e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00196%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DX.%26aulast%3DYosaatmadja%26aufirst%3DY.%26aulast%3DKalyukina%26aufirst%3DM.%26aulast%3DMiddleditch%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DSquire%26aufirst%3DC.%2BJ.%26atitle%3DRotational%2520Freedom%252C%2520Steric%2520Hindrance%252C%2520and%2520Protein%2520Dynamics%2520Explain%2520BLU554%2520Selectivity%2520for%2520the%2520Hinge%2520Cysteine%2520of%2520FGFR4%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1180%26epage%3D1186%26doi%3D10.1021%2Facsmedchemlett.9b00196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i138"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00174">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_46780"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00174?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00174</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings of all test compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00174/suppl_file/jm1c00174_si_001.csv">CSV</a>)</p></li><li><p class="inline">PDB file is for the Supporting Information (Figure S4) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00174/suppl_file/jm1c00174_si_002.pdb">PDB</a>)</p></li><li><p class="inline">Copies of <sup>1</sup>H/<sup>13</sup>C NMR spectrum of all compounds and intermediates (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00174/suppl_file/jm1c00174_si_003.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00174/suppl_file/jm1c00174_si_001.csv">jm1c00174_si_001.csv (2.77 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00174/suppl_file/jm1c00174_si_002.pdb">jm1c00174_si_002.pdb (753.92 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00174/suppl_file/jm1c00174_si_003.pdf">jm1c00174_si_003.pdf (13.04 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00174&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-13%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00174" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00174" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b16888ca321a6","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
